0001140361-23-015369.txt : 20230331 0001140361-23-015369.hdr.sgml : 20230331 20230331162803 ACCESSION NUMBER: 0001140361-23-015369 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 71 CONFORMED PERIOD OF REPORT: 20221231 FILED AS OF DATE: 20230331 DATE AS OF CHANGE: 20230331 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VirnetX Holding Corp CENTRAL INDEX KEY: 0001082324 STANDARD INDUSTRIAL CLASSIFICATION: PATENT OWNERS & LESSORS [6794] IRS NUMBER: 770390628 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33852 FILM NUMBER: 23788169 BUSINESS ADDRESS: STREET 1: 308 DORLA COURT STREET 2: SUITE 206 CITY: ZEPHYR COVE STATE: NV ZIP: 89448 BUSINESS PHONE: (831) 438-8200 MAIL ADDRESS: STREET 1: 308 DORLA COURT STREET 2: SUITE 206 CITY: ZEPHYR COVE STATE: NV ZIP: 89448 FORMER COMPANY: FORMER CONFORMED NAME: PASW INC DATE OF NAME CHANGE: 20001109 FORMER COMPANY: FORMER CONFORMED NAME: PACIFIC SOFTWORKS INC DATE OF NAME CHANGE: 19990322 10-K 1 brhc10048883_10k.htm 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-K

(Mark One)

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2022

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                    to                   

Commission File Number: 001-33852

VirnetX Holding Corporation
(Exact name of registrant as specified in its charter)

Delaware
 
77-0390628
(State or other jurisdiction of incorporation or organization)
 
(I.R.S. Employer Identification No.)

308 Dorla Court, Suite 206
Zephyr Cove, Nevada
 
89448
(Address of principal executive offices)
 
(Zip Code)

Registrant’s telephone number, including area code: 775-548-1785
Securities registered pursuant to Section 12(b) of the Act:

Title of each class
 
Trading Symbol(s)
 
Name of each exchange on which registered
Common Stock, par value $0.0001 per share
 
VHC
 
NYSE

Securities registered pursuant to section 12(g) of the Act:
None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes  No 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes  No 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer
Accelerated filer
Non-accelerated filer
Emerging growth company 
Smaller reporting company
 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).  

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant as of June 30, 2022, was $73,662,208 based upon the closing price of the common shares of the registrant on June 30, 2022. This calculation does not reflect a determination that certain persons are affiliates of the registrant for any other purpose.

71,424,650 shares of the registrant’s Common Stock were outstanding as of March 27, 2023.

DOCUMENTS INCORPORATED BY REFERENCE
 
The information required by Part III of this Annual Report on Form 10-K, to the extent not set forth herein, is incorporated by reference from the registrant’s definitive proxy statement to be filed with the Securities and Exchange Commission not later than 120 days after December 31, 2022 relating to the registrant’s 2023 Annual Meeting of Stockholders.



INDEX

   
Page
 
PART I
 
     
Item 1.
4
Item 1A.
9
Item 1B.
24
Item 2.
24
Item 3.
24
Item 4.
24
     
 
PART II
 
     
Item 5.
24
Item 6.
25
Item 7.
25
Item 7A.
30
Item 8.
31
Item 9.
52
Item 9A.
52
Item 9B.
53
Item 9C.
53
     
 
PART III
 
     
Item 10.
53
Item 11.
53
Item 12.
53
Item 13.
54
Item 14.
54
     
 
PART IV
 
     
Item 15.
54

SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS

We have included or incorporated by reference in this Annual Report on Form 10-K (this “Report”), and from time to time we may make statements that may constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These forward-looking statements are based upon our current expectations, estimates, assumptions, and beliefs concerning future events and conditions and may discuss, among other things, anticipated future performance (including sales and earnings), products, expected growth, future business plans and costs and the impact of potential, ongoing litigation and the expectation of future stockholder distributions. Any statement that is not historical in nature is a forward- looking statement and may be identified by the use of words and phrases such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “will be,” “will continue,” “will likely result in,” and similar expressions. These statements include our beliefs and statements regarding general industry and market conditions and growth rates, as well as general domestic and international economic conditions. Readers are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements are necessarily subject to risks, uncertainties, and other factors, many of which are outside our control, which could cause actual results to differ materially from such statements and from our historical results and experience. These risks, uncertainties and other factors include, but are not limited to those described in Item 1A - Risk Factors of this Report and elsewhere in this Report and those described from time to time in our future reports filed with the Securities and Exchange Commission (the “SEC”). Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be considered a complete list. Any forward-looking statement speaks only as of the date on which such statement is made, and we undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Among others, the forward-looking statements appearing in this Report that may not occur include statements that:


In the VirnetX Inc. v. Apple, Inc. (Case Nos. 6:11-cv-00563-RWS, 6:12-cv-00855-RWS) (“Apple II”) litigation, the United States Court of Appeals for the Federal Circuit (the “Federal Circuit”) in November 2019, affirmed-in-part, and reversed-in-part the judgment issued by the United States District Court for the Eastern District of Texas (the “district court”) in the case awarding VirnetX damages of $595.9 million. On October 30, 2020, after a trial in the district court, a jury returned a verdict in favor of VirnetX, awarding VirnetX over $502 million in damages. On January 15, 2021, the district court denied Apple’s motion for judgment as a matter of law and affirmed the jury findings. This may imply that VirnetX may soon receive over $500 million in cash; however, Apple has appealed to the Federal Circuit with regards to the judgement from the district court. Oral arguments for this appeal were heard on September 8, 2022. On March 31, 2023, the Federal Circuit issued its decision vacating the district court’s judgement in this matter and remanding it back to the district court with instructions to dismiss the case as moot. We are evaluating all of our available options in this matter, including potentially seeking rehearing or certiorari review. In addition, the patents in this case are being challenged in the United States Patent and Trademark Office. If those challenges are successful, the award in the case may be reduced, eliminated and/or delayed for a lengthy period. The continuation of this litigation is distracting to our management, expensive, and these distractions and expenses may continue.


We have undertaken activities to commercialize our products and patent portfolio in and outside the United States including VirnetX One™, War Room™, VirnetX Matrix™, GABRIEL Connection Technology™ and our Secured Domain Names. These statements may imply that the worldwide market for our commercialized products is large and will result in significant future licensing or software revenue for us. However, commercialization of products such as ours is subject to significant obstacles and risks, including but not limited to a perception by some potential partners and customers that they should await the outcome of the Apple II litigation before entering or considering entering any agreement with us, and that or other factors may prevent significant future revenues for us.

EXCEPT AS REQUIRED BY LAW, WE UNDERTAKE NO OBLIGATION TO UPDATE OR REVISE ANY FORWARD- LOOKING STATEMENT AS A RESULT OF NEW INFORMATION, FUTURE EVENTS OR OTHERWISE.

3

PART I

Item 1.
Business

The Company

We are an Internet security software and technology company with industry-leading, patented technology for Zero Trust Network Access (“ZTNA”) based secure network communications. VirnetX’s software and technology solutions, including its Secure Domain Name Registry and Technology, VirnetX One™, War Room™, VirnetX Matrix™, and Gabriel Connection Technology™, are designed to be device- and location-independent, and enable a secure real-time communication environment for all types of enterprise applications, services, and critical infrastructures. Our technology generates secure connections on a “single-click” basis, significantly simplifying the deployment of secure real-time communication solutions by eliminating the need for end-users to enter any encryption information. Our portfolio of intellectual property is the foundation of our business model. We currently own approximately 205 total patents and pending applications, including 72 U.S. patents/patent applications and 133 foreign patents/validations/pending applications. Our patent portfolio is primarily focused on securing real-time communications over the Internet, and related services, and is used in all our technology and products, some of which were acquired by our principal operating subsidiary; VirnetX, Inc., from Leidos, Inc., or Leidos, (f/k/a Science Applications International Corporation, or SAIC) in 2006.

Our product portfolio includes sophisticated technologies, products and services that are available for sale worldwide. Our next-generation, VirnetX One™ platform builds upon our patented Secure Domain Names and GABRIEL Connection Technology™ to further enhance the security and efficiency of our patented secure communication links.  VirnetX One™ is a security-as-a-service platform that protects enterprise applications, services, and infrastructure from cyber-attacks. Our platform allows businesses and other enterprises of all sizes to add a “security umbrella” as an added layer on top of their existing infrastructure to further reduce risk and bolster security against ever-growing cyberthreats to data, operating systems, other infrastructure products and gateway security controllers.

Our War Room™ software product provides an industry leading, safe, and secure video conferencing meeting environment where sensitive communications and data is invisible to those not authorized to view it. War Room™ validates permissions of all the users, and devices requesting access to any secure meeting room prior to granting access. We believe our War Room™ will be an attractive solution for government and law enforcement agencies as well as all professional sectors such as legal, financial, and medical where limiting access to confidential data is a critical requirement.

Our VirnetX Matrix™ product provides superior security for internet-enabled enterprise applications and their connected devices, and for control systems currently deployed by those enterprises (e.g., file servers, data back-up systems, VPN/firewalls). VirnetX MatrixTM provides a true “zero-trust” access protection, “single-click” ease of use, and is a highly-effective added layer of protection that is deployed simply, without the need for changes to an enterprise’s existing, in-place infrastructure. We believe VirnetX Matrix™ is an attractive solution for all businesses, cloud and on-premise application service providers, and OEMs, looking to improve visibility and management of their networks to mitigate morphing attacks on their networks and for real time access and control of their users.

Our GABRIEL Collaboration Suite™ is a set of communication applications and tools that use our GABRIEL Secure Communication Platform™. It enables seamless and secure cross platform communications between devices that are enrolled in our “VIRNETX SECURED” network and have our software installed. Our GABRIEL Collaboration Suite™ is available for download and free trial, for Android, iOS, Windows, Linux, and Mac OS X platforms, at https://virnetx.com.

During the fourth quarter of 2022 and the first quarter of 2023, the Company engaged in discussions with certain third-parties to pitch the capabilities of VirnetX One™. The Company believes that these parties have interest to secure devices and systems in areas such as healthcare, finance, legal, oil and gas, medical, law enforcement, national defense and related support industries. Although there can be no assurance in this regard, the Company believes that there are opportunities for Company products sales directly to, resale arrangements with and/or adoption as vendor standards by, one or more of these third parties.

We have an ongoing licensing program under which we offer licenses to a portion of our patent portfolio, technology, and software, including our secure domain name registry service, to domain infrastructure providers, communication service providers as well as to system integrators. Our GABRIEL Connection Technology™ License is offered to original equipment manufacturer (“OEM”) customers who want to adopt the GABRIEL Connection Technology™ as their solution for establishing secure connections using secure domain names within their products. We have developed GABRIEL Connection Technology™ Software Development Kit (“SDK”) to assist with rapid integration of these techniques into existing software implementations. Customers who want to develop their own implementation of the VirnetX patented techniques for supporting secure domain names, or other techniques that are covered by our patent portfolio for establishing secure communication links, can purchase a patent license. The number of patents licensed, and therefore the cost of the patent license to the customer, will depend upon which of the patents are used in a particular product or service. These licenses will typically include an initial license fee, as well as an ongoing royalty.

We expect to continue to launch new and enhanced security platforms, software products, and services based on our GABRIEL Connection Technology™. We will provide updates to new and existing customers as they are released to the public. Many small and medium businesses have installed our software products in their corporate networks. We intend to continue to expand our customer base with targeted promotions and direct sales initiatives.

Our employees include the core development team behind our patent portfolio, technology, and software. Some members of this team have worked together for over twenty years and were on same team that invented and developed this technology while working at Leidos. The team has continued its research and development work and expanded the set of patents we acquired in 2006 from Leidos, into a larger patent portfolio. This portfolio now serves as the foundation of our products, services, and our licensing business. It is expected to generate most of our future revenue in license fees and royalties. We intend to continue our efforts to develop new products and technologies and further strengthen and expand our patent portfolio. We intend to continue using an outsourced and leveraged model to maintain efficiency and manage costs as we grow our licensing business by, for example, offering incentives to early licensing targets or asserting our rights for use of our patents.

4

Industry Overview & Trends

We believe that the rapid growth in remote work has accelerated digital business transformation initiatives that would have taken years, into a matter of months. The demand to work remotely, explosive growth of video conferencing tools and rapid growth in the cloud has created an opportunity to secure communications regardless of a user’s location, network, or BYOD (bring your own device).

The shift to remote work and expansion of the enterprise network perimeter has driven the growth of ZTNA solutions. The Zero Trust concept treats all networks like the Internet, where all users and devices are untrusted by default. Their location within the network is not a factor for deciding trust. Each user and device on the network requires authentication and authorization, based on policy, prior to accessing any applications or resources on the network. ZTNA facilitates security around remote work, because Zero Trust policies enable granular access control, end-to-end encryption of network communications and remove application visibility from the public Internet which reduces the potential attack surface. Based on our estimates, using publicly available market data, we believe that the Zero Trust security market size is projected to grow from $24.8 billion in 2022 to over $60 billion by 2027, at a Compound Annual Growth Rate (CAGR) of 19.4% during the forecast period. We believe Zero Trust represents a growing market and an ideal fit for our technology and products.

The global coronavirus COVID-19 pandemic forced many organizations to shift their business processes – and their employees are having to embrace a work-from-home or “hybrid” culture on a scale never before attempted. Remote work has accelerated the adoption of video conferencing and meeting applications across all industries making them essential tools for connection with remote customers, workforces, and employees to limit person-to-person direct contact. Based on our estimates, using publicly available market data, we believe that the worldwide video conferencing market size is projected to grow from $7.69 billion in 2022 to $18.1 billion by 2027, at a CAGR of 18.7% during the forecast period. This rapid adoption, learning curve and demand to continue working remotely has created significant security concerns and breaches for enterprises. Our market research has focused on security conscious verticals such as healthcare, banking, legal and government where security breaches can significantly impact outcomes. In many cases, these enterprises adopted industry standard video conferencing tools and are now looking at more secure alternative solutions. Enterprises want video conferencing solutions that protect their information and allow them greater security control and visibility, while continuing to be reliable, easy to use and cost effective. Enterprises in these verticals are also looking for video conferencing solutions that integrate into their existing workflows and better align with specific use cases instead of forcing them to adapt to more one size fits all solutions on the market. We believe our War Room™ represents a starting point to offer secure video conferencing tools built on a Zero Trust architecture.

Cloud computing growth has rapidly expanded as enterprises continue to move applications and services to the cloud. The cloud offers scalability, operations and development efficiency and remote access benefits for their workforce. The cloud technology adoption is expected to continue to increase quite significantly in industries where the work-from-home initiative is helped to sustain enterprise business functions. However, shifting critical data to the cloud has resulted in security concerns and the need for enterprises to control access and gain visibility into how information is being used, who is accessing it and where it is going. Based on our estimates, using publicly available market data, we believe that the global cloud computing security market size is expected to grow from approximately $43.6 billion in 2022 to over $92.7 billion by 2028, at a CAGR of 13.4% during the forecast period. We believe our scalable technology allows enterprises to secure applications and services regardless of whether hosting is on-premise or in the cloud.

As billions of connected Internet of Things (“IoT”) devices come online in support of enterprise operations, products, and industrial controls they will need to be secured and integrated into the enterprise. Facilitated by advancements in 4G/Advanced LTE and high-speed 5G networks, IoT devices will be able to operate from any network, transmit higher volumes of data including video streaming and sensor data collection and require real-time decisions based on that data. Without next generation security, these IoT devices represent a large attack surface that manages and controls critical enterprise infrastructure. These IoT devices can operate from anywhere, and will need to be secured with the same level of network security and ZTNA solutions enterprises are already deploying for their remote workforce. We believe that the market opportunity for our software and technology solutions is large and expanding as secure domain names are now an integral part of securing the next generation 5G and 4G/LTE Advanced wireless networks and IoT communications. Based on our estimates, using publicly available market data, we believe that the size of the global Industrial IoT security market is projected to grow from $4.76 billion in 2022 to approximately $23.17 billion by 2028 at a CAGR of 30.2% during the forecasted period with a growing investment in securing the infrastructure around these devices.

Our Approach & Strategy

We believe that VirnetX One™ software products are positioned to help enterprises adapt to the rapidly evolving threat landscape in work environments and the growing need to secure communications regardless of a user’s location, network, or device using our GABRIEL Connection Technology™.

VirnetX One™ products deliver ZTNA, allowing enterprises to secure their information, control access and gain visibility into how information is being used, who is accessing it and where it is going. Our patented technology allows enterprises to license our technology for integration into their products and services, easily deploy our technology through our VirnetX One™ family of products for endpoint security or securing their communications with our mobile and desktop applications.

5

Our strategy is to become the market leader in securing real-time communications over the Internet and to establish our VirnetX One™ and GABRIEL Connection Technology™ as the industry standard security platforms. Key elements of our strategy are to:


Actively recruit partners in various vertical markets, including healthcare, finance, legal, government to help us expand our enterprise customer base.


Promote our next-generation VirnetX One™ platform as a solution for delivering ZTNA, and securing enterprise applications, services, and infrastructure.


Continue to grow our technology licensing program to commercialize our intellectual property, including our GABRIEL Connection Technology™.


Grow registration of VirnetX Secure Domain Names as the network segmentation component of our ZTNA solution. Establish VirnetX as the exclusive, universal registry of secure domain names and enable our customers to act as registrars for their users and broker secure communication between devices.


Promote War RoomTM video conferencing product in the general market for sale to end-user enterprises, directly and with partners, with targeted promotions and other marketing programs to assist remote workers and offer an industry leading secure meeting solution.


Promote VirnetX Matrix™ enterprise applications, services, and infrastructure.

Our patent portfolio serves as the foundation of our GABRIEL Connection Technology™, software products, services, and our licensing business. We currently own approximately 205 total patents and pending applications, including 72 U.S. patents/patent applications and 133 foreign patents/validations/pending applications. It is expected to generate the majority of our future revenue in license fees and royalties.

Competitive Strengths

We believe the following competitive strengths will enable our success in the marketplace:

Unique patented technology. We are focused on developing innovative technology for securing real-time communications over the Internet and establishing the exclusive secure domain name registry in the United States and other key markets around the world. Our unique solutions combine industry standard encryption methods and communication protocols with our patented techniques for automated DNS lookup mechanisms. Our technology and patented approach enable users to create a secure communication link by generating secure domain names. We currently own approximately 205 total patents and pending applications, including 72 U.S. patents/patent applications and 133 foreign patents/validations/pending applications. Our portfolio includes patents and pending patent applications in the United States and other key markets that support our secure domain name registry service for the Internet.

Scalable licensing business model. We are actively engaged in pursuing additional licensing agreements with industry participants OEMs, service providers and system integrators within the IP-telephony, mobility, mobile-to-mobile communications, fixed-mobile convergence, and unified communications end-markets.

Highly experienced research and development team. Our research and development team is comprised of nationally recognized network security and encryption technology scientists and experts that have worked together as a team for over ten years. During their careers, this team has developed several cutting-edge technologies for U.S. national defense, intelligence, and civilian agencies, many of which remain critical to our national security today. Prior to joining VirnetX, our team worked for Leidos, during which time they invented the core technology that is the foundation of our current technology and software. Based on the collective knowledge and experience of our development team, we believe that we have one of the most experienced and sophisticated groups of security experts researching vulnerability and threats to real-time communication over the Internet and developing solutions to mitigate these problems.

License and Service Offerings

We offer a diversified portfolio of licenses, software and service offerings focused on securing real-time communications over the Internet. We believe software products will allow enterprises to seamlessly integrate ZTNA protection into their networks to secure their applications, services, virtualized resources, and data as it moves into the cloud. Enterprises can quickly deploy VirnetX One software products to protect legacy applications, secure new cloud-based services and remove application visibility from the public Internet. Enterprises can move towards more granular network access control to protect their network at the edge and away from legacy VPN technologies. VirnetX One family of software products enables remote employees to securely interact with on-premise and cloud-based applications, regardless of their location. Enterprises can use VirnetX One platform to secure open-source applications powering communications, data and analytics, infrastructure, and business services with a focus on making those applications easier to secure, access and manage.

6

We believe our software products and technologies provide the foundation for securing real-time communications and collaboration applications for the enterprise remote workforce. We are exploring creating a marketplace of applications secured by our VirnetX One platform. This approach will allow us to offer a portfolio of certified applications that can be deployed by the enterprise customers in their business networks with confidence in keeping their confidential data and communications secure. This marketplace strategy will allow us to offer more flexible licensing options to solve specific customer use-cases, align with partner product offerings and create upsell opportunities for our products.

Customers

Our software products are available for download and free trial, for Android, iOS, Windows, Linux, and Mac OS X platforms, at http://www.virnetx.com/. We continue to enhance our products and add new functionality to our products. Small and medium businesses have installed our software products in their corporate networks. We continue to expand our customer base with targeted promotions and direct sales initiatives.

We have signed Patent License Agreements with Aastra USA, Inc. Avaya, Inc., Microsoft Corporation, Mitel Networks Corporation, NEC Corporation and NEC Corporation of America, Siemens Enterprise Communications GmbH & Co. KG, and Siemens Enterprise Communications Inc. to license certain of our patents, for a one-time payment and an ongoing royalty for all future sales through the expiration of the licensed patents with respect to certain current and future IP-encrypted products.

We are seeking further licensing of our technology, to developers and original equipment manufacturers, or OEMs, of chips, servers, Desktop, mobile devices such as smart phones, tablets, laptops, net books, and other devices, within the IP-telephony, mobility, fixed- mobile convergence, and unified communications markets including 5G and 4G/LTE. We have published our royalty rates and guidelines on our website. All forward moving licenses have adhered to these guidelines and have met or exceeded these rates and we will use these rates and guidelines in all future license negotiations.

Marketing and Sales

We employ a leveraged, partner-oriented, marketing strategy for our technology licenses and software product offerings. We have successfully signed a number of Resellers & Managed Service Provider Agreements in various market segments, including, healthcare, finance, legal, government, etc., to assist us in selling our software products to their customers. A list of our partners can be found on our website at https://virnetx.com/partners. We plan to continue working on a number of sales and marketing promotions, in the U.S. and Japan, to recruit more resellers and partners along with direct sales programs as we seek to extend out our customer base internationally.

We plan to directly market our software products, domain name registry services to our service provider and system integrator customers. We market our software products directly to small and medium businesses using online marketing programs and tools.

We expect to leverage our relationship with Leidos, to extend our offering to departments and agencies within the federal government. Leidos is a FORTUNE 500® scientific, engineering and technology applications company that uses its deep domain knowledge to solve problems of vital importance to the nation and the world, in national security, energy and the environment, critical infrastructure, and health. We intend to leverage our sales team for managing current accounts and pursuing sales opportunities with new customers. We continue to rapidly expand our customer base with targeted promotions and direct sales initiatives.

We added a Chief Operating Officer to our Japanese team to further our technology licensing efforts in Japan. We have signed a non-exclusive Distribution and Service Agreement with IP Dream, a Japanese based strategic technology developer and service provider, to sell our software products as well as VirnetX’s Secure Domain Name technology to its clients in Japan and greater Asia. Jointly with IP Dream, we are currently pursuing several OEM opportunities with some of the largest services providers in Japan. Along with our efforts with IP Dream, we continue to explore alternative strategies to pursue opportunities to work with other third parties in Japan, and elsewhere, using an approach that will seek to capitalize on these opportunities in part by placing more emphasis on the use of our own employees.

We intend to continue to license our patent portfolio, technology, and software, including our secure domain name registry service, to domain infrastructure providers, communication service providers as well as to system integrators. We intend to seek further license of our technology and software products, to enterprise customers, developers and original equipment manufacturers, or OEMs, of chips, servers, Desktop, mobile devices such as smart phones, tablets, laptops, net books, and other devices, within the IP-telephony, mobility, fixed- mobile convergence, and unified communications markets including 5G and 4G/LTE. We have published our royalty rates and guidelines on our website at https://virnetx.com/licensing. All forward moving licenses have adhered to these guidelines and have met or exceeded these rates and we will use these rates and guidelines in all future license negotiations.

Intellectual Property and Patent Rights

Our intellectual property is primarily comprised of trade secrets, patented know-how, issued and pending patents, copyrights and technological innovation.

7

We currently own approximately 205 total patents and pending applications, including 72 U.S. patents/patent applications and 133 foreign patents/validations/pending applications. Our portfolio includes many patents that describe unique systems and methods for securing real- time communications over the Internet, as well as related services such as the establishment and maintenance of a secure domain name registry. Our software and technology solutions also may have additional applications relating to operating systems and network security. A complete list of our U.S. patents is available on our website located at http://www.virnetx.com. Each patent is publicly accessible on U.S. Patent and Trademark Office website at http://www.uspto.gov. Some of our issued U.S. and foreign patents expire at various times during the period from 2023 to 2034.

Notwithstanding anything to the contrary set forth in any of our filings under the Securities Act or the Exchange Act that might incorporate future filings, the information set forth on the United States Patent and Trademark Office (the “USPTO”) website, shall not be deemed to be a part of or incorporated by reference into any such filings. We do not warrant the accuracy, or completeness or adequacy of the USPTO website, and expressly disclaim liability for errors or omissions on such website.

Assignment of Patents

Some of our issued patents and pending patent applications were acquired by our principal operating subsidiary, VirnetX, Inc., from Leidos, pursuant to an Assignment Agreement dated December 21, 2006, and a Patent License and Assignment Agreement dated August 12, 2005, as amended on November 2, 2006, including documents prepared pursuant to the November amendment, and as further amended on March 12, 2008. We recorded the assignment from Leidos, with the U.S. Patent Office on December 21, 2006.

Key terms of these agreements are as follows:


Patent Assignment. Leidos, unconditionally and irrevocably conveyed, transferred, assigned, and quitclaimed all its right, title, and interest in and to the patents and patent applications, as specifically set forth in the assignment document recorded with the U.S. Patent Office, including, without limitation, the right to sue for past infringement.


License to Leidos, Outside the Field of Use. Effective March 12, 2008, we granted to Leidos, a non-exclusive, royalty free, fully paid, perpetual, worldwide, irrevocable, sub licensable and transferable right and license permitting Leidos, and its assignees to make, have made, import, use, offer for sale, and sell products and services covered by, and to make improvements to, the patents and patent applications we acquired from Leidos, solely outside our field of use.


Compensation Obligations. As consideration for the assignment of the patents and for the rights we obtained from Leidos, as amended, we are required to make payments to Leidos, based on cash or certain other values generated from those patents. The amount of such payments depends upon the type of value generated, and certain categories are subject to maximums and other limitations. In 2010, we met our maximum royalty payment requirement; however, Leidos is also entitled under certain circumstances to receive a portion of the proceeds paid to us for certain acquisitions of VirnetX and the settlement of certain patent infringement claims of ours.

Government Regulation

We are subject to various federal, state, local, and foreign laws and regulations, including those relating to privacy, data protection and security, intellectual property, employment and labor, workplace safety, consumer protection, anti-bribery, import and export controls, immigration, federal securities, and tax.  Additional laws and regulations relating to these areas likely will be passed in the future, and these or existing laws and regulations may be interpreted or enforced in new or expanded manners, each of which could result in significant limitations on how we operate our business.

In particular, the laws governing online secure communications remain unsettled in various respects, even in areas where there has been legislative action. Uncertainty regarding the interpretation and enforcement of laws governing matters such as intellectual property, privacy, data protection and libel in the context of online communications and media is likely to remain. New and existing legislation, or changes in its interpretation and enforcement, may interfere with the growth in use of online secure communications and decrease the acceptance of online secure communications as a viable solution, which could adversely affect our business.

Due to the Internet’s increasing and evolving use, new laws regulating secure communications may be adopted. These laws and regulations may cover, among other things, issues relating to privacy, data protection, cybersecurity, pricing, taxation, telecommunications over the Internet, content, copyrights, distribution and quality of products and services. We intend to work to comply with all new applicable laws and regulations as they are adopted and put in force. New and evolving laws and regulations, and changes in their enforcement and interpretation, may have material impacts upon our development and commercialization plans or business practices, and may significantly increase our compliance costs and otherwise adversely affect our business, financial condition, and results of operations.

8

The U.S. government has controlled the authoritative domain name system, or DNS, root server since the inception of the Internet. On July 1, 1997, the President of the United States directed the U.S. Secretary of Commerce to privatize the management of the domain name system in a manner that increases competition and facilitates international participation in its management.

On September 29, 2006, the U.S. Department of Commerce extended its delegation of authority by entering into a new agreement with the Internet Corporation for Assigned Names and Numbers, or ICANN, a California non-profit corporation headquartered in Marina Del Rey, California. ICANN is responsible for managing the accreditation of registry providers and registrars that manage the assignment of top- level domain names associated with the authoritative DNS root directory. Although it is possible to create and manage other DNS root directories privately without accreditation from ICANN, the possibility of conflicting name and number assignments makes it less likely that users would widely adopt a top-level domain name associated with an alternative DNS root directory provided by a non-ICANN- accredited registry service.

Employees and Human Capital

As of December 31, 2022, we had 25 full and part time employees, most of whom work remotely from our corporate offices. We have had a work-from-home workforce since our inception. The emphasis of our employees is on our technology research and product development with 14 employees focused on this effort. Our team has been working on enhancing our products and adding new functionality along with successfully filing several new patent applications in 2022. We also continue building our sales and marketing teams to expand our product-lines and customer base. In 2021, we added a Chief Operating Officer to our team in Japan who will be focused on growing our market and products in that region.

In addition to our regular employees, we also engage with consultants on a regular basis. These consultants can be involved in our product development, customer relations, legal, and/or regulatory compliance and reporting. We have experienced low employee turnover rates over the years with both employees and consultants participating in our equity incentive plan.

Available Information

We file or furnish various reports, such as registration statements, periodic and current reports, proxy statements and other materials with the SEC. Our website address is http://www.virnetx.com. You may obtain, free of charge on our website, copies of our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. The information we post is intended for reference purposes only; none of the information posted on our website is part of this report or incorporated by reference herein.

The SEC also maintains website at http://www.sec.gov that contains reports, proxy and other information statements, and other information regarding issuers, including us, that file electronically with the SEC.

Item 1A.
Risk Factors

Our operations and financial results are subject to various risks and uncertainties, including those described below, which could adversely affect our business, financial condition, results of operations, cash flows, and the trading price of our common and capital stock. You should carefully consider the risks and uncertainties described below in addition to the other information set forth in this Report, including in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our consolidated financial statements and related notes, before making any investment in our common stock. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also adversely affect our business. If any of these risk factors occur, you could lose substantial value or your entire investment in our shares.

Summary Risk Factors

An investment in our common stock involves a high degree of risk, and the following is a summary of key risk factors when considering an investment.

You should read this summary together with the more detailed description of each risk factor contained in the subheadings further below.

Our business has been, and may continue to be, negatively affected by shareholders intent upon alternate business strategies.

We may not generate significant sales revenues from our new software products and services.

We are involved and will continue to be involved in litigation defending our patent portfolio, which can be time-consuming and costly, and we cannot anticipate the results.

We may not be able to capitalize on market opportunities related to our product strategy, our licensing strategy or our patent portfolio.

9

If we are not able to adequately protect our patent rights and trade secrets, our business would be negatively impacted.

Because our business is conducted or expected to be conducted in an environment that is subject to rapid change, we may be subject to various developments in regulation, law, and consumer preferences to which we may not be able to adapt successfully.

Our exposure to outside influences beyond our control, including new legislation, court rulings or actions by the USPTO could adversely affect our licensing and enforcement activities and results of operations.

New legislation, regulations or court rulings related to enforcing patents could harm our business and operating results.

Privacy and data security concerns, and data collection and transfer restrictions and related domestic or foreign regulations may limit the use and adoption of our solutions and adversely affect our business.

If we are unable to expand our revenue sources or establish, sustain, grow, or replace relationships with a diversified customer base, our revenues may be limited.

We have limited technical resources and are at an early stage in commercialization of our software products.

Our international expansion will subject us to additional costs and risks, and our plans may not be successful.

We have had to restate our previously issued financial statements and in connection with such process identified a material weakness in our internal control over financial reporting.

We may face litigation over the restatement of our previously issued financial statements.

Risks Related to Our Business and Our Financial Reporting

Our business has been, and may continue to be, negatively affected by shareholders intent upon alternate business strategies.

Responding to actions by activist shareholders is costly and time-consuming, has diverted some the attention of management, our board of directors and our employees, and may be disruptive to our operations. Additionally, perceived uncertainties as to our future direction as a result of shareholder activism or changes to the composition of our board of directors may lead to the perception of a change in the direction of our business or other instability, which may be exploited by our competitors, cause concern to our current or potential customers, and make it more difficult to attract and retain qualified personnel. The change in composition of our board of directors could jeopardize our ability to execute our strategic plan and materially harm our business. Due to the current status of our ongoing litigation proceedings, it is critical for us to retain our current board members for proper and timely execution of our strategy in this matter for maximizing shareholder equity value. Additionally, if customers choose to delay, defer or reduce transactions with us or do business with our competitors instead of us, then our business, financial condition and operating results would be adversely affected. In addition, our share price could experience periods of increased volatility as a result of shareholder activism.

We may not generate significant sales revenues from our new software products and services.

In March and April 2022, we launched War Room™ and VirnetX Matrix™ on our VirnetX One™ platform in the U.S. We currently expect to launch these products in Asia Pacific and Europe in fiscal year 2023. We also intend to continue to introduce new products on our VirnetX One™ platform in the future. The introduction and launch of new products is subject to significant costs, risks of slow market acceptance, and variable costs and timing of customer acquisition. While we believe our software products will be attractive to businesses, government agencies, cloud and on-premise application service providers, and OEMs, if we are unable to overcome these risks, we may never generate significant revenue from the sales of these products.

We are involved and will continue to be involved in litigation defending our patent portfolio, which can be time-consuming and costly, and we cannot anticipate the results.

We spend a significant amount of our financial and management resources to pursue our current litigation. We believe that this litigation and others that we may pursue in the future could continue for years and consume significant financial and management resources. The counterparties to our litigation include large, well-financed companies with substantially greater resources than us. Patent litigation is risky, and the outcome is uncertain, and we cannot assure you that any of our current or future litigation matters will result in a favorable outcome for us. In addition, even if we obtain favorable interim rulings or verdicts, they may be inconsistent with the ultimate resolution of the dispute. Furthermore, any awards we receive may be subject to obligations to Leidos and fee arrangements with outside counsel. Also, we cannot assure you that we will not be exposed to claims or sanctions against us which may be costly or impossible for us to defend. Unfavorable or adverse outcomes may result in losses, exhaustion of financial resources or other adverse effects, which could reduce our ability to return cash to our shareholders by way of distributions or otherwise to develop and commercialize our products.

10

We may not be able to capitalize on market opportunities related to our product strategy, our licensing strategy or our patent portfolio.

A large part of our business strategy includes licensing our patents and technology to other companies in order to reach a larger end-user base than we could reach through direct sales and marketing efforts; as such, our business strategy and revenues may depend on intellectual property licensing fees and royalties for the majority of our revenues. We currently derive minimal revenue from licensing activities, and royalties, and we cannot assure you that we will successfully capitalize on our market opportunities or that this portion of our business strategy will succeed.

Although to date we have entered into a limited number of settlement and license agreements, we may not be successful in entering into further licensing relationships, or if we are successful in entering into such relationships, the acquisition of them may be expensive, and they, as well as our existing settlement and our existing and pending license agreements may not generate the financial results, we expect.

Factors that may affect our ability to execute our current business strategy include, but are not limited to, the following:

Third parties may challenge the validity of our patents;

The pendency of our various litigations may cause potential licensees not to do business with us;

Our patents may expire before we can make our business strategy successful;

We face, and we expect to continue to face, intense competition from new and established competitors who may have superior products and services or better marketing, financial or other capacities than we do; and

It is possible that one or more of our potential customers or licensees develops or otherwise sources products or technologies similar to, competitive with or superior to ours.

If we are not able to adequately protect our patent rights and trade secrets, our business would be negatively impacted.

We believe our patents are valid, enforceable, and valuable. Notwithstanding this belief, third parties may make claims of infringement or invalidity claims with respect to our patents or become aware of our trade secrets by way of leaks from bad actors within or outside of our employee base or otherwise, and such claims could give rise to material cost for defense or settlement or both, and such claims or leaks could jeopardize or substantially delay a successful outcome of litigation we are or may become involved in, divert resources away from our other activities, limit or cease our related revenues, or otherwise materially and adversely affect our business. Additionally, several of our patents are currently, and other patents may in the future be, subject to USPTO post-grant inter partes review proceedings (“IPR”) which may result in all, or part of these patents being invalidated, or the claims of our patents being limited. Unfavorable or adverse outcomes in our litigation or IPRs or material leaks of trade secrets may result in losses, exhaustion of financial resources, reduction in our ability to protect our intellectual property rights, or other adverse effects, which could encumber our ability to develop and commercialize our products. Even if we are successful in protecting our intellectual property rights, they may not ultimately provide us with any competitive advantages and may be less valuable than we currently expect. These risks may be heightened in countries other than the United States where laws regarding patent protection are less developed and may be negatively affected by the fact that legal standards in the United States and elsewhere for protection of intellectual property rights in Internet-related businesses are uncertain and still evolving. In addition, there are a significant number of United States and foreign patents and patent applications in our areas of interest, and we expect that significant litigation in these areas will continue and will add uncertainty to the value of certain patents and other intellectual property rights in our areas of interest. If we are unable to protect our intellectual property rights or otherwise realize value from them, our business would be negatively affected.

11

We can provide no assurances that the licensing of our essential security patents under FRAND will be successful.

At the request of the European Telecommunications Standards Institute (“ETSI”), and the Alliance for Telecommunications Industry Solutions (“ATIS”), we agreed to update our licensing declaration to ETSI and ATIS under their respective Intellectual Property Rights policies. This was in response to our Statement of Patent Holder identifying a group of our patents and patent applications that we believe are or may become essential to certain developing specifications in the 3rd Generation Partnership Project Long Term Evolution (“LTE”), Systems Architecture Evolution project. We will make available a non-exclusive patent license under FRAND (fair, reasonable and non- discriminatory terms, and conditions, with compensation) for the patents identified by us that are or become essential to applicants desiring to implement the Technical Specifications identified by us, as set forth in the updated licensing declaration under the ATIS and ETSI Intellectual Property Rights policies. Our licensing declarations under the ATIS and ETSI Intellectual Property Rights policies may limit our flexibility in determining royalties and license terms for certain of our patents. Consequently, we cannot assure you that the licensing of the essential security patents will be successful or that third parties will be willing to enter into licenses with us on reasonable terms or at all, which could have an adverse effect on our business and harm our competitive position.

Because our business is conducted or expected to be conducted in an environment that is subject to rapid change, we may be subject to various developments in regulation, law, and consumer preferences to which we may not be able to adapt successfully.

The current regulatory environment for our products and services remains unclear. We can give no assurance that our planned product offerings will be in compliance with laws and regulations of local, state, United States federal or foreign authorities. Further, we can give no assurance that we will not unintentionally violate such laws or regulations or that such laws or regulations will not be modified, or that new laws or regulations will be enacted in the future which would cause us to be in violation of such laws or regulations. For example, Voice-Over-Internet Protocol (“VoIP”) services are not currently subject to all the same regulations that apply to traditional telephony, but it is possible that similar regulations may be applied to VoIP in the future and that these could result in substantial costs to us which could adversely affect the marketability of our products and planned products related to VoIP. For further example, the use of the Internet and private Internet Protocol (“IP”) networks for communication is largely unregulated within the United States, but may become regulated in the future; additionally, several foreign governments have enacted measures that could restrict or prohibit voice communications services over the Internet or private IP networks.

Our business depends on the growth of instant messaging, VoIP, mobile services, streaming video, file transfer and remote desktop and other next-generation Internet-based applications. A decline in the use of these applications due to complexity or cost relative to alternate traditional or newly developed communications channels, or development of alternative technologies, could cause a material decline in the number of users in these areas.

More aggressive domestic or international regulation of the Internet in general, and Internet telephony providers and services specifically may materially and adversely affect our business, financial condition, operating results, and future prospects.

Our exposure to outside influences beyond our control, including new legislation, court rulings or actions by the USPTO, could adversely affect our licensing and enforcement activities and results of operations.

Our licensing and enforcement activities are subject to numerous risks from outside influences, including the following:

New legislation, regulations or rules related to obtaining patents or enforcing patents could significantly increase our operating costs and decrease our revenue. For instance, the United States Supreme Court has modified some tests used by the USPTO in granting patents during the past 20 years which may decrease the likelihood that we will be able to obtain patents and increase the likelihood of challenge of any patents we obtain or license. In addition, in 2012, the United States enacted sweeping changes to the United States patent system under the Leahy-Smith America Invents Act, including changes that transition the United States from a “first-to-invent” system to a “first to file” system and alter the processes for challenging issued patents;

More patent applications are filed each year resulting in longer delays in getting patents issued by the USPTO;

Federal courts are becoming more crowded, and as a result, patent enforcement litigation is taking longer; and

As patent enforcement becomes more prevalent, it may become more difficult for us to voluntarily license our patents.

12

New legislation, regulations or court rulings related to enforcing patents could harm our business and operating results.

Intellectual property is the subject of intense scrutiny by the courts, legislatures, and executive branches of governments around the world. Various patent offices, governments or intergovernmental bodies may implement new legislation, regulations or rulings that impact the patent enforcement process, or the rights of patent holders and such changes could negatively affect licensing efforts and/or litigations. For example, limitations on the ability to bring patent enforcement claims, limitations on potential liability for patent infringement, lower evidentiary standards for invalidating patents, increases in the cost to resolve patent disputes and other similar developments could negatively affect our ability to assert our patent or other intellectual property rights.

It is impossible to determine the extent of the impact of any new laws, regulations or initiatives that may be proposed, or whether any of the proposals will become enacted as laws. Compliance with any new or existing laws or regulations could be difficult and expensive, affect the manner in which we conduct our business and negatively impact our business, prospects, financial condition, and results of operations.

If we experience security breaches or incidents, we could be exposed to liability and our reputation and business could suffer.

We expect to retain certain confidential and proprietary customer information in our secure data centers and secure domain name registry, as well as personal data and other confidential and proprietary information relating to our business. It will be critical to our business strategy that our facilities and infrastructure remain secure and are perceived by the marketplace to be secure. Our secure domain name registry operations will also depend on our ability to maintain our computer and telecommunications equipment in effective working order and to reasonably protect our systems against interruption, and potentially depend on protection by other registrars in the shared registration system. The secure domain name servers that we will operate will be critical hardware to our registry services operations. Additionally, we maintain confidential and proprietary business information, including trade secrets. We expect to have to expend significant time and money to maintain or increase the security of our products, facilities, and infrastructure. Security technologies are constantly being tested by computer professionals, academics and “hackers.” Advances in computer capabilities and the techniques for attacking security solutions, new discoveries in the field of cryptography or other events or developments could result in compromises or breaches of our security measures and could make some or all our products obsolete or unmarketable. Likewise, we may need to dedicate engineering and other resources to eliminate security vulnerabilities and may find it necessary or appropriate to repair or replace products already sold or licensed to our customers. Despite the security measures that we and our service providers utilize, our infrastructure and that of our service providers may be vulnerable to physical break-ins, ransomware, computer viruses, other malicious code attacks by hackers, phishing attacks, social engineering, or similar disruptive problems. Any disruption or security breach or incident that we or our service providers suffer or are perceived to suffer, including any such disruption, breach or incident resulting in a loss of, or damage to, data or systems, or inappropriate disclosure, access, loss, or other processing of confidential, financial, proprietary or personal information, including data related to our personnel, could result in loss, disclosure or other unauthorized processing of such data, could delay our research and development or commercialization efforts, could compel us to comply with breach notification laws and regulations, subject us to mandatory corrective action, and otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information.  It is possible that we may have to expend additional financial and other resources to address such problems. The COVID-19 pandemic has resulted in increasing vulnerability to cyber-attacks, as more individuals and companies work online, which increases these risks. As a provider of Internet security software and technology, we may be the target of dedicated efforts by hackers and other third parties to overcome or defeat our security measures. Any physical or electronic break-in or other security breach or incident or compromise impacting our products or any information stored at our secure data centers and domain name registration systems, including any compromise due to human error or employee or contractor malfeasance, may jeopardize the security of information stored on our premises or in the computer systems and networks of our customers. Additionally, any such data security incident, or the perception that one has occurred could also result in adverse publicity, harm to our reputation and competitive position, and therefore adversely affect the market’s perception of the security of electronic commerce and communications over IP networks as well as the security or reliability of our services.

A security breach or other security incident, or the perception any such event has occurred, could require a substantial level of financial resources to address and otherwise respond to, may be difficult to identify or address in a timely manner, and could result in claims, investigations, inquiries, and other proceedings or actions by private parties or governmental entities that may divert management’s attention and require the expenditure of significant time and resources, and which may cause us to incur substantial fines, penalties, or other liability and related legal and other costs. Any actual or perceived security breach or other security incident may also harm our reputation, result in a loss of customers, and make it more difficult or impossible for us to successfully market to others. Any of the foregoing matters could harm our operating results and financial condition.

13

Privacy and data security concerns, and data collection and transfer restrictions and related domestic or foreign regulations may limit the use and adoption of our solutions and adversely affect our business.

Personal privacy, information security, and data protection are significant issues in the United States, Europe, and many other jurisdictions where we have operations or offer our products. The regulatory framework governing the collection, processing, storage and use of confidential and proprietary business information and personal data is rapidly evolving. The United States federal and various state and foreign governments have adopted or proposed requirements regarding the collection, distribution, use, security and storage of personally identifiable information and other data relating to individuals, and federal and state consumer protection laws are being applied to enforce regulations related to the online collection, use and dissemination of data.

Further, many foreign countries and governmental bodies, including the European Union (“EU”), where we conduct business, have laws and regulations concerning the collection and use of personal data obtained from their residents or by businesses operating within their jurisdiction. These laws and regulations often are more restrictive than those in the United States. Laws and regulations in these jurisdictions apply broadly to the collection, use, storage, disclosure, and security of data that identifies or may be used to identify or locate an individual, such as names, email addresses and, in some jurisdictions, IP addresses.

We also expect that there will continue to be new proposed laws, regulations and industry standards concerning privacy, data protection and information security in the United States, the EU, and other jurisdictions. For example, the European Commission adopted a General Data Protection Regulation (the “GDPR”) that became fully effective on May 25, 2018, superseding prior EU data protection legislation, imposing more stringent EU data protection requirements, and providing for greater penalties for noncompliance. The United Kingdom has enacted a Data Protection Act and legislation referred to as the UK GDPR that substantially implements the GDPR. We are evaluating obligations imposed on us by the GDPR and we may be required to incur substantial expense in order to make significant changes to our product and business operations in connection with obtaining and maintaining compliance with the GDPR and similar legislation, such as the UK GDPR and UK Data Protection Act, all of which may adversely affect our revenue and product sales. California has enacted legislation, the California Consumer Privacy Act (the “CCPA”) that, among other things, requires covered companies to provide disclosures to California consumers, and afford such consumers abilities to opt-out of certain sales of personal information. Additionally, the California Privacy Rights Act (the “CPRA”), was approved by California voters in the November 2020 election. The CPRA significantly modifies the CCPA, creating obligations relating to consumer data which began on January 1, 2022, with enforcement beginning July 1, 2023. Additionally, other U.S. states continue to propose, and in certain cases adopt, privacy-focused legislation. For example, Virginia, Colorado, Utah, and Connecticut have all enacted legislation that has become, or will become, effective in  2023. We cannot yet fully determine the impact these or future laws, regulations and standards may have on our business, but they may require us to modify our data processing practices and policies and to incur substantial costs and expenses in an effort to comply. Privacy, data protection and information security laws and regulations are often subject to differing interpretations, may be inconsistent among jurisdictions, and may be alleged to be inconsistent with our current or future practices. Additionally, we may be bound by contractual requirements applicable to our collection, use, processing, and disclosure of various types of data, including personal data, and may be bound by, or voluntarily comply with, self-regulatory or other industry standards relating to these matters. These and other requirements could reduce demand for our products, increase our costs, impair our ability to grow our business, or restrict our ability to store and process data or, in some cases, impact our ability to offer our service in some locations and may subject us to liability. Any failure or perceived failure to comply with applicable laws, regulations, industry standards, and contractual obligations may adversely affect our business. Further, in view of new or modified federal, state, or foreign laws and regulations, industry standards, contractual obligations and other legal obligations, or any changes in their interpretation, we may find it necessary or desirable to fundamentally change our business activities and practices or to expend significant resources to modify our product and otherwise adapt to these changes. We may be unable to make such changes and modifications in a commercially reasonable manner or at all, and our ability to develop new products and features could be limited.

The costs of compliance with and other burdens imposed by laws, regulations and standards may limit the use and adoption of our service and reduce overall demand for it, or lead to significant fines, penalties, or liabilities for any noncompliance. Privacy, information security, and data protection concerns, whether valid or not valid, may inhibit market adoption of our platform, particularly in certain industries and foreign countries.

We expect that we will experience long and unpredictable sales cycles, which may impact our operating results.

The sales cycle between initial customer contact and execution of a contract or license agreement with a customer or purchaser of our products can vary widely. We expect that our sales cycles will be long and unpredictable due to several factors, including but not limited to:


The need to educate potential customers about our patent rights and our product and service capabilities;

14


Our customers’ willingness to invest potentially substantial resources and modify their network infrastructures to take advantage of our products;


Our customers’ budgetary constraints;


The timing of our customers’ budget cycles;


Delays caused by customers’ internal review processes; and


Long sales cycles that may increase the risk that our financial resources are exhausted before we are able to generate significant revenue.

In addition, potential customers of our products include local, state, federal and foreign government authorities. Sales to government authorities can be extended and unpredictable. Government authorities generally have complex budgeting, purchasing, and regulatory processes that govern their capital spending, and their spending is likely to be adversely impacted by economic conditions. In addition, in many instances, sales to government authorities may require field trials and may be delayed by the time it takes for government officials to evaluate multiple competing bids, negotiate terms, and award contracts.

For these reasons, the sales cycle associated with our products is subject to a number of significant risks that are beyond our control. Consequently, if customer orders are not realized or delayed, our revenues and results of operations could be materially and adversely affected.

If we are unable to expand our revenue sources or establish, sustain, grow, or replace relationships with a diversified customer base, our revenues may be limited.

We currently generate revenue from a limited number of customers that have entered settlement and license agreements. Our software products and services currently generating limited revenue, and it will take time for us to grow our installed user base and generate new customers. Additionally, there is no guarantee that we will be able to derive revenue from new customers, sustain or increase revenue from existing customers or replace customers from whom we currently generate revenue. As a result, our revenue may be limited or static.

We have limited technical resources and are at an early stage in commercialization of our VirnetX One™ platform and software products.

Part of our business includes the internal development of commercial products we seek to monetize. This aspect of our business may require significant capital, time and resources and we cannot guarantee that it will be successful or meet our expectations. As such, we have a small technical team, which may limit our ability to rapidly adapt our product to customer requirements or add new product features to maintain our competitive edge and drive adoption.

Based on the scale of our technical resources, our limited historical financial data upon which to base our projected revenue or planned operating expenses related to our software products and services, we may not be able to effectively:

Generate revenues or profit from product sales;

Drive adoption of our products;

Attract and retain customers for our products;

Provide appropriate levels of customer training and support for our products;

Implement an effective marketing strategy to promote awareness of our products;

Focus our research and development efforts in areas that generate returns on our efforts;

Anticipate and adapt to changes in our market; or

Protect our products from any system failures or other breaches.

In addition, a high percentage of our expenses are and will continue to be fixed. Accordingly, if we do not generate revenue as and when anticipated, our losses may be greater than expected and our operating results will suffer.

15

Our products are highly technical and may contain undetected errors, which could cause harm to our reputation and adversely affect our business.

Our products are highly technical and complex and, when deployed, may contain errors or defects. Despite testing, some errors in our products may only be discovered after a product has been installed and used by customers. Any errors or defects discovered in our products after commercial release could result in failure to achieve market acceptance, loss of revenue or delay in revenue recognition, loss of customers and increased service and warranty cost, any of which could adversely affect our business, operating results, and financial condition. In addition, we could face claims for product liability, tort, or breach of warranty, including claims relating to changes to our products made by our channel partners. The performance of our products could have unforeseen or unknown adverse effects on the networks over which they are delivered as well as on third-party applications and services that utilize our services, which could result in legal claims against us, harming our business. Furthermore, we expect to provide implementation, consulting, and other technical services in connection with the implementation and ongoing maintenance of our products, which typically involves working with sophisticated software, computing, and communications systems. We expect that our contracts with customers will contain provisions relating to warranty disclaimers and liability limitations, which may not be upheld. Defending a lawsuit, regardless of its merit, is costly and may divert management’s attention and adversely affect the market’s perception of us and our products. In addition, if our business liability insurance coverage proves inadequate or future coverage is unavailable on acceptable terms or at all, our business, operating results, and financial condition could be adversely impacted.

Malfunctions of third-party communications infrastructure, hardware and software expose us to a variety of risks that we cannot control.

Our business will depend upon, among other things, the capacity, reliability, security, and unimpeded access of the infrastructure owned by third parties that we will use to deploy our offerings. We have no control over the operation, quality, or maintenance of a significant portion of that infrastructure or whether those third parties will upgrade or improve their equipment. We depend on these companies to maintain the operational integrity of our connections. If one or more of these companies is unable or unwilling to supply or expand its levels of service to us in the future, our operations could be severely interrupted. Also, to the extent that the number of users of networks utilizing our current or future products suddenly increases, the technology platform and secure hosting services which will be required to accommodate a higher volume of traffic may result in slower response times or service interruptions. System interruptions or increases in response time could result in a loss of potential or existing users and, if sustained or repeated, could reduce the appeal of the networks to users. In addition, users depend on real-time communications; outages caused by increased traffic could result in delays and system failures. These types of occurrences could cause users to perceive that our solution does not function properly and could therefore adversely affect our ability to attract and retain licensees, strategic partners, and customers.

System failure or interruption or our failure to meet increasing demands on our systems could harm our business.

The success of our license and service offerings will depend on the uninterrupted operation of various systems, secure data centers and other computer and communication networks that we establish. To the extent, the number of users of networks utilizing our future products suddenly increases, the technology platform and hosting services which will be required to accommodate a higher volume of traffic may result in slower response times, service interruptions or delays or system failures. Our systems and operations will also be vulnerable to damage or interruption from, among other things:

Power loss, transmission cable cuts and other telecommunications failures;

Damage or interruption caused by fire, earthquake, and other natural disasters;

Computer viruses or software defects; and

Physical or electronic break-ins, sabotage, intentional acts of vandalism, terrorist attacks and other events beyond our control.

System interruptions or failures and increases or delays in response time could result in a loss of potential or existing users and, if sustained or repeated, could reduce the appeal of the networks to users. These types of occurrences could cause users to perceive that our solution does not function properly and could therefore adversely affect our ability to attract and retain licensees, strategic partners, and customers.

16

Any significant problem with our systems or operations could result in lost revenue, customer dissatisfaction or lawsuits against us. A failure in the operation of our secure domain name registration system could result in the inability of one or more registrars to register and maintain secure domain names for a period of time. A failure in the operation or update of the master directory that we plan to maintain could result in deletion or discontinuation of assigned secure domain names for a period of time. The inability of the registrar systems we establish, including our back-office billing and collections infrastructure, and telecommunications systems to meet the demands of an increasing number of secure domain name requests could result in substantial degradation in our customer support service and our ability to process registration requests in a timely manner.

Our ability to sell our solutions will be dependent on the quality of our technical support, and our failure to deliver high-quality technical support services could have a material adverse effect on our sales and results of operations.

If we do not effectively assist our customers in deploying our products, succeed in helping our customers quickly resolve post deployment issues and provide effective ongoing support, or if potential customers perceive that we may not be able achieve to the foregoing, our ability to sell our products would be adversely affected, and our reputation with current and potential customers could be harmed. In addition, as we expand our operations internationally, our technical support team will face additional challenges, including those associated with delivering support, training, and documentation in languages other than English. Our failure to deliver and maintain high-quality technical support services to our customers could result in customers choosing to use our competitors’ products and support services instead of ours in the future.

Our international expansion will subject us to additional costs and risks, and our plans may not be successful.

We expect to expand our presence internationally in Japan and elsewhere through third party arrangements such as international partnerships, joint ventures and potentially establishing international subsidiaries and offices. Our international expansion may present challenges and risks, including those inherent in international operations, to us and may require significant attention from management. For example, the COVID-19 pandemic has and could continue to disrupt and slow our international expansion and partnership efforts, as our international partners’ businesses could continue to be disrupted. We may not be successful in our international partnerships, expansion efforts, and we may incur significant operating expenses in our efforts to expand internationally.

The global COVID-19 pandemic may harm our business, financial condition, and results of operations.

The COVID-19 pandemic continues to impact worldwide economic activity and financial markets. In light of the uncertain and rapidly evolving situation relating to the spread of COVID-19, we continue to take precautionary measures intended to minimize the risk of the virus to our employees, our customers, and other third parties with whom we interact. We continue to require all employees to work remotely and have also suspended all non-essential travel worldwide for our employees. While we have a distributed workforce and our employees are accustomed to working remotely or working with other remote employees, our workforce is not fully remote. Our employees and consultants travel frequently to establish and maintain relationships with one another, our customers and prospective customers, partners, and investors. Although we continue to monitor the situation and may adjust our current policies as more information and public health guidance becomes available, temporarily suspending travel and restricting the ability to do business in person could negatively affect our customer success efforts, sales and marketing efforts, challenge our ability to enter into customer contracts in a timely manner, slow down our recruiting efforts, or create operational or other challenges, any of which could harm our business, financial condition and results of operations. Furthermore, if a natural disaster, power outage, connectivity issue, or other event occurred that impacted our employees’ ability to work remotely, it may be difficult or, in certain cases, not possible, for us to continue our business for a substantial period of time. The increase in remote working may also result in consumer privacy, IT security and fraud concerns as well as increase our exposure to potential wage and hour issues. In addition, the COVID-19 pandemic may disrupt the operations of our customers, partners, suppliers, and other third-party providers for an indefinite period of time, including as a result of travel restrictions, adverse effects on budget planning processes, and/or business shutdowns, all of which could negatively impact our business, financial condition, and results of operations. More generally, despite continued actions taken by governments and businesses to attempt to contain and treat the disease, and related variants, including the distribution and administration of effective vaccines, the COVID-19 pandemic could continue to adversely affect economies and financial markets globally, potentially leading to an economic downturn, which could decrease technology spending and adversely affect our business.

Risks Related to Ownership of Our Common Stock

We do not regularly pay dividends on our common stock and thus stockholders must look to appreciation of our common stock to realize a gain on their investments.

17

Our dividend policy is within the discretion of our Board of Directors and will depend upon various factors, including our business, financial condition, results of operations, capital requirements, and investment opportunities. We therefore cannot make assurances that our Board of Directors will determine to pay regular or special dividends in the future. Accordingly, unless our Board of Directors determines to pay dividends, stockholders will be required to look to appreciation of our common stock to realize a gain on their investment, which may not occur.

The exercise of our outstanding stock options, warrants, and RSUs and issuance of new shares would result in a dilution of our current stockholders’ voting power and an increase in the number of shares eligible for future resale in the public market which may negatively impact the market price of our stock.

The exercise of our outstanding vested stock options, warrants, and RSUs would dilute the ownership interests of our existing stockholders. As of December 31, 2022, we had outstanding options, warrants and RSUs to purchase an aggregate of 7,393,130 shares of common stock representing approximately 10% of our total shares outstanding of which 5,260,355 were vested and therefore exercisable. To the extent outstanding stock options or warrants are exercised, additional shares of common stock will be issued, existing stockholders’ percentage voting interests will decline and the number of shares eligible for resale in the public market will increase. Such increase may have a negative effect on the value or market trading price of our common stock.

Because ownership of our common stock is concentrated, investors may have limited influence on stockholder decisions.

As of December 31, 2022, our executive officers and directors beneficially owned approximately 14% of our outstanding common stock. Because of their beneficial ownership interest, our officers and directors could significantly influence stockholder actions of which you disapprove or that are contrary to your interests. This ability to exercise significant influence could prevent or significantly delay another company from acquiring or merging with us.

Our protective provisions in our amended and restated certificate of incorporation and bylaws could make it difficult for a third party to successfully acquire us even if you would like to sell your stock to them.

We have a number of protective provisions in our amended and restated certificate of incorporation and bylaws that could delay, discourage, or prevent a third party from acquiring control of us without the approval of our Board of Directors. These protective provisions include:

A staggered Board of Directors: This means that only one or two directors (since we have a five-person Board of Directors) will be up for election at any given annual meeting. This has the effect of delaying the ability of stockholders to affect a change in control of us because it would take two annual meetings to effectively replace a majority of the Board of Directors.

Blank check preferred stock: Our Board of Directors has the authority to establish the rights, preferences, and privileges of our 10,000,000 authorized, but unissued, shares of preferred stock. Therefore, this stock may be issued at the discretion of our Board of Directors with preferences over your shares of our common stock in a manner that is materially dilutive to you. In addition, blank check preferred stock can be used to create a “poison pill” which is designed to deter a hostile bidder from buying a controlling interest in our stock without the approval of our Board of Directors. We have not adopted such a “poison pill;” but our Board of Directors has the ability to do so in the future, very rapidly and without stockholder approval.

Advance notice requirements for director nominations and for business to be brought before stockholder meetings: Stockholders wishing to submit director nominations or raise matters to a vote of the stockholders must provide notice to us within very specific date windows and in very specific form in order to have the matter voted on at a stockholder meeting. This has the effect of giving our Board of Directors and management more time to react to stockholder proposals generally and could also have the effect of permitting us to disregard a stockholder proposal to the extent such proposal is not submitted in accordance with the bylaws.

No stockholder actions by written consent: No stockholder or group of stockholders may take action by written consent. Along with the advance notice requirements described above, this provision also gives our Board of Directors and management more time to react to proposed stockholder actions.

Super majority requirement for stockholder amendments to the bylaws: Stockholder proposals to alter or amend our bylaws or to adopt new bylaws can only be approved by the affirmative vote of at least 66 2/3% of the outstanding shares of our common stock.

No ability of stockholders to call a special meeting of the stockholders: A special meeting of the stockholders, other than as required by statute, may be called at any time by the Board of Directors, or by the chairman of the board, or by the president, but a special meeting may not be called by any other person or persons and any power of stockholders to call a special meeting of stockholders is specifically denied. This could mean that stockholders, even those who represent a significant percentage of our shares of common stock, may need to wait for the annual meeting before nominating directors or raising other business proposals to be voted on by the stockholders.

18

In addition, the provisions of Section 203 of the Delaware General Corporation Law govern us. These provisions may prohibit large stockholders, particularly those owning 15% or more of our outstanding voting stock, from merging or combining with us for a certain period of time.

These and other provisions in our amended and restated certificate of incorporation, our bylaws and under Delaware law could discourage potential takeover attempts, reduce the price that investors might be willing to pay for shares of our common stock in the future and result in the market price being lower than it would be without these provisions.

Our amended and restated bylaws designate a state or federal court located within the State of Delaware as the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders’ ability to choose the judicial forum for disputes with us or our directors, officers, or employees.

Our amended and restated bylaws provide that, unless we consent in writing to the selection of an alternative forum, the sole and exclusive forum for (1) any derivative action or proceeding brought on our behalf, (2) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, stockholders, officers, or other employees to us or our stockholders, (3) any action arising pursuant to any provision of the Delaware General Corporation Law, or our amended and restated certificate of incorporation or amended and restated bylaws or (4) any other action asserting a claim that is governed by the internal affairs doctrine shall be the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, another State court in Delaware or the federal district court for the District of Delaware), in all cases subject to the court having jurisdiction over indispensable parties named as defendants.

However, notwithstanding the exclusive forum provisions, our amended and restated bylaws explicitly state that they would not preclude the filing of claims brought to enforce any liability or duty created under federal securities laws, including the Securities Act or the Exchange Act.

Any person or entity purchasing or otherwise acquiring any interest in any of our securities shall be deemed to have notice of and consented to this provision. This exclusive-forum provision may limit a stockholder’s ability to bring a claim in a judicial forum of its choosing for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers, and other employees. If a court were to find this exclusive-forum provision in our amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving the dispute in other jurisdictions, which could harm our results of operations.

Our failure to meet the continued listing requirements of the NYSE could result in a delisting of our common stock.

If we fail to satisfy the continued listing requirements of the NYSE, such as the corporate governance requirements or the minimum closing bid price requirement, the NYSE may take steps to delist our common stock. Such a delisting would likely have a negative effect on the price of our common stock and would impair your ability to sell or purchase our common stock when you wish to do so. In the event of a delisting, we can provide no assurance that any action taken by us to restore compliance with listing requirements would allow our common stock to become listed again, stabilize the market price or improve the liquidity of our common stock, prevent our common stock from dropping below the NYSE minimum bid price requirement or prevent future non-compliance with NYSE’s listing requirements.

General Risk Factors

We may need to raise additional capital to support our business growth, and this capital may be dilutive, may cause our stock price to drop or may not be available on acceptable terms, if at all.

We may need to raise additional capital, which may not be available to us when needed or may not be available on terms acceptable to us, to support our business growth or to respond to business opportunities, challenges, or unforeseen circumstances, including sales under our past and any future shelf registration statements. Our ability to obtain additional capital, if and when required, will depend on our business plans, investor demand, our operating performance, the condition of the capital markets, the terms of our current contractual obligations and other factors.

If we raise additional funds through the issuance of equity, equity-linked or debt securities, including those under our past and any future shelf registration statements, those securities may have rights, preferences, or privileges senior to the rights of our common stock, and our existing stockholders may experience dilution. Additionally, we are unable to predict the future success of any future offerings. Sales of a substantial number of shares of our common stock in the public market, or the perception that these sales or other financings might occur, could depress the market price of our common stock, and could also impair our ability to raise capital through the sale of additional equity securities. If we issue debt securities or incur indebtedness, we could experience increased future payment obligations and a need to comply with restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. If we are unable to obtain additional capital or are unable to obtain additional capital on satisfactory terms, our ability to continue to support our business growth or to respond to business opportunities, challenges, or other circumstances could be adversely affected, and our business may be harmed.

19

The departure of Kendall Larsen, our Chief Executive Officer and President, and/or other key personnel could compromise our ability to execute our strategic plan and materially harm our business.

Our success depends on the skills, experience, and performance of our key personnel. Due to the specialized nature of our business and limited staff, we are particularly dependent on Kendall Larsen, our Chief Executive Officer and President. We have no employment agreements with any of our key executives that prevent them from leaving us at any time. In addition, we do not maintain key person life insurance for any of our officers or key employees. The loss of Mr. Larsen, or our failure to retain other key personnel or plan for the succession of key personnel, would jeopardize our ability to execute our strategic plan and materially harm our business.

We will need to recruit and retain additional qualified personnel to successfully grow our business.

Our future success will depend, in part, on our ability to attract and retain qualified engineering, operations, marketing, sales and executive personnel. Inability to attract and retain such personnel could adversely affect our business. Competition for engineering, operations, marketing, sales, and executive personnel is intense, particularly in the technology and Internet sectors and in the regions where we conduct our business. We may need to invest significant amounts of cash and equity to attract and retain employees and expend significant time and resources to identify, recruit, train and integrate such employees, and we may never realize returns on these investments. Additionally, we can provide no assurance that we will attract or retain such personnel.

We have incurred and will continue to incur significant costs as a result of operating as a public company, and our management will be required to continue to devote substantial time to various compliance initiatives.

The Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, as well as other rules implemented by the SEC and the New York Stock Exchange (“NYSE”), impose various requirements on public companies, including requiring changes in corporate governance practices. These and proposed corporate governance laws and regulations under consideration may further increase our compliance costs. If compliance with these various legal and regulatory requirements diverts our management’s attention from other business concerns, it could have a material adverse effect on our business, financial condition, and operating results. The Sarbanes-Oxley Act requires, among other things, that we assess the effectiveness of our internal control over financial reporting annually and disclosure controls and procedures quarterly. If we are unable to assert in any future reporting periods that our internal control over financial reporting is effective (or if our independent registered public accounting firm is unable to express an opinion on the effectiveness of our internal controls), such as our restatement of our previously issued consolidated financial statements, we could lose investor confidence in the accuracy and completeness of our financial reports, which would have an adverse effect on our share price.

Although we believe that we currently maintain effective control over our disclosures and procedures and internal control over financial reporting, we have identified in the past and may identify in the future deficiencies regarding the design and effectiveness of our system of internal control over financial reporting. If we experience any material weaknesses in our internal control over financial reporting in the future or are unable to provide unqualified management or attestation reports about our internal controls, we may be unable to meet financial and other reporting deadlines and may incur costs associated with remediation, and any of which could cause our share price to decline. Moreover, if we identify deficiencies in our internal control over financial reporting that are deemed to be material weaknesses in future periods, the market price of our common stock could decline, and we could be subject to potential delisting by the NYSE and review by the NYSE, the SEC, or other regulatory authorities, which would require the expenditure by us of additional financial and management resources. As a result, our shareholders could lose confidence in our financial reporting, which would harm our business and the market price of our common stock.

There are inherent uncertainties involved in estimates, judgments and assumptions used in the preparation of financial statements in accordance with U.S. GAAP. Any changes in estimates, judgments and assumptions could have a material adverse effect on our business, financial condition, and operating results.

The preparation of financial statements in accordance with U.S. GAAP involves making estimates, judgments and assumptions that affect reported amounts of assets (including intangible assets), liabilities and related reserves, revenues, expenses, and income. Estimates, judgments, and assumptions are inherently subject to change in the future, and any such changes could result in corresponding changes to the amounts of assets, liabilities, revenues, expenses, and income. Any such changes could have a material adverse effect on our business, financial condition, and operating results.

Our results of operations and financial condition could be materially affected by the enactment of legislation implementing changes in the U.S. or foreign taxation of international business activities or the adoption of other tax reform policies.

20

As we expand the scale of our international business activities, any changes in the U.S. or foreign taxation of such activities may increase our worldwide effective tax rate and harm our business, results of operations, and financial condition. For example, the current administration has proposed to increase the U.S. corporate income tax rate, increase U.S. taxation of international business operations, and impose a global minimum tax which has agreement from, many countries and the Organization for Economic Cooperation and Development. Also, starting in fiscal year 2022, the Tax Cuts and Jobs Act requires taxpayers to capitalize research and development expenditures and to amortize domestic expenditures over five years and foreign expenditures over fifteen years. If Congress does not modify or repeal this provision, it may reduce our cash flows beginning in fiscal year 2022. Other countries have recently proposed or recommended changes to existing tax laws or have enacted new laws that could impact our tax obligations in countries where we do business or cause us to change the way we operate our business. The impact of future changes to U.S. and foreign tax law on our business is uncertain and could be adverse, and we will continue to monitor and assess the impact of any such changes on our future tax provisions.

War, terrorism, other acts of violence, or natural or manmade disasters may affect the markets in which we operate, our clients and our service delivery.

Our business may be adversely affected by instability, disruption, or destruction in a geographic region in which we operate, regardless of cause, including war, terrorism, riot, civil insurrection, or social unrest, and natural or manmade disasters, including famine, flood, fire, earthquake, storm, or pandemic events and spread of disease, such as the COVID-19 pandemic and the Russian invasion of Ukraine. Such events may cause our customers to delay their decisions on spending for the services we provide and give rise to sudden significant changes in regional and global economic conditions and cycles. These events may also pose risks to our personnel and to physical facilities and operations, which could adversely affect our financial results.

Trading in our common stock is limited and the price of our common shares may be subject to substantial volatility.

Our common stock is currently listed on the NYSE and was previously listed on the NYSE American LLC (formerly the NYSE MKT LLC). Over the past years, the market price of our common stock has experienced significant fluctuations. Between January 1, 2022, and December 31, 2022, the adjusted closing price on the NYSE for our common stock ranged between $1.03 and $2.69 per share. The price of our common stock may continue to be volatile as a result of several factors, some of which are beyond our control. These factors include, but not limited to, the following:

Developments or lack thereof in any then-outstanding litigation;

Quarterly variations in our operating results;

Large purchases or sales of common stock or derivative transactions related to our stock;

Actual or anticipated announcements of new products or services by us or competitors;

General conditions in the markets in which we compete; and

General social, political, economic, and financial conditions, including the significant volatility in the global financial markets.

In addition, we believe there has been and may continue to be substantial trading in derivatives of our stock, including short selling activity or related similar activities, which are beyond our control, and which may be beyond the full control of the SEC and Financial Institutions Regulatory Authority or “FINRA.” While the SEC and FINRA rules prohibit some forms of short selling and other activities that may result in stock price manipulation, such activity may nonetheless occur without detection or enforcement. We have held conversations with regulators concerning trading activity in our stock; however, there can be no assurance that should there be any illegal manipulation in the trading of our stock, it will be detected, prosecuted, or successfully eradicated. Significant short selling market manipulation could cause our stock trading price to decline, to become more volatile, or both.

The market price of our common stock has been and may continue to be volatile, and you could lose all or part of your investment.

The trading price of our common stock has been historically volatile and is likely to continue to be volatile. Factors that could cause fluctuations in the market price of our common stock include, but are not limited to the following:

Price and volume fluctuations in the overall stock market from time to time, including fluctuations due to general economic uncertainty or negative market sentiment;

Volatility in the market prices and trading volumes of companies in our industry or companies that investors consider comparable;

Changes in operating performance and stock market valuations of other companies generally, or those in our industry;

21

Sales of shares of our common stock by us or our stockholders;

Failure of securities analysts to maintain coverage of us, changes in financial estimates by securities analysts who follow us, or our failure to meet these estimates or the expectations of investors;

The financial projections we may provide to the public, any changes in those projections or our failure to meet those projections;

Announcements by us or our competitors of new products or services;

The public’s reaction to court rulings, our press releases, other public announcements, and filings with the SEC;

Rumors and market speculation involving us or other companies in our industry;

Actual or anticipated changes in our results of operations;

Actual or anticipated developments in our business, our competitors’ businesses, or the competitive landscape generally;

Litigation involving us, our industry or both, or investigations by regulators into our operations or those of our competitors;

Announced or completed acquisitions of businesses or technologies by us or our competitors;

New laws or regulations or new interpretations of existing laws or regulations applicable to our business;

Changes in accounting standards, policies, guidelines, interpretations, or principles;

Any significant change in our management;

Other events or factors, including those resulting from war, incidents of terrorism, pandemics, including the  COVID-19 pandemic, or responses to these events;  and

General economic conditions such as rising inflation or interest rates in the United States and slow or negative growth of our markets.

Further, in recent years the stock markets have experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many companies. These fluctuations often have been unrelated or disproportionate to the operating performance of those companies. In addition, the stock prices of many technology companies have experienced wide fluctuations that have often been unrelated to the operating performance of those companies. These broad market and industry fluctuations, as well as general economic, political and market conditions such as recessions, government shutdowns, global pandemics (such as the COVID-19 pandemic), interest rate changes the stability of the EU including, but not limited to, effects from the exit of the United Kingdom, the Russia-Ukraine conflict  or international currency fluctuations, may cause the market price of our common stock to decline. In the past, following periods of volatility in the overall market and the market price of a particular company’s securities, securities class action litigation has often been instituted against these companies.

We have broad discretion in how we apply our funds, and we may not use these funds effectively, which could affect our results of operations and cause our stock price to decline.

Our management has broad discretion in the application of our existing cash, cash equivalents and investments and could spend these funds in ways that do not improve our results of operations or enhance the value of our common stock. Pending their use, we may invest our available funds in a manner that does not produce income or that loses value. The failure by our management to apply our available funds effectively could result in financial losses that could cause the price of our common stock to decline and delay the development of our products.

In addition, an entity that, among other things, is or holds itself out as being engaged primarily, or proposes to engage primarily, in the business of investing, reinvesting, owning, trading, or holding certain types of securities would be deemed an Investment Company under the Investment Company Act of 1940 (the “1940 Act”). If we do not manage our investments and business in a manner that meets the requirements for an exemption under the 1940 Act, we may be deemed to be an investment company under the 1940 Act and subject to additional limitations on operating our business including limitations on the issuance of securities, which may make it difficult for us to raise capital.

The market price of our common stock may decline because our operating results may not be consistent and may be difficult to predict.

Our operating results have fluctuated in the past due to several factors. We expect that our future operating results may also fluctuate due to the same or similar factors. We had a net loss of $36.3 million for the year ended December 31, 2022. We had a net loss of $42.9 million for the year ended December 31, 2021 and net income of $280.4 million for the year ended December 31, 2020. As of December 31, 2022, we had an accumulated deficit of $87.2 million. The following include some of the factors that may cause our operating results to fluctuate:

22

The outcome of actions to enforce our intellectual property rights currently in progress or that we may undertake in the future, and the timing thereof;

The impact of the COVID-19 pandemic on our sales cycle and results;

The amount and timing of receipt of license fees from potential infringers, licensees, or customers;

The rate of adoption of our patented technologies;

The number of new license arrangements we may execute, or that may expire, within a particular period and the scope of those licenses, including the number of our patents which are licensed, the extent of prior infringement of our patent rights, royalty rates, timing of payment obligations, expiration date etc.;

The success of a licensee in selling products that use our patented technologies; and

The amount and timing of expenses related to our patent filings and enforcement proceedings, including litigation, related to our intellectual property rights.

These fluctuations may make our business particularly difficult to manage, adversely affect our business and operating results, make our operating results difficult for investors to predict and, further, cause our results to fall below investor’s expectations and adversely affect the market price of our common stock.

Risks Related to Restatement of our Consolidated Financial Statements

We have had to restate our previously issued consolidated financial statements and as part of that process identified a material weakness in our internal control over financial reporting as of December 31, 2021. If we are unable to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results in a timely manner, which may adversely affect investor confidence in us and materially and adversely affect our business and results of operations.

On May 9, 2022, the audit committee of our board of directors concluded, after discussion with our management and Farber Hass Hurley LLP, our auditors, that the previously issued financial statements during the year ended December 31, 2021 (1) should no longer be relied upon due to an overstatement of the Company’s deferred tax asset, as described in the Amendment, and (2) require restatement. As part of the restatement process, we identified a material weakness in our internal control over financial reporting. We remediated our procedures to address the material weakness and believe the enhanced control is operating effectively. Any failure to maintain effective internal controls could adversely impact our ability to report our financial position and results of operations on a timely and accurate basis. If our financial statements are not accurate, investors may not have a complete understanding of our operations. Likewise, if our financial statements are not filed on a timely basis, we could be subject to sanctions or investigations by the stock exchange on which our ordinary shares and other securities are listed, the SEC or other regulatory authorities. In either case, there could result a material adverse effect on our business. Ineffective internal controls could also cause investors to lose confidence in our reported financial information which could have a negative effect on the trading price of our stock. There is also the potential for litigation or other disputes which may include, among others, claims invoking the federal and state securities laws, contractual claims or other claims arising from the restatement and the material weakness in our internal control over financial reporting and the preparation of our financial statements.

23

Item 1B.
Unresolved Staff Comments.

None.

Item 2.
Properties

Our principal executive offices are located at 308 Dorla Court, Suite 206, Zephyr Cove, Nevada, 89448. We lease this property, which comprises approximately 2,090 square feet of office space, from a third party for a term that ends in October 2023. We have no other properties and believe that our office facility is suitable and appropriately supports our current business needs.

Item 3.
Legal Proceedings

See Note 12 in the notes to our consolidated financial statements.

Item 4.
Mine Safety Disclosure

Not applicable.

PART II

Item 5.
Market for the Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Market Information

Our common stock currently trades under the symbol “VHC” on the NYSE.

Holders of Record

As of March 28, 2023, we had 56 stockholders of record. Because many of our shares of common stock are held of record by brokers and other institutions on behalf of stockholders, we are unable to estimate the total number of beneficial stockholders represented by such record holders.

Dividend Policy

See Note 8 in the notes to our consolidated financial statements.

Since our founding as a public company in 2007, each time we have been successful in generating cash relating to the successful outcome of litigation, we have made a special distribution to common shareholders. In 2010, a distribution of $0.50 per common share closely followed a litigation outcome that resulted in our receipt of $200 million. In 2020, a distribution of $1.00 per share closely followed a litigation outcome that resulted in our receipt of $454 million. On March 30, 2023, we declared a special cash dividend of $1.00 per common share to be paid on or about April 17, 2023 to shareholders of record on April 10, 2023. Including this special dividend, over the course of VirnetX’s history as a public company VirnetX will have distributed over $165.9 million in cash to shareholders. If the final outcome of the Apple II litigation described elsewhere in this Form 10-K results in proceeds to us, we are committed to distribute to our shareholders a substantial portion of the net proceeds (after legal costs, licensing costs and taxes), after the case concludes.

Securities Authorized for Issuance under Equity Compensation Plan

See Item 12, Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters for information regarding securities authorized for issuance.

Stock Performance Graph

This performance graph shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or incorporated by reference into any filing of VirnetX Holding Corporation under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. The stock price performance reflected on this graph is not necessarily indicative of future stock price performance. See the disclosure in part I, Item 1A. “Risk Factors” for more information regarding the risks in investing in our common stock.

The graph below matches VirnetX Holding Corp’s cumulative 5-Year total shareholder return on common stock with the cumulative total returns of the S&P 500 index and the RDG Technology Composite index. The graph tracks the performance of a $100 investment in our common stock and in each index (with the reinvestment of all dividends) from 12/31/2017 to 12/31/2022.
 
24

graphic

 
12/17
12/18
12/19
12/20
12/21
12/22
             
VirnetX Holding Corp
100.00
64.86
102.70
186.05
95.98
47.99
S&P 500
100.00
95.62
125.72
148.85
191.58
156.89
RDG Technology Composite
100.00
93.54
133.70
208.19
249.39
169.48

Recent Sales of Unregistered Securities

None.

Item 6.
[Reserved]

Item 7.
Management’s Discussion and Analysis of Financial Condition and Results of Operations

The Company

We are an Internet security software and technology company with industry-leading, patented technology for Zero Trust Network Access (“ZTNA”) based secure network communications. VirnetX’s software and technology solutions, including its Secure Domain Name Registry and Technology, VirnetX One™, War Room™, VirnetX Matrix™, and Gabriel Connection Technology™, are designed to be device- and location-independent, and enable a secure real-time communication environment for all types of enterprise applications, services, and critical infrastructures. Our technology generates secure connections on a “single-click” basis, significantly simplifying the deployment network security solutions by eliminating the need for end-users to enter any encryption information. Our portfolio of intellectual property is the foundation of our business model. We currently own approximately 205 total patents and pending applications, including 72 U.S. patents/patent applications and 133 foreign patents/validations/pending applications. Our patent portfolio is primarily focused on securing real-time communications over the Internet, and related services, and is used in all our technology and products, some of which were acquired by our principal operating subsidiary; VirnetX, Inc., from Leidos, Inc., or Leidos, (f/k/a Science Applications International Corporation, or SAIC) in 2006.

25

Our product portfolio includes sophisticated technologies, products and services that are available for sale worldwide. Our next-generation, VirnetX One™ platform builds upon our patented Secure Domain Names and GABRIEL Connection Technology™ to further enhance the security and efficiency of our patented secure communication links. VirnetX One™ is a security-as-a-service platform that protects enterprise applications, services, and infrastructure from cyber-attacks. Our platform allows enterprises of all sizes to add a “security umbrella” as an added layer on top of their existing infrastructure to further reduce risk and bolster security against ever-growing cyberthreats to data, operating systems, other infrastructure products and gateway security controllers.

Our War Room™ software product provides an industry leading, safe, and secure video conferencing meeting environment where sensitive communications and data is invisible to those not authorized to view it. War Room™ validates permissions of all the users, and devices requesting access to any secure meeting room prior to granting access. We believe our War Room™ will be an attractive solution for government agencies and law enforcement as well as all professional sectors such as legal, financial, and medical where limiting access to confidential data is a critical requirement.

Our VirnetX Matrix™ product provides superior security for internet-enabled enterprise applications and their connected devices, and for control systems currently deployed by those enterprises (e.g., file servers, data back-up systems, VPN/firewalls). VirnetX MatrixTM provides a true “zero-trust” access protection, “single-click” ease of use, and is a highly-effective added layer of protection that is deployed simply, without the need for changes to an enterprise’s existing, in-place infrastructure. We believe VirnetX Matrix™ is an attractive solution for all businesses, cloud and on-premise application service providers, and OEMs, looking to improve visibility and management of their networks to mitigate morphing attacks on their networks and for real time access and control of their users.

Our GABRIEL Collaboration Suite™ is a set of communication applications and tools that use our GABRIEL Secure Communication Platform™. It enables seamless and secure cross platform communications between devices that are enrolled in our “VIRNETX SECURED” network and have our software installed. Our GABRIEL Collaboration Suite™ is available for download and free trial, for Android, iOS, Windows, Linux, and Mac OS X platforms, at https://virnetx.com.

During the fourth quarter of 2022 and the first quarter of 2023, the Company engaged in discussions with certain third-parties to pitch the capabilities of VirnetX One™. The Company believes that these parties have interest to secure devices and systems in areas such as healthcare, finance, legal, oil and gas, medical, law enforcement, national defense and related support industries. Although there can be no assurance in this regard, the Company believes that there are opportunities for Company products sales directly to, resale arrangements with and/or adoption as vendor standards by, one or more of these third parties.

We have an ongoing licensing program under which we offer licenses to a portion of our patent portfolio, technology, and software, including our secure domain name registry service, to domain infrastructure providers, communication service providers as well as to system integrators. Our GABRIEL Connection Technology™ License is offered to original equipment manufacturer (“OEM”) customers who want to adopt the GABRIEL Connection Technology™ as their solution for establishing secure connections using secure domain names within their products. We have developed GABRIEL Connection Technology™ Software Development Kit (“SDK”) to assist with rapid integration of these techniques into existing software implementations. Customers who want to develop their own implementation of the VirnetX patented techniques for supporting secure domain names, or other techniques that are covered by our patent portfolio for establishing secure communication links, can purchase a patent license. The number of patents licensed, and therefore the cost of the patent license to the customer, will depend upon which of the patents are used in a particular product or service. These licenses will typically include an initial license fee, as well as an ongoing royalty.

We expect to continue to launch new and enhanced security platforms, software products, and services based on our GABRIEL Connection Technology™. We expect to provide updates to new and existing customers as they are released to the public. Many small and medium businesses have installed our software products in their corporate networks. We intend to continue to expand our customer base with targeted promotions and direct sales initiatives.

Our employees include the core development team behind our patent portfolio, technology, and software. Some members of this team have worked together for over twenty years and were on same team that invented and developed this technology while working at Leidos. The team has continued its research and development work and expanded the set of patents we acquired in 2006 from Leidos, into a larger patent portfolio. This portfolio now serves as the foundation of our products, services, and our licensing business. It is expected to generate most of our future revenue in license fees and royalties. We intend to continue our efforts to develop new products and technologies and further strengthen and expand our patent portfolio. We intend to continue using an outsourced and leveraged model to maintain efficiency and manage costs as we grow our licensing business by, for example, offering incentives to early licensing targets or asserting our rights forum of our patents.

26

Our employees include the core development team behind our patent portfolio, technology, and software. Some members of this team have worked together for over twenty years and were on same team that invented and developed this technology while working at Leidos. The team has continued its research and development work and expanded the set of patents we acquired in 2006 from Leidos, into a larger patent portfolio. This portfolio now serves as the foundation of our products, services, and our licensing business. It is expected to generate most of our future revenue in license fees and royalties. We intend to continue our efforts to develop new products and technologies and further strengthen and expand our patent portfolio. We intend to continue using an outsourced and leveraged model to maintain efficiency and manage costs as we grow our licensing business by, for example, offering incentives to early licensing targets or asserting our rights for use of our patents.

Litigation

We are subject to various legal proceedings, the outcomes of which are inherently uncertain. We record any potential gains related to legal proceedings only after cash is collected. We record a liability when it is probable that a loss has been incurred and the amount is reasonably estimable, the determination of which requires significant judgment. Resolution of legal matters in a manner inconsistent with management’s expectations could have a material impact on our financial condition and operating results. See Note 12 in the notes to our consolidated financial statements for more information.

Commitments and Related Party Transactions

We lease our offices under an operating lease with a third party expiring in October 2023. We recognize rent expense on a straight-line basis over the term of the lease.

We entered into a service agreement for the use of an aircraft from K2 Investment Fund LLC (“LLC”) for business travel for our employees. We incurred approximately $1,123, $791, and $324 in rental fees and reimbursements to the LLC in 2022, 2021 and 2020, respectively. We pay for the Company’s business usage of the aircraft and have no right to purchase. Our Chief Executive Officer and Chief Administrative Officer are the managing partners of the LLC and control the equity interests of the LLC. We entered into a 12-month non-exclusive agreement with the LLC for use of the plane at a rate of $8 per flight hour, with no minimum usage requirement. The agreement contains other terms and conditions normal in such transactions and can be cancelled by either us or the LLC with 30 days’ notice. The agreement renews on an annual basis unless terminated by either party. Neither party has exercised their termination rights.

Critical Accounting Policies and Estimates

The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reported period. The critical accounting policies we employ in the preparation of our consolidated financial statements are those which involve income taxes, fair value of financial instruments and stock-based compensation.

Use of Estimates

We prepare our consolidated financial statements in accordance with U.S. GAAP. In doing so, we have to make estimates and assumptions that affect our reported amounts of assets, liabilities, revenues, and expenses, as well as related disclosure of contingent assets and liabilities. In some cases, we could reasonably have used different accounting policies and estimates. In some cases, changes in the accounting estimates are reasonably likely to occur from period to period. Accordingly, actual results could differ materially from our estimates. To the extent that there are material differences between these estimates and actual results, our financial condition or results of operations will be affected. We base our estimates on past experience and other assumptions that we believe are reasonable under the circumstances, and we evaluate these estimates on an ongoing basis. We refer to accounting estimates of this type as critical accounting policies and estimates, which we discuss further below. We have reviewed our critical accounting policies and estimates with the Audit Committee of our Board of Directors.

27

Income Taxes

We account for income taxes using the asset and liability method. The asset and liability method require the recognition of deferred tax assets and liabilities for expected future tax consequences of temporary differences that currently exist between the tax basis and financial reporting basis of our assets and liabilities. We calculate current and deferred tax provisions based on estimates and assumptions that could differ from actual results reflected on the income tax returns filed during the following years. Adjustments based on filed returns are recorded when identified in the subsequent years. The effect on deferred taxes for a change in tax rates is recognized in income in the period that the tax rate change is enacted. In assessing our deferred tax assets, we consider whether it is more likely than not that all or some portion of the deferred tax assets will not be realized.

A valuation allowance is provided for deferred income tax assets when, in our judgment, based upon currently available information and other factors, it is more likely than not that all or a portion of such deferred income tax assets will not be realized. The determination of the need for a valuation allowance is based on an on-going evaluation of current information including, among other things, historical operating results, estimates of future earnings in different taxing jurisdictions and the expected timing of the reversals of temporary differences. We believe the determination to record a valuation allowance to reduce a deferred income tax asset is a significant accounting estimate because it is based, among other things, on an estimate of future taxable income in the United States and certain other jurisdictions, which is susceptible to change and may or may not occur, and because the impact of adjusting a valuation allowance may be material. In determining when to release the valuation allowance established against our net deferred income tax assets, we consider all available evidence, both positive and negative. We continually assess our ability to generate sufficient taxable income during future periods in which our deferred tax assets may be realized. If and when we believe it is more likely than not that we will recover our deferred tax assets, we will reverse the valuation allowance if any, as an income tax benefit in our statements of operations.

We account for our uncertain tax positions in accordance with U.S. GAAP. The U.S. GAAP method of accounting for uncertain tax positions utilizes a two-step approach to evaluate tax positions. Step one, recognition, requires evaluation of the tax position to determine if based solely on technical merits it is more likely than not to be sustained upon examination. Step two, measurement, is addressed only if a position is more likely than not to be sustained. In step two, the tax benefit is measured as the largest amount of benefit, determined on a cumulative probability basis, which is more likely than not to be realized upon ultimate settlement with tax authorities. If a position does not meet the more likely than not threshold for recognition in step one, no benefit is recorded until the first subsequent period in which the more likely than not standard is met, the issue is resolved with the taxing authority, or the statute of limitations expires. Positions previously recognized are derecognized when we subsequently determine the position no longer is more likely than not to be sustained. Evaluation of tax positions, their technical merits, and measurements using cumulative probability are highly subjective management estimates. Actual results could differ materially from these estimates.

Fair Value

Fair value is the price that would result from an orderly transaction between market participants at the measurement date. A fair value hierarchy prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement). Level 2 measurements utilize either directly or indirectly observable inputs in markets other than quoted prices in active markets.

Our financial instruments are stated at amounts that equal, or approximate, fair value. When we estimate fair value, we utilize market data or assumptions that we believe market participants would use in pricing the financial instrument, including assumptions about risk and inputs to the valuation technique. We use valuation techniques, primarily the income and market approach, which maximizes the use of observable inputs and minimize the use of unobservable inputs for recurring fair value measurements.

Stock-based Compensation

We account for stock-based compensation using the fair value recognition method in accordance with U.S. GAAP. We recognize these compensation costs on a straight-line basis over the requisite service period of the award, which is generally a vesting term of 4 years. We recognize forfeitures, if any, when they occur. In addition, we record stock-based compensation expense for awards granted to non-employees at fair value of the consideration received or the fair value of the equity instruments issued, as they vest, over the performance period. See Note 6 in the notes to our consolidated financial statements for more information.

28

Results of Operations (all amounts in this section are expressed in thousands)

Revenue

   
2022
   
2021
   
2020
 
Revenue
 
$
48
   
$
35
   
$
302,636
 

Revenue generated in 2022 was $48, compared to $35 in 2021 and $302,636 in 2020. In 2020, we collected a lump sum payment of $454,034 from Apple, Inc., as a result of a favorable court decision relating to a patent infringement case. The one-time payment included past royalties, damages for willful infringement, interest, court costs and attorneys’ fees. See Note 2 in the notes to our consolidated financial statements for more information.

We recognized royalty revenue as part of license agreements entered into with customers during the patent infringement actions (see “Litigation”). These revenues relate to payment for use of our patented technology prior to the signing of a license agreement, and royalty payments after the execution of the license agreements.

Licensing Costs

   
2022
   
2021
   
2020
 
Licensing costs
 
$
(4
)
 
$
(9,083
)
 
$
90,101
 

Included in operating expenses for 2020 was $90,101 in licensing costs we incurred in conjunction with the proceeds received in the case regarding Apple, Inc. discussed above. Accrued licensing costs of $9,083 were reversed in the year ended December 31, 2021, as a result of litigation. See Note 12 in the notes to our consolidated financial statements for more information.

Research and Development Expenses

   
2022
   
2021
   
2020
 
Research and Development
 
$
6,406
   
$
5,577
   
$
8.830
 

Research and development costs include expenses paid to outside development consultants and compensation-related expenses for our engineering staff. Research and development costs are expensed as incurred.

Our research and development expenses in 2022 were $6,406 compared to $5,577 in 2021 and $8,830 in 2020. The fluctuation in 2022 compared to 2021 and 2020 was primarily due to changes in engineering staff compensation costs.

Selling, General and Administrative Expenses

   
2022
   
2021
   
2020
 
Selling, General and Administrative
 
$
15,722
   
$
52,715
   
$
45,812
 

Selling, general and administrative expenses include compensation costs for management and administrative personnel, as well as expenses for outside legal, accounting, and consulting services.

Our selling, general and administrative expenses in 2022 were $15,722 compared to $52,715 in 2021 and $45,812 in 2020. The volatility within selling, general and administrative expenses was primarily due to legal fees related to cases involving the defense of our patents. Legal fees were $3,305, $41,828, and $30,699 in 2022, 2021 and 2020, respectively and represented approximately 21% of selling, general and administrative expenses for 2022 compared to 80% for 2021 and 67% for 2020.

29

Gain on Settlement

In 2020, we recorded a gain of $41,271 pursuant to a favorable court ruling in the case regarding Apple, Inc. discussed above. See Note 2 in the notes to our consolidated financial statements for more information.

Interest and Other Income, net

   
2022
   
2021
   
2020
 
Interest and Other Income
 
$
1,848
   
$
48
   
$
108,288
 

Interest and other income in 2022 was $1,848 compared to $48 in 2021 and $108,288 in 2020. During 2020 we received interest of $108,221 pursuant to a favorable court ruling in the case with Apple, Inc. discussed above. See Note 2 in the notes to our consolidated financial statements for more information.

Effective Income Tax Rate

A reconciliation of the United States federal statutory income tax rate to our effective income tax rate is as follows:


 
Year Ended
December 31,
2022
   
Year Ended
December 31,
2021
   
Year Ended
December 31,
2020
 
United States federal statutory rate
   
21.00
%
   
21.00
%
   
21.00
%
State taxes, net of federal benefit
   
(0.55
)%
   
(0.31
)%
   
0.17
%
Valuation allowance
   
(91.21
)%
   
%
   
(12.22
)%
Stock based compensation
   
(9.44
%)
   
(6.68
)%
   
(0.01
)%
R&D Credit
   
1.22
%
   
0.19
%
   
(0.21
)%
Other
   
(0.29
)%
   
(1.57
)%
   
0.06
%
Effective income tax rate
   
(79.27
)%
   
12.63
%
   
8.79
%

The Company’s effective tax rate for 2022 and 2020 was substantially lower than the statutory Federal income tax rate primarily due to the change in valuation allowance. The Company’s effective tax rate for 2021 was substantially lower than the statutory Federal income tax rate primarily due to the effect of stock based compensation, including expiring options.

Liquidity and Capital Resources

As of December 31, 2022, our cash and cash equivalents totaled $86,561 and our short-term investments totaled $65,462 compared to $142,018 and $27,254, respectively, as of December 31, 2021.

We expect that our cash and cash equivalents and short-term investments as of December 31, 2022, will be sufficient to fund our current level of selling, general and administration costs, including legal expenses and provide related working capital for the foreseeable future. Over the longer term, we expect to derive the majority of our future revenue from license fees and royalties associated with our patent portfolio, technology, software and secure domain name registry and product sales in the United States and other markets around the world.

Universal Shelf Registration and ATM Offering

On July 30, 2018 we filed a universal shelf registration statement on SEC Form S-3. This replacement registration statement was declared effective by the SEC on August 16, 2018. We used the universal shelf proceeds for development and marketing of our software product and services, and general corporate purposes. The universal shelf registration expired August 16, 2021.
 
Item 7A.
Quantitative and Qualitative Disclosures about Market Risk

Consistent with the rules applicable to “smaller reporting companies,” we have omitted the information required by Item 7A.
 
30

Item 8.
Financial Statements and Supplementary Data

Set forth below, are the audited consolidated financial statements for our company accompanied by all reports thereon of Farber Hass Hurley LLP (PCAOB No. 223)
 
FINANCIAL STATEMENTS
 
Financial Statements Index
 
 
Page
   
32
34
35
36
37
38
39

31

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Board of Directors and
Stockholders of VirnetX Holding Corporation
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of VirnetX Holding Corporation (the “Company”) as of December 31, 2022 and 2021, and the related consolidated statements of operations, comprehensive income (loss), stockholders’ equity, and cash flows for each of the years in the three-year period ended December 31, 2022, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2022, in conformity with accounting principles generally accepted in the United States of America.
Basis for Opinion
These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
Critical Audit Matter
The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.
 
32

 
Deferred Taxes
   
Description of the Matter
As discussed in Notes 2 and 10 to the financial statements, the Company recorded a full valuation allowance against the deferred tax assets as of December 31, 2022. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized in the future. In assessing the ability to realize the deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The valuation allowance is based on management’s estimates of future taxable income and available evidence, both positive and negative.

Our determination that valuation of deferred taxes is a critical audit matter results from the significant judgment by management when assessing the ability to realize the deferred tax assets, particularly as it relates to estimates of future taxable income. This in turn led to a high degree of auditor judgment, subjectivity, and effort in performing procedures relating to management’s assessment of the realizability of deferred tax assets.
 
 
Audit Procedures
Our principal audit procedures related to the Company’s deferred taxes included the following:

-     We evaluated management’s estimates of future taxable income which involved evaluating whether the estimates used by management were reasonable considering the current and past performance of the respective entity and whether the estimates were consistent with evidence obtained in other areas of the audit.
-     We evaluated management’s assessment of all relevant data that would affect management’s estimate of future taxable income to determine whether a deferred tax asset would be realized in the future.
/s/ Farber Hass Hurley LLP
We have served as the Company’s auditor since 2008.
Chatsworth, California
March 31, 2023

33

VIRNETX HOLDING CORPORATION
CONSOLIDATED BALANCE SHEETS
(in thousands, except share amounts)

 
As of
December 31, 2022
   
As of
December 31, 2021
 
ASSETS
           
Current assets:
           
Cash and cash equivalents
 
$
86,561
   
$
142,018
 
Investments available for sale
   
65,462
     
27,254
 
Accounts receivables
   
14
     
17
 
Prepaid income tax
   
     
 
Prepaid expenses and other current assets
   
224
     
203
 
Total current assets
   
152,261
     
169,492
 
Prepaid expenses and other assets
   
703
     
1,056
 
Property and equipment, net
   
11
     
18
 
Deferred tax asset
   
     
15,950
 
Total assets
 
$
152,975
   
$
186,516
 
LIABILITIES AND STOCKHOLDERS’ EQUITY
               
Current liabilities:
               
Accounts payable and accrued liabilities
 
$
373
   
$
338
 
Accrued payroll and related expenses
   
311
     
270
 
Accrued licensing costs
   
     
355
 
Other liabilities, current
   
47
     
58
 
Total current liabilities
   
731
     
1,021
 
                 
Other liabilities
   
     
46
 
Total liabilities
   
731
     
1,067
 
Commitments and contingencies (Note 4)
   
     
 
                 
Stockholders’ equity:
               
Preferred stock, par value $0.0001 per share Authorized: 10,000,000 shares at December 31, 2022 and December 31, 2021, Issued and outstanding: 0 shares at December 31, 2022 and December 31, 2021
   
     
 
Common stock, par value $0.0001 per share
               
Authorized: 100,000,000 shares at December 31, 2022 and December 31, 2021, Issued and outstanding: 71,424,650 and 71,232,856 shares, at December 31, 2022 and December 31, 2021, respectively
   
7
     
7
 
Additional paid-in capital
   
239,746
     
236,445
 
Accumulated deficit
   
(87,195
)
   
(50,935
)
Accumulated other comprehensive loss
   
(314
)
   
(68
)
Total stockholders’ equity
   
152,244
     
185,449
 
Total liabilities and stockholders’ equity
 
$
152,975
   
$
186,516
 

See accompanying notes to consolidated financial statements.

34

VIRNETX HOLDING CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except share and per share amounts)

 
 
Year Ended
December 31, 2022
   
Year Ended
December 31, 2021
   
Year Ended
December 31, 2020
 
Revenue
 
$
48
   
$
35
   
$
302,636
 
Operating expense:
                       
Licensing costs
   
(4
)
   
(9,083
)
   
90,101
 
Research and development
   
6,406
     
5,577
     
8,830
 
Selling, general and administrative expenses
   
15,722
     
52,715
     
45,812
 
Total operating expense
   
22,124
     
49,209
     
144,743
 
(Loss) income from operations
   
(22,076
)
   
(49,174
)
   
157,893
 
Gain on settlement
   
     
     
41,271
 
Interest and other income, net
   
1,848
     
48
     
108,288
 
(Loss) income before taxes
   
(20,228
)
   
(49,126
)
   
307,452
 
Income tax (provision) benefit
   
(16,032
)
   
6,205
     
(27,023
)
Net (loss) income
 
$
(36,260
)
 
$
(42,921
)
 
$
280,429
 
Basic (loss) earnings per share
 
$
(0.51
)
 
$
(0.60
)
 
$
3.96
 
Diluted (loss) earnings per share
 
$
(0.51
)
 
$
(0.60
)
 
$
3.92
 
Weighted average shares outstanding basic
   
71,335,046
     
71,159,458
     
70,850,311
 
Weighted average shares outstanding diluted
   
71,335,046
     
71,159,458
     
71,615,843
 

See accompanying notes to consolidated financial statements.

35

VIRNETX HOLDING CORPORATION
CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME
(in thousands)

 
 
Year Ended
December 31, 2022
   
Year Ended
December 31, 2021
   
Year Ended
December 31, 2020
 
Net (loss) income
 
$
(36,260
)
 
$
(42,921
)
 
$
280,429
 
Other comprehensive (loss) income, net of tax:
                       
Change in unrealized (loss) gain on investments, net
   
(246
)
   
(51
)
   
 
Change in foreign currency translation, net
   
     
(4
)
   
1
 
Total other comprehensive (loss) gain, net of tax
   
(246
)
   
(55
)
   
1
 
Comprehensive (loss) income
 
$
(36,506
)
 
$
(42,976
)
 
$
280,430
 

See accompanying notes to consolidated financial statements.

36

VIRNETX HOLDING CORPORATION
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(in thousands, except share amounts)

    Year Ended
 
    December 31,
 
   
2022
   
2021
   
2020
 
Total shareholders’ equity, beginning balances
 
$
185,449
   
$
224,437
   
$
5,628
 
                         
Common stock and additional paid-in capital:
                       
Beginning balances
   
236,452
     
232,464
     
223,244
 
Common stock issued for cash, net
   
     
     
4,488
 
Common stock issued for options/RSUs, net
   
(29
)
   
(196
)
   
690
 
Warrants issued for services
   
     
     
104
 
Stock-based compensation
   
3,330
     
4,184
     
3,938
 
Ending balances
   
239,753
     
236,452
     
232,464
 
                         
Accumulated deficit (retained earnings)
                       
Beginning balances
   
(50,935
)
   
(8,014
)
   
(217,602
)
Net (loss) income
   
(36,260
)
   
(42,921
)
   
280,429
 
Dividends
   
     
     
(70,841
)
Ending balances
   
(87,195
)
   
(50,935
)
   
(8,014
)
                         
Accumulated other comprehensive loss:
                       
Beginning balances
   
(68
)
   
(13
)
   
(14
)
Change in unrealized investment (loss) gain, net
   
(246
)
   
(51
)
   
 
Change in foreign currency translation, net
   
     
(4
)
   
1
 
Ending balances
   
(314
)
   
(68
)
   
(13
)
                         
Total shareholders’ equity, ending balances
 
$
152,244
   
$
185,449
   
$
224,437
 
                         
Dividends per share
  $     $     $ 1.00  

See accompanying notes to consolidated financial statements.

37

VIRNETX HOLDING CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)

 
 
Year Ended
December 31, 2022
   
Year Ended
December 31, 2021
   
Year Ended
December 31, 2020
 
Cash flows from operating activities:
 
                 
Net (loss) income
 
$
(36,260
)
 
$
(42,921
)
 
$
280,429
 
Adjustments to reconcile net (loss) income to
net cash from operating activities:
                       
Depreciation
   
7
     
4
     
5
 
Stock-based compensation
   
3,330
     
4,184
     
3,938
 
Amortization of warrants issuance costs
   
     
34
     
69
 
Deferred income taxes
   
16,032
   
(6,901
)
   
(9,049
)
Changes in assets and liabilities:
                       
Prepaid expenses and other current assets
   
331
     
271
     
419
 
Accounts payable and accrued liabilities
   
35
     
(316
)
   
(692
)
Other liabilities
   
(54
)
   
60
     
(193
)
Accrued payroll and related expenses
   
41
     
50
     
(67
)
Accrued licensing costs
   
(355
)
   
(9,083
)
   
9,438
 
Accounts receivable
   
3
     
(9
)
   
(3
)
Prepaid income taxes
   
(3
)
   
2,905
     
(2,905
)
Net cash (used in) provided by operating activities
   
(16,893
)
   
(51,722
)
   
281,389
 
Cash flows from investing activities:
                       
Purchase of property and equipment
   
     
(11
)
   
 
Purchase of investments
   
(67,070
)
   
(26,332
)
   
(33,065
)
Proceeds from sale or maturity of investments
   
28,535
     
27,371
     
7,112
 
Net cash (used in) provided by investing activities
   
(38,535
)
   
1,028
     
(25,953
)
Cash flows from financing activities:
                       
Proceeds from exercise of options
   
     
     
1,046
 
Proceeds from sale of common stock
   
     
     
4,488
 
Dividends paid on common stock
   
     
     
(70,841
)
Taxes paid on cashless exercise of restricted stock units
   
(29
)
   
(196
)
   
(356
)
Net cash used in financing activities
   
(29
)
   
(196
)
   
(65,663
)
Net (decrease) increase in cash and cash equivalents
   
(55,457
)
   
(50,890
)
   
189,773
 
Cash and cash equivalents, beginning of period
   
142,018
     
192,908
     
3,135
 
Cash and cash equivalents, end of period
 
$
86,561
   
$
142,018
   
$
192,908
 
Cash paid for income taxes
 
$
2
   
$
2
   
$
38,977
 

See accompanying notes to consolidated financial statements.

38

VIRNETX HOLDING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands except share, per share and per device amounts)

Note 1 − Formation and Business of the Company

VirnetX Holding Corporation, which we refer to as “we”, “us”, “our”, “the Company” or “VirnetX”, is engaged in the business of commercializing a portfolio of patents. We seek to derive revenue from selling our software products including VirnetX War Room™ and VirnetX Matrix™ and licensing our technology, including VirnetX One™, and our secure domain name technology GABRIEL Connection Technology™, to various original equipment manufacturers (“OEMs”) and others, that use our technologies in the development and manufacturing of their own products within the IP-telephony, mobility, fixed-mobile convergence, and unified communications markets or who seek to secure their systems and applications. During 2020, we had revenues from settlement of a patent infringement dispute whereby we received consideration for past sales of licensee that utilized our technology, where there was no prior patent license agreement.

Our portfolio of intellectual property is the foundation of our business model. We currently own approximately 205 total patents and pending applications, including 72 U.S. patents/patent applications and 133 foreign patents/validations/pending applications. Our patent portfolio is primarily focused on securing real-time communications over the Internet, as well as related services such as the establishment and maintenance of a secure domain name registry. Our patented methods also have additional applications in the key areas of device operating systems and network security. The subject matter of all our U.S and foreign patents and pending applications relates generally to securing communications over the Internet and such covers all our technology and other products. Some of our issued U.S. and foreign patents expire at various times during the period from 2023 to 2034.

Note 2 − Summary of Significant Accounting Policies

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reported period. The critical accounting policies we employ in the preparation of our consolidated financial statements are those which involve impairment of long-lived assets, income taxes, fair value of financial instruments and stock-based compensation.

Use of Estimates

We prepare our consolidated financial statements in accordance with U.S. GAAP. In doing so, we have to make estimates and assumptions that affect our reported amounts of assets, liabilities, revenues, and expenses, as well as related disclosure of contingent assets and liabilities. In some cases, we could reasonably have used different accounting policies and estimates. In some cases, changes in the accounting estimates are reasonably likely to occur from period to period. Accordingly, actual results could differ materially from our estimates. To the extent that there are material differences between these estimates and actual results, our financial condition or results of operations will be affected. We base our estimates on past experience and other assumptions that we believe are reasonable under the circumstances, and we evaluate these estimates on an ongoing basis. We refer to accounting estimates of this type as critical accounting policies and estimates, which we discuss further below. We have reviewed our critical accounting policies and estimates with the Audit Committee of our Board of Directors.

Basis of Consolidation

The consolidated financial statements include the accounts of VirnetX Holding Corporation and our wholly owned subsidiaries. All intercompany balances and transactions have been eliminated.

39

Revenue Recognition

The Company derives revenue from licensing and royalty fees from contracts with customers which often span several years. We account for this revenue in accordance with Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. Our revenue arrangements may consist of multiple-element arrangements, with revenue for each unit of accounting recognized as the product or service is delivered to the customer.

With the licensing of our patents, performance obligations are generally satisfied at a point in time as work is complete when our patent rights are transferred to our customers. We generally have no further obligation to our customers regarding our technology.

Certain contracts may require our customers to enter into a hosting arrangement with us and for these arrangements, revenue is recognized over time, generally over the life of the servicing contract.

The Company actively monitors and enforces its intellectual property (“IP”) rights, including seeking appropriate compensation from third parties that utilize the Company’s IP without a license. As a result, the Company may, from time to time, receive payments as part of a settlement or compensation for a patent infringement dispute. Proceeds received are allocated to each element identified in the settlement or compensation, based on the fair value of each element. Generally, settlements and compensation may include the following elements: the value of a license or royalty agreement, cost reimbursement, damages, and interest. Elements identified related to licensing and royalty are recognized as revenue. Elements identified as reimbursed costs are generally recorded as a reduction to the reported expenses. Elements identified as damages or interest are generally recorded in other income in the condensed consolidated statement of operations. During the year ended December 31, 2020, the Company collected a lump sum payment of $454,034 from Apple, Inc., because of a favorable court decision relating to a patent infringement case. The court decision identified the following as the basis of the award: $302,428 for past royalties, $41,271 in damages for willful infringement, $108,221 for interest, and $2,114 in reimbursement for court costs and attorney’s fees. Elements of the payment were recognized in the Company’s condensed consolidated statement of operations as follows:

Classification of Payment Received in the Company’s Condensed Consolidated Statement of Operations
 
Year Ended:
 
 
December 31, 2020
 
Revenue (royalties)
 
$
302,428
 
Operating expenses: selling, general and administrative (reimbursed litigation costs)
   
2,114
 
Other income: gain (willful infringement)
   
41,271
 
Other income: interest income (pre- and post-judgment interest)
   
108,221
 
Total cash received
 
$
454,034
 

Licensing Costs

Included in operating expenses are licensing costs we incurred in conjunction with the proceeds received from Apple Inc., pursuant to a favorable court decision relating to a patent infringement case.

Contingent Gains

ASC Topic 450-30-25, Contingent Gains, prohibits recognition of contingent gains until realized. Accordingly, we do not record contingent gains ahead of such realization. Management generally considers any such gains as realized only upon the collection of cash.

Cash and Cash Equivalents

We consider all highly liquid investments purchased with original maturities of three months or less at the date of purchase to be cash equivalents. Our cash and cash equivalents are not subject to significant interest rate risk due to the short maturities of these investments.

Investments

Investments are classified as available-for-sale and are recorded at fair market value. Unrealized gains and losses are reported as other comprehensive income. Realized gains and losses are recorded in income in the period they are realized using specific identification of each security’s cost basis. We invest our excess cash primarily in highly liquid debt instruments including corporate, government and federal agency securities, with contractual maturities less than two years. By policy, we limit the amount of credit exposure to any one issuer.

40

Concentration of Credit Risk and Other Risks and Uncertainties

Our cash and cash equivalents are primarily maintained at two major financial institutions in the United States. Deposits held with these financial institutions may exceed the amount of insurance provided on such deposits. A portion of those balances are insured by the Federal Deposit Insurance Corporation, or FDIC. In 2022, we had, at times, funds that were uninsured. We do not believe that we are subject to any unusual financial risk beyond the normal risk associated with commercial banking relationships. We have not experienced any losses on our deposits of cash and cash equivalents.

Fair Value

The carrying amounts of our financial instruments, including cash equivalents, accounts payable, and accrued liabilities, approximate fair value because of their generally short maturities.

Property and Equipment

Property and equipment are stated at historical cost, less accumulated depreciation, and amortization. Depreciation and amortization are computed using the accelerated and straight-line methods over the estimated useful lives of the assets, which range from five to seven years. Repair and maintenance costs are charged to expense as incurred.

Leases

The Company determines if an arrangement is a lease at inception in accordance with ASC Topic 842. Operating lease right-of-use (“ROU”) assets are included in Prepaid expenses, and other assets on the Condensed Consolidated Balance Sheets. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term.

Intangible Assets

We record intangible assets at cost, less accumulated amortization. Amortization of intangible assets is provided over their estimated useful lives, which can range from 3 to 15 years, on either a straight-line basis or as revenue is generated by the assets.

Impairment of Long-Lived Assets

We identify and record impairment losses on long-lived assets used in operations when events and changes in circumstances indicate that the carrying amount of an asset might not be recoverable, but not less than annually. Recoverability is measured by comparison of the anticipated future net undiscounted cash flows to the related assets’ carrying value. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the asset.

Research and Development

Research and development costs include expenses paid to outside development consultants and compensation related expenses for our engineering staff. Research and development costs are expensed as incurred.

41

Income Taxes

We account for income taxes using the asset and liability method. The asset and liability method requires the recognition of deferred tax assets and liabilities for expected future tax consequences of temporary differences that currently exist between the tax basis and financial reporting basis of our assets and liabilities. We calculate current and deferred tax provisions based on estimates and assumptions that could differ from actual results reflected on the income tax returns filed during the following years. Adjustments based on filed returns are recorded when identified in the subsequent years. The effect on deferred taxes for a change in tax rates is recognized in income in the period that the tax rate change is enacted. In assessing our deferred tax assets, we consider whether it is more likely than not that all or some portion of the deferred tax assets will not be realized.

The 2017 U.S. Tax Cuts and Jobs Act changes IRC Section 174, regarding capitalization of book research and development (“R&D”) expenses for income tax purposes.  Effective for tax years beginning in 2022 IRC Section 174 requires the capitalization of book R&D expenses which are capitalized and amortized over 5 years for domestic R&D expenses and over 15 years for foreign R&D expenses.  To date there has been limited guidance from the IRS on how to quantify the amount of book R&D expenses subject to capitalization, including the indirect expenses supporting the R&D function.  Due to the limited guidance, some assumptions were made in our estimates.

A valuation allowance is provided for deferred income tax assets when, in our judgment, based upon currently available information and other factors, it is more likely than not that all or a portion of such deferred income tax assets will not be realized. The determination of the need for a valuation allowance is based on an on-going evaluation of current information including, among other things, historical operating results, estimates of future earnings in different taxing jurisdictions and the expected timing of the reversals of temporary differences. We believe the determination to record a valuation allowance to reduce a deferred income tax asset is a significant accounting estimate because it is based, among other things, on an estimate of future taxable income in the United States and certain other jurisdictions, which is susceptible to change and may or may not occur, and because the impact of adjusting a valuation allowance may be material. In determining when to release the valuation allowance established against our net deferred income tax assets, we consider all available evidence, both positive and negative. We continually assess our ability to generate sufficient taxable income during future periods in which our deferred tax assets may be realized. If and when we believe it is more likely than not that we will recover our deferred tax assets, we will reverse the valuation allowance as an income tax benefit in our statements of operations.

We account for our uncertain tax positions in accordance with U.S. GAAP, which utilizes a two-step approach to evaluate tax positions. Step one, recognition, requires evaluation of the tax position to determine if based solely on technical merits it is more likely than not to be sustained upon examination. Step two, measurement, is addressed only if a position is more likely than not to be sustained. In step two, the tax benefit is measured as the largest amount of benefit, determined on a cumulative probability basis, which is more likely than not to be realized upon ultimate settlement with tax authorities. If a position does not meet the more likely than not threshold for recognition in step one, no benefit is recorded until the first subsequent period in which the more likely than not standard is met, the issue is resolved with the taxing authority, or the statute of limitations expires. Positions previously recognized are derecognized when we subsequently determine the position no longer is more likely than not to be sustained. Evaluation of tax positions, their technical merits, and measurements using cumulative probability are highly subjective management estimates. Actual results could differ materially from these estimates.

Stock-Based Compensation

We account for stock-based compensation using the fair value recognition method in accordance with U.S. GAAP. We recognize these compensation costs on a straight-line basis over the requisite service period of the award, which is generally a vesting term of 4 years. We recognize forfeitures, if any, when they occur. In addition, we record stock-based compensation expense for awards granted to non-employees at fair value of the consideration received or the fair value of the equity instruments issued, as they vest, over the performance period (See Note 6 - Stock-Based Compensation).

Earnings per Share

Basic earnings per share are computed by dividing earnings available to common stockholders by the weighted average number of outstanding common shares during the period. Diluted earnings per share is computed by dividing net income by the weighted average number of shares outstanding during the period increased to include the number of additional shares of common stock that would have been outstanding if the potentially dilutive securities had been issued.

42

New Accounting Pronouncements

In December 2019, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2019-12 Income Taxes (Topic 740). The amendments in this ASU simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify U. S. GAAP for other areas of Topic 740 by clarifying and amending existing guidance. The amendments in this ASU are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. We adopted this ASU on January 1, 2021 and there was no material impact on our financial position or cash flows as a result.

Note 3 − Property and Equipment
 
Our major classes of property and equipment were as follows:

 
December 31
 
   
2022
   
2021
 
Office furniture
 
$
79
   
$
79
 
Computer equipment
   
92
     
92
 
Total
   
171
     
171
 
Less accumulated depreciation
   
(160
)
   
(153
)
Total property and equipment, net
 
$
11
   
$
18
 

Depreciation expense for 2022, 2021 and 2020 was $7, $4, and $5, respectively.

Note 4 − Commitments, Contingencies and Related Party Transactions

We lease our offices under an operating lease with a third party expiring in October 2023. We recognize rent expense on a straight-line basis over the term of the lease. Rent expense was $54 in 2022 and $56 for both 2021 and 2020. Future minimum rents due under the lease total $46 in 2023, when the lease expires.

We entered into a service agreement for the use of an aircraft from K2 Investment Fund LLC (“LLC”) for business travel for our employees. We incurred approximately $1,123, $791, and $324 in rental fees and reimbursements to the LLC in 2022, 2021 and 2020, respectively. We pay for the Company’s business usage of the aircraft and have no right to purchase. Our Chief Executive Officer and Chief Administrative Officer are the managing partners of the LLC and control the equity interests of the LLC. We entered into a 12-month non-exclusive agreement with the LLC for use of the plane at a rate of $8 per flight hour, with no minimum usage requirement. The agreement contains other terms and conditions normal in such transactions and can be cancelled by either us or the LLC with 30 days’ notice. The agreement renews on an annual basis unless terminated by either party. Neither party has exercised their termination rights.

Note 5 − Stock Plan

We have an equity incentive plan for employees and others called the VirnetX Holding Corporation 2013 Equity Incentive Plan (the “2013 Plan”), which has been approved by our stockholders. To the extent that any award should expire, become un-exercisable or is otherwise forfeited, the shares subject to such award will again become available for issuance under the 2013 Plan. The 2013 Plan provides for the granting of stock options and restricted stock units purchase rights (“RSUs”) to our employees and consultants. Stock options granted under the 2013 Plan may be incentive stock options or nonqualified stock options. Incentive stock options (“ISOs”) may only be granted to our employees (including officers and directors). Nonqualified stock options (“NSOs”) and stock purchase rights may be granted to our employees and consultants. The 2013 Plan expires in 2023.

43

In April 2021, the Board approved an amendment and restatement of the 2013 Plan to, among other things, increase the shares reserved under the Plan by 2,500,000 shares (the “Plan Amendment”). Our stockholders approved the Plan Amendment at the 2021 Annual Meeting of the Stockholders held on June 3, 2021. The 2013 Plan generally provides for the granting of shares of our common stock, including stock options and RSUs. Options may be granted under the 2013 Plan with an exercise price determined by our Board of Directors, or a duly appointed committee thereof, provided, however, that the exercise price of an option granted to any employee shall be not less than 100% of the fair market value at the date of grant in the case of ISOs or 85% of the fair market value at the date of grant in the case of an NSO. The exercise price of an ISO or NSO granted to one of our Named Executive Officers shall not be less than 100% fair market value of the shares at the date of grant and the exercise price of an ISO granted to a 10% shareholder shall not be less than 110% of the fair market value of the shares on the date of grant. Stock options granted under the 2013 Plan typically vest over four years and have a 10-year term. All RSUs are considered to be granted at the fair value of our stock on the date of grant because they have no exercise price. RSUs typically vest over four years. As of December 31, 2022, there were 1,563,345 shares available for grant under the 2013 Plan.

Note 6 − Stock-Based Compensation

The following tables summarize information and activity under the plan for the indicated periods.

Options Outstanding
   
Options Vested and Exercisable
 
Range of
Exercise Prices
 
Number
Outstanding
   
Weighted
Average
Remaining
Contractual
Life (Years)
   
Weighted
Average
Exercise
Price
   
Number
Exercisable
   
Weighted
Average
Remaining
Contractual
Life (Years)
   
Weighted
Average
Exercise
Price
 
$ 1.22 - 1.58     801,004       9.40     $
1.48       122,001       9.38     $
1.45  
$ 2.35 -  6.95
   
5,504,396
     
5.66
   
$
4.50
     
4,602,729
     
5.17
   
$
4.42
 
$ 14.52 - 35.05
   
510,625
     
0.93
   
$
20.32
     
510,625
     
0.93
   
$
20.32
 
     
6,816,025
     
5.75
   
$
5.33
     
5,235,355
     
4.86
   
$
5.90
 

 
Options
 
   
Number of
Shares
   
Weighted
Average
Exercise
Price
   
Weighted
Average
Remaining
Contractual
Life (Years)
   
Aggregate
Intrinsic
Value
 
Outstanding at December 31, 2019     5,630,021     $
8.49           $
 
Options granted     747,500       6.07              
Options exercised     (262,031 )     3.99              
Options cancelled     (302,969 )     5.30              
Outstanding at December 31, 2020
   
5,812,521
   
$
8.55
     
   
$
 
Options granted
   
999,500
     
4.43
     
     
 
Options exercised
   
   
     
     
 
Options cancelled
   
(414,584
)
   
22.54
     
     
 
Outstanding at December 31, 2021
   
6,397,437
   
$
6.99
     
   
$
 
Options granted
   
801,004
     
1.48
     
     
 
Options exercised
   
     
     
     
 
Options cancelled
   
(382,416
)
   
25.06
     
     
 
Outstanding at December 31, 2022
   
6,816,025
   
$
5.33
     
5.75
   
$
3
 
Options exercisable at December 31, 2022
   
5,235,355
   
$
5.90
     
4.86
   
$
2
 

44

 
RSUs
 
   
Number of
RSUs
   
Weighted
Average
Grant Date
Fair Value
   
Aggregate
Intrinsic
Value
 
Outstanding at December 31, 2019     498,489     $ 4.71     $  
RSUs granted     218,329       6.89      
 
RSUs vested     (212,495 )     4.63      
 
RSUs cancelled                  
Outstanding at December 31, 2020
   
504,323
   
$
5.69
   
$
 
RSUs granted
   
236,661
     
4.61
     
 
RSUs vested
   
(215,165
)
   
5.23
     
 
RSUs cancelled
   
(16,664
)
   
5.45
     
 
Outstanding at December 31, 2021
   
509,155
   
$
5.38
   
$
 
RSUs granted
   
258,363
     
1.46
     
 
RSUs vested
   
(215,413
)
   
5.15
     
 
RSUs cancelled
                 
Outstanding at December 31, 2022
   
552,105
   
$
3.65
   
$
 

Intrinsic value is calculated as the difference between the per-share market price of our common stock on the last trading day of 2022, which was $1.30 and the exercise price of the options. For options exercised, the intrinsic value is the difference between market price and the exercise price on the date of exercise. In 2022 and 2021, no options were exercised. In 2020, we received cash proceeds of $1,046 from stock options exercised. The total intrinsic value of options exercised was $151 in 2020.

Stock-based compensation expense is included in operating expense for each period as follows:

Stock-Based Compensation by Type of Award
 
Year Ended
December 31, 2022
   
Year Ended
December 31, 2021
   
Year Ended
December 31, 2020
 
Stock options
 
$
2,303
   
$
3,067
    $
2,872  
RSUs
   
1,027
     
1,117
      1,066  
Total stock-based compensation expense
 
$
3,330
   
$
4,184
    $
3,938  

As of December 31, 2022, there was $3,972 of unrecognized stock-based compensation expense related to unvested stock options and $1,449 of unrecognized stock-based compensation expense related to unvested RSUs. These costs are expected to be recognized over a weighted-average period of 2.66 and 2.43 years, respectively.

The fair value of each option grant was estimated on the date of grant using the Black-Scholes option pricing model using the following weighted average assumptions:

 
Year Ended
December 31, 2022
   
Year Ended
December 31, 2021
   
Year Ended
December 31, 2020
 
Expected stock price volatility
   
85.39
%
   
90.58
%
    93.45 %
Risk-free interest rate
   
3.09
%
   
1.06
%
    0.63 %
Expected life term
 
6.2 years
   
6.2 years
      6.2 years  
Expected dividends
   
0
%
   
0
%
    0 %

Based on the Black-Scholes option pricing model, the weighted average estimated fair value of employee stock options granted was $1.09, $3.32 and $4.62 per share during 2022, 2021 and 2020, respectively.
The expected life was determined using the simplified method outlined in ASC 718, “Compensation - Stock Compensation”. Expected volatility of the stock options was based upon historical data and other relevant factors.

Note 7 − Earnings Per Share

Basic earnings per share are based on the weighted average number of shares outstanding for a period. Diluted earnings per share are based upon the weighted average number of shares and potentially dilutive common shares outstanding. Potential common shares outstanding principally include stock options and RSUs under our stock plan and warrants. During 2022 and 2021, we incurred losses; therefore, the effect of any common stock equivalent would be anti-dilutive during those years.

45

The table below sets forth the basic and diluted loss per share calculations:

    Year Ended December 31,  
 
2022
   
2021
    2020
 
Net (loss) income
 
$
(36,260
)
 
$
(42,921
)
  $ 280,429  
                         
Basic weighted average number of shares outstanding
    71,335
      71,159
      70,850  
Effect of dilutive securities
   
     
      766  
Diluted weighted average number of shares outstanding
   
71,335
     
71,159
      71,616  
                         
Basic (loss) earnings per share
 
$
(0.51
)
 
$
(0.60
)
  $ 3.96  
Diluted (loss) earnings per share
 
$
(0.51
)
 
$
(0.60
)
  $ 3.92  

Note 8 − Common Stock

Each share of common stock has the right to one vote. The holders of common stock are entitled to receive dividends whenever funds are legally available and when declared by our Board of Directors, subject to the prior rights of holders of all classes of stock outstanding having priority rights as to dividends. Our restated articles of incorporation authorize us to issue up to 100,000,000 shares of $0.0001 par value common stock.

On July 30, 2018 we filed a universal shelf registration statement on SEC Form S-3. This replacement registration statement was declared effective by the SEC on August 16, 2018. We used the universal shelf proceeds for development and marketing of our software product and services, and general corporate purposes. The universal shelf registration expired August 16, 2021.

Dividends

On May 8, 2020, we declared a special cash dividend to shareholders of record as of the close of business on May 18, 2020 of $1 per share of common stock, payable on May 26, 2020. The timing and amounts of future dividends, if any, will depend on market conditions, corporate business and financial considerations and regulatory requirements.

Warrants

In 2020, we issued warrants for the purchase of 25,000 shares of common stock at an exercise price of $5.75 per share, exercisable on the date of grant expiring in April 2025. The weighted average fair value at the grant date was $4.16 per warrant. The fair value at the grant date was estimated utilizing the Black-Scholes valuation model with the following weighted average assumptions (i) dividend yield on our common stock of 0 percent (ii) expected stock price volatility of 97 percent (iii) a risk-free interest rate of 0.27 percent and (iv) and expected option term of 5 years.

Warrants Issued
   
Exercise
Price
   
Outstanding and
Exercisable
December 31, 2021
   
Issued
   
Exercised
   
Terminated /
Cancelled
   
Outstanding and
Exercisable
December 31, 2022
 
Expiration Date
 
 
25,000
   
$
5.75
     
25,000
     
     
     
     
25,000
 
April 30, 2025
 

In April 2020, 25,000 warrants with an exercise price of $7.00 per share expired.

Note 9 − Employee Benefit Plan

We sponsor a defined contribution 401k plan covering substantially all our employees. Our matching contribution to the plan was approximately $179, $145, and $112 in 2022, 2021 and 2020, respectively.

46

Note 10 − Income Taxes

The income tax provision (benefit) is comprised of the following:

 
Year Ended
December 31, 2022
   
Year Ended
December 31, 2021
    Year Ended
December 31, 2020
 
Current:
                 
Federal
 
$
   
$
661
    $ 35,122  
State
   
3
     
35
      950  
Foreign                  
     
3
     
696
      36,072  
Deferred:
                       
Federal
   
15,920
     
(7,025
)
    (8,816 )
State
   
109
     
124
      (233 )

    16,029       (6,901 )     (9,049 )
Total income tax (benefit) provision
  $ 16,032    
$
(6,205
)
  $ 27,023  
 
A reconciliation of the United States federal statutory income tax rate to our effective income tax rate is as follows:

 
Year Ended
December 31, 2022
   
Year Ended
December 31, 2021
    Year Ended
December 31, 2020
 
United States federal statutory rate
   
21.00
%
   
21.00
%
    21.00 %
State taxes, net of federal benefit
   
(0.55
)%
   
(0.31
)%
    0.17 %
Valuation allowance
   
(91.21
)%
   
      (12.22 )%
Stock based compensation
   
(9.44
)%
   
(6.68
)%
    (0.01 )%
R&D Credit
   
1.22
%
   
0.19
%
    (0.21 )%
Other
   
(0.29
)%
   
(1.57
)%
    0.06 %
Effective income tax rate
    (79.27 )%    
12.63
%
    8.79 %

The Company’s effective tax rate for 2022 and 2020 was substantially lower than the statutory Federal income tax rate primarily due to the change in valuation allowance. The Company’s effective tax rate for 2021 was substantially lower than the statutory Federal income tax rate primarily due to the effect of stock based compensation, including expiring options.
 
Deferred tax assets (liabilities) consist of the following:

 
As of
December 31, 2022
   
As of
December 31, 2021
 
Deferred tax assets:
           
Reserves and accruals
 
$
147
   
$
58
 
Research and development credits and other credits
   
430
     
92
 
Net operating loss carry forward
   
11,988
     
9,519
 
Stock based compensation
   
5,018
     
6,287
 
Other
   
970
     
 
Total deferred tax assets
 
$
18,553
   
$
15,956
 
                 
Valuation allowance
   
(18,553)
     
 
Deferred tax assets after valuation allowance
   
     
15,956
 
                 
Total deferred tax liability – depreciation and amortization
   
     
(6
)
                 
Net deferred tax assets
 
$
   
$
15,950
 

Pursuant to changes in IRC Section 174 effective for 2022, we capitalized direct and indirect research and development costs in our tax return totaling $5,140; $514 of these expenses will be amortized in our 2022 tax return. At December 31, 2022, we had federal and state net operating loss carryforwards of approximately $57,085 and $108,745, respectively. Federal net operating loss carryforwards do not expire. None of the state net operating loss carryforward is apportioned to a deferred tax asset, because currently we do not have operations in states where losses accumulated. The state net operating loss carryforward begins expiring in 2029.

47

We are required to recognize the financial statement effects of a tax position when it is more likely than not, based on the technical merits, that the position will be sustained upon examination. At December 31, 2022, we have no uncertain tax positions.
Our tax years for 2005 and forward are subject to examination by the U.S. tax authority and various state tax authorities. These years are open due to NOLs and tax credits generated in these years were utilized in 2020. The statute of limitation for these years shall expire three years after the date of filing 2020 income tax returns, which is October 2024.
Our policy is to recognize interest and penalties, if any, accrued on any unrecognized tax benefits, as a component of income tax expense. We had no interest or penalties accrued in 2022.

Note 11 − Fair Value Measurement

Fair value is the price that would result from an orderly transaction between market participants at the measurement date. A fair value hierarchy prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement). Level 2 measurements utilize either directly or indirectly observable inputs in markets other than quoted prices in active markets.

Our financial instruments are stated at amounts that equal, or approximate, fair value. When we estimate fair value, we utilize market data or assumptions that we believe market participants would use in pricing the financial instrument, including assumptions about risk and inputs to the valuation technique. We use valuation techniques, primarily the income and market approach, which maximizes the use of observable inputs and minimize the use of unobservable inputs for recurring fair value measurements.
Mutual funds: Valued at the quoted net asset value (NAV) of shares held.
U.S. agency and treasury securities: Fair value measured at the closing price reported on the active market on which the individual securities are traded.

The following table shows the adjusted cost, gross unrealized gains, gross unrealized losses, and fair value of our financial assets as of December 31, 2022 and 2021 (in thousands):

 
December 31, 2022
 
   
Adjusted
Cost
   
Unrealized
Gains
   
Unrealized
Losses
   
Fair
Value
   
Cash
and Cash
Equivalents
   
Investments
Available
for Sale
 
Cash
 
$
16,949
   
$
   
$
   
$
16,949
   
$
16,949
   
$
 
Level 1:
                                               
Mutual funds
   
66,493
     
     
     
66,493
     
66,493
     
 
U.S. agency and treasury securities
   
68,958
     
9
     
(386
)
   
68,581
     
3,119
     
65,462
 
     
135,451
     
9
     
(386
)
   
135,074
     
69,612
     
65,462
 
Total
 
$
152,400
   
$
9
   
$
(386
)
 
$
152,023
   
$
86,561
   
$
65,462
 

48

 
December 31, 2021
 
   
Adjusted
Cost
   
Unrealized
Gains
   
Unrealized
Losses
   
Fair
Value
   
Cash
and Cash
Equivalents
   
Investments
Available
for Sale
 
Cash
 
$
35,428
   
$
   
$
   
$
35,428
   
$
35,428
   
$
 
Level 1:
                                               
Mutual funds
   
106,590
     
     
     
106,590
     
106,590
     
 
U.S. agency and treasury securities
    27,304             (50 )     27,254             27,254  
     
133,894
     
     
(50
)
   
133,844
     
106,590
     
27,254
 
Total
 
$
169,322
   
$
   
$
(50
)
 
$
169,272
   
$
142,018
   
$
27,254
 

The maturities of our investments generally range from within one to two years. Actual maturities could differ from contractual maturities due to call or prepayment provisions.

Note 12 − Litigation (all dollar amounts in this section are expressed in thousands except for rates per device)

We have several intellectual property infringement lawsuits pending in the United States Court of Appeals for the Federal Circuit (“USCAFC”).

VirnetX Inc. v. Apple, Inc. (Case 6:12-CV-00855-LED) (“Apple II”)

This case began on November 6, 2012, when we filed a complaint against Apple in United States District Court (“USDC”) in which we alleged that Apple infringed on certain of our patents, (U.S. Patent Nos. 6,502,135, 7,418,504, 7,921,211 and 7,490,151). We sought damages and injunctive relief. The accused products include the iPhone 5, iPod Touch 5th Generation, iPad 4th Generation, iPad mini, and the latest Macintosh computers. Post-trial motions hearing was held on July 18, 2018. On August 31, 2018, the USDC entered a Final Judgment and issued its Memorandum Opinion and Order regarding post-trial motions, affirming the jury’s verdict of $502,600 and granting VirnetX motions for supplemental damages, a sunset royalty, and the royalty rate of $1.20 per infringing iPhone, iPad and Mac products, pre-judgment and post-judgment interest and costs. Apple filed a notice of appeal with the United States Court of Appeals for the Federal Circuit (“USCAFC”) in the Apple II case.

On October 9, 2018, USCAFC docketed the appeal as Case No. 19-1050 - VirnetX Inc. v. Apple Inc. On January 24, 2019 Apple filed its opening brief. We filed our response brief on March 1, 2019. Apple filed its reply brief on April 5, 2019. The oral arguments were heard on October 4, 2019. On November 22, 2019, the USCAFC issued an opinion affirming the district court’s findings that Apple is precluded from making certain invalidity arguments and that Apple infringed the ‘135 and ‘151 patents; reversing the USDC’s finding that Apple infringed the ‘504 and ‘211 patents; and remanding the case for proceedings on damages. Apple sought panel and en banc rehearing, which the USCAFC denied on February 10, 2020.

On February 22, 2020, the USDC issued a scheduling order for the parties to brief the court about the need for a new trial for recalculating the damages. We filed our motion for entry of judgment on February 28, 2020. The arguments on this matter were heard on April 14, 2020. In its order, unsealed on May 1, 2020, the USDC denied VirnetX’s motion for entry of a new judgment based on the prior jury verdict and ordered a new jury trial on damages. On August 10, 2020, the USDC granted Apple’s motion for continuance and reset the date to October 26, 2020. On October 30, 2020, a jury returned a $502,800 verdict in favor of VirnetX based on Apple’s infringement of two network security patents: VirnetX US Patents No. 6,502,135 and No. 7,490,151. The jury verdict called for damages of $0.84 per accused device since the 2013 launch of Apple’s iOS 7 operating system and represents 598,629,580 infringing units from US sales only. On January 15, 2021, the district court denied Apple’s motion for judgment as a matter of law, and on February 4, 2021, Apple filed a notice of appeal to the USCAFC.

On February 22, 2021, USCAFC docketed the appeal as Case No. 19-1672. Apple’s opening brief was filed on June 2, 2021. VirnetX filed its responsive brief on July 26, 2021. Apple filed its reply brief on September 13, 2021. The briefing is complete, and oral arguments were held on September 8, 2022. On March 31, 2023, the Federal Circuit issued its decision vacating the district court’s judgement in this matter and remanding it back to the district court with instructions to dismiss the case as moot. We are evaluating all of our available options in this matter, including potentially seeking rehearing or certiorari review.

49

VirnetX Inc. v. Mangrove Partners Master Fund, Ltd., Apple Inc. (USCAFC Case 20-2271) and VirnetX Inc. v. Mangrove Partners Master Fund, Ltd., Apple Inc., and Black Swamp, LLC (USCAFC Case 20-2272)

On September 15, 2020, we filed with the USCAFC an appeal of the invalidity findings by the Patent Trial and Appeal Board (“PTAB”) in inter-partes review proceedings IPR2015-01046 and IPR2016-00062 involving our U.S. Patent No. 6,502,135, and an appeal of the invalidity findings by the PTAB in inter-partes review proceedings IPR2015-1047, IPR2016- 00063, and IPR2016-00167 involving our U.S. Patent No. 7,490,151. On September 25, 2020, the USCAFC issued an order consolidating the two appeals. On December 15, 2020, we filed a motion to vacate the PTAB decisions below and to remand these appeals to the PTAB. On March 16, 2021, the USCAFC denied the motion without prejudice to us raising the challenges made in the motion in our opening brief. Our opening brief was filed on June 7, 2021.

On June 23, 2021, the USCAFC entered an order directing us (and parties in other appeals that raised Appointments Clause challenges) to file a brief explaining how they believe their cases should proceed in light of the Supreme Court’s decision in United States v. Arthrex, Inc., 141 S. Ct. 1970 (2021). On July 7, 2021, we filed a brief in response to the court’s order. Other parties, including the U.S. Patent and Trademark Office (“USPTO”) filed their responses on July 21, 2021. On August 19, 2021, USCAFC issued an order remanding these appeals for the limited purpose of allowing VirnetX the opportunity to request rehearing of the PTAB’s final written decisions by the Director of the USPTO. The USCAFC retained jurisdiction over the appeals in the meantime. On September 20, 2021, we filed our requests for Director rehearing with the USPTO. On October 29, 2021, our requests for Director rehearing were denied. We subsequently filed an amended opening brief to the USCAFC on December 10, 2021, the other parties filed response briefs on February 2, 2022, and we filed a reply brief on February 22, 2022. All the briefings have been completed. The oral arguments in this matter were held on September 8, 2022. On March 30, 2023, the USCAFC issued its decision affirming PTAB’s decisions finding certain claims of the ‘135 patent and the ‘151 patent to be unpatentable. We are evaluating all of our available options in this matter, including potentially seeking rehearing or certiorari review.

VirnetX Inc. v. Hirshfeld (USCAFC Case 17-2593, -2594)

On September 22, 2017, we filed with the USCAFC an appeal of the invalidity findings by the PTAB in inter-partes review proceeding IPR2016-00693 involving our U.S. Patent No. 7,418,504, and an appeal of the invalidity findings by the PTAB in inter-partes review proceeding IPR2016-00957 involving our U.S. Patent No. 7,921,211. On September 16, 2021, USCAFC issued an order remanding these appeals for the limited purpose of allowing VirnetX the opportunity to request rehearing of the PTAB’s final written decisions by the Director of the USPTO. The USCAFC retained jurisdiction over the appeals in the meantime. On October 18, 2021, we filed our requests for Director rehearing with the USPTO. On January 7, 2022, our requests for Director rehearing were denied. On January 21, 2022, we informed the USCAFC about the denial of Director rehearing and requested that the court dismiss the appeal involving IPR2016-00957 as moot and vacate the PTAB’s underlying decision. On April 4, 2022, the USCAFC vacated the PTAB’s decision in IPR2016-00957 and remanded Appeal No. 17-2594 with instructions to dismiss. In the April 4, 2022 order, the USCAFC further set a briefing schedule, in Appeal No. 17-2593. VirnetX filed its opening brief on September 12, 2022. The USPTO filed its response brief on December 20, 2022. VirnetX filed its reply brief on February 14, 2023, and we currently await scheduling of oral arguments.

VirnetX Inc. v. Cisco Systems, Inc. (USCAFC Case 19-1671)

On March 18, 2019, we filed with the USCAFC an appeal of the invalidity findings by the PTAB in inter-partes re-examination proceeding 95/001,679 involving our U.S. Patent No. 6,502,135. On October 5, 2021, USCAFC issued an order remanding these appeals for the limited purpose of allowing VirnetX the opportunity to request rehearing of the PTAB’s final written decisions by the Director of the PTO. The USCAFC retained jurisdiction over the appeals in the meantime. Our request for Director rehearing with the PTO was filed on November 5, 2021. On January 10, 2022, our request for Director rehearing was denied. We informed the USCAFC about the denial of Director rehearing. VirnetX’s opening brief was filed on June 23, 2022. The USPTO’s response brief was filed on August 2, 2022, and Cisco’s response brief was filed on September 2, 2022. VirnetX filed its reply brief on October 7, 2022, and we currently await scheduling of oral arguments.

VirnetX Inc. v. Apple Inc. (USCAFC Case 22-1523) (“Apple Reexam I”)

On March 10, 2022, we filed with the USCAFC an appeal of the invalidity findings by the PTAB in inter-partes re-examination proceeding 95/001,682 involving our U.S. Patent No. 6,502,135. Our opening brief was filed on August 22, 2022. Apple and USPTO each filed a response brief on December 28, 2022. VirnetX filed its reply brief on February 8, 2023, and we currently await scheduling of oral arguments.

50

VirnetX Inc. v. Apple Inc. (USCAFC Case 22-1997) (“Apple Reexam II”)

On July 6, 2022, we filed with the USCAFC an appeal of the invalidity findings by the PTAB in inter-partes re-examination proceeding 95/001,697 involving our U.S. Patent No. 7,490,151. On October 17, 2022, we filed a motion to remand the appeal in light of the PTAB’s refusal to permit Director rehearing. On January 23, 2023, the USCAFC denied that motion without prejudice to the parties raising their arguments in the merits briefs. VirnetX’s opening brief is currently due April 24, 2023.

VirnetX Inc. v. Cisco Systems, Inc. (USCAFC Case 22-2234)

On September 16, 2022, we filed with the USCAFC an appeal of the invalidity findings by the PTAB in inter-partes re-examination proceeding 95/001,851 involving our U.S. Patent No. 7,418,504. We filed our opening brief on February 28, 2023.

McKool Smith P.C. v. VirnetX, Inc., AAA Case No. 01-20-0003-7975

On March 23, 2020, the law firm of McKool Smith, P.C. (“McKool”) filed a Demand for Arbitration against VirnetX, Inc. with the American Arbitration Association (“AAA”). In its demand, McKool claimed that a retention agreement it entered into in 2010 with VirnetX entitled it to a contingency fee arising from the recent 2020 payment made in the Apple I case. McKool claimed it was owed approximately $36,300 (or 8% of the Apple I payment). We filed a general response with the AAA denying McKool’s claim and contested the matter vigorously. An evidentiary hearing was held on the matter during the week of February 22, 2021 and the parties submitted additional briefings. On April 19, 2021, the arbitrator awarded McKool $36,323 in damages, plus pre-judgment interest in the amount of 5% simple interest from March 23, 2020 to April 18, 2021, and post-judgment interest in the amount of 5%, compounded annually, until payment of the award. We accrued the resulting $38,284 as of March 31, 2021 and paid that amount to McKool on April 20, 2021. This matter is now closed.

Other Legal Matters

One or more potential intellectual property infringement claims may also be available to us against certain other companies who have the resources to defend against any such claims. Although we believe these potential claims are likely valid, commencing a lawsuit can be expensive and time-consuming, and there is no assurance that we could prevail on such potential claims if we made them. In addition, bringing a lawsuit may lead to potential counterclaims which may distract our management and our other resources, including capital resources, from efforts to successfully commercialize our products.

Currently, we are not a party to any other pending legal proceedings and are not aware of any proceeding threatened or contemplated against us.

Note 13 − Leases

We lease office space under an operating lease which expires on October 31, 2023. At December 31, 2022, the underlying ROU asset and lease liability totaled $45. At December 31, 2021, the underlying ROU asset and lease liability totaled $98. Lease expense totaled $54 in 2022 and $56 in 2021 and 2020.

We also lease a facility for corporate promotional and marketing purposes which was prepaid at inception and originally expired in 2024. In September 2020, the lease was extended for one year to 2025, due to COVID use-restrictions. No other terms of the original agreement were affected and there was no impact on cash flow. At December 31, 2022 and 2021, the ROU asset totaled $648 and $948, respectively; lease expense totaled $300, $300 and $356, during 2022, 2021 and 2020, respectively.

Note 14 − Subsequent Event
On March 30, 2023, we declared a special cash dividend of $1.00 per common share to be paid on or about April 17, 2023 to shareholders of record on April 10, 2023. If the final outcome of the Apple II litigation described elsewhere in this Form 10-K results in proceeds to us, we are committed to distribute to our shareholders a substantial portion of the net proceeds (after legal costs, licensing costs and taxes), after the case concludes.

51

Item 9.
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

None.

Item 9A.
Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, December 31, 2022.

The purpose of this evaluation was to determine whether as of December 31, 2022 our disclosure controls and procedures were effective to provide reasonable assurance that the information we are required to disclose in our filings with the SEC, (i) is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

Based on their evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that as of December 31, 2022, our disclosure controls and procedures were effective.

Changes in Internal Control Over Financial Reporting

We modified supervisory review procedures over the tax professionals who perform the accounting and reporting of deferred taxes, to include detailed discussions of current operations and changes in accounting standards and tax law that could affect our calculations, and detailed review including walkthrough of infrequent transactions and complex matters affecting deferred tax calculations. We have tested these procedures and believe the enhanced control is operating effectively. Additionally, our accounting professionals participated in deferred tax accounting training to further enhance our in-house technical abilities. There were no other changes in our internal controls over financial reporting (as such term is defined in rules 13a-15(f) under the Securities Exchange Act of 1934, as amended) during the fiscal year ended December 31, 2022, that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

We have not experienced any material impact to our internal controls over financial reporting despite the fact that most of our employees are working remotely; we are continually monitoring and assessing the impact on our internal controls to minimize the impact on their design and operating effectiveness.

Management’s Report on Internal Control Over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting for the Company. Internal control over financial reporting is a process to provide reasonable assurance regarding the reliability of our financial reporting for external purposes in accordance with accounting principles generally accepted in the United States of America. Internal control over financial reporting includes maintaining records that in reasonable detail accurately and fairly reflect our transactions; providing reasonable assurance that transactions are recorded as necessary for preparation of our financial statements; providing reasonable assurance that receipts and expenditures of Company assets are made in accordance with management authorization; and providing reasonable assurance that unauthorized acquisition, use or disposition of Company assets that could have a material effect on our financial statements would be prevented or detected on a timely basis. Because of its inherent limitations, internal control over financial reporting is not intended to provide absolute assurance that a misstatement of our financial statements would be prevented or detected.

Management conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this evaluation, management concluded that the Company’s internal control over financial reporting was effective as of December 31, 2022. Changes made in our internal control over financial reporting during the period ended December 31, 2022 are discussed above; no other change were made to our internal control over financial reporting during the period, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

52

Item 9B.
Other Information

None.

Item 9C.
Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

None.

PART III

Item 10.
Directors, Executive Officers and Corporate Governance

The information required by this item will be contained in our definitive proxy statement to be filed with the SEC in connection with our 2022 Annual Meeting of Stockholders (the “Proxy Statement”), which is expected to be filed not later than 120 days after the end of our fiscal year ended December 31, 2022 and is incorporated in this report by reference.

Item 11.
Executive Compensation

The information required by this item will be set forth in the Proxy Statement and is incorporated herein by reference.

Item 12.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

The information required by this item will be set forth in the Proxy Statement and is incorporated herein by reference.

Securities Authorized for Issuance Under the Equity Compensation Plans

We have an equity incentive plan for employees and others called the VirnetX Holding Corporation 2013 Equity Incentive Plan (the “2013 Plan”), which has been approved by our stockholders. To the extent that any award should expire, become un-exercisable or is otherwise forfeited, the shares subject to such award will again become available for issuance under the 2013 Plan. The 2013 Plan provides for the granting of stock options and restricted stock units purchase rights (“RSUs”) to our employees and consultants. Stock options granted under the 2013 Plan may be incentive stock options or nonqualified stock options. Incentive stock options (“ISOs”) may only be granted to our employees (including officers and directors). Nonqualified stock options (“NSOs”) and stock purchase rights may be granted to our employees and consultants. The 2013 Plan expires in 2023. In April 2021, our Board of Directors approved an amendment and restatement of the 2013 Plan to, among other things, increase the shares reserved under the Plan by 2,500,000 shares (the “Plan Amendment”). Our stockholders approved the Plan Amendment at the 2021 Annual Meeting of the Stockholders held on June 3, 2021.

As of December 31, 2022, there were 1,563,345 shares available to be granted under the Plan. We had 6,816,025 and 6,397,437 options outstanding as of December 31, 2022 and December 31, 2021, respectively, with an average exercise price of $5.33 and $6.99, respectively. We had 552,105 and 509,155 RSUs outstanding as of December 31, 2022 and December 31, 2021, respectively, with a weighted average grant price of $3.65 and $5.38, respectively.

53

Plan Category
 
Number of
Securities to be
Issued Upon
Exercise of
Outstanding
Options and
RSUs
   
Weighted-Average
Exercise Price of
Outstanding
Options and RSUs
   
Number of
Securities
Remaining
Available for
Future Issuance
Under Equity
Compensation
Plans
 
Equity compensation plans approved by security holders
   
7,368,130
   
$
5.21
     
1,563,345
 
Equity compensation plans not approved by security holders
   
     
         
Total
   
7,368,130
   
$
5.21
     
1,563,345
 

On June 3, 2022, the Compensation Committee of our Board of Directors (the “Compensation Committee”) granted 37,500 stock options and 24,999 RSUs to members of our Board of Directors. On June 7, 2022, the Compensation Committee granted 763,504 stock options and 233,364 RSUs to our employees.

Item 13.
Certain Relationships and Related Transactions, and Director Independence

The information required by this item will be set forth in the Proxy Statement and is incorporated herein by reference.

Item 14.
Principal Accountant Fees and Services

The information required by this item will be set forth in the Proxy Statement and is incorporated herein by reference.

PART IV

Item 15.
Exhibits and Financial Statement Schedules


(a)
The following documents are filed as part of this Annual Report on Form 10-K


(1)
Financial Statements: See the Index to Consolidated Financial Statements under Item 8 of this Annual Report on Form 10-K.


(2)
Financial Statement Schedule: Financial statement schedules are omitted because they are not applicable, or the required information is shown in the financial statements or notes thereto. All other schedules are omitted because of the absence of conditions under which they are required or because the required information is given in the financial statements or the notes thereto.


(3)
Exhibits: The documents listed in the Exhibit Index of this Annual Report on Form 10-K are incorporated by reference or are filed with this Annual Report on Form 10-K, in each case as indicated therein (numbered in accordance with Item 601 of Regulation S-K).

54

EXHIBIT INDEX

Exhibit
Number
 
Description
Incorporated by reference herein
 
Form
Exhibit No.
Filing Date
File No.

Filed Herewith

3.1
8-K
3.1
11/01/2007
000-26895
 
3.2
8-K
3.1
1/27/2023
001-33852
 
4.2
S-3
4.1
07/30/2018
333-226413
 
4.3
S-3
4.2
07/30/2018
333-226413
 
4.4
S-3
4.4
07/30/2018
333-226413
 
4.5
10-K
4.6
03/16/2020
001-33852
 
10.1
10-K
10.1
03/18/2019
001-33852
 
10.2*
10-Q
10.2
05/10/2012
001-33852
 
10.3*
10-Q
4.5
05/10/2011
001-33852
 
10.4*
10-Q
10.3
05/10/2012
001-33852
 
10.5*
DEF 14A
Appendix A
04/13/2021
001-33852
 
10.6*
10-K
10.6
03/02/2015
001-33852
 
10.7*
10-K
10.7
03/02/2015
001-33852
 
10.12
8-K
10.4
07/12/2007
000-26895
 
10.13**
8-K
10.6
07/12/2007
000-26895
 
10.14
8-K
10.1
03/18/2008
001-33852
 
10.15
8-K
10.5
07/12/2007
000-26895
 
10.16
8-K
10.7
07/12/2007
000-26895
 
10.17
8-K
10.8
07/12/2007
000-26895
 
10.18**
10-Q/A
10.1
01/31/2011
001-33852
 
10.19**
10-K
10.23
03/02/2015
001-33852
 
10.20**
10-Q
10.1
11/09/2017
001-33852
 
10.21
10-Q
10.2
11/09/2017
001-33852
 
10.22
8-K
10.1
08/31/2018
001-33852
 
10.23*
10-Q
10.1
11/08/2021
001-33852
 
21.1
10-K
21.1
03/16/2021
001-33852
 

55

Consent of Farber Hass Hurley LLP, Independent Registered Public Accounting Firm.
        X
Power of Attorney (contained on signature page hereto)
        X
Chief Executive Officer Certification pursuant to Rule 13a-14(a) of the Securities Exchange Act.
        X
Chief Financial Officer Certification pursuant to Rule 13a-14(a) of the Securities Exchange Act.
        X
Chief Executive Officer Certification pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
        X
Chief Financial Officer Certification pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
        X
101.INS
XBRL Instance Document
        X
101.SCH
XBRL Taxonomy Extension Schema Document
        X
101.CAL
XBRL Taxonomy Extension Calculation Linkbase Document
        X
101.DEF
XBRL Taxonomy Extension Definition Linkbase Document
        X
101.LAB
XBRL Taxonomy Extension Label Linkbase Document
        X
101.PRE
XBRL Taxonomy Extension Presentation Linkbase Document
       
104
Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)
        X



*
Indicates management contract or compensatory plan.

**
Confidential treatment has been granted by the SEC as to certain portions of this exhibit.

***
Portions of this exhibit have been omitted pending a determination by the SEC as to whether these portions should be granted confidential treatment.

The certifications attached as Exhibit 32.1 and 32.2 that accompany this Report are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of VirnetX Holding Corporation under the Securities Act or the Exchange Act, whether before or after the date of this Report, irrespective of any general incorporation language contained in such filing.

56

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.

 
VirnetX Holding Corporation
     
 
By:
/s/ Kendall Larsen
   
Name: Kendall Larsen
   
Title: Chief Executive Officer and President
     
Dated: March 31, 2023
   

57

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Kendall Larsen as his attorney-in-fact, with full power of substitution, for him in any and all capacities, to sign any amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith with the Securities and Exchange Commission, hereby ratifying and confirming all that said attorney-in-fact, or his substitute or substitutes may do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the registrant and in the capacities indicated.

Name
 
Capacity
 
Date
         
/s/Kendall Larsen
 
Director, Chief Executive Officer and President
 
March 31, 2023
Kendall Larsen
 
(Principal Executive Officer)
 
         
/s/Katherine Allanson
 
Chief Financial Officer
 
March 31, 2023
Katherine Allanson
 
(Principal Financial Officer and
Principal Accounting Officer)
   
         
/s/Robert D. Short III
 
Director
 
March 31, 2023
Robert D. Short III
       
         
/s/Gary Feiner
 
Director
 
March 31, 2023
Gary Feiner
       
         
/s/Michael F. Angelo
 
Director
 
March 31, 2023
Michael F. Angelo
       
         
/s/Thomas M. O’Brien
 
Director
 
March 31, 2023
Thomas M. O’Brien
       


58

EX-23.1 2 brhc10048883_ex23-1.htm EXHIBIT 23.1

EXHIBIT 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-149883, 333-196064, 333-218467, and 333-258131) of our reports dated March 31, 2023, relating to the consolidated financial statements of VirnetX Holding Corporation (the “Company”), appearing in this Annual Report on Form 10-K of the Company for the year ended December 31, 2022.

/s/ Farber Hass Hurley LLP

Chatsworth, California
March 31, 2023



EX-31.1 3 brhc10048883_ex31-1.htm EXHIBIT 31.1

EXHIBIT 31.1

CERTIFICATIONS

I, Kendall Larsen, certify that:

1.
I have reviewed this Annual Report on Form 10-K of VirnetX Holding Corporation for the fiscal year ended December 31, 2022;

2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:


(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;


(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;


(c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and


(d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):


(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and


(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 
/s/ Kendall Larsen
 
Kendall Larsen
 
President and Chief Executive Officer
 
(Principal Executive Officer)
Date: March 31, 2023
 



EX-31.2 4 brhc10048883_ex31-2.htm EXHIBIT 31.2

EXHIBIT 31.2

CERTIFICATIONS

I, Katherine Allanson, certify that:

1.
I have reviewed this Annual Report on Form 10-K of VirnetX Holding Corporation for the fiscal year ended December 31, 2022;

2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:


(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;


(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;


(c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and


(d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):


(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and


(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 
/s/ Katherine Allanson
 
Katherine Allanson
 
Chief Financial Officer
 
(Principal Accounting and Financial Officer)
Date: March 31, 2023
 



EX-32.1 5 brhc10048883_ex32-1.htm EXHIBIT 32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of VirnetX Holding Corporation (the “Company”) on Form 10-K for the fiscal year ended December 31, 2022 as filed with the Securities and Exchange Commission on March 31, 2023 (the “Report”), I, Kendall Larsen, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:


(1)
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and


(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 
/s/ Kendall Larsen
 
Kendall Larsen
 
President and Chief Executive Officer
 
(Principal Executive Officer)
Date: March 31, 2023
 



EX-32.2 6 brhc10048883_ex32-2.htm EXHIBIT 32.2
EXHIBIT 32.2

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of VirnetX Holding Corporation (the “Company”) on Form 10-K for the fiscal year ended December 31, 2022 as filed with the Securities and Exchange Commission on March 31, 2023 (the “Report”), I, Katherine Allanson, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:


(1)
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and


(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 
/s/ Katherine Allanson
 
Katherine Allanson
 
Chief Financial Officer
 
(Principal Accounting and Financial Officer)
Date: March 31, 2023
 



EX-101.SCH 7 vhc-20221231.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 010000 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 010100 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 020000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 030000 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME link:presentationLink link:calculationLink link:definitionLink 040000 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 040100 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 050000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 060100 - Disclosure - Formation and Business of the Company link:presentationLink link:calculationLink link:definitionLink 060200 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 060300 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 060400 - Disclosure - Commitments, Contingencies and Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 060500 - Disclosure - Stock Plan link:presentationLink link:calculationLink link:definitionLink 060600 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 060700 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 060800 - Disclosure - Common Stock link:presentationLink link:calculationLink link:definitionLink 060900 - Disclosure - Employee Benefit Plan link:presentationLink link:calculationLink link:definitionLink 061000 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 061100 - Disclosure - Fair Value Measurement link:presentationLink link:calculationLink link:definitionLink 061200 - Disclosure - Litigation link:presentationLink link:calculationLink link:definitionLink 061300 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 061400 - Disclosure - Subsequent Event link:presentationLink link:calculationLink link:definitionLink 070200 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 080200 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 080300 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 080600 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 080700 - Disclosure - Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 080800 - Disclosure - Common Stock (Tables) link:presentationLink link:calculationLink link:definitionLink 081000 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 081100 - Disclosure - Fair Value Measurement (Tables) link:presentationLink link:calculationLink link:definitionLink 090100 - Disclosure - Formation and Business of the Company (Details) link:presentationLink link:calculationLink link:definitionLink 090200 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 090300 - Disclosure - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 090400 - Disclosure - Commitments, Contingencies and Related Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 090500 - Disclosure - Stock Plan (Details) link:presentationLink link:calculationLink link:definitionLink 090600 - Disclosure - Stock-Based Compensation, Information about Stock Options Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 090602 - Disclosure - Stock-Based Compensation, Summary of Activity (Details) link:presentationLink link:calculationLink link:definitionLink 090604 - Disclosure - Stock-Based Compensation, Stock-Based Compensation by Type of Award (Details) link:presentationLink link:calculationLink link:definitionLink 090606 - Disclosure - Stock-Based Compensation, Fair Value Assumptions Used (Details) link:presentationLink link:calculationLink link:definitionLink 090700 - Disclosure - Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 090800 - Disclosure - Common Stock, Summary (Details) link:presentationLink link:calculationLink link:definitionLink 090802 - Disclosure - Common Stock, Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 090900 - Disclosure - Employee Benefit Plan (Details) link:presentationLink link:calculationLink link:definitionLink 091000 - Disclosure - Income Taxes, Components of Provision (Benefit) for Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 091002 - Disclosure - Income Taxes, Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details) link:presentationLink link:calculationLink link:definitionLink 091004 - Disclosure - Income Taxes, Components of Deferred Tax Assets (Liabilities) (Details) link:presentationLink link:calculationLink link:definitionLink 091006 - Disclosure - Income Taxes, Pre-tax Income (Losses) and Operating Loss Carryforwards (Details) link:presentationLink link:calculationLink link:definitionLink 091008 - Disclosure - Income Taxes, Income Tax Uncertainties (Details) link:presentationLink link:calculationLink link:definitionLink 091100 - Disclosure - Fair Value Measurement (Details) link:presentationLink link:calculationLink link:definitionLink 091200 - Disclosure - Litigation (Details) link:presentationLink link:calculationLink link:definitionLink 091300 - Disclosure - Leases (Details) link:presentationLink link:calculationLink link:definitionLink 091400 - Disclosure - Subsequent Event (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 vhc-20221231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 vhc-20221231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 vhc-20221231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Award Type [Axis] Award Date [Axis] Award Date [Domain] Total Investment Securities [Member] Available-for-Sale Securities [Member] Summary of Significant Accounting Policies [Abstract] Accounts payable and accrued liabilities Accounts Payable and Accrued Liabilities, Current Accounts receivables Accounts Receivable, after Allowance for Credit Loss, Current Less accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Accumulated Other Comprehensive Loss [Member] AOCI Attributable to Parent [Member] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Additional paid-in capital Additional Paid in Capital Warrants issued for services Adjustments to reconcile net (loss) income to net cash from operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Aircraft [Member] Air Transportation Equipment [Member] Rental fees incurred for use of aircraft Stock-based compensation Stock-based compensation expense Adjusted Cost, Gross Unrealized Gains, Gross Unrealized Losses and Fair Value of Financial Assets [Abstract] Assets, Fair Value Disclosure [Abstract] ASSETS Assets [Abstract] Total assets Assets Total current assets Assets, Current Current assets: Unrealized Gains Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Investments available for sale Debt Securities, Available-for-Sale, Current Building [Member] Office [Member] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Cash [Member] Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Net (decrease) increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Cash and Cash Equivalents Cash and Cash Equivalents, Fair Value Disclosure Cash and Cash Equivalents Warrants issued (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Class of Warrant or Right [Line Items] Class of Warrant or Right [Table] Exercise price (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Common Stock [Abstract] Class of Stock Disclosures [Abstract] Commitments, Contingencies and Related Party Transactions [Abstract] Commitments and contingencies (Note 4) Commitments, Contingencies and Related Party Transactions Common Stock [Member] Dividends per share (in dollars per share) Common stock, par value (in dollars per share) Common stock, par value (in dollars per share) Common stock, par value $0.0001 per share Authorized: 100,000,000 shares at December 31, 2022 and December 31, 2021, Issued and outstanding: 71,424,650 and 71,232,856 shares, at December 31, 2022 and December 31, 2021, respectively Common Stock, Value, Issued Common stock, shares issued (in shares) Common stock, shares authorized (in shares) Common stock, shares authorized (in shares) Common stock, shares outstanding (in shares) Employee Benefit Plan [Abstract] Deferred tax assets [Abstract] Components of Deferred Tax Assets and Liabilities [Abstract] Comprehensive (loss) income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Computer Equipment [Member] Concentration of Credit Risk and Other Risks and Uncertainties Basis of Consolidation State Federal Foreign Current Foreign Tax Expense (Benefit) Current income tax provision (benefit) Current Income Tax Expense (Benefit) Current [Abstract] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Table] Highly Liquid Debt Investments [Member] Debt Securities [Member] Deferred tax assets Federal Deferred Federal Income Tax Expense (Benefit) Total deferred tax liability - depreciation and amortization Deferred Tax Liabilities, Gross Deferred [Abstract] Deferred income tax provision (benefit) Deferred Income Tax Expense (Benefit) Net deferred tax assets Deferred Tax Assets, Net State Deferred State and Local Income Tax Expense (Benefit) Deferred tax assets after valuation allowance Deferred Tax Assets, Net of Valuation Allowance Total deferred tax assets Deferred Tax Assets, Gross Income Taxes [Abstract] Deferred Tax Assets, Operating Loss Carryforwards, Components [Abstract] Net operating loss carry forward Other Deferred Tax Assets, Other Research and development credits and other credits Reserves and accruals Stock based compensation Valuation allowance Deferred Tax Assets, Valuation Allowance Matching contribution to defined contribution plan Depreciation Depreciation expense Stock-Based Compensation Share-Based Payment Arrangement [Text Block] Stock-Based Compensation [Abstract] Dividend payable date Dividends Payable, Date to be Paid Cash dividend (in dollars per share) Dividends Payable, Amount Per Share Dividend declared date Dividends Payable, Date Declared Dividend record date Dividends Payable, Date of Record Dividends Dividends, Cash Federal [Member] Calculation of basic and diluted loss per share [Abstract] Earnings per Share Basic (loss) earnings per share (in dollars per share) Earnings Per Share, Basic Diluted (loss) earnings per share (in dollars per share) Earnings Per Share, Diluted Earnings Per Share Earnings Per Share [Text Block] Earnings Per Share [Abstract] United States federal statutory rate Valuation allowance Stock based compensation Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent State taxes, net of federal benefit Effective income tax rate Effective Income Tax Rate Reconciliation, Percent Other R&D Credit Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent Effective Tax Rate Reconciliation [Abstract] Compensation cost not yet recognized [Abstract] Stock Options [Member] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Unrecognized stock-based compensation expense expected to be recognized related to unvested RSUs Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Weighted-average period for recognition of unrecognized stock-based compensation expense Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Unrecognized stock-based compensation expense expected to be recognized related to unvested stock options Accrued payroll and related expenses Stock Plan [Abstract] Share-Based Payment Arrangement, Additional Disclosure [Abstract] Equity Component [Domain] Measurement Frequency [Axis] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Asset Class [Domain] Fair Value Measurement [Abstract] Asset Class [Axis] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Hierarchy and NAV [Axis] Recurring [Member] Fair Value, Measurement Frequency [Domain] Fair Value Hierarchy and NAV [Domain] Fair Value Measurement Fair Value Disclosures [Text Block] Fair Value Adjusted Cost, Gross Unrealized Gains, Gross Unrealized Losses and Fair Value of Financial Assets Level 1 [Member] Financial Instrument [Axis] Intangible Assets [Abstract] Finite-Lived Intangible Assets, Net [Abstract] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets [Line Items] Estimated useful lives Litigation [Abstract] Gain Contingency, Quantities, Patents [Abstract] Number of patents allegedly infringed upon by Apple, Inc. Gain Contingencies [Table] Gain (willful infringement) Gain on settlement Gain Contingency, Nature [Domain] Gain Contingencies [Line Items] Gain Contingencies, Nature [Axis] Geographic Distribution [Domain] Geographic Distribution [Axis] Intangible Assets Intellectual Property [Member] Impairment of Long-Lived Assets Income Statement Location [Axis] Income Taxes [Abstract] (Loss) income before taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income Statement Location [Domain] Income Tax Authority [Axis] Income Taxes Income Tax Disclosure [Text Block] CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract] Income Tax Authority [Domain] Total income tax (benefit) provision Income tax (provision) benefit Income Tax Expense (Benefit) Cash paid for income taxes Income Taxes Prepaid income taxes Increase (Decrease) in Prepaid Taxes Accounts payable and accrued liabilities Accounts receivable Increase (Decrease) in Accounts Receivable Accrued payroll and related expenses Increase (Decrease) in Employee Related Liabilities Deferred income taxes Increase (Decrease) in Deferred Income Taxes Changes in assets and liabilities: Other liabilities Increase (Decrease) in Other Operating Liabilities Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Interest and other income, net Interest and Other Income Other Income [Abstract] Investments Investment, Policy [Policy Text Block] Investments [Abstract] 10% Shareholder [Member] Investor [Member] Leases Leases Lessee, Leases [Policy Text Block] Term of lease Lessee, Operating Lease, Term of Contract Future minimum rents due in 2023 Lessee, Lease, Description [Table] Lessee, Lease, Description [Line Items] Leases [Abstract] Lessee, Operating Lease, Description [Abstract] Operating lease, expiration date Lease Expiration Date Commitments, Contingencies and Related Party Transactions [Abstract] Leases, Operating [Abstract] Leases [Abstract] Litigation Legal Matters and Contingencies [Text Block] LIABILITIES AND STOCKHOLDERS' EQUITY Total liabilities and stockholders' equity Liabilities and Equity Total liabilities Liabilities Total current liabilities Liabilities, Current Current liabilities: Interest income (pre- and post-judgment interest) Litigation Settlement Interest Selling, general and administrative (reimbursed litigation costs) Litigation Settlement, Expense Total cash received Loss Contingency, Damages Paid, Value Amount of damages awarded in patent infringement case Loss Contingency, Damages Awarded, Value Contingency fee sought by plaintiff Contingency accrued amount paid Contingency accrued amount Mutual Funds [Member] Mutual Fund [Member] Cash flows from financing activities: Net cash (used in) provided by operating activities Net Cash Provided by (Used in) Operating Activities Net cash (used in) provided by investing activities Net Cash Provided by (Used in) Investing Activities Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Cash flows from investing activities: Cash flows from operating activities: Net (loss) income Net (loss) income New Accounting Pronouncements Foreign [Member] Non-US [Member] Office Furniture [Member] Lease liability Operating lease ROU assets Lease expense Rent expense Operating loss carryforwards, expiration date Operating Leased Assets [Line Items] (Loss) income from operations Operating Income (Loss) Operating expense [Abstract] Operating expense: Operating Expense [Member] Total operating expense Operating Expenses Operating Loss Carryforwards [Line Items] Net operating loss carryforwards Operating Loss Carryforwards [Table] Formation and Business of the Company Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Formation and Business of the Company [Abstract] Change in foreign currency translation, net Change in foreign currency translation, net Change in unrealized investment (loss) gain, net Change in unrealized (loss) gain on investments, net Other liabilities, current Other liabilities Total other comprehensive (loss) gain, net of tax Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Other comprehensive (loss) income, net of tax: Patents [Member] Taxes paid on cashless exercise of restricted stock units Payment, Tax Withholding, Share-Based Payment Arrangement Dividends paid on common stock Payments of Ordinary Dividends, Common Stock Dividend [Abstract] Subsequent Event [Abstract] Purchase of investments Payments to Acquire Debt Securities, Available-for-Sale Purchase of property and equipment Payments to Acquire Property, Plant, and Equipment Employee Benefit Plan Retirement Benefits [Text Block] Plan Name [Domain] Plan Name [Axis] Positive Outcome of Litigation [Member] Preferred stock, shares issued (in shares) Preferred stock, par value (in dollars per share) Preferred stock, shares authorized (in shares) Preferred stock, par value $0.0001 per share Authorized: 10,000,000 shares at December 31, 2022 and December 31, 2021, Issued and outstanding: 0 shares at December 31, 2022 and December 31, 2021 Preferred Stock, Value, Issued Preferred stock, shares outstanding (in shares) Prepaid income tax Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Prepaid expenses and other assets Prepaid Expense and Other Assets, Noncurrent Proceeds from sale of common stock Proceeds from sale or maturity of investments Proceeds from exercise of options Useful lives Property and Equipment Property, Plant and Equipment Disclosure [Text Block] Property, Plant and Equipment [Line Items] Property and Equipment [Line Items] Property and Equipment Property, Plant and Equipment [Table Text Block] Long-Lived Tangible Asset [Axis] Property and Equipment [Abstract] Property and equipment, net Property and equipment, net Property and equipment, gross Property, Plant and Equipment, Gross Property and Equipment Long-Lived Tangible Asset [Domain] Property and Equipment [Abstract] Property, Plant and Equipment, Net, by Type [Abstract] Research and development Research and Development Expense Research and Development RSUs [Member] Restricted Stock Units (RSUs) [Member] Restricted Stock Purchase Rights ("RSU") [Member] Accumulated deficit Accumulated Deficit (Retained Earnings) [Member] Revenue (royalties) Revenue Revenue from Contract with Customer, Excluding Assessed Tax Revenue Recognition Revenue Recognition [Abstract] Revenue Recognition [Abstract] Concentration of Credit Risk and Other Risks and Uncertainties [Abstract] Term of award Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Options outstanding, weighted average remaining contractual life Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term Options outstanding, weighted average exercise price (in dollars per share) Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price Outstanding, end of period Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding Expected option term Expected life term Options vested and exercisable, weighted average exercise price (in dollars per share) Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price RSUs, aggregate intrinsic value [Abstract] Options exercisable, aggregate intrinsic value Options vested and exercisable, weighted average remaining contractual life Options exercisable, weighted average remaining contractual life Options outstanding, weighted average remaining contractual life Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Sale of Stock [Domain] Schedule of Operating Leased Assets [Table] RSU Activity Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Fair Value Assumptions Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Stock-Based Compensation by Type of Award Share-Based Payment Arrangement, Cost by Plan [Table Text Block] Basic and Diluted Loss Per Share Calculations Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Income Tax Provision (Benefit) Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Effective Income Tax Rate Reconciliation Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Schedule of Finite-Lived Intangible Assets [Table] Deferred Tax Assets and Liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Schedule of Available-for-sale Securities [Line Items] Schedule of Available-for-sale Securities [Table] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Schedule of Property, Plant and Equipment [Table] Information about Stock Options Outstanding Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table] Information about Warrants Outstanding Schedule of Stock by Class [Table] Selling, general and administrative expenses RSUs cancelled (in dollars per share) Option vesting term Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised Options granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price RSUs, weighted average grant date fair value [Abstract] Options exercised (in dollars per share) Outstanding and Exercisable (in shares) Outstanding and Exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number Options granted (in shares) Increase of shares authorized (in shares) Issued (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted Options, weighted average exercise price [Roll Forward] Per share market price of common stock on last trading day of year (in dollars per share) Share Price Terminated/ cancelled (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations RSUs, number of RSUs [Roll Forward] Information about Stock Options Outstanding [Abstract] Share-Based Payment Arrangement, Disclosure [Abstract] Weighted average fair value of warrants at grant date (in dollars per share) Outstanding, beginning of period (in dollars per share) Outstanding, end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value RSUs granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Share-based Compensation Arrangement by Share-based Payment Award [Line Items] RSUs cancelled (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Outstanding, end of period (in shares) Outstanding, beginning of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number RSUs vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period RSUs granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Stock-Based Compensation [Abstract] Share-based Compensation [Abstract] Share-Based Payment Arrangement, Noncash Expense [Abstract] Fair value assumptions used in estimating fair value of each option grant [Abstract] Options, additional disclosures [Abstract] RSUs vested (in dollars per share) Shares available for grant (in shares) Options exercisable, end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Total intrinsic value of options exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Options exercisable, end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Expected stock price volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Risk-free interest rate Dividend yield Expected dividends Options outstanding, aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Outstanding, beginning of period (in shares) Outstanding, end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Outstanding, beginning of period (in dollars per share) Outstanding, end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Options granted, weighted average grant date fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Options cancelled (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Options cancelled (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Options, number of shares [Roll Forward] Options outstanding, number outstanding (in shares) Options vested and exercisable, number exercisable (in shares) Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] Equity Award [Domain] Exercise Price Range [Axis] Exercise price range, lower range limit (in dollars per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain] Stock-Based Compensation Share-Based Payment Arrangement [Policy Text Block] Exercise price range, upper range limit (in dollars per share) Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] State [Member] CONSOLIDATED BALANCE SHEETS [Abstract] CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME [Abstract] Equity Components [Axis] Statement [Line Items] CONSOLIDATED STATEMENTS OF CASH FLOWS [Abstract] Statement [Table] CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY [Abstract] Common stock issued for cash, net Common stock issued for options/RSUs, net Options exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Balance Balance Total stockholders' equity Stockholders' Equity Attributable to Parent Stockholders' equity: Subsequent Event Subsequent Event [Table] Subsequent Event Type [Domain] Subsequent Event [Member] Subsequent Event Type [Axis] Subsequent Event [Line Items] Subsequent Event [Abstract] Sale of Stock [Axis] Subsidiary, Sale of Stock [Line Items] Financial Instruments [Domain] Accrued interest and penalties Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Uncertain tax positions Use of Estimates Use of Estimates, Policy [Policy Text Block] U.S. Agency and Treasury Securities [Member] US Treasury and Government [Member] Warrants [Member] Diluted weighted average number of shares outstanding (in shares) Weighted average shares outstanding diluted (in shares) Basic weighted average number of shares outstanding (in shares) Weighted average shares outstanding basic (in shares) Effect of dilutive securities (in shares) Counterparty Name [Axis] Named Executive Officers [Member] Executive Officer [Member] Litigation Case [Axis] Litigation Case [Domain] Maximum [Member] Minimum [Member] Statistical Measurement [Axis] Statistical Measurement [Domain] Counterparty Name [Domain] Classification of Payment Received in Condensed Consolidated Statement of Operations Title of Individual [Axis] Relationship to Entity [Domain] U.S. [Member] UNITED STATES Cover [Abstract] Document Type Document Annual Report Document Transition Report Entity Interactive Data Current Amendment Flag ICFR Auditor Attestation Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Current Fiscal Year End Date Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Shell Company Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Public Float Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Common Stock, Shares Outstanding Auditor Name Auditor Location Auditor Firm ID Common stock that is subordinate to all other stock of the issuer and excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders related to additional paid-in capital. Common Stock and Additional Paid-in Capital [Member] Common Stock and Additional Paid-in Capital [Member] This item represents the cost of cash and debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any. Cash and Available-for-sale Securities, Amortized Cost Basis Adjusted Cost Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading, excluding cash and cash equivalents. Available-for-sale Securities, Excluding Cash and Cash Equivalents Investments Available for Sale Period of maturity of a debt security categorized as neither trading nor held-to-maturity, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Available-for-sale Securities, Debt Maturity Period Maturities of investments Fair value portion of cash and investment in debt and equity securities categorized neither as held-to-maturity nor trading. Cash and Available-for-sale Securities, Fair Value Disclosure Fair Value The amount of capitalized direct and indirect research and development costs. Capitalized Direct and Indirect Research and Development Costs Capitalized direct and indirect research and development costs The amortization of capitalized direct and indirect research and development costs during the period. Amortization of Capitalized Direct and Indirect Research and Development Costs Amortization of capitalized direct and indirect research and development costs Amortization of warrant issuance costs during the period. Amortization of Warrant Issuance Costs Amortization of warrants issuance costs The increase (decrease) in accrued licensing costs during the reporting period. Increase (Decrease) in Accrued Licensing Costs Accrued licensing costs Litigation [Abstract] Number of appeals consolidated in a court order. Loss Contingency, Number of Appeals Consolidated Number of appeals consolidated Information about litigation regarding VirnetX Inc. v. Apple, Inc. (Case 6:12-CV-00855-LED) ("Apple II"). VirnetX Inc. v. Apple, Inc. (Case 6:12-CV-00855-LED) ("Apple II") [Member] The pre-judgment interest percentage. Loss Contingency, Pre-Judgment Interest Parentage Pre-judgment interest percentage Damages awarded to the plaintiff per accused device. Loss Contingency Damages Per Accused Device Damages awarded per accused device The contingency fee as a percentage of the award the plaintiff seeks in the legal matter. Loss Contingency, Damages Sought, Contingency Fee, Percentage Contingency fee as percentage of payment The post-judgment interest percentage. Loss Contingency, Post Judgment Interest Parentage Post-judgment interest percentage Number of infringing units in judgment or settlement of litigation. Litigation Settlement, Number of Infringing Units Number of infringing units Information about litigation regarding McKool Smith P.C. v. VirnetX, Inc., AAA (Case No. 01-20-0003-7975). McKool Smith P.C. v. VirnetX, Inc., AAA (Case No. 01-20-0003-7975) [Member] McKool Smith P.C. v. VirnetX, Inc., AAA (Case No. 01-20-0003-7975) [Member] Royalty rate per device used in calculating infringement damages by the court. Royalty Rate per Device Used in Infringement Damages Royalty rate per device used in calculating infringement damages Information about litigation regarding VirnetX Inc. v. Cisco Systems, Inc. et al. (Case 6:10-CV-00417-LED) ("Apple I"). VirnetX Inc. v. Cisco Systems, Inc. et al. (Case 6:10-CV-00417-LED) ("Apple I") [Member] Information about litigation regarding VirnetX Inc. v. The Mangrove Partners (Case 20-2271 and Case 20-2272) ("Consolidated Appeal"). VirnetX Inc. v. The Mangrove Partners (Case 20-2271 and Case 20-2272) ("Consolidated Appeal") [Member] VirnetX Inc. v. The Mangrove Partners (Case 20-2271 and Case 20-2272) ("Consolidated Appeal") [Member] Number of financial institutions holding the company's cash and cash equivalents. Concentration Risk, Number of Financial Institutions Number of financial institutions holding company's cash Period of time between issuance and maturity of investment securities, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Contractual Maturities of Investment Securities Contractual maturities of investment securities Common Stock [Abstract] The entire disclosure for common stock. Common Stock Disclosure [Text Block] Common Stock Issuance date of warrant that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount. Warrant Issuance Date 2 [Member] Warrants Issued in 2020 [Member] Information About Warrants [Abstract] Warrants [Abstract] Date the warrants or rights are to expire, in CCYY-MM-DD format. Class of Warrant or Right, Expiration Date Expiration date The aggregate licensing costs related to revenues. Licensing Costs Licensing costs Carrying value as of the balance sheet date of costs incurred and are directly related to generating license revenue. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Accrued Licensing Costs Accrued licensing costs Represents number of patents and pending applications owned by the entity. Number of patents and pending applications owned Number of patents and pending applications Formation and Business of the Company Disclosure [Abstract] Formation and Business of the Company Disclosure [Abstract] Represents options within the stated exercise price range. Exercise Price Range 3 [Member] $14.52 - 35.05 [Member] Represents Options within the stated exercise price range. Exercise Price Range 2 [Member] $2.35 - 6.95 [Member] Represents Options within the stated exercise price range. Exercise Price Range 1 [Member] $1.22 - 1.58 [Member] The extension period of lease agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Lease Extension Period Lease extension period Operating lease for a facility used for corporate promotional and marketing purposes. Promotional and Marketing [Member] Corporate Promotional and Marketing Facility [Member] Operating lease for office space. Office [Member] Office [Member] Disclosure of accounting policy for the licensing costs. Licensing Costs [Policy Text Block] Licensing Costs Disclosure of accounting policy for an existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) that might result in a gain, typically reflecting care to avoid misleading implications as to the likelihood of realization, and describes and quantifies a gain recognized in the period resulting from resolution of a previously disclosed gain contingency. Gain Contingencies [Policy Text Block] Contingent Gains Refers to the term of notice for cancellation of lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Term of Notice for Cancellation of Lease Term of notice for cancellation of lease The counterparty from which the Company leased the use of an aircraft for business travel for employees of the Company K2 Investment Fund LLC [Member] Refers to the rate of aircraft lease in dollars per flight hour. Rate of Aircraft Lease Rate of aircraft lease (in dollars per flight hour) Stock Plan [Abstract] The entire disclosure of the description of the plan, the basis for determining contributions, including the employee groups covered, and the nature and effect of significant matters affecting comparability of information for all periods presented. For leveraged ESOPs and pension reversion ESOPs, the disclosure may include the basis for releasing shares and how dividends on allocated and unallocated shares are used. Stock Plan [Text Block] Stock Plan A type of employee stock option where the holders pay ordinary income tax on the difference between the grant price and the price at which they exercise the option. Nonqualified Stock Options [Member] A type of employee stock option that can be granted only to employees and confer a U.S. tax benefit. ISOs are also sometimes referred to as incentive share options or Qualified Stock Options by IRS. Incentive Stock Options [Member] Refers to plan 2013 of equity based compensation arrangement plan. Plan 2013 [Member] 2013 Plan [Member] Exercise price of stock options granted as percentage of fair market value of shares at the date of grant. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercise Price as Percentage of Fair Value Exercise price of option granted as percentage of fair market value of shares at date of grant An at-the-market ("ATM") equity offering sales agreement. ATM Agreement [Member] Refers to number of votes entitled to each share of common stock. Number of votes entitled to each share of common stock Refers to single prospectus for multiple, undefined future offerings. Universal Shelf Registration Statement [Member] EX-101.PRE 11 vhc-20221231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 12 image00001.jpg begin 644 image00001.jpg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�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htm IDEA: XBRL DOCUMENT v3.23.1
Document and Entity Information - USD ($)
12 Months Ended
Dec. 31, 2022
Mar. 27, 2023
Jun. 30, 2022
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Period End Date Dec. 31, 2022    
Current Fiscal Year End Date --12-31    
Document Fiscal Year Focus 2022    
Document Fiscal Period Focus FY    
Document Transition Report false    
Entity File Number 001-33852    
Entity Registrant Name VirnetX Holding Corp    
Entity Central Index Key 0001082324    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 77-0390628    
Entity Address, Address Line One 308 Dorla Court    
Entity Address, Address Line Two Suite 206    
Entity Address, City or Town Zephyr Cove    
Entity Address, State or Province NV    
Entity Address, Postal Zip Code 89448    
City Area Code 775    
Local Phone Number 548-1785    
Title of 12(b) Security Common Stock, par value $0.0001 per share    
Trading Symbol VHC    
Security Exchange Name NYSE    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag false    
Entity Shell Company false    
Entity Public Float     $ 73,662,208
Entity Common Stock, Shares Outstanding   71,424,650  
Auditor Firm ID 223    
Auditor Name Farber Hass Hurley LLP    
Auditor Location Chatsworth, California    
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.23.1
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 86,561 $ 142,018
Investments available for sale 65,462 27,254
Accounts receivables 14 17
Prepaid income tax 0 0
Prepaid expenses and other current assets 224 203
Total current assets 152,261 169,492
Prepaid expenses and other assets 703 1,056
Property and equipment, net 11 18
Deferred tax assets 0 15,950
Total assets 152,975 186,516
Current liabilities:    
Accounts payable and accrued liabilities 373 338
Accrued payroll and related expenses 311 270
Accrued licensing costs 0 355
Other liabilities, current 47 58
Total current liabilities 731 1,021
Other liabilities 0 46
Total liabilities 731 1,067
Commitments and contingencies (Note 4)
Stockholders' equity:    
Preferred stock, par value $0.0001 per share Authorized: 10,000,000 shares at December 31, 2022 and December 31, 2021, Issued and outstanding: 0 shares at December 31, 2022 and December 31, 2021 0 0
Common stock, par value $0.0001 per share Authorized: 100,000,000 shares at December 31, 2022 and December 31, 2021, Issued and outstanding: 71,424,650 and 71,232,856 shares, at December 31, 2022 and December 31, 2021, respectively 7 7
Additional paid-in capital 239,746 236,445
Accumulated deficit (87,195) (50,935)
Accumulated other comprehensive loss (314) (68)
Total stockholders' equity 152,244 185,449
Total liabilities and stockholders' equity $ 152,975 $ 186,516
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.23.1
CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Dec. 31, 2022
Dec. 31, 2021
Stockholders' equity:    
Preferred stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Preferred stock, shares authorized (in shares) 10,000,000 10,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Common stock, shares authorized (in shares) 100,000,000 100,000,000
Common stock, shares issued (in shares) 71,424,650 71,232,856
Common stock, shares outstanding (in shares) 71,424,650 71,232,856
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.23.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]      
Revenue $ 48 $ 35 $ 302,636
Operating expense:      
Licensing costs (4) (9,083) 90,101
Research and development 6,406 5,577 8,830
Selling, general and administrative expenses 15,722 52,715 45,812
Total operating expense 22,124 49,209 144,743
(Loss) income from operations (22,076) (49,174) 157,893
Gain on settlement 0 0 41,271
Interest and other income, net 1,848 48 108,288
(Loss) income before taxes (20,228) (49,126) 307,452
Income tax (provision) benefit (16,032) 6,205 (27,023)
Net (loss) income $ (36,260) $ (42,921) $ 280,429
Basic (loss) earnings per share (in dollars per share) $ (0.51) $ (0.6) $ 3.96
Diluted (loss) earnings per share (in dollars per share) $ (0.51) $ (0.6) $ 3.92
Weighted average shares outstanding basic (in shares) 71,335,046 71,159,458 70,850,311
Weighted average shares outstanding diluted (in shares) 71,335,046 71,159,458 71,615,843
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.23.1
CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME [Abstract]      
Net (loss) income $ (36,260) $ (42,921) $ 280,429
Other comprehensive (loss) income, net of tax:      
Change in unrealized (loss) gain on investments, net (246) (51) 0
Change in foreign currency translation, net 0 (4) 1
Total other comprehensive (loss) gain, net of tax (246) (55) 1
Comprehensive (loss) income $ (36,506) $ (42,976) $ 280,430
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.23.1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Common Stock and Additional Paid-in Capital [Member]
Accumulated Deficit (Retained Earnings) [Member]
Accumulated Other Comprehensive Loss [Member]
Total
Balance at Dec. 31, 2019 $ 223,244 $ (217,602) $ (14) $ 5,628
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Common stock issued for cash, net 4,488      
Common stock issued for options/RSUs, net 690      
Warrants issued for services 104      
Stock-based compensation 3,938      
Net (loss) income   280,429   280,429
Dividends   (70,841)    
Change in unrealized investment (loss) gain, net     0 0
Change in foreign currency translation, net     1 1
Balance at Dec. 31, 2020 232,464 (8,014) (13) 224,437
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Common stock issued for cash, net 0      
Common stock issued for options/RSUs, net (196)      
Warrants issued for services 0      
Stock-based compensation 4,184      
Net (loss) income   (42,921)   (42,921)
Dividends   0    
Change in unrealized investment (loss) gain, net     (51) (51)
Change in foreign currency translation, net     (4) (4)
Balance at Dec. 31, 2021 236,452 (50,935) (68) 185,449
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Common stock issued for cash, net 0      
Common stock issued for options/RSUs, net (29)      
Warrants issued for services 0      
Stock-based compensation 3,330      
Net (loss) income   (36,260)   (36,260)
Dividends   0    
Change in unrealized investment (loss) gain, net     (246) (246)
Change in foreign currency translation, net     0 0
Balance at Dec. 31, 2022 $ 239,753 $ (87,195) $ (314) $ 152,244
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.23.1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) - $ / shares
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY [Abstract]      
Dividends per share (in dollars per share) $ 0 $ 0 $ 1
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.23.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Cash flows from operating activities:      
Net (loss) income $ (36,260) $ (42,921) $ 280,429
Adjustments to reconcile net (loss) income to net cash from operating activities:      
Depreciation 7 4 5
Stock-based compensation 3,330 4,184 3,938
Amortization of warrants issuance costs 0 34 69
Deferred income taxes 16,032 (6,901) (9,049)
Changes in assets and liabilities:      
Prepaid expenses and other current assets 331 271 419
Accounts payable and accrued liabilities 35 (316) (692)
Other liabilities (54) 60 (193)
Accrued payroll and related expenses 41 50 (67)
Accrued licensing costs (355) (9,083) 9,438
Accounts receivable 3 (9) (3)
Prepaid income taxes (3) 2,905 (2,905)
Net cash (used in) provided by operating activities (16,893) (51,722) 281,389
Cash flows from investing activities:      
Purchase of property and equipment 0 (11) 0
Purchase of investments (67,070) (26,332) (33,065)
Proceeds from sale or maturity of investments 28,535 27,371 7,112
Net cash (used in) provided by investing activities (38,535) 1,028 (25,953)
Cash flows from financing activities:      
Proceeds from exercise of options 0 0 1,046
Proceeds from sale of common stock 0 0 4,488
Dividends paid on common stock 0 0 (70,841)
Taxes paid on cashless exercise of restricted stock units (29) (196) (356)
Net cash used in financing activities (29) (196) (65,663)
Net (decrease) increase in cash and cash equivalents (55,457) (50,890) 189,773
Cash and cash equivalents, beginning of period 142,018 192,908 3,135
Cash and cash equivalents, end of period 86,561 142,018 192,908
Cash paid for income taxes $ 2 $ 2 $ 38,977
XML 21 R9.htm IDEA: XBRL DOCUMENT v3.23.1
Formation and Business of the Company
12 Months Ended
Dec. 31, 2022
Formation and Business of the Company [Abstract]  
Formation and Business of the Company
Note 1 − Formation and Business of the Company

VirnetX Holding Corporation, which we refer to as “we”, “us”, “our”, “the Company” or “VirnetX”, is engaged in the business of commercializing a portfolio of patents. We seek to derive revenue from selling our software products including VirnetX War Room™ and VirnetX Matrix™ and licensing our technology, including VirnetX One™, and our secure domain name technology GABRIEL Connection Technology™, to various original equipment manufacturers (“OEMs”) and others, that use our technologies in the development and manufacturing of their own products within the IP-telephony, mobility, fixed-mobile convergence, and unified communications markets or who seek to secure their systems and applications. During 2020, we had revenues from settlement of a patent infringement dispute whereby we received consideration for past sales of licensee that utilized our technology, where there was no prior patent license agreement.

Our portfolio of intellectual property is the foundation of our business model. We currently own approximately 205 total patents and pending applications, including 72 U.S. patents/patent applications and 133 foreign patents/validations/pending applications. Our patent portfolio is primarily focused on securing real-time communications over the Internet, as well as related services such as the establishment and maintenance of a secure domain name registry. Our patented methods also have additional applications in the key areas of device operating systems and network security. The subject matter of all our U.S and foreign patents and pending applications relates generally to securing communications over the Internet and such covers all our technology and other products. Some of our issued U.S. and foreign patents expire at various times during the period from 2023 to 2034.
XML 22 R10.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies
12 Months Ended
Dec. 31, 2022
Summary of Significant Accounting Policies [Abstract]  
Summary of Significant Accounting Policies
Note 2 − Summary of Significant Accounting Policies

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reported period. The critical accounting policies we employ in the preparation of our consolidated financial statements are those which involve impairment of long-lived assets, income taxes, fair value of financial instruments and stock-based compensation.

Use of Estimates

We prepare our consolidated financial statements in accordance with U.S. GAAP. In doing so, we have to make estimates and assumptions that affect our reported amounts of assets, liabilities, revenues, and expenses, as well as related disclosure of contingent assets and liabilities. In some cases, we could reasonably have used different accounting policies and estimates. In some cases, changes in the accounting estimates are reasonably likely to occur from period to period. Accordingly, actual results could differ materially from our estimates. To the extent that there are material differences between these estimates and actual results, our financial condition or results of operations will be affected. We base our estimates on past experience and other assumptions that we believe are reasonable under the circumstances, and we evaluate these estimates on an ongoing basis. We refer to accounting estimates of this type as critical accounting policies and estimates, which we discuss further below. We have reviewed our critical accounting policies and estimates with the Audit Committee of our Board of Directors.

Basis of Consolidation

The consolidated financial statements include the accounts of VirnetX Holding Corporation and our wholly owned subsidiaries. All intercompany balances and transactions have been eliminated.

Revenue Recognition

The Company derives revenue from licensing and royalty fees from contracts with customers which often span several years. We account for this revenue in accordance with Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. Our revenue arrangements may consist of multiple-element arrangements, with revenue for each unit of accounting recognized as the product or service is delivered to the customer.

With the licensing of our patents, performance obligations are generally satisfied at a point in time as work is complete when our patent rights are transferred to our customers. We generally have no further obligation to our customers regarding our technology.

Certain contracts may require our customers to enter into a hosting arrangement with us and for these arrangements, revenue is recognized over time, generally over the life of the servicing contract.

The Company actively monitors and enforces its intellectual property (“IP”) rights, including seeking appropriate compensation from third parties that utilize the Company’s IP without a license. As a result, the Company may, from time to time, receive payments as part of a settlement or compensation for a patent infringement dispute. Proceeds received are allocated to each element identified in the settlement or compensation, based on the fair value of each element. Generally, settlements and compensation may include the following elements: the value of a license or royalty agreement, cost reimbursement, damages, and interest. Elements identified related to licensing and royalty are recognized as revenue. Elements identified as reimbursed costs are generally recorded as a reduction to the reported expenses. Elements identified as damages or interest are generally recorded in other income in the condensed consolidated statement of operations. During the year ended December 31, 2020, the Company collected a lump sum payment of $454,034 from Apple, Inc., because of a favorable court decision relating to a patent infringement case. The court decision identified the following as the basis of the award: $302,428 for past royalties, $41,271 in damages for willful infringement, $108,221 for interest, and $2,114 in reimbursement for court costs and attorney’s fees. Elements of the payment were recognized in the Company’s condensed consolidated statement of operations as follows:

Classification of Payment Received in the Company’s Condensed Consolidated Statement of Operations
 
Year Ended:
 
 
December 31, 2020
 
Revenue (royalties)
 
$
302,428
 
Operating expenses: selling, general and administrative (reimbursed litigation costs)
   
2,114
 
Other income: gain (willful infringement)
   
41,271
 
Other income: interest income (pre- and post-judgment interest)
   
108,221
 
Total cash received
 
$
454,034
 

Licensing Costs

Included in operating expenses are licensing costs we incurred in conjunction with the proceeds received from Apple Inc., pursuant to a favorable court decision relating to a patent infringement case.

Contingent Gains

ASC Topic 450-30-25, Contingent Gains, prohibits recognition of contingent gains until realized. Accordingly, we do not record contingent gains ahead of such realization. Management generally considers any such gains as realized only upon the collection of cash.

Cash and Cash Equivalents

We consider all highly liquid investments purchased with original maturities of three months or less at the date of purchase to be cash equivalents. Our cash and cash equivalents are not subject to significant interest rate risk due to the short maturities of these investments.

Investments

Investments are classified as available-for-sale and are recorded at fair market value. Unrealized gains and losses are reported as other comprehensive income. Realized gains and losses are recorded in income in the period they are realized using specific identification of each security’s cost basis. We invest our excess cash primarily in highly liquid debt instruments including corporate, government and federal agency securities, with contractual maturities less than two years. By policy, we limit the amount of credit exposure to any one issuer.

Concentration of Credit Risk and Other Risks and Uncertainties

Our cash and cash equivalents are primarily maintained at two major financial institutions in the United States. Deposits held with these financial institutions may exceed the amount of insurance provided on such deposits. A portion of those balances are insured by the Federal Deposit Insurance Corporation, or FDIC. In 2022, we had, at times, funds that were uninsured. We do not believe that we are subject to any unusual financial risk beyond the normal risk associated with commercial banking relationships. We have not experienced any losses on our deposits of cash and cash equivalents.

Fair Value

The carrying amounts of our financial instruments, including cash equivalents, accounts payable, and accrued liabilities, approximate fair value because of their generally short maturities.

Property and Equipment

Property and equipment are stated at historical cost, less accumulated depreciation, and amortization. Depreciation and amortization are computed using the accelerated and straight-line methods over the estimated useful lives of the assets, which range from five to seven years. Repair and maintenance costs are charged to expense as incurred.

Leases

The Company determines if an arrangement is a lease at inception in accordance with ASC Topic 842. Operating lease right-of-use (“ROU”) assets are included in Prepaid expenses, and other assets on the Condensed Consolidated Balance Sheets. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term.

Intangible Assets

We record intangible assets at cost, less accumulated amortization. Amortization of intangible assets is provided over their estimated useful lives, which can range from 3 to 15 years, on either a straight-line basis or as revenue is generated by the assets.

Impairment of Long-Lived Assets

We identify and record impairment losses on long-lived assets used in operations when events and changes in circumstances indicate that the carrying amount of an asset might not be recoverable, but not less than annually. Recoverability is measured by comparison of the anticipated future net undiscounted cash flows to the related assets’ carrying value. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the asset.

Research and Development

Research and development costs include expenses paid to outside development consultants and compensation related expenses for our engineering staff. Research and development costs are expensed as incurred.

Income Taxes

We account for income taxes using the asset and liability method. The asset and liability method requires the recognition of deferred tax assets and liabilities for expected future tax consequences of temporary differences that currently exist between the tax basis and financial reporting basis of our assets and liabilities. We calculate current and deferred tax provisions based on estimates and assumptions that could differ from actual results reflected on the income tax returns filed during the following years. Adjustments based on filed returns are recorded when identified in the subsequent years. The effect on deferred taxes for a change in tax rates is recognized in income in the period that the tax rate change is enacted. In assessing our deferred tax assets, we consider whether it is more likely than not that all or some portion of the deferred tax assets will not be realized.

The 2017 U.S. Tax Cuts and Jobs Act changes IRC Section 174, regarding capitalization of book research and development (“R&D”) expenses for income tax purposes.  Effective for tax years beginning in 2022 IRC Section 174 requires the capitalization of book R&D expenses which are capitalized and amortized over 5 years for domestic R&D expenses and over 15 years for foreign R&D expenses.  To date there has been limited guidance from the IRS on how to quantify the amount of book R&D expenses subject to capitalization, including the indirect expenses supporting the R&D function.  Due to the limited guidance, some assumptions were made in our estimates.

A valuation allowance is provided for deferred income tax assets when, in our judgment, based upon currently available information and other factors, it is more likely than not that all or a portion of such deferred income tax assets will not be realized. The determination of the need for a valuation allowance is based on an on-going evaluation of current information including, among other things, historical operating results, estimates of future earnings in different taxing jurisdictions and the expected timing of the reversals of temporary differences. We believe the determination to record a valuation allowance to reduce a deferred income tax asset is a significant accounting estimate because it is based, among other things, on an estimate of future taxable income in the United States and certain other jurisdictions, which is susceptible to change and may or may not occur, and because the impact of adjusting a valuation allowance may be material. In determining when to release the valuation allowance established against our net deferred income tax assets, we consider all available evidence, both positive and negative. We continually assess our ability to generate sufficient taxable income during future periods in which our deferred tax assets may be realized. If and when we believe it is more likely than not that we will recover our deferred tax assets, we will reverse the valuation allowance as an income tax benefit in our statements of operations.

We account for our uncertain tax positions in accordance with U.S. GAAP, which utilizes a two-step approach to evaluate tax positions. Step one, recognition, requires evaluation of the tax position to determine if based solely on technical merits it is more likely than not to be sustained upon examination. Step two, measurement, is addressed only if a position is more likely than not to be sustained. In step two, the tax benefit is measured as the largest amount of benefit, determined on a cumulative probability basis, which is more likely than not to be realized upon ultimate settlement with tax authorities. If a position does not meet the more likely than not threshold for recognition in step one, no benefit is recorded until the first subsequent period in which the more likely than not standard is met, the issue is resolved with the taxing authority, or the statute of limitations expires. Positions previously recognized are derecognized when we subsequently determine the position no longer is more likely than not to be sustained. Evaluation of tax positions, their technical merits, and measurements using cumulative probability are highly subjective management estimates. Actual results could differ materially from these estimates.

Stock-Based Compensation

We account for stock-based compensation using the fair value recognition method in accordance with U.S. GAAP. We recognize these compensation costs on a straight-line basis over the requisite service period of the award, which is generally a vesting term of 4 years. We recognize forfeitures, if any, when they occur. In addition, we record stock-based compensation expense for awards granted to non-employees at fair value of the consideration received or the fair value of the equity instruments issued, as they vest, over the performance period (See Note 6 - Stock-Based Compensation).

Earnings per Share

Basic earnings per share are computed by dividing earnings available to common stockholders by the weighted average number of outstanding common shares during the period. Diluted earnings per share is computed by dividing net income by the weighted average number of shares outstanding during the period increased to include the number of additional shares of common stock that would have been outstanding if the potentially dilutive securities had been issued.

New Accounting Pronouncements

In December 2019, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2019-12 Income Taxes (Topic 740). The amendments in this ASU simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify U. S. GAAP for other areas of Topic 740 by clarifying and amending existing guidance. The amendments in this ASU are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. We adopted this ASU on January 1, 2021 and there was no material impact on our financial position or cash flows as a result.
XML 23 R11.htm IDEA: XBRL DOCUMENT v3.23.1
Property and Equipment
12 Months Ended
Dec. 31, 2022
Property and Equipment [Abstract]  
Property and Equipment
Note 3 − Property and Equipment
 
Our major classes of property and equipment were as follows:

 
December 31
 
   
2022
   
2021
 
Office furniture
 
$
79
   
$
79
 
Computer equipment
   
92
     
92
 
Total
   
171
     
171
 
Less accumulated depreciation
   
(160
)
   
(153
)
Total property and equipment, net
 
$
11
   
$
18
 

Depreciation expense for 2022, 2021 and 2020 was $7, $4, and $5, respectively.
XML 24 R12.htm IDEA: XBRL DOCUMENT v3.23.1
Commitments, Contingencies and Related Party Transactions
12 Months Ended
Dec. 31, 2022
Commitments, Contingencies and Related Party Transactions [Abstract]  
Commitments, Contingencies and Related Party Transactions
Note 4 − Commitments, Contingencies and Related Party Transactions

We lease our offices under an operating lease with a third party expiring in October 2023. We recognize rent expense on a straight-line basis over the term of the lease. Rent expense was $54 in 2022 and $56 for both 2021 and 2020. Future minimum rents due under the lease total $46 in 2023, when the lease expires.

We entered into a service agreement for the use of an aircraft from K2 Investment Fund LLC (“LLC”) for business travel for our employees. We incurred approximately $1,123, $791, and $324 in rental fees and reimbursements to the LLC in 2022, 2021 and 2020, respectively. We pay for the Company’s business usage of the aircraft and have no right to purchase. Our Chief Executive Officer and Chief Administrative Officer are the managing partners of the LLC and control the equity interests of the LLC. We entered into a 12-month non-exclusive agreement with the LLC for use of the plane at a rate of $8 per flight hour, with no minimum usage requirement. The agreement contains other terms and conditions normal in such transactions and can be cancelled by either us or the LLC with 30 days’ notice. The agreement renews on an annual basis unless terminated by either party. Neither party has exercised their termination rights.
XML 25 R13.htm IDEA: XBRL DOCUMENT v3.23.1
Stock Plan
12 Months Ended
Dec. 31, 2022
Stock Plan [Abstract]  
Stock Plan
Note 5 − Stock Plan

We have an equity incentive plan for employees and others called the VirnetX Holding Corporation 2013 Equity Incentive Plan (the “2013 Plan”), which has been approved by our stockholders. To the extent that any award should expire, become un-exercisable or is otherwise forfeited, the shares subject to such award will again become available for issuance under the 2013 Plan. The 2013 Plan provides for the granting of stock options and restricted stock units purchase rights (“RSUs”) to our employees and consultants. Stock options granted under the 2013 Plan may be incentive stock options or nonqualified stock options. Incentive stock options (“ISOs”) may only be granted to our employees (including officers and directors). Nonqualified stock options (“NSOs”) and stock purchase rights may be granted to our employees and consultants. The 2013 Plan expires in 2023.

In April 2021, the Board approved an amendment and restatement of the 2013 Plan to, among other things, increase the shares reserved under the Plan by 2,500,000 shares (the “Plan Amendment”). Our stockholders approved the Plan Amendment at the 2021 Annual Meeting of the Stockholders held on June 3, 2021. The 2013 Plan generally provides for the granting of shares of our common stock, including stock options and RSUs. Options may be granted under the 2013 Plan with an exercise price determined by our Board of Directors, or a duly appointed committee thereof, provided, however, that the exercise price of an option granted to any employee shall be not less than 100% of the fair market value at the date of grant in the case of ISOs or 85% of the fair market value at the date of grant in the case of an NSO. The exercise price of an ISO or NSO granted to one of our Named Executive Officers shall not be less than 100% fair market value of the shares at the date of grant and the exercise price of an ISO granted to a 10% shareholder shall not be less than 110% of the fair market value of the shares on the date of grant. Stock options granted under the 2013 Plan typically vest over four years and have a 10-year term. All RSUs are considered to be granted at the fair value of our stock on the date of grant because they have no exercise price. RSUs typically vest over four years. As of December 31, 2022, there were 1,563,345 shares available for grant under the 2013 Plan.
XML 26 R14.htm IDEA: XBRL DOCUMENT v3.23.1
Stock-Based Compensation
12 Months Ended
Dec. 31, 2022
Stock-Based Compensation [Abstract]  
Stock-Based Compensation
Note 6 − Stock-Based Compensation

The following tables summarize information and activity under the plan for the indicated periods.

Options Outstanding
   
Options Vested and Exercisable
 
Range of
Exercise Prices
 
Number
Outstanding
   
Weighted
Average
Remaining
Contractual
Life (Years)
   
Weighted
Average
Exercise
Price
   
Number
Exercisable
   
Weighted
Average
Remaining
Contractual
Life (Years)
   
Weighted
Average
Exercise
Price
 
$ 1.22 - 1.58     801,004       9.40     $
1.48       122,001       9.38     $
1.45  
$ 2.35 -  6.95
   
5,504,396
     
5.66
   
$
4.50
     
4,602,729
     
5.17
   
$
4.42
 
$ 14.52 - 35.05
   
510,625
     
0.93
   
$
20.32
     
510,625
     
0.93
   
$
20.32
 
     
6,816,025
     
5.75
   
$
5.33
     
5,235,355
     
4.86
   
$
5.90
 

 
Options
 
   
Number of
Shares
   
Weighted
Average
Exercise
Price
   
Weighted
Average
Remaining
Contractual
Life (Years)
   
Aggregate
Intrinsic
Value
 
Outstanding at December 31, 2019     5,630,021     $
8.49           $
 
Options granted     747,500       6.07              
Options exercised     (262,031 )     3.99              
Options cancelled     (302,969 )     5.30              
Outstanding at December 31, 2020
   
5,812,521
   
$
8.55
     
   
$
 
Options granted
   
999,500
     
4.43
     
     
 
Options exercised
   
   
     
     
 
Options cancelled
   
(414,584
)
   
22.54
     
     
 
Outstanding at December 31, 2021
   
6,397,437
   
$
6.99
     
   
$
 
Options granted
   
801,004
     
1.48
     
     
 
Options exercised
   
     
     
     
 
Options cancelled
   
(382,416
)
   
25.06
     
     
 
Outstanding at December 31, 2022
   
6,816,025
   
$
5.33
     
5.75
   
$
3
 
Options exercisable at December 31, 2022
   
5,235,355
   
$
5.90
     
4.86
   
$
2
 

 
RSUs
 
   
Number of
RSUs
   
Weighted
Average
Grant Date
Fair Value
   
Aggregate
Intrinsic
Value
 
Outstanding at December 31, 2019     498,489     $ 4.71     $  
RSUs granted     218,329       6.89      
 
RSUs vested     (212,495 )     4.63      
 
RSUs cancelled                  
Outstanding at December 31, 2020
   
504,323
   
$
5.69
   
$
 
RSUs granted
   
236,661
     
4.61
     
 
RSUs vested
   
(215,165
)
   
5.23
     
 
RSUs cancelled
   
(16,664
)
   
5.45
     
 
Outstanding at December 31, 2021
   
509,155
   
$
5.38
   
$
 
RSUs granted
   
258,363
     
1.46
     
 
RSUs vested
   
(215,413
)
   
5.15
     
 
RSUs cancelled
                 
Outstanding at December 31, 2022
   
552,105
   
$
3.65
   
$
 

Intrinsic value is calculated as the difference between the per-share market price of our common stock on the last trading day of 2022, which was $1.30 and the exercise price of the options. For options exercised, the intrinsic value is the difference between market price and the exercise price on the date of exercise. In 2022 and 2021, no options were exercised. In 2020, we received cash proceeds of $1,046 from stock options exercised. The total intrinsic value of options exercised was $151 in 2020.

Stock-based compensation expense is included in operating expense for each period as follows:

Stock-Based Compensation by Type of Award
 
Year Ended
December 31, 2022
   
Year Ended
December 31, 2021
   
Year Ended
December 31, 2020
 
Stock options
 
$
2,303
   
$
3,067
    $
2,872  
RSUs
   
1,027
     
1,117
      1,066  
Total stock-based compensation expense
 
$
3,330
   
$
4,184
    $
3,938  

As of December 31, 2022, there was $3,972 of unrecognized stock-based compensation expense related to unvested stock options and $1,449 of unrecognized stock-based compensation expense related to unvested RSUs. These costs are expected to be recognized over a weighted-average period of 2.66 and 2.43 years, respectively.

The fair value of each option grant was estimated on the date of grant using the Black-Scholes option pricing model using the following weighted average assumptions:

 
Year Ended
December 31, 2022
   
Year Ended
December 31, 2021
   
Year Ended
December 31, 2020
 
Expected stock price volatility
   
85.39
%
   
90.58
%
    93.45 %
Risk-free interest rate
   
3.09
%
   
1.06
%
    0.63 %
Expected life term
 
6.2 years
   
6.2 years
      6.2 years  
Expected dividends
   
0
%
   
0
%
    0 %

Based on the Black-Scholes option pricing model, the weighted average estimated fair value of employee stock options granted was $1.09, $3.32 and $4.62 per share during 2022, 2021 and 2020, respectively.
The expected life was determined using the simplified method outlined in ASC 718, “Compensation - Stock Compensation”. Expected volatility of the stock options was based upon historical data and other relevant factors.
XML 27 R15.htm IDEA: XBRL DOCUMENT v3.23.1
Earnings Per Share
12 Months Ended
Dec. 31, 2022
Earnings Per Share [Abstract]  
Earnings Per Share
Note 7 − Earnings Per Share

Basic earnings per share are based on the weighted average number of shares outstanding for a period. Diluted earnings per share are based upon the weighted average number of shares and potentially dilutive common shares outstanding. Potential common shares outstanding principally include stock options and RSUs under our stock plan and warrants. During 2022 and 2021, we incurred losses; therefore, the effect of any common stock equivalent would be anti-dilutive during those years.

The table below sets forth the basic and diluted loss per share calculations:

    Year Ended December 31,  
 
2022
   
2021
    2020
 
Net (loss) income
 
$
(36,260
)
 
$
(42,921
)
  $ 280,429  
                         
Basic weighted average number of shares outstanding
    71,335
      71,159
      70,850  
Effect of dilutive securities
   
     
      766  
Diluted weighted average number of shares outstanding
   
71,335
     
71,159
      71,616  
                         
Basic (loss) earnings per share
 
$
(0.51
)
 
$
(0.60
)
  $ 3.96  
Diluted (loss) earnings per share
 
$
(0.51
)
 
$
(0.60
)
  $ 3.92  
XML 28 R16.htm IDEA: XBRL DOCUMENT v3.23.1
Common Stock
12 Months Ended
Dec. 31, 2022
Common Stock [Abstract]  
Common Stock
Note 8 − Common Stock

Each share of common stock has the right to one vote. The holders of common stock are entitled to receive dividends whenever funds are legally available and when declared by our Board of Directors, subject to the prior rights of holders of all classes of stock outstanding having priority rights as to dividends. Our restated articles of incorporation authorize us to issue up to 100,000,000 shares of $0.0001 par value common stock.

On July 30, 2018 we filed a universal shelf registration statement on SEC Form S-3. This replacement registration statement was declared effective by the SEC on August 16, 2018. We used the universal shelf proceeds for development and marketing of our software product and services, and general corporate purposes. The universal shelf registration expired August 16, 2021.

Dividends

On May 8, 2020, we declared a special cash dividend to shareholders of record as of the close of business on May 18, 2020 of $1 per share of common stock, payable on May 26, 2020. The timing and amounts of future dividends, if any, will depend on market conditions, corporate business and financial considerations and regulatory requirements.

Warrants

In 2020, we issued warrants for the purchase of 25,000 shares of common stock at an exercise price of $5.75 per share, exercisable on the date of grant expiring in April 2025. The weighted average fair value at the grant date was $4.16 per warrant. The fair value at the grant date was estimated utilizing the Black-Scholes valuation model with the following weighted average assumptions (i) dividend yield on our common stock of 0 percent (ii) expected stock price volatility of 97 percent (iii) a risk-free interest rate of 0.27 percent and (iv) and expected option term of 5 years.

Warrants Issued
   
Exercise
Price
   
Outstanding and
Exercisable
December 31, 2021
   
Issued
   
Exercised
   
Terminated /
Cancelled
   
Outstanding and
Exercisable
December 31, 2022
 
Expiration Date
 
 
25,000
   
$
5.75
     
25,000
     
     
     
     
25,000
 
April 30, 2025
 

In April 2020, 25,000 warrants with an exercise price of $7.00 per share expired.
XML 29 R17.htm IDEA: XBRL DOCUMENT v3.23.1
Employee Benefit Plan
12 Months Ended
Dec. 31, 2022
Employee Benefit Plan [Abstract]  
Employee Benefit Plan
Note 9 − Employee Benefit Plan

We sponsor a defined contribution 401k plan covering substantially all our employees. Our matching contribution to the plan was approximately $179, $145, and $112 in 2022, 2021 and 2020, respectively.
XML 30 R18.htm IDEA: XBRL DOCUMENT v3.23.1
Income Taxes
12 Months Ended
Dec. 31, 2022
Income Taxes [Abstract]  
Income Taxes
Note 10 − Income Taxes

The income tax provision (benefit) is comprised of the following:

 
Year Ended
December 31, 2022
   
Year Ended
December 31, 2021
    Year Ended
December 31, 2020
 
Current:
                 
Federal
 
$
   
$
661
    $ 35,122  
State
   
3
     
35
      950  
Foreign                  
     
3
     
696
      36,072  
Deferred:
                       
Federal
   
15,920
     
(7,025
)
    (8,816 )
State
   
109
     
124
      (233 )

    16,029       (6,901 )     (9,049 )
Total income tax (benefit) provision
  $ 16,032    
$
(6,205
)
  $ 27,023  
 
A reconciliation of the United States federal statutory income tax rate to our effective income tax rate is as follows:

 
Year Ended
December 31, 2022
   
Year Ended
December 31, 2021
    Year Ended
December 31, 2020
 
United States federal statutory rate
   
21.00
%
   
21.00
%
    21.00 %
State taxes, net of federal benefit
   
(0.55
)%
   
(0.31
)%
    0.17 %
Valuation allowance
   
(91.21
)%
   
      (12.22 )%
Stock based compensation
   
(9.44
)%
   
(6.68
)%
    (0.01 )%
R&D Credit
   
1.22
%
   
0.19
%
    (0.21 )%
Other
   
(0.29
)%
   
(1.57
)%
    0.06 %
Effective income tax rate
    (79.27 )%    
12.63
%
    8.79 %

The Company’s effective tax rate for 2022 and 2020 was substantially lower than the statutory Federal income tax rate primarily due to the change in valuation allowance. The Company’s effective tax rate for 2021 was substantially lower than the statutory Federal income tax rate primarily due to the effect of stock based compensation, including expiring options.
 
Deferred tax assets (liabilities) consist of the following:

 
As of
December 31, 2022
   
As of
December 31, 2021
 
Deferred tax assets:
           
Reserves and accruals
 
$
147
   
$
58
 
Research and development credits and other credits
   
430
     
92
 
Net operating loss carry forward
   
11,988
     
9,519
 
Stock based compensation
   
5,018
     
6,287
 
Other
   
970
     
 
Total deferred tax assets
 
$
18,553
   
$
15,956
 
                 
Valuation allowance
   
(18,553)
     
 
Deferred tax assets after valuation allowance
   
     
15,956
 
                 
Total deferred tax liability – depreciation and amortization
   
     
(6
)
                 
Net deferred tax assets
 
$
   
$
15,950
 

Pursuant to changes in IRC Section 174 effective for 2022, we capitalized direct and indirect research and development costs in our tax return totaling $5,140; $514 of these expenses will be amortized in our 2022 tax return. At December 31, 2022, we had federal and state net operating loss carryforwards of approximately $57,085 and $108,745, respectively. Federal net operating loss carryforwards do not expire. None of the state net operating loss carryforward is apportioned to a deferred tax asset, because currently we do not have operations in states where losses accumulated. The state net operating loss carryforward begins expiring in 2029.

We are required to recognize the financial statement effects of a tax position when it is more likely than not, based on the technical merits, that the position will be sustained upon examination. At December 31, 2022, we have no uncertain tax positions.
Our tax years for 2005 and forward are subject to examination by the U.S. tax authority and various state tax authorities. These years are open due to NOLs and tax credits generated in these years were utilized in 2020. The statute of limitation for these years shall expire three years after the date of filing 2020 income tax returns, which is October 2024.
Our policy is to recognize interest and penalties, if any, accrued on any unrecognized tax benefits, as a component of income tax expense. We had no interest or penalties accrued in 2022.
XML 31 R19.htm IDEA: XBRL DOCUMENT v3.23.1
Fair Value Measurement
12 Months Ended
Dec. 31, 2022
Fair Value Measurement [Abstract]  
Fair Value Measurement
Note 11 − Fair Value Measurement

Fair value is the price that would result from an orderly transaction between market participants at the measurement date. A fair value hierarchy prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement). Level 2 measurements utilize either directly or indirectly observable inputs in markets other than quoted prices in active markets.

Our financial instruments are stated at amounts that equal, or approximate, fair value. When we estimate fair value, we utilize market data or assumptions that we believe market participants would use in pricing the financial instrument, including assumptions about risk and inputs to the valuation technique. We use valuation techniques, primarily the income and market approach, which maximizes the use of observable inputs and minimize the use of unobservable inputs for recurring fair value measurements.
Mutual funds: Valued at the quoted net asset value (NAV) of shares held.
U.S. agency and treasury securities: Fair value measured at the closing price reported on the active market on which the individual securities are traded.

The following table shows the adjusted cost, gross unrealized gains, gross unrealized losses, and fair value of our financial assets as of December 31, 2022 and 2021 (in thousands):

 
December 31, 2022
 
   
Adjusted
Cost
   
Unrealized
Gains
   
Unrealized
Losses
   
Fair
Value
   
Cash
and Cash
Equivalents
   
Investments
Available
for Sale
 
Cash
 
$
16,949
   
$
   
$
   
$
16,949
   
$
16,949
   
$
 
Level 1:
                                               
Mutual funds
   
66,493
     
     
     
66,493
     
66,493
     
 
U.S. agency and treasury securities
   
68,958
     
9
     
(386
)
   
68,581
     
3,119
     
65,462
 
     
135,451
     
9
     
(386
)
   
135,074
     
69,612
     
65,462
 
Total
 
$
152,400
   
$
9
   
$
(386
)
 
$
152,023
   
$
86,561
   
$
65,462
 

 
December 31, 2021
 
   
Adjusted
Cost
   
Unrealized
Gains
   
Unrealized
Losses
   
Fair
Value
   
Cash
and Cash
Equivalents
   
Investments
Available
for Sale
 
Cash
 
$
35,428
   
$
   
$
   
$
35,428
   
$
35,428
   
$
 
Level 1:
                                               
Mutual funds
   
106,590
     
     
     
106,590
     
106,590
     
 
U.S. agency and treasury securities
    27,304             (50 )     27,254             27,254  
     
133,894
     
     
(50
)
   
133,844
     
106,590
     
27,254
 
Total
 
$
169,322
   
$
   
$
(50
)
 
$
169,272
   
$
142,018
   
$
27,254
 

The maturities of our investments generally range from within one to two years. Actual maturities could differ from contractual maturities due to call or prepayment provisions.
XML 32 R20.htm IDEA: XBRL DOCUMENT v3.23.1
Litigation
12 Months Ended
Dec. 31, 2022
Litigation [Abstract]  
Litigation
Note 12 − Litigation (all dollar amounts in this section are expressed in thousands except for rates per device)

We have several intellectual property infringement lawsuits pending in the United States Court of Appeals for the Federal Circuit (“USCAFC”).

VirnetX Inc. v. Apple, Inc. (Case 6:12-CV-00855-LED) (“Apple II”)

This case began on November 6, 2012, when we filed a complaint against Apple in United States District Court (“USDC”) in which we alleged that Apple infringed on certain of our patents, (U.S. Patent Nos. 6,502,135, 7,418,504, 7,921,211 and 7,490,151). We sought damages and injunctive relief. The accused products include the iPhone 5, iPod Touch 5th Generation, iPad 4th Generation, iPad mini, and the latest Macintosh computers. Post-trial motions hearing was held on July 18, 2018. On August 31, 2018, the USDC entered a Final Judgment and issued its Memorandum Opinion and Order regarding post-trial motions, affirming the jury’s verdict of $502,600 and granting VirnetX motions for supplemental damages, a sunset royalty, and the royalty rate of $1.20 per infringing iPhone, iPad and Mac products, pre-judgment and post-judgment interest and costs. Apple filed a notice of appeal with the United States Court of Appeals for the Federal Circuit (“USCAFC”) in the Apple II case.

On October 9, 2018, USCAFC docketed the appeal as Case No. 19-1050 - VirnetX Inc. v. Apple Inc. On January 24, 2019 Apple filed its opening brief. We filed our response brief on March 1, 2019. Apple filed its reply brief on April 5, 2019. The oral arguments were heard on October 4, 2019. On November 22, 2019, the USCAFC issued an opinion affirming the district court’s findings that Apple is precluded from making certain invalidity arguments and that Apple infringed the ‘135 and ‘151 patents; reversing the USDC’s finding that Apple infringed the ‘504 and ‘211 patents; and remanding the case for proceedings on damages. Apple sought panel and en banc rehearing, which the USCAFC denied on February 10, 2020.

On February 22, 2020, the USDC issued a scheduling order for the parties to brief the court about the need for a new trial for recalculating the damages. We filed our motion for entry of judgment on February 28, 2020. The arguments on this matter were heard on April 14, 2020. In its order, unsealed on May 1, 2020, the USDC denied VirnetX’s motion for entry of a new judgment based on the prior jury verdict and ordered a new jury trial on damages. On August 10, 2020, the USDC granted Apple’s motion for continuance and reset the date to October 26, 2020. On October 30, 2020, a jury returned a $502,800 verdict in favor of VirnetX based on Apple’s infringement of two network security patents: VirnetX US Patents No. 6,502,135 and No. 7,490,151. The jury verdict called for damages of $0.84 per accused device since the 2013 launch of Apple’s iOS 7 operating system and represents 598,629,580 infringing units from US sales only. On January 15, 2021, the district court denied Apple’s motion for judgment as a matter of law, and on February 4, 2021, Apple filed a notice of appeal to the USCAFC.

On February 22, 2021, USCAFC docketed the appeal as Case No. 19-1672. Apple’s opening brief was filed on June 2, 2021. VirnetX filed its responsive brief on July 26, 2021. Apple filed its reply brief on September 13, 2021. The briefing is complete, and oral arguments were held on September 8, 2022. On March 31, 2023, the Federal Circuit issued its decision vacating the district court’s judgement in this matter and remanding it back to the district court with instructions to dismiss the case as moot. We are evaluating all of our available options in this matter, including potentially seeking rehearing or certiorari review.

VirnetX Inc. v. Mangrove Partners Master Fund, Ltd., Apple Inc. (USCAFC Case 20-2271) and VirnetX Inc. v. Mangrove Partners Master Fund, Ltd., Apple Inc., and Black Swamp, LLC (USCAFC Case 20-2272)

On September 15, 2020, we filed with the USCAFC an appeal of the invalidity findings by the Patent Trial and Appeal Board (“PTAB”) in inter-partes review proceedings IPR2015-01046 and IPR2016-00062 involving our U.S. Patent No. 6,502,135, and an appeal of the invalidity findings by the PTAB in inter-partes review proceedings IPR2015-1047, IPR2016- 00063, and IPR2016-00167 involving our U.S. Patent No. 7,490,151. On September 25, 2020, the USCAFC issued an order consolidating the two appeals. On December 15, 2020, we filed a motion to vacate the PTAB decisions below and to remand these appeals to the PTAB. On March 16, 2021, the USCAFC denied the motion without prejudice to us raising the challenges made in the motion in our opening brief. Our opening brief was filed on June 7, 2021.

On June 23, 2021, the USCAFC entered an order directing us (and parties in other appeals that raised Appointments Clause challenges) to file a brief explaining how they believe their cases should proceed in light of the Supreme Court’s decision in United States v. Arthrex, Inc., 141 S. Ct. 1970 (2021). On July 7, 2021, we filed a brief in response to the court’s order. Other parties, including the U.S. Patent and Trademark Office (“USPTO”) filed their responses on July 21, 2021. On August 19, 2021, USCAFC issued an order remanding these appeals for the limited purpose of allowing VirnetX the opportunity to request rehearing of the PTAB’s final written decisions by the Director of the USPTO. The USCAFC retained jurisdiction over the appeals in the meantime. On September 20, 2021, we filed our requests for Director rehearing with the USPTO. On October 29, 2021, our requests for Director rehearing were denied. We subsequently filed an amended opening brief to the USCAFC on December 10, 2021, the other parties filed response briefs on February 2, 2022, and we filed a reply brief on February 22, 2022. All the briefings have been completed. The oral arguments in this matter were held on September 8, 2022. On March 30, 2023, the USCAFC issued its decision affirming PTAB’s decisions finding certain claims of the ‘135 patent and the ‘151 patent to be unpatentable. We are evaluating all of our available options in this matter, including potentially seeking rehearing or certiorari review.

VirnetX Inc. v. Hirshfeld (USCAFC Case 17-2593, -2594)

On September 22, 2017, we filed with the USCAFC an appeal of the invalidity findings by the PTAB in inter-partes review proceeding IPR2016-00693 involving our U.S. Patent No. 7,418,504, and an appeal of the invalidity findings by the PTAB in inter-partes review proceeding IPR2016-00957 involving our U.S. Patent No. 7,921,211. On September 16, 2021, USCAFC issued an order remanding these appeals for the limited purpose of allowing VirnetX the opportunity to request rehearing of the PTAB’s final written decisions by the Director of the USPTO. The USCAFC retained jurisdiction over the appeals in the meantime. On October 18, 2021, we filed our requests for Director rehearing with the USPTO. On January 7, 2022, our requests for Director rehearing were denied. On January 21, 2022, we informed the USCAFC about the denial of Director rehearing and requested that the court dismiss the appeal involving IPR2016-00957 as moot and vacate the PTAB’s underlying decision. On April 4, 2022, the USCAFC vacated the PTAB’s decision in IPR2016-00957 and remanded Appeal No. 17-2594 with instructions to dismiss. In the April 4, 2022 order, the USCAFC further set a briefing schedule, in Appeal No. 17-2593. VirnetX filed its opening brief on September 12, 2022. The USPTO filed its response brief on December 20, 2022. VirnetX filed its reply brief on February 14, 2023, and we currently await scheduling of oral arguments.

VirnetX Inc. v. Cisco Systems, Inc. (USCAFC Case 19-1671)

On March 18, 2019, we filed with the USCAFC an appeal of the invalidity findings by the PTAB in inter-partes re-examination proceeding 95/001,679 involving our U.S. Patent No. 6,502,135. On October 5, 2021, USCAFC issued an order remanding these appeals for the limited purpose of allowing VirnetX the opportunity to request rehearing of the PTAB’s final written decisions by the Director of the PTO. The USCAFC retained jurisdiction over the appeals in the meantime. Our request for Director rehearing with the PTO was filed on November 5, 2021. On January 10, 2022, our request for Director rehearing was denied. We informed the USCAFC about the denial of Director rehearing. VirnetX’s opening brief was filed on June 23, 2022. The USPTO’s response brief was filed on August 2, 2022, and Cisco’s response brief was filed on September 2, 2022. VirnetX filed its reply brief on October 7, 2022, and we currently await scheduling of oral arguments.

VirnetX Inc. v. Apple Inc. (USCAFC Case 22-1523) (“Apple Reexam I”)

On March 10, 2022, we filed with the USCAFC an appeal of the invalidity findings by the PTAB in inter-partes re-examination proceeding 95/001,682 involving our U.S. Patent No. 6,502,135. Our opening brief was filed on August 22, 2022. Apple and USPTO each filed a response brief on December 28, 2022. VirnetX filed its reply brief on February 8, 2023, and we currently await scheduling of oral arguments.

VirnetX Inc. v. Apple Inc. (USCAFC Case 22-1997) (“Apple Reexam II”)

On July 6, 2022, we filed with the USCAFC an appeal of the invalidity findings by the PTAB in inter-partes re-examination proceeding 95/001,697 involving our U.S. Patent No. 7,490,151. On October 17, 2022, we filed a motion to remand the appeal in light of the PTAB’s refusal to permit Director rehearing. On January 23, 2023, the USCAFC denied that motion without prejudice to the parties raising their arguments in the merits briefs. VirnetX’s opening brief is currently due April 24, 2023.

VirnetX Inc. v. Cisco Systems, Inc. (USCAFC Case 22-2234)

On September 16, 2022, we filed with the USCAFC an appeal of the invalidity findings by the PTAB in inter-partes re-examination proceeding 95/001,851 involving our U.S. Patent No. 7,418,504. We filed our opening brief on February 28, 2023.

McKool Smith P.C. v. VirnetX, Inc., AAA Case No. 01-20-0003-7975

On March 23, 2020, the law firm of McKool Smith, P.C. (“McKool”) filed a Demand for Arbitration against VirnetX, Inc. with the American Arbitration Association (“AAA”). In its demand, McKool claimed that a retention agreement it entered into in 2010 with VirnetX entitled it to a contingency fee arising from the recent 2020 payment made in the Apple I case. McKool claimed it was owed approximately $36,300 (or 8% of the Apple I payment). We filed a general response with the AAA denying McKool’s claim and contested the matter vigorously. An evidentiary hearing was held on the matter during the week of February 22, 2021 and the parties submitted additional briefings. On April 19, 2021, the arbitrator awarded McKool $36,323 in damages, plus pre-judgment interest in the amount of 5% simple interest from March 23, 2020 to April 18, 2021, and post-judgment interest in the amount of 5%, compounded annually, until payment of the award. We accrued the resulting $38,284 as of March 31, 2021 and paid that amount to McKool on April 20, 2021. This matter is now closed.

Other Legal Matters

One or more potential intellectual property infringement claims may also be available to us against certain other companies who have the resources to defend against any such claims. Although we believe these potential claims are likely valid, commencing a lawsuit can be expensive and time-consuming, and there is no assurance that we could prevail on such potential claims if we made them. In addition, bringing a lawsuit may lead to potential counterclaims which may distract our management and our other resources, including capital resources, from efforts to successfully commercialize our products.

Currently, we are not a party to any other pending legal proceedings and are not aware of any proceeding threatened or contemplated against us.
XML 33 R21.htm IDEA: XBRL DOCUMENT v3.23.1
Leases
12 Months Ended
Dec. 31, 2022
Leases [Abstract]  
Leases
Note 13 − Leases

We lease office space under an operating lease which expires on October 31, 2023. At December 31, 2022, the underlying ROU asset and lease liability totaled $45. At December 31, 2021, the underlying ROU asset and lease liability totaled $98. Lease expense totaled $54 in 2022 and $56 in 2021 and 2020.

We also lease a facility for corporate promotional and marketing purposes which was prepaid at inception and originally expired in 2024. In September 2020, the lease was extended for one year to 2025, due to COVID use-restrictions. No other terms of the original agreement were affected and there was no impact on cash flow. At December 31, 2022 and 2021, the ROU asset totaled $648 and $948, respectively; lease expense totaled $300, $300 and $356, during 2022, 2021 and 2020, respectively.
XML 34 R22.htm IDEA: XBRL DOCUMENT v3.23.1
Subsequent Event
12 Months Ended
Dec. 31, 2022
Subsequent Event [Abstract]  
Subsequent Event
Note 14 − Subsequent Event
On March 30, 2023, we declared a special cash dividend of $1.00 per common share to be paid on or about April 17, 2023 to shareholders of record on April 10, 2023. If the final outcome of the Apple II litigation described elsewhere in this Form 10-K results in proceeds to us, we are committed to distribute to our shareholders a substantial portion of the net proceeds (after legal costs, licensing costs and taxes), after the case concludes.
XML 35 R23.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies (Policies)
12 Months Ended
Dec. 31, 2022
Summary of Significant Accounting Policies [Abstract]  
Use of Estimates
Use of Estimates

We prepare our consolidated financial statements in accordance with U.S. GAAP. In doing so, we have to make estimates and assumptions that affect our reported amounts of assets, liabilities, revenues, and expenses, as well as related disclosure of contingent assets and liabilities. In some cases, we could reasonably have used different accounting policies and estimates. In some cases, changes in the accounting estimates are reasonably likely to occur from period to period. Accordingly, actual results could differ materially from our estimates. To the extent that there are material differences between these estimates and actual results, our financial condition or results of operations will be affected. We base our estimates on past experience and other assumptions that we believe are reasonable under the circumstances, and we evaluate these estimates on an ongoing basis. We refer to accounting estimates of this type as critical accounting policies and estimates, which we discuss further below. We have reviewed our critical accounting policies and estimates with the Audit Committee of our Board of Directors.
Basis of Consolidation
Basis of Consolidation

The consolidated financial statements include the accounts of VirnetX Holding Corporation and our wholly owned subsidiaries. All intercompany balances and transactions have been eliminated.
Revenue Recognition
Revenue Recognition

The Company derives revenue from licensing and royalty fees from contracts with customers which often span several years. We account for this revenue in accordance with Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. Our revenue arrangements may consist of multiple-element arrangements, with revenue for each unit of accounting recognized as the product or service is delivered to the customer.

With the licensing of our patents, performance obligations are generally satisfied at a point in time as work is complete when our patent rights are transferred to our customers. We generally have no further obligation to our customers regarding our technology.

Certain contracts may require our customers to enter into a hosting arrangement with us and for these arrangements, revenue is recognized over time, generally over the life of the servicing contract.

The Company actively monitors and enforces its intellectual property (“IP”) rights, including seeking appropriate compensation from third parties that utilize the Company’s IP without a license. As a result, the Company may, from time to time, receive payments as part of a settlement or compensation for a patent infringement dispute. Proceeds received are allocated to each element identified in the settlement or compensation, based on the fair value of each element. Generally, settlements and compensation may include the following elements: the value of a license or royalty agreement, cost reimbursement, damages, and interest. Elements identified related to licensing and royalty are recognized as revenue. Elements identified as reimbursed costs are generally recorded as a reduction to the reported expenses. Elements identified as damages or interest are generally recorded in other income in the condensed consolidated statement of operations. During the year ended December 31, 2020, the Company collected a lump sum payment of $454,034 from Apple, Inc., because of a favorable court decision relating to a patent infringement case. The court decision identified the following as the basis of the award: $302,428 for past royalties, $41,271 in damages for willful infringement, $108,221 for interest, and $2,114 in reimbursement for court costs and attorney’s fees. Elements of the payment were recognized in the Company’s condensed consolidated statement of operations as follows:

Classification of Payment Received in the Company’s Condensed Consolidated Statement of Operations
 
Year Ended:
 
 
December 31, 2020
 
Revenue (royalties)
 
$
302,428
 
Operating expenses: selling, general and administrative (reimbursed litigation costs)
   
2,114
 
Other income: gain (willful infringement)
   
41,271
 
Other income: interest income (pre- and post-judgment interest)
   
108,221
 
Total cash received
 
$
454,034
 
Licensing Costs
Licensing Costs

Included in operating expenses are licensing costs we incurred in conjunction with the proceeds received from Apple Inc., pursuant to a favorable court decision relating to a patent infringement case.
Contingent Gains
Contingent Gains

ASC Topic 450-30-25, Contingent Gains, prohibits recognition of contingent gains until realized. Accordingly, we do not record contingent gains ahead of such realization. Management generally considers any such gains as realized only upon the collection of cash.
Cash and Cash Equivalents
Cash and Cash Equivalents

We consider all highly liquid investments purchased with original maturities of three months or less at the date of purchase to be cash equivalents. Our cash and cash equivalents are not subject to significant interest rate risk due to the short maturities of these investments.
Investments
Investments

Investments are classified as available-for-sale and are recorded at fair market value. Unrealized gains and losses are reported as other comprehensive income. Realized gains and losses are recorded in income in the period they are realized using specific identification of each security’s cost basis. We invest our excess cash primarily in highly liquid debt instruments including corporate, government and federal agency securities, with contractual maturities less than two years. By policy, we limit the amount of credit exposure to any one issuer.
Concentration of Credit Risk and Other Risks and Uncertainties
Concentration of Credit Risk and Other Risks and Uncertainties

Our cash and cash equivalents are primarily maintained at two major financial institutions in the United States. Deposits held with these financial institutions may exceed the amount of insurance provided on such deposits. A portion of those balances are insured by the Federal Deposit Insurance Corporation, or FDIC. In 2022, we had, at times, funds that were uninsured. We do not believe that we are subject to any unusual financial risk beyond the normal risk associated with commercial banking relationships. We have not experienced any losses on our deposits of cash and cash equivalents.
Fair Value
Fair Value

The carrying amounts of our financial instruments, including cash equivalents, accounts payable, and accrued liabilities, approximate fair value because of their generally short maturities.
Property and Equipment
Property and Equipment

Property and equipment are stated at historical cost, less accumulated depreciation, and amortization. Depreciation and amortization are computed using the accelerated and straight-line methods over the estimated useful lives of the assets, which range from five to seven years. Repair and maintenance costs are charged to expense as incurred.
Leases
Leases

The Company determines if an arrangement is a lease at inception in accordance with ASC Topic 842. Operating lease right-of-use (“ROU”) assets are included in Prepaid expenses, and other assets on the Condensed Consolidated Balance Sheets. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term.
Intangible Assets
Intangible Assets

We record intangible assets at cost, less accumulated amortization. Amortization of intangible assets is provided over their estimated useful lives, which can range from 3 to 15 years, on either a straight-line basis or as revenue is generated by the assets.
Impairment of Long-Lived Assets
Impairment of Long-Lived Assets

We identify and record impairment losses on long-lived assets used in operations when events and changes in circumstances indicate that the carrying amount of an asset might not be recoverable, but not less than annually. Recoverability is measured by comparison of the anticipated future net undiscounted cash flows to the related assets’ carrying value. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the asset.
Research and Development
Research and Development

Research and development costs include expenses paid to outside development consultants and compensation related expenses for our engineering staff. Research and development costs are expensed as incurred.
Income Taxes
Income Taxes

We account for income taxes using the asset and liability method. The asset and liability method requires the recognition of deferred tax assets and liabilities for expected future tax consequences of temporary differences that currently exist between the tax basis and financial reporting basis of our assets and liabilities. We calculate current and deferred tax provisions based on estimates and assumptions that could differ from actual results reflected on the income tax returns filed during the following years. Adjustments based on filed returns are recorded when identified in the subsequent years. The effect on deferred taxes for a change in tax rates is recognized in income in the period that the tax rate change is enacted. In assessing our deferred tax assets, we consider whether it is more likely than not that all or some portion of the deferred tax assets will not be realized.

The 2017 U.S. Tax Cuts and Jobs Act changes IRC Section 174, regarding capitalization of book research and development (“R&D”) expenses for income tax purposes.  Effective for tax years beginning in 2022 IRC Section 174 requires the capitalization of book R&D expenses which are capitalized and amortized over 5 years for domestic R&D expenses and over 15 years for foreign R&D expenses.  To date there has been limited guidance from the IRS on how to quantify the amount of book R&D expenses subject to capitalization, including the indirect expenses supporting the R&D function.  Due to the limited guidance, some assumptions were made in our estimates.

A valuation allowance is provided for deferred income tax assets when, in our judgment, based upon currently available information and other factors, it is more likely than not that all or a portion of such deferred income tax assets will not be realized. The determination of the need for a valuation allowance is based on an on-going evaluation of current information including, among other things, historical operating results, estimates of future earnings in different taxing jurisdictions and the expected timing of the reversals of temporary differences. We believe the determination to record a valuation allowance to reduce a deferred income tax asset is a significant accounting estimate because it is based, among other things, on an estimate of future taxable income in the United States and certain other jurisdictions, which is susceptible to change and may or may not occur, and because the impact of adjusting a valuation allowance may be material. In determining when to release the valuation allowance established against our net deferred income tax assets, we consider all available evidence, both positive and negative. We continually assess our ability to generate sufficient taxable income during future periods in which our deferred tax assets may be realized. If and when we believe it is more likely than not that we will recover our deferred tax assets, we will reverse the valuation allowance as an income tax benefit in our statements of operations.

We account for our uncertain tax positions in accordance with U.S. GAAP, which utilizes a two-step approach to evaluate tax positions. Step one, recognition, requires evaluation of the tax position to determine if based solely on technical merits it is more likely than not to be sustained upon examination. Step two, measurement, is addressed only if a position is more likely than not to be sustained. In step two, the tax benefit is measured as the largest amount of benefit, determined on a cumulative probability basis, which is more likely than not to be realized upon ultimate settlement with tax authorities. If a position does not meet the more likely than not threshold for recognition in step one, no benefit is recorded until the first subsequent period in which the more likely than not standard is met, the issue is resolved with the taxing authority, or the statute of limitations expires. Positions previously recognized are derecognized when we subsequently determine the position no longer is more likely than not to be sustained. Evaluation of tax positions, their technical merits, and measurements using cumulative probability are highly subjective management estimates. Actual results could differ materially from these estimates.
Stock-Based Compensation
Stock-Based Compensation

We account for stock-based compensation using the fair value recognition method in accordance with U.S. GAAP. We recognize these compensation costs on a straight-line basis over the requisite service period of the award, which is generally a vesting term of 4 years. We recognize forfeitures, if any, when they occur. In addition, we record stock-based compensation expense for awards granted to non-employees at fair value of the consideration received or the fair value of the equity instruments issued, as they vest, over the performance period (See Note 6 - Stock-Based Compensation).
Earnings per Share
Earnings per Share

Basic earnings per share are computed by dividing earnings available to common stockholders by the weighted average number of outstanding common shares during the period. Diluted earnings per share is computed by dividing net income by the weighted average number of shares outstanding during the period increased to include the number of additional shares of common stock that would have been outstanding if the potentially dilutive securities had been issued.
New Accounting Pronouncements
New Accounting Pronouncements

In December 2019, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2019-12 Income Taxes (Topic 740). The amendments in this ASU simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify U. S. GAAP for other areas of Topic 740 by clarifying and amending existing guidance. The amendments in this ASU are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. We adopted this ASU on January 1, 2021 and there was no material impact on our financial position or cash flows as a result.
XML 36 R24.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies (Tables)
12 Months Ended
Dec. 31, 2022
Summary of Significant Accounting Policies [Abstract]  
Classification of Payment Received in Condensed Consolidated Statement of Operations
Classification of Payment Received in the Company’s Condensed Consolidated Statement of Operations
 
Year Ended:
 
 
December 31, 2020
 
Revenue (royalties)
 
$
302,428
 
Operating expenses: selling, general and administrative (reimbursed litigation costs)
   
2,114
 
Other income: gain (willful infringement)
   
41,271
 
Other income: interest income (pre- and post-judgment interest)
   
108,221
 
Total cash received
 
$
454,034
 
XML 37 R25.htm IDEA: XBRL DOCUMENT v3.23.1
Property and Equipment (Tables)
12 Months Ended
Dec. 31, 2022
Property and Equipment [Abstract]  
Property and Equipment
Our major classes of property and equipment were as follows:

 
December 31
 
   
2022
   
2021
 
Office furniture
 
$
79
   
$
79
 
Computer equipment
   
92
     
92
 
Total
   
171
     
171
 
Less accumulated depreciation
   
(160
)
   
(153
)
Total property and equipment, net
 
$
11
   
$
18
 
XML 38 R26.htm IDEA: XBRL DOCUMENT v3.23.1
Stock-Based Compensation (Tables)
12 Months Ended
Dec. 31, 2022
Stock-Based Compensation [Abstract]  
Information about Stock Options Outstanding
The following tables summarize information and activity under the plan for the indicated periods.

Options Outstanding
   
Options Vested and Exercisable
 
Range of
Exercise Prices
 
Number
Outstanding
   
Weighted
Average
Remaining
Contractual
Life (Years)
   
Weighted
Average
Exercise
Price
   
Number
Exercisable
   
Weighted
Average
Remaining
Contractual
Life (Years)
   
Weighted
Average
Exercise
Price
 
$ 1.22 - 1.58     801,004       9.40     $
1.48       122,001       9.38     $
1.45  
$ 2.35 -  6.95
   
5,504,396
     
5.66
   
$
4.50
     
4,602,729
     
5.17
   
$
4.42
 
$ 14.52 - 35.05
   
510,625
     
0.93
   
$
20.32
     
510,625
     
0.93
   
$
20.32
 
     
6,816,025
     
5.75
   
$
5.33
     
5,235,355
     
4.86
   
$
5.90
 
Stock Option Activity

 
Options
 
   
Number of
Shares
   
Weighted
Average
Exercise
Price
   
Weighted
Average
Remaining
Contractual
Life (Years)
   
Aggregate
Intrinsic
Value
 
Outstanding at December 31, 2019     5,630,021     $
8.49           $
 
Options granted     747,500       6.07              
Options exercised     (262,031 )     3.99              
Options cancelled     (302,969 )     5.30              
Outstanding at December 31, 2020
   
5,812,521
   
$
8.55
     
   
$
 
Options granted
   
999,500
     
4.43
     
     
 
Options exercised
   
   
     
     
 
Options cancelled
   
(414,584
)
   
22.54
     
     
 
Outstanding at December 31, 2021
   
6,397,437
   
$
6.99
     
   
$
 
Options granted
   
801,004
     
1.48
     
     
 
Options exercised
   
     
     
     
 
Options cancelled
   
(382,416
)
   
25.06
     
     
 
Outstanding at December 31, 2022
   
6,816,025
   
$
5.33
     
5.75
   
$
3
 
Options exercisable at December 31, 2022
   
5,235,355
   
$
5.90
     
4.86
   
$
2
 
RSU Activity
 
RSUs
 
   
Number of
RSUs
   
Weighted
Average
Grant Date
Fair Value
   
Aggregate
Intrinsic
Value
 
Outstanding at December 31, 2019     498,489     $ 4.71     $  
RSUs granted     218,329       6.89      
 
RSUs vested     (212,495 )     4.63      
 
RSUs cancelled                  
Outstanding at December 31, 2020
   
504,323
   
$
5.69
   
$
 
RSUs granted
   
236,661
     
4.61
     
 
RSUs vested
   
(215,165
)
   
5.23
     
 
RSUs cancelled
   
(16,664
)
   
5.45
     
 
Outstanding at December 31, 2021
   
509,155
   
$
5.38
   
$
 
RSUs granted
   
258,363
     
1.46
     
 
RSUs vested
   
(215,413
)
   
5.15
     
 
RSUs cancelled
                 
Outstanding at December 31, 2022
   
552,105
   
$
3.65
   
$
 
Stock-Based Compensation by Type of Award
Stock-based compensation expense is included in operating expense for each period as follows:

Stock-Based Compensation by Type of Award
 
Year Ended
December 31, 2022
   
Year Ended
December 31, 2021
   
Year Ended
December 31, 2020
 
Stock options
 
$
2,303
   
$
3,067
    $
2,872  
RSUs
   
1,027
     
1,117
      1,066  
Total stock-based compensation expense
 
$
3,330
   
$
4,184
    $
3,938  
Fair Value Assumptions
The fair value of each option grant was estimated on the date of grant using the Black-Scholes option pricing model using the following weighted average assumptions:

 
Year Ended
December 31, 2022
   
Year Ended
December 31, 2021
   
Year Ended
December 31, 2020
 
Expected stock price volatility
   
85.39
%
   
90.58
%
    93.45 %
Risk-free interest rate
   
3.09
%
   
1.06
%
    0.63 %
Expected life term
 
6.2 years
   
6.2 years
      6.2 years  
Expected dividends
   
0
%
   
0
%
    0 %
XML 39 R27.htm IDEA: XBRL DOCUMENT v3.23.1
Earnings Per Share (Tables)
12 Months Ended
Dec. 31, 2022
Earnings Per Share [Abstract]  
Basic and Diluted Loss Per Share Calculations
The table below sets forth the basic and diluted loss per share calculations:

    Year Ended December 31,  
 
2022
   
2021
    2020
 
Net (loss) income
 
$
(36,260
)
 
$
(42,921
)
  $ 280,429  
                         
Basic weighted average number of shares outstanding
    71,335
      71,159
      70,850  
Effect of dilutive securities
   
     
      766  
Diluted weighted average number of shares outstanding
   
71,335
     
71,159
      71,616  
                         
Basic (loss) earnings per share
 
$
(0.51
)
 
$
(0.60
)
  $ 3.96  
Diluted (loss) earnings per share
 
$
(0.51
)
 
$
(0.60
)
  $ 3.92  
XML 40 R28.htm IDEA: XBRL DOCUMENT v3.23.1
Common Stock (Tables)
12 Months Ended
Dec. 31, 2022
Common Stock [Abstract]  
Information about Warrants Outstanding
Warrants Issued
   
Exercise
Price
   
Outstanding and
Exercisable
December 31, 2021
   
Issued
   
Exercised
   
Terminated /
Cancelled
   
Outstanding and
Exercisable
December 31, 2022
 
Expiration Date
 
 
25,000
   
$
5.75
     
25,000
     
     
     
     
25,000
 
April 30, 2025
 
XML 41 R29.htm IDEA: XBRL DOCUMENT v3.23.1
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2022
Income Taxes [Abstract]  
Income Tax Provision (Benefit)
The income tax provision (benefit) is comprised of the following:

 
Year Ended
December 31, 2022
   
Year Ended
December 31, 2021
    Year Ended
December 31, 2020
 
Current:
                 
Federal
 
$
   
$
661
    $ 35,122  
State
   
3
     
35
      950  
Foreign                  
     
3
     
696
      36,072  
Deferred:
                       
Federal
   
15,920
     
(7,025
)
    (8,816 )
State
   
109
     
124
      (233 )

    16,029       (6,901 )     (9,049 )
Total income tax (benefit) provision
  $ 16,032    
$
(6,205
)
  $ 27,023  
Effective Income Tax Rate Reconciliation
A reconciliation of the United States federal statutory income tax rate to our effective income tax rate is as follows:

 
Year Ended
December 31, 2022
   
Year Ended
December 31, 2021
    Year Ended
December 31, 2020
 
United States federal statutory rate
   
21.00
%
   
21.00
%
    21.00 %
State taxes, net of federal benefit
   
(0.55
)%
   
(0.31
)%
    0.17 %
Valuation allowance
   
(91.21
)%
   
      (12.22 )%
Stock based compensation
   
(9.44
)%
   
(6.68
)%
    (0.01 )%
R&D Credit
   
1.22
%
   
0.19
%
    (0.21 )%
Other
   
(0.29
)%
   
(1.57
)%
    0.06 %
Effective income tax rate
    (79.27 )%    
12.63
%
    8.79 %
Deferred Tax Assets and Liabilities
Deferred tax assets (liabilities) consist of the following:

 
As of
December 31, 2022
   
As of
December 31, 2021
 
Deferred tax assets:
           
Reserves and accruals
 
$
147
   
$
58
 
Research and development credits and other credits
   
430
     
92
 
Net operating loss carry forward
   
11,988
     
9,519
 
Stock based compensation
   
5,018
     
6,287
 
Other
   
970
     
 
Total deferred tax assets
 
$
18,553
   
$
15,956
 
                 
Valuation allowance
   
(18,553)
     
 
Deferred tax assets after valuation allowance
   
     
15,956
 
                 
Total deferred tax liability – depreciation and amortization
   
     
(6
)
                 
Net deferred tax assets
 
$
   
$
15,950
 
XML 42 R30.htm IDEA: XBRL DOCUMENT v3.23.1
Fair Value Measurement (Tables)
12 Months Ended
Dec. 31, 2022
Fair Value Measurement [Abstract]  
Adjusted Cost, Gross Unrealized Gains, Gross Unrealized Losses and Fair Value of Financial Assets
The following table shows the adjusted cost, gross unrealized gains, gross unrealized losses, and fair value of our financial assets as of December 31, 2022 and 2021 (in thousands):

 
December 31, 2022
 
   
Adjusted
Cost
   
Unrealized
Gains
   
Unrealized
Losses
   
Fair
Value
   
Cash
and Cash
Equivalents
   
Investments
Available
for Sale
 
Cash
 
$
16,949
   
$
   
$
   
$
16,949
   
$
16,949
   
$
 
Level 1:
                                               
Mutual funds
   
66,493
     
     
     
66,493
     
66,493
     
 
U.S. agency and treasury securities
   
68,958
     
9
     
(386
)
   
68,581
     
3,119
     
65,462
 
     
135,451
     
9
     
(386
)
   
135,074
     
69,612
     
65,462
 
Total
 
$
152,400
   
$
9
   
$
(386
)
 
$
152,023
   
$
86,561
   
$
65,462
 

 
December 31, 2021
 
   
Adjusted
Cost
   
Unrealized
Gains
   
Unrealized
Losses
   
Fair
Value
   
Cash
and Cash
Equivalents
   
Investments
Available
for Sale
 
Cash
 
$
35,428
   
$
   
$
   
$
35,428
   
$
35,428
   
$
 
Level 1:
                                               
Mutual funds
   
106,590
     
     
     
106,590
     
106,590
     
 
U.S. agency and treasury securities
    27,304             (50 )     27,254             27,254  
     
133,894
     
     
(50
)
   
133,844
     
106,590
     
27,254
 
Total
 
$
169,322
   
$
   
$
(50
)
 
$
169,272
   
$
142,018
   
$
27,254
 
XML 43 R31.htm IDEA: XBRL DOCUMENT v3.23.1
Formation and Business of the Company (Details) - Patents [Member]
Dec. 31, 2022
Patent
Formation and Business of the Company Disclosure [Abstract]  
Number of patents and pending applications 205
U.S. [Member]  
Formation and Business of the Company Disclosure [Abstract]  
Number of patents and pending applications 72
Foreign [Member]  
Formation and Business of the Company Disclosure [Abstract]  
Number of patents and pending applications 133
XML 44 R32.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies (Details)
$ in Thousands
12 Months Ended
Dec. 31, 2022
USD ($)
Institution
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Revenue Recognition [Abstract]      
Revenue (royalties) $ 48 $ 35 $ 302,636
Other Income [Abstract]      
Gain (willful infringement) $ 0 $ 0 41,271
Concentration of Credit Risk and Other Risks and Uncertainties [Abstract]      
Number of financial institutions holding company's cash | Institution 2    
Stock-Based Compensation [Abstract]      
Option vesting term 4 years    
Minimum [Member]      
Property and Equipment [Abstract]      
Useful lives 5 years    
Intangible Assets [Abstract]      
Estimated useful lives 3 years    
Maximum [Member]      
Property and Equipment [Abstract]      
Useful lives 7 years    
Intangible Assets [Abstract]      
Estimated useful lives 15 years    
Positive Outcome of Litigation [Member]      
Revenue Recognition [Abstract]      
Revenue (royalties)     302,428
Operating expense [Abstract]      
Selling, general and administrative (reimbursed litigation costs)     2,114
Other Income [Abstract]      
Gain (willful infringement)     41,271
Interest income (pre- and post-judgment interest)     108,221
Total cash received     $ 454,034
Highly Liquid Debt Investments [Member] | Maximum [Member]      
Investments [Abstract]      
Contractual maturities of investment securities 2 years    
XML 45 R33.htm IDEA: XBRL DOCUMENT v3.23.1
Property and Equipment (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Property and Equipment [Abstract]      
Property and equipment, gross $ 171 $ 171  
Less accumulated depreciation (160) (153)  
Property and equipment, net 11 18  
Depreciation expense 7 4 $ 5
Office Furniture [Member]      
Property and Equipment [Abstract]      
Property and equipment, gross 79 79  
Computer Equipment [Member]      
Property and Equipment [Abstract]      
Property and equipment, gross $ 92 $ 92  
XML 46 R34.htm IDEA: XBRL DOCUMENT v3.23.1
Commitments, Contingencies and Related Party Transactions (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Commitments, Contingencies and Related Party Transactions [Abstract]      
Future minimum rents due in 2023 $ 46    
Office [Member]      
Commitments, Contingencies and Related Party Transactions [Abstract]      
Operating lease, expiration date Oct. 31, 2023    
Rent expense $ 54 $ 56 $ 56
K2 Investment Fund LLC [Member] | Aircraft [Member]      
Commitments, Contingencies and Related Party Transactions [Abstract]      
Rental fees incurred for use of aircraft $ 1,123 $ 791 $ 324
Term of lease 12 months    
Rate of aircraft lease (in dollars per flight hour) $ 8    
Term of notice for cancellation of lease 30 days    
XML 47 R35.htm IDEA: XBRL DOCUMENT v3.23.1
Stock Plan (Details) - shares
1 Months Ended 12 Months Ended
Apr. 30, 2021
Dec. 31, 2022
Stock Plan [Abstract]    
Vesting period   4 years
2013 Plan [Member]    
Stock Plan [Abstract]    
Increase of shares authorized (in shares) 2,500,000  
Shares available for grant (in shares)   1,563,345
2013 Plan [Member] | Stock Options [Member]    
Stock Plan [Abstract]    
Vesting period   4 years
Term of award   10 years
2013 Plan [Member] | Stock Options [Member] | Named Executive Officers [Member] | Minimum [Member]    
Stock Plan [Abstract]    
Exercise price of option granted as percentage of fair market value of shares at date of grant   100.00%
2013 Plan [Member] | Stock Options [Member] | 10% Shareholder [Member] | Minimum [Member]    
Stock Plan [Abstract]    
Exercise price of option granted as percentage of fair market value of shares at date of grant   110.00%
2013 Plan [Member] | Incentive Stock Options [Member] | Minimum [Member]    
Stock Plan [Abstract]    
Exercise price of option granted as percentage of fair market value of shares at date of grant   100.00%
2013 Plan [Member] | Nonqualified Stock Options [Member] | Minimum [Member]    
Stock Plan [Abstract]    
Exercise price of option granted as percentage of fair market value of shares at date of grant   85.00%
2013 Plan [Member] | Restricted Stock Purchase Rights ("RSU") [Member]    
Stock Plan [Abstract]    
Vesting period   4 years
XML 48 R36.htm IDEA: XBRL DOCUMENT v3.23.1
Stock-Based Compensation, Information about Stock Options Outstanding (Details) - Stock Options [Member]
12 Months Ended
Dec. 31, 2022
$ / shares
shares
Information about Stock Options Outstanding [Abstract]  
Options outstanding, number outstanding (in shares) | shares 6,816,025
Options outstanding, weighted average remaining contractual life 5 years 9 months
Options outstanding, weighted average exercise price (in dollars per share) $ 5.33
Options vested and exercisable, number exercisable (in shares) | shares 5,235,355
Options vested and exercisable, weighted average remaining contractual life 4 years 10 months 9 days
Options vested and exercisable, weighted average exercise price (in dollars per share) $ 5.9
$1.22 - 1.58 [Member]  
Information about Stock Options Outstanding [Abstract]  
Exercise price range, lower range limit (in dollars per share) 1.22
Exercise price range, upper range limit (in dollars per share) $ 1.58
Options outstanding, number outstanding (in shares) | shares 801,004
Options outstanding, weighted average remaining contractual life 9 years 4 months 24 days
Options outstanding, weighted average exercise price (in dollars per share) $ 1.48
Options vested and exercisable, number exercisable (in shares) | shares 122,001
Options vested and exercisable, weighted average remaining contractual life 9 years 4 months 17 days
Options vested and exercisable, weighted average exercise price (in dollars per share) $ 1.45
$2.35 - 6.95 [Member]  
Information about Stock Options Outstanding [Abstract]  
Exercise price range, lower range limit (in dollars per share) 2.35
Exercise price range, upper range limit (in dollars per share) $ 6.95
Options outstanding, number outstanding (in shares) | shares 5,504,396
Options outstanding, weighted average remaining contractual life 5 years 7 months 28 days
Options outstanding, weighted average exercise price (in dollars per share) $ 4.5
Options vested and exercisable, number exercisable (in shares) | shares 4,602,729
Options vested and exercisable, weighted average remaining contractual life 5 years 2 months 1 day
Options vested and exercisable, weighted average exercise price (in dollars per share) $ 4.42
$14.52 - 35.05 [Member]  
Information about Stock Options Outstanding [Abstract]  
Exercise price range, lower range limit (in dollars per share) 14.52
Exercise price range, upper range limit (in dollars per share) $ 35.05
Options outstanding, number outstanding (in shares) | shares 510,625
Options outstanding, weighted average remaining contractual life 11 months 4 days
Options outstanding, weighted average exercise price (in dollars per share) $ 20.32
Options vested and exercisable, number exercisable (in shares) | shares 510,625
Options vested and exercisable, weighted average remaining contractual life 11 months 4 days
Options vested and exercisable, weighted average exercise price (in dollars per share) $ 20.32
XML 49 R37.htm IDEA: XBRL DOCUMENT v3.23.1
Stock-Based Compensation, Summary of Activity (Details) - USD ($)
$ / shares in Units, $ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Share-based Compensation [Abstract]        
Per share market price of common stock on last trading day of year (in dollars per share) $ 1.3      
Proceeds from exercise of options $ 0 $ 0 $ 1,046  
Stock Options [Member]        
Options, number of shares [Roll Forward]        
Outstanding, beginning of period (in shares) 6,397,437 5,812,521 5,630,021  
Options granted (in shares) 801,004 999,500 747,500  
Options exercised (in shares) 0 0 (262,031)  
Options cancelled (in shares) (382,416) (414,584) (302,969)  
Outstanding, end of period (in shares) 6,816,025 6,397,437 5,812,521  
Options exercisable, end of period (in shares) 5,235,355      
Options, weighted average exercise price [Roll Forward]        
Outstanding, beginning of period (in dollars per share) $ 6.99 $ 8.55 $ 8.49  
Options granted (in dollars per share) 1.48 4.43 6.07  
Options exercised (in dollars per share) 0 0 3.99  
Options cancelled (in dollars per share) 25.06 22.54 5.3  
Outstanding, end of period (in dollars per share) 5.33 $ 6.99 $ 8.55  
Options exercisable, end of period (in dollars per share) $ 5.9      
Options, additional disclosures [Abstract]        
Options outstanding, weighted average remaining contractual life 5 years 9 months      
Options exercisable, weighted average remaining contractual life 4 years 10 months 9 days      
Options outstanding, aggregate intrinsic value $ 3 $ 0    
Options exercisable, aggregate intrinsic value $ 2      
Share-based Compensation [Abstract]        
Proceeds from exercise of options     $ 1,046  
Total intrinsic value of options exercised     $ 151  
Restricted Stock Units (RSUs) [Member]        
RSUs, number of RSUs [Roll Forward]        
Outstanding, beginning of period (in shares) 509,155 504,323 498,489  
RSUs granted (in shares) 258,363 236,661 218,329  
RSUs vested (in shares) (215,413) (215,165) (212,495)  
RSUs cancelled (in shares) 0 (16,664) 0  
Outstanding, end of period (in shares) 552,105 509,155 504,323  
RSUs, weighted average grant date fair value [Abstract]        
Outstanding, beginning of period (in dollars per share) $ 5.38 $ 5.69 $ 4.71  
RSUs granted (in dollars per share) 1.46 4.61 6.89  
RSUs vested (in dollars per share) 5.15 5.23 4.63  
RSUs cancelled (in dollars per share) 0 5.45 0  
Outstanding, end of period (in dollars per share) $ 3.65 $ 5.38 $ 5.69  
RSUs, aggregate intrinsic value [Abstract]        
Outstanding, end of period $ 0 $ 0 $ 0 $ 0
XML 50 R38.htm IDEA: XBRL DOCUMENT v3.23.1
Stock-Based Compensation, Stock-Based Compensation by Type of Award (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Share-based Compensation [Abstract]      
Stock-based compensation expense $ 3,330 $ 4,184 $ 3,938
Operating Expense [Member]      
Share-based Compensation [Abstract]      
Stock-based compensation expense 3,330 4,184 3,938
Stock Options [Member]      
Compensation cost not yet recognized [Abstract]      
Unrecognized stock-based compensation expense expected to be recognized related to unvested stock options $ 3,972    
Weighted-average period for recognition of unrecognized stock-based compensation expense 2 years 7 months 28 days    
Stock Options [Member] | Operating Expense [Member]      
Share-based Compensation [Abstract]      
Stock-based compensation expense $ 2,303 3,067 2,872
RSUs [Member]      
Compensation cost not yet recognized [Abstract]      
Unrecognized stock-based compensation expense expected to be recognized related to unvested RSUs $ 1,449    
Weighted-average period for recognition of unrecognized stock-based compensation expense 2 years 5 months 4 days    
RSUs [Member] | Operating Expense [Member]      
Share-based Compensation [Abstract]      
Stock-based compensation expense $ 1,027 $ 1,117 $ 1,066
XML 51 R39.htm IDEA: XBRL DOCUMENT v3.23.1
Stock-Based Compensation, Fair Value Assumptions Used (Details) - $ / shares
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Fair value assumptions used in estimating fair value of each option grant [Abstract]      
Expected stock price volatility 85.39% 90.58% 93.45%
Risk-free interest rate 3.09% 1.06% 0.63%
Expected life term 6 years 2 months 12 days 6 years 2 months 12 days 6 years 2 months 12 days
Expected dividends 0.00% 0.00% 0.00%
Options granted, weighted average grant date fair value (in dollars per share) $ 1.09 $ 3.32 $ 4.62
XML 52 R40.htm IDEA: XBRL DOCUMENT v3.23.1
Earnings Per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Calculation of basic and diluted loss per share [Abstract]      
Net (loss) income $ (36,260) $ (42,921) $ 280,429
Basic weighted average number of shares outstanding (in shares) 71,335,046 71,159,458 70,850,311
Effect of dilutive securities (in shares) 0 0 766,000
Diluted weighted average number of shares outstanding (in shares) 71,335,046 71,159,458 71,615,843
Basic (loss) earnings per share (in dollars per share) $ (0.51) $ (0.6) $ 3.96
Diluted (loss) earnings per share (in dollars per share) $ (0.51) $ (0.6) $ 3.92
XML 53 R41.htm IDEA: XBRL DOCUMENT v3.23.1
Common Stock, Summary (Details)
12 Months Ended
Dec. 31, 2022
Vote
$ / shares
shares
Dec. 31, 2021
$ / shares
shares
May 08, 2020
$ / shares
Common Stock [Abstract]      
Common stock, shares authorized (in shares) | shares 100,000,000 100,000,000  
Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001  
Dividend [Abstract]      
Dividend declared date May 08, 2020    
Dividend record date May 18, 2020    
Cash dividend (in dollars per share)     $ 1
Dividend payable date May 26, 2020    
Common Stock [Member]      
Common Stock [Abstract]      
Number of votes entitled to each share of common stock | Vote 1    
Common stock, shares authorized (in shares) | shares 100,000,000    
Common stock, par value (in dollars per share) $ 0.0001    
XML 54 R42.htm IDEA: XBRL DOCUMENT v3.23.1
Common Stock, Warrants (Details) - $ / shares
1 Months Ended 12 Months Ended
Apr. 30, 2020
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Warrants [Abstract]        
Dividend yield   0.00% 0.00% 0.00%
Expected stock price volatility   85.39% 90.58% 93.45%
Risk-free interest rate   3.09% 1.06% 0.63%
Expected option term   6 years 2 months 12 days 6 years 2 months 12 days 6 years 2 months 12 days
Warrants [Member]        
Warrants [Abstract]        
Exercise price (in dollars per share) $ 7      
Terminated/ cancelled (in shares) (25,000)      
Warrants [Member] | Warrants Issued in 2020 [Member]        
Warrants [Abstract]        
Weighted average fair value of warrants at grant date (in dollars per share)       $ 4.16
Dividend yield       0.00%
Expected stock price volatility       97.00%
Risk-free interest rate       0.27%
Expected option term   5 years    
Warrants issued (in shares)     25,000 25,000
Exercise price (in dollars per share)     $ 5.75 $ 5.75
Outstanding and Exercisable (in shares)   25,000    
Issued (in shares)   0    
Exercised (in shares)   0    
Terminated/ cancelled (in shares)   0    
Outstanding and Exercisable (in shares)   25,000 25,000  
Expiration date   Apr. 30, 2025    
XML 55 R43.htm IDEA: XBRL DOCUMENT v3.23.1
Employee Benefit Plan (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Employee Benefit Plan [Abstract]      
Matching contribution to defined contribution plan $ 179 $ 145 $ 112
XML 56 R44.htm IDEA: XBRL DOCUMENT v3.23.1
Income Taxes, Components of Provision (Benefit) for Income Taxes (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Current [Abstract]      
Federal $ 0 $ 661 $ 35,122
State 3 35 950
Foreign 0 0 0
Current income tax provision (benefit) 3 696 36,072
Deferred [Abstract]      
Federal 15,920 (7,025) (8,816)
State 109 124 (233)
Deferred income tax provision (benefit) 16,029 (6,901) (9,049)
Total income tax (benefit) provision $ 16,032 $ (6,205) $ 27,023
XML 57 R45.htm IDEA: XBRL DOCUMENT v3.23.1
Income Taxes, Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Effective Tax Rate Reconciliation [Abstract]      
United States federal statutory rate 21.00% 21.00% 21.00%
State taxes, net of federal benefit (0.55%) (0.31%) 0.17%
Valuation allowance (91.21%) 0.00% (12.22%)
Stock based compensation (9.44%) (6.68%) (0.01%)
R&D Credit 1.22% 0.19% (0.21%)
Other (0.29%) (1.57%) 0.06%
Effective income tax rate (79.27%) 12.63% 8.79%
XML 58 R46.htm IDEA: XBRL DOCUMENT v3.23.1
Income Taxes, Components of Deferred Tax Assets (Liabilities) (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Deferred tax assets [Abstract]    
Reserves and accruals $ 147 $ 58
Research and development credits and other credits 430 92
Net operating loss carry forward 11,988 9,519
Stock based compensation 5,018 6,287
Other 970 0
Total deferred tax assets 18,553 15,956
Valuation allowance (18,553) 0
Deferred tax assets after valuation allowance 0 15,956
Total deferred tax liability - depreciation and amortization 0 (6)
Net deferred tax assets $ 0 $ 15,950
XML 59 R47.htm IDEA: XBRL DOCUMENT v3.23.1
Income Taxes, Pre-tax Income (Losses) and Operating Loss Carryforwards (Details)
$ in Thousands
12 Months Ended
Dec. 31, 2022
USD ($)
Income Taxes [Abstract]  
Capitalized direct and indirect research and development costs $ 5,140
Amortization of capitalized direct and indirect research and development costs 514
Federal [Member]  
Income Taxes [Abstract]  
Net operating loss carryforwards 57,085
State [Member]  
Income Taxes [Abstract]  
Net operating loss carryforwards $ 108,745
Operating loss carryforwards, expiration date Dec. 31, 2029
XML 60 R48.htm IDEA: XBRL DOCUMENT v3.23.1
Income Taxes, Income Tax Uncertainties (Details)
$ in Thousands
Dec. 31, 2022
USD ($)
Income Taxes [Abstract]  
Uncertain tax positions $ 0
Accrued interest and penalties $ 0
XML 61 R49.htm IDEA: XBRL DOCUMENT v3.23.1
Fair Value Measurement (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Adjusted Cost, Gross Unrealized Gains, Gross Unrealized Losses and Fair Value of Financial Assets [Abstract]    
Adjusted Cost $ 152,400 $ 169,322
Fair Value $ 152,023 169,272
Minimum [Member]    
Adjusted Cost, Gross Unrealized Gains, Gross Unrealized Losses and Fair Value of Financial Assets [Abstract]    
Maturities of investments 1 year  
Maximum [Member]    
Adjusted Cost, Gross Unrealized Gains, Gross Unrealized Losses and Fair Value of Financial Assets [Abstract]    
Maturities of investments 2 years  
Cash [Member]    
Adjusted Cost, Gross Unrealized Gains, Gross Unrealized Losses and Fair Value of Financial Assets [Abstract]    
Adjusted Cost $ 16,949 35,428
Fair Value 16,949 35,428
Total Investment Securities [Member]    
Adjusted Cost, Gross Unrealized Gains, Gross Unrealized Losses and Fair Value of Financial Assets [Abstract]    
Adjusted Cost 135,451 133,894
Unrealized Gains 9 0
Unrealized Losses (386) (50)
Fair Value 135,074 133,844
Mutual Funds [Member]    
Adjusted Cost, Gross Unrealized Gains, Gross Unrealized Losses and Fair Value of Financial Assets [Abstract]    
Adjusted Cost 66,493 106,590
Unrealized Gains 0 0
Unrealized Losses 0 0
Fair Value 66,493 106,590
U.S. Agency and Treasury Securities [Member]    
Adjusted Cost, Gross Unrealized Gains, Gross Unrealized Losses and Fair Value of Financial Assets [Abstract]    
Adjusted Cost 68,958 27,304
Unrealized Gains 9 0
Unrealized Losses (386) (50)
Fair Value 68,581 27,254
Recurring [Member]    
Adjusted Cost, Gross Unrealized Gains, Gross Unrealized Losses and Fair Value of Financial Assets [Abstract]    
Cash and Cash Equivalents 86,561 142,018
Investments Available for Sale 65,462 27,254
Recurring [Member] | Cash [Member]    
Adjusted Cost, Gross Unrealized Gains, Gross Unrealized Losses and Fair Value of Financial Assets [Abstract]    
Cash and Cash Equivalents 16,949 35,428
Recurring [Member] | Level 1 [Member] | Total Investment Securities [Member]    
Adjusted Cost, Gross Unrealized Gains, Gross Unrealized Losses and Fair Value of Financial Assets [Abstract]    
Cash and Cash Equivalents 69,612 106,590
Investments Available for Sale 65,462 27,254
Recurring [Member] | Level 1 [Member] | Mutual Funds [Member]    
Adjusted Cost, Gross Unrealized Gains, Gross Unrealized Losses and Fair Value of Financial Assets [Abstract]    
Cash and Cash Equivalents 66,493 106,590
Investments Available for Sale 0 0
Recurring [Member] | Level 1 [Member] | U.S. Agency and Treasury Securities [Member]    
Adjusted Cost, Gross Unrealized Gains, Gross Unrealized Losses and Fair Value of Financial Assets [Abstract]    
Cash and Cash Equivalents 3,119 0
Investments Available for Sale $ 65,462 $ 27,254
XML 62 R50.htm IDEA: XBRL DOCUMENT v3.23.1
Litigation (Details)
$ in Thousands
1 Months Ended
Apr. 20, 2021
USD ($)
Apr. 19, 2021
USD ($)
Oct. 30, 2020
USD ($)
Infringment
Patent
$ / Device
Sep. 25, 2020
Appeal
Mar. 23, 2020
USD ($)
Aug. 31, 2018
USD ($)
$ / Device
Apr. 18, 2021
Mar. 31, 2021
USD ($)
McKool Smith P.C. v. VirnetX, Inc., AAA (Case No. 01-20-0003-7975) [Member]                
Litigation [Abstract]                
Amount of damages awarded in patent infringement case   $ 36,323            
Contingency fee sought by plaintiff         $ 36,300      
Contingency fee as percentage of payment         8.00%      
Pre-judgment interest percentage             5.00%  
Post-judgment interest percentage   5.00%            
Contingency accrued amount               $ 38,284
Contingency accrued amount paid $ 38,284              
Positive Outcome of Litigation [Member] | VirnetX Inc. v. Apple, Inc. (Case 6:12-CV-00855-LED) ("Apple II") [Member]                
Litigation [Abstract]                
Amount of damages awarded in patent infringement case     $ 502,800     $ 502,600    
Royalty rate per device used in calculating infringement damages | $ / Device           1.2    
Number of patents allegedly infringed upon by Apple, Inc. | Patent     2          
Damages awarded per accused device | $ / Device     0.84          
Number of infringing units | Infringment     598,629,580          
Positive Outcome of Litigation [Member] | VirnetX Inc. v. The Mangrove Partners (Case 20-2271 and Case 20-2272) ("Consolidated Appeal") [Member]                
Litigation [Abstract]                
Number of appeals consolidated | Appeal       2        
XML 63 R51.htm IDEA: XBRL DOCUMENT v3.23.1
Leases (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Building [Member]      
Leases [Abstract]      
Lease expense $ 54 $ 56 $ 56
Office [Member]      
Leases [Abstract]      
Operating lease ROU assets 45 98  
Lease liability 45 98  
Lease expense $ 54 56 56
Corporate Promotional and Marketing Facility [Member]      
Leases [Abstract]      
Lease extension period 1 year    
Operating lease ROU assets $ 648 948  
Lease expense $ 300 $ 300 $ 356
XML 64 R52.htm IDEA: XBRL DOCUMENT v3.23.1
Subsequent Event (Details) - $ / shares
12 Months Ended
Mar. 30, 2023
Dec. 31, 2022
May 08, 2020
Subsequent Event [Abstract]      
Dividend declared date   May 08, 2020  
Cash dividend (in dollars per share)     $ 1
Dividend payable date   May 26, 2020  
Dividend record date   May 18, 2020  
Subsequent Event [Member]      
Subsequent Event [Abstract]      
Dividend declared date Mar. 30, 2023    
Cash dividend (in dollars per share) $ 1    
Dividend payable date Apr. 17, 2023    
Dividend record date Apr. 10, 2023    
XML 65 brhc10048883_10k_htm.xml IDEA: XBRL DOCUMENT 0001082324 2022-01-01 2022-12-31 0001082324 2022-06-30 0001082324 2023-03-27 0001082324 2022-12-31 0001082324 2021-12-31 0001082324 2021-01-01 2021-12-31 0001082324 2020-01-01 2020-12-31 0001082324 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001082324 us-gaap:RetainedEarningsMember 2021-12-31 0001082324 vhc:CommonStockAndAdditionalPaidInCapitalMember 2020-12-31 0001082324 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001082324 vhc:CommonStockAndAdditionalPaidInCapitalMember 2019-12-31 0001082324 2020-12-31 0001082324 us-gaap:RetainedEarningsMember 2020-12-31 0001082324 2019-12-31 0001082324 us-gaap:RetainedEarningsMember 2019-12-31 0001082324 vhc:CommonStockAndAdditionalPaidInCapitalMember 2021-12-31 0001082324 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001082324 vhc:CommonStockAndAdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001082324 vhc:CommonStockAndAdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001082324 vhc:CommonStockAndAdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001082324 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001082324 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001082324 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001082324 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0001082324 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0001082324 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0001082324 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001082324 us-gaap:RetainedEarningsMember 2022-12-31 0001082324 vhc:CommonStockAndAdditionalPaidInCapitalMember 2022-12-31 0001082324 us-gaap:PatentsMember 2022-12-31 0001082324 us-gaap:PatentsMember country:US 2022-12-31 0001082324 us-gaap:PatentsMember us-gaap:NonUsMember 2022-12-31 0001082324 us-gaap:PositiveOutcomeOfLitigationMember 2020-01-01 2020-12-31 0001082324 srt:MaximumMember us-gaap:DebtSecuritiesMember 2022-01-01 2022-12-31 0001082324 srt:MaximumMember 2022-01-01 2022-12-31 0001082324 srt:MinimumMember 2022-01-01 2022-12-31 0001082324 us-gaap:OfficeEquipmentMember 2021-12-31 0001082324 us-gaap:ComputerEquipmentMember 2021-12-31 0001082324 us-gaap:OfficeEquipmentMember 2022-12-31 0001082324 us-gaap:ComputerEquipmentMember 2022-12-31 0001082324 us-gaap:BuildingMember 2022-01-01 2022-12-31 0001082324 us-gaap:BuildingMember 2021-01-01 2021-12-31 0001082324 us-gaap:BuildingMember 2020-01-01 2020-12-31 0001082324 vhc:K2InvestmentFundLLCMember us-gaap:AirTransportationEquipmentMember 2020-01-01 2020-12-31 0001082324 vhc:K2InvestmentFundLLCMember us-gaap:AirTransportationEquipmentMember 2021-01-01 2021-12-31 0001082324 vhc:K2InvestmentFundLLCMember us-gaap:AirTransportationEquipmentMember 2022-01-01 2022-12-31 0001082324 vhc:K2InvestmentFundLLCMember us-gaap:AirTransportationEquipmentMember 2022-12-31 0001082324 vhc:Plan2013Member 2021-04-01 2021-04-30 0001082324 srt:MinimumMember vhc:IncentiveStockOptionsMember vhc:Plan2013Member 2022-01-01 2022-12-31 0001082324 srt:MinimumMember srt:ExecutiveOfficerMember us-gaap:EmployeeStockOptionMember vhc:Plan2013Member 2022-01-01 2022-12-31 0001082324 srt:MinimumMember us-gaap:InvestorMember us-gaap:EmployeeStockOptionMember vhc:Plan2013Member 2022-01-01 2022-12-31 0001082324 srt:MinimumMember vhc:NonqualifiedStockOptionsMember vhc:Plan2013Member 2022-01-01 2022-12-31 0001082324 us-gaap:EmployeeStockOptionMember vhc:Plan2013Member 2022-01-01 2022-12-31 0001082324 us-gaap:RestrictedStockUnitsRSUMember vhc:Plan2013Member 2022-01-01 2022-12-31 0001082324 vhc:Plan2013Member 2022-12-31 0001082324 us-gaap:EmployeeStockOptionMember vhc:ExercisePriceRange1Member 2022-01-01 2022-12-31 0001082324 us-gaap:EmployeeStockOptionMember vhc:ExercisePriceRange3Member 2022-01-01 2022-12-31 0001082324 us-gaap:EmployeeStockOptionMember vhc:ExercisePriceRange2Member 2022-01-01 2022-12-31 0001082324 us-gaap:EmployeeStockOptionMember vhc:ExercisePriceRange3Member 2022-12-31 0001082324 us-gaap:EmployeeStockOptionMember 2022-12-31 0001082324 us-gaap:EmployeeStockOptionMember vhc:ExercisePriceRange2Member 2022-12-31 0001082324 us-gaap:EmployeeStockOptionMember vhc:ExercisePriceRange1Member 2022-12-31 0001082324 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0001082324 us-gaap:EmployeeStockOptionMember 2020-12-31 0001082324 us-gaap:EmployeeStockOptionMember 2019-12-31 0001082324 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001082324 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001082324 us-gaap:EmployeeStockOptionMember 2021-12-31 0001082324 us-gaap:RestrictedStockUnitsRSUMember 2020-12-31 0001082324 us-gaap:RestrictedStockUnitsRSUMember 2019-12-31 0001082324 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-12-31 0001082324 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-12-31 0001082324 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0001082324 us-gaap:RestrictedStockUnitsRSUMember 2022-12-31 0001082324 us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0001082324 us-gaap:OperatingExpenseMember 2021-01-01 2021-12-31 0001082324 us-gaap:EmployeeStockOptionMember us-gaap:OperatingExpenseMember 2022-01-01 2022-12-31 0001082324 us-gaap:EmployeeStockOptionMember us-gaap:OperatingExpenseMember 2020-01-01 2020-12-31 0001082324 us-gaap:RestrictedStockUnitsRSUMember us-gaap:OperatingExpenseMember 2021-01-01 2021-12-31 0001082324 us-gaap:OperatingExpenseMember 2020-01-01 2020-12-31 0001082324 us-gaap:RestrictedStockUnitsRSUMember us-gaap:OperatingExpenseMember 2022-01-01 2022-12-31 0001082324 us-gaap:RestrictedStockUnitsRSUMember us-gaap:OperatingExpenseMember 2020-01-01 2020-12-31 0001082324 us-gaap:OperatingExpenseMember 2022-01-01 2022-12-31 0001082324 us-gaap:EmployeeStockOptionMember us-gaap:OperatingExpenseMember 2021-01-01 2021-12-31 0001082324 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001082324 us-gaap:CommonStockMember 2022-12-31 0001082324 2020-05-08 0001082324 vhc:WarrantIssuanceDate2Member us-gaap:WarrantMember 2020-12-31 0001082324 vhc:WarrantIssuanceDate2Member us-gaap:WarrantMember 2020-01-01 2020-12-31 0001082324 vhc:WarrantIssuanceDate2Member us-gaap:WarrantMember 2022-01-01 2022-12-31 0001082324 vhc:WarrantIssuanceDate2Member us-gaap:WarrantMember 2021-12-31 0001082324 us-gaap:WarrantMember 2020-04-30 0001082324 us-gaap:WarrantMember 2020-04-01 2020-04-30 0001082324 vhc:WarrantIssuanceDate2Member us-gaap:WarrantMember 2022-12-31 0001082324 us-gaap:DomesticCountryMember 2022-12-31 0001082324 us-gaap:StateAndLocalJurisdictionMember 2022-12-31 0001082324 us-gaap:StateAndLocalJurisdictionMember 2022-01-01 2022-12-31 0001082324 us-gaap:USTreasuryAndGovernmentMember 2022-12-31 0001082324 us-gaap:AvailableforsaleSecuritiesMember 2021-12-31 0001082324 us-gaap:USTreasuryAndGovernmentMember 2021-12-31 0001082324 us-gaap:CashMember 2022-12-31 0001082324 us-gaap:CashMember 2021-12-31 0001082324 us-gaap:MutualFundMember 2021-12-31 0001082324 us-gaap:AvailableforsaleSecuritiesMember 2022-12-31 0001082324 us-gaap:MutualFundMember 2022-12-31 0001082324 us-gaap:CashMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001082324 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001082324 us-gaap:AvailableforsaleSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001082324 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001082324 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001082324 us-gaap:AvailableforsaleSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001082324 us-gaap:MutualFundMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001082324 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001082324 us-gaap:MutualFundMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001082324 us-gaap:CashMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001082324 vhc:McKoolSmithPCVVirnetXIncAAACaseNo012000037975Member 2021-04-19 2021-04-19 0001082324 vhc:VirnetXIncVAppleIncCase612CV00855LEDAppleIIMember us-gaap:PositiveOutcomeOfLitigationMember 2020-10-30 2020-10-30 0001082324 vhc:VirnetXIncVAppleIncCase612CV00855LEDAppleIIMember us-gaap:PositiveOutcomeOfLitigationMember 2018-08-31 2018-08-31 0001082324 vhc:VirnetXIncVTheMangrovePartnersCase202271AndCase202272ConsolidatedAppealMember us-gaap:PositiveOutcomeOfLitigationMember 2020-09-25 2020-09-25 0001082324 vhc:McKoolSmithPCVVirnetXIncAAACaseNo012000037975Member 2020-03-23 2020-03-23 0001082324 vhc:McKoolSmithPCVVirnetXIncAAACaseNo012000037975Member 2021-03-23 2021-04-18 0001082324 vhc:McKoolSmithPCVVirnetXIncAAACaseNo012000037975Member 2021-03-31 0001082324 vhc:McKoolSmithPCVVirnetXIncAAACaseNo012000037975Member 2021-04-20 2021-04-20 0001082324 vhc:PromotionalAndMarketingMember 2022-01-01 2022-12-31 0001082324 vhc:OfficeMember 2021-12-31 0001082324 vhc:OfficeMember 2022-12-31 0001082324 vhc:PromotionalAndMarketingMember 2022-12-31 0001082324 vhc:PromotionalAndMarketingMember 2021-12-31 0001082324 vhc:OfficeMember 2022-01-01 2022-12-31 0001082324 vhc:OfficeMember 2020-01-01 2020-12-31 0001082324 vhc:PromotionalAndMarketingMember 2020-01-01 2020-12-31 0001082324 vhc:PromotionalAndMarketingMember 2021-01-01 2021-12-31 0001082324 vhc:OfficeMember 2021-01-01 2021-12-31 0001082324 us-gaap:SubsequentEventMember 2023-03-30 2023-03-30 0001082324 us-gaap:SubsequentEventMember 2023-03-30 iso4217:USD shares iso4217:USD shares vhc:Patent vhc:Institution pure vhc:Vote iso4217:USD vhc:Device vhc:Infringment vhc:Appeal false --12-31 2022 FY 0001082324 P5Y P1Y 223 2023-10-31 2025-04-30 2029-12-31 10-K true 2022-12-31 false 001-33852 VirnetX Holding Corp DE 77-0390628 308 Dorla Court Suite 206 Zephyr Cove NV 89448 775 548-1785 Common Stock, par value $0.0001 per share VHC NYSE No No Yes Yes Non-accelerated Filer false true false false 73662208 71424650 Farber Hass Hurley LLP Chatsworth, California 86561000 142018000 65462000 27254000 14000 17000 0 0 224000 203000 152261000 169492000 703000 1056000 11000 18000 0 15950000 152975000 186516000 373000 338000 311000 270000 0 355000 47000 58000 731000 1021000 0 46000 731000 1067000 0.0001 0.0001 10000000 10000000 0 0 0 0 0 0 0.0001 0.0001 100000000 100000000 71424650 71424650 71232856 71232856 7000 7000 239746000 236445000 -87195000 -50935000 -314000 -68000 152244000 185449000 152975000 186516000 48000 35000 302636000 -4000 -9083000 90101000 6406000 5577000 8830000 15722000 52715000 45812000 22124000 49209000 144743000 -22076000 -49174000 157893000 0 0 41271000 1848000 48000 108288000 -20228000 -49126000 307452000 16032000 -6205000 27023000 -36260000 -42921000 280429000 -0.51 -0.6 3.96 -0.51 -0.6 3.92 71335046 71159458 70850311 71335046 71159458 71615843 -36260000 -42921000 280429000 -246000 -51000 0 0 -4000 1000 -246000 -55000 1000 -36506000 -42976000 280430000 185449000 224437000 5628000 236452000 232464000 223244000 0 0 4488000 -29000 -196000 690000 0 0 104000 3330000 4184000 3938000 239753000 236452000 232464000 -50935000 -8014000 -217602000 -36260000 -42921000 280429000 0 0 70841000 -87195000 -50935000 -8014000 -68000 -13000 -14000 -246000 -51000 0 0 -4000 1000 -314000 -68000 -13000 152244000 185449000 224437000 0 0 1 -36260000 -42921000 280429000 7000 4000 5000 3330000 4184000 3938000 0 34000 69000 -16032000 6901000 9049000 -331000 -271000 -419000 35000 -316000 -692000 -54000 60000 -193000 41000 50000 -67000 -355000 -9083000 9438000 -3000 9000 3000 3000 -2905000 2905000 -16893000 -51722000 281389000 0 11000 0 67070000 26332000 33065000 28535000 27371000 7112000 -38535000 1028000 -25953000 0 0 1046000 0 0 4488000 0 0 70841000 29000 196000 356000 -29000 -196000 -65663000 -55457000 -50890000 189773000 142018000 192908000 3135000 86561000 142018000 192908000 2000 2000 38977000 <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Note 1 − Formation and Business of the Company</div> <div style="text-align: left;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">VirnetX Holding Corporation, which we refer to as “we”, “us”, “our”, “the Company” or “VirnetX”, is engaged in the business of commercializing a portfolio of patents. We seek to derive revenue from selling our software products including VirnetX War Room™ and VirnetX Matrix™ and licensing our technology, including VirnetX One™, and our secure domain name technology GABRIEL Connection Technology™, to various original equipment manufacturers (“OEMs”) and others, that use our technologies in the development and manufacturing of their own products within the IP-telephony, mobility, fixed-mobile convergence, and unified communications markets or who seek to secure their systems and applications. During 2020, we had revenues from settlement of a patent infringement dispute whereby we received consideration for past sales of licensee that utilized our technology, where there was no prior patent license agreement.</div> <div style="text-align: left;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Our portfolio of intellectual property is the foundation of our business model. We currently own approximately 205 total patents and pending applications, including 72 U.S. patents/patent applications and 133 foreign patents/validations/pending applications. Our patent portfolio is primarily focused on securing real-time communications over the Internet, as well as related services such as the establishment and maintenance of a secure domain name registry. Our patented methods also have additional applications in the key areas of device operating systems and network security. The subject matter of all our U.S and foreign patents and pending applications relates generally to securing communications over the Internet and such covers all our technology and other products. Some of our issued U.S. and foreign patents expire at various times during the period from 2023 to 2034.</div> 205 72 133 <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Note 2 − Summary of Significant Accounting Policies</div> <div><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reported period. The critical accounting policies we employ in the preparation of our consolidated financial statements are those which involve impairment of long-lived assets, income taxes, fair value of financial instruments and stock-based compensation.</div> <div><br/> </div> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Use of Estimates</div> <div style="text-align: left;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">We prepare our consolidated financial statements in accordance with U.S. GAAP. In doing so, we have to make estimates and assumptions that affect our reported amounts of assets, liabilities, revenues, and expenses, as well as related disclosure of contingent assets and liabilities. In some cases, we could reasonably have used different accounting policies and estimates. In some cases, changes in the accounting estimates are reasonably likely to occur from period to period. Accordingly, actual results could differ materially from our estimates. To the extent that there are material differences between these estimates and actual results, our financial condition or results of operations will be affected. We base our estimates on past experience and other assumptions that we believe are reasonable under the circumstances, and we evaluate these estimates on an ongoing basis. We refer to accounting estimates of this type as critical accounting policies and estimates, which we discuss further below. We have reviewed our critical accounting policies and estimates with the Audit Committee of our Board of Directors.</div> <div><br/> </div> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Basis of Consolidation</div> <div><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The consolidated financial statements include the accounts of VirnetX Holding Corporation and our wholly owned subsidiaries. All intercompany balances and transactions have been eliminated.</div> <div><br/> </div> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Revenue Recognition</div> <div><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company derives revenue from licensing and royalty fees from contracts with customers which often span several years. We account for this revenue in accordance with Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. Our revenue arrangements may consist of multiple-element arrangements, with revenue for each unit of accounting recognized as the product or service is delivered to the customer.</div> <div><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">With the<span style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"> </span>licensing of our patents, performance obligations are generally satisfied at a point in time as work is complete when our patent rights are transferred to our customers. We generally have no further obligation to our customers regarding our technology.</div> <div><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Certain contracts may require our customers to enter into a hosting arrangement with us and for these arrangements, revenue is recognized over time, generally over the life of the servicing contract.</div> <div><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company actively monitors and enforces its intellectual property (“IP”) rights, including seeking appropriate compensation from third parties that utilize the Company’s IP without a license. As a result, the Company may, from time to time, receive payments as part of a settlement or compensation for a patent infringement dispute. Proceeds received are allocated to each element identified in the settlement or compensation, based on the fair value of each element. Generally, settlements and compensation may include the following elements: the value of a license or royalty agreement, cost reimbursement, damages, and interest. Elements identified related to licensing and royalty are recognized as revenue. Elements identified as reimbursed costs are generally recorded as a reduction to the reported expenses. Elements identified as damages or interest are generally recorded in other income in the condensed consolidated statement of operations. During the year ended December 31, 2020, the Company collected a lump sum payment of $454,034 from Apple, Inc., because of a favorable court decision relating to a patent infringement case. The court decision identified the following as the basis of the award: $302,428 for past royalties, $41,271 in damages for willful infringement, $108,221 for interest, and $2,114 in reimbursement for court costs and attorney’s fees. Elements of the payment were recognized in the Company’s condensed consolidated statement of operations as follows:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td colspan="4" style="vertical-align: middle;" valign="bottom"> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Classification of Payment Received in the Company’s Condensed Consolidated Statement of Operations</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td colspan="4" style="vertical-align: middle; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Year Ended:</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: middle; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">December 31, 2020</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; width: 88%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Revenue (royalties)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">302,428</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; width: 88%;" valign="bottom"> <div style="text-align: left; text-indent: -9pt; margin-left: 9pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Operating expenses: selling, general and administrative (reimbursed litigation costs)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2,114</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; width: 88%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Other income: gain (willful infringement)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">41,271</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; width: 88%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -9pt; margin-left: 9pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Other income: interest income (pre- and post-judgment interest)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">108,221</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Total cash received</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">454,034</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Licensing Costs</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Included in operating expenses are licensing costs we incurred in conjunction with the proceeds received from Apple Inc., pursuant to a favorable court decision relating to a patent infringement case.</div> <div><br/> </div> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Contingent Gains</div> <div><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">ASC Topic 450-30-25, Contingent Gains, prohibits recognition of contingent gains until realized. Accordingly, we do not record contingent gains ahead of such realization. Management generally considers any such gains as realized only upon the collection of cash.</div> <div><br/> </div> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Cash and Cash Equivalents</div> <div><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">We consider all highly liquid investments purchased with original maturities of three months or less at the date of purchase to be cash equivalents. Our cash and cash equivalents are not subject to significant interest rate risk due to the short maturities of these investments.</div> <div><br/> </div> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Investments</div> <div><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Investments are classified as available-for-sale and are recorded at fair market value. Unrealized gains and losses are reported as other comprehensive income. Realized gains and losses are recorded in income in the period they are realized using specific identification of each security’s cost basis. We invest our excess cash primarily in highly liquid debt instruments including corporate, government and federal agency securities, with contractual maturities less than two years. By policy, we limit the amount of credit exposure to any one issuer.</div> <div><br/> </div> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Concentration of Credit Risk and Other Risks and Uncertainties</div> <div><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Our cash and cash equivalents are primarily maintained at two major financial institutions in the United States. Deposits held with these financial institutions may exceed the amount of insurance provided on such deposits. A portion of those balances are insured by the Federal Deposit Insurance Corporation, or FDIC. In 2022, we had, at times, funds that were uninsured. We do not believe that we are subject to any unusual financial risk beyond the normal risk associated with commercial banking relationships. We have not experienced any losses on our deposits of cash and cash equivalents.</div> <div><br/> </div> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Fair Value</div> <div><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The carrying amounts of our financial instruments, including cash equivalents, accounts payable, and accrued liabilities, approximate fair value because of their generally short maturities.</div> <div><br/> </div> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Property and Equipment</div> <div><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Property and equipment are stated at historical cost, less accumulated depreciation, and amortization. Depreciation and amortization are computed using the accelerated and straight-line methods over the estimated useful lives of the assets, which range from <span style="-sec-ix-hidden:Fact_be8da1632eb444e58e0db2ef072b6f03">five</span> to seven years. Repair and maintenance costs are charged to expense as incurred.</div> <div><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Leases</div> <div><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company determines if an arrangement is a lease at inception in accordance with ASC Topic 842. Operating lease right-of-use (“ROU”) assets are included in Prepaid expenses, and other assets on the Condensed Consolidated Balance Sheets. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term.</div> <div><br/> </div> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Intangible Assets</div> <div><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">We record intangible assets at cost, less accumulated amortization. Amortization of intangible assets is provided over their estimated useful lives, which can range from 3 to 15 years, on either a straight-line basis or as revenue is generated by the assets.</div> <div><br/> </div> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Impairment of Long-Lived Assets</div> <div><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">We identify and record impairment losses on long-lived assets used in operations when events and changes in circumstances indicate that the carrying amount of an asset might not be recoverable, but not less than annually. Recoverability is measured by comparison of the anticipated future net undiscounted cash flows to the related assets’ carrying value. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the asset.</div> <div><br/> </div> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Research and Development</div> <div><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Research and development costs include expenses paid to outside development consultants and compensation related expenses for our engineering staff. Research and development costs are expensed as incurred.</div> <div><br/></div> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Income Taxes</div> <div><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">We account for income taxes using the asset and liability method. The asset and liability method requires the recognition of deferred tax assets and liabilities for expected future tax consequences of temporary differences that currently exist between the tax basis and financial reporting basis of our assets and liabilities. We calculate current and deferred tax provisions based on estimates and assumptions that could differ from actual results reflected on the income tax returns filed during the following years. Adjustments based on filed returns are recorded when identified in the subsequent years. The effect on deferred taxes for a change in tax rates is recognized in income in the period that the tax rate change is enacted. In assessing our deferred tax assets, we consider whether it is more likely than not that all or some portion of the deferred tax assets will not be realized.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">The 2017 U.S. Tax Cuts and Jobs Act changes IRC Section 174, regarding capitalization of book research and development (“R&amp;D”) expenses for income tax purposes.  Effective for tax years beginning in 2022 IRC Section 174 requires the capitalization of book R&amp;D expenses which are capitalized and amortized over 5 years for domestic R&amp;D expenses and over 15 years for foreign R&amp;D expenses.  To date there has been limited guidance from the IRS on how to quantify the amount of book R&amp;D expenses subject to capitalization, including the indirect expenses supporting the R&amp;D function.  Due to the limited guidance, some assumptions were made in our estimates.</div> <div><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">A valuation allowance is provided for deferred income tax assets when, in our judgment, based upon currently available information and other factors, it is more likely than not that all or a portion of such deferred income tax assets will not be realized. The determination of the need for a valuation allowance is based on an on-going evaluation of current information including, among other things, historical operating results, estimates of future earnings in different taxing jurisdictions and the expected timing of the reversals of temporary differences. We believe the determination to record a valuation allowance to reduce a deferred income tax asset is a significant accounting estimate because it is based, among other things, on an estimate of future taxable income in the United States and certain other jurisdictions, which is susceptible to change and may or may not occur, and because the impact of adjusting a valuation allowance may be material. In determining when to release the valuation allowance established against our net deferred income tax assets, we consider all available evidence, both positive and negative. We continually assess our ability to generate sufficient taxable income during future periods in which our deferred tax assets may be realized. If and when we believe it is more likely than not that we will recover our deferred tax assets, we will reverse the valuation allowance as an income tax benefit in our statements of operations.</div> <div><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">We account for our uncertain tax positions in accordance with U.S. GAAP, which utilizes a two-step approach to evaluate tax positions. Step one, recognition, requires evaluation of the tax position to determine if based solely on technical merits it is more likely than not to be sustained upon examination. Step two, measurement, is addressed only if a position is more likely than not to be sustained. In step two, the tax benefit is measured as the largest amount of benefit, determined on a cumulative probability basis, which is more likely than not to be realized upon ultimate settlement with tax authorities. If a position does not meet the more likely than not threshold for recognition in step one, no benefit is recorded until the first subsequent period in which the more likely than not standard is met, the issue is resolved with the taxing authority, or the statute of limitations expires. Positions previously recognized are derecognized when we subsequently determine the position no longer is more likely than not to be sustained. Evaluation of tax positions, their technical merits, and measurements using cumulative probability are highly subjective management estimates. Actual results could differ materially from these estimates.</div> <div><br/> </div> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Stock-Based Compensation</div> <div><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">We account for stock-based compensation using the fair value recognition method in accordance with U.S. GAAP. We recognize these compensation costs on a straight-line basis over the requisite service period of the award, which is generally a vesting term of 4 years. We recognize forfeitures, if any, when they occur. In addition, we record stock-based compensation expense for awards granted to non-employees at fair value of the consideration received or the fair value of the equity instruments issued, as they vest, over the performance period (See Note 6 - Stock-Based Compensation).</div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"> <br/></div> <div><span style="font-style: italic; font-weight: bold;"><span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-variant: normal; text-transform: none;">Earnings per Share </span> </span> </div> <div><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Basic earnings per share are computed by dividing earnings available to common stockholders by the weighted average number of outstanding common shares during the period. Diluted earnings per share is computed by dividing net income by the weighted average number of shares outstanding during the period increased to include the number of additional shares of common stock that would have been outstanding if the potentially dilutive securities had been issued.</div> <div><br/> </div> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">New Accounting Pronouncements</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">In </span>December 2019, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2019-12 Income Taxes (Topic 740). The amendments in this ASU simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify U. S. GAAP for other areas of Topic 740 by clarifying and amending existing guidance. The amendments in this ASU are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. We adopted this ASU on January 1, 2021 and there was no material impact on our financial position or cash flows as a result.</div> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Use of Estimates</div> <div style="text-align: left;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">We prepare our consolidated financial statements in accordance with U.S. GAAP. In doing so, we have to make estimates and assumptions that affect our reported amounts of assets, liabilities, revenues, and expenses, as well as related disclosure of contingent assets and liabilities. In some cases, we could reasonably have used different accounting policies and estimates. In some cases, changes in the accounting estimates are reasonably likely to occur from period to period. Accordingly, actual results could differ materially from our estimates. To the extent that there are material differences between these estimates and actual results, our financial condition or results of operations will be affected. We base our estimates on past experience and other assumptions that we believe are reasonable under the circumstances, and we evaluate these estimates on an ongoing basis. We refer to accounting estimates of this type as critical accounting policies and estimates, which we discuss further below. We have reviewed our critical accounting policies and estimates with the Audit Committee of our Board of Directors.</div> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Basis of Consolidation</div> <div><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The consolidated financial statements include the accounts of VirnetX Holding Corporation and our wholly owned subsidiaries. All intercompany balances and transactions have been eliminated.</div> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Revenue Recognition</div> <div><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company derives revenue from licensing and royalty fees from contracts with customers which often span several years. We account for this revenue in accordance with Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. Our revenue arrangements may consist of multiple-element arrangements, with revenue for each unit of accounting recognized as the product or service is delivered to the customer.</div> <div><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">With the<span style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"> </span>licensing of our patents, performance obligations are generally satisfied at a point in time as work is complete when our patent rights are transferred to our customers. We generally have no further obligation to our customers regarding our technology.</div> <div><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Certain contracts may require our customers to enter into a hosting arrangement with us and for these arrangements, revenue is recognized over time, generally over the life of the servicing contract.</div> <div><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company actively monitors and enforces its intellectual property (“IP”) rights, including seeking appropriate compensation from third parties that utilize the Company’s IP without a license. As a result, the Company may, from time to time, receive payments as part of a settlement or compensation for a patent infringement dispute. Proceeds received are allocated to each element identified in the settlement or compensation, based on the fair value of each element. Generally, settlements and compensation may include the following elements: the value of a license or royalty agreement, cost reimbursement, damages, and interest. Elements identified related to licensing and royalty are recognized as revenue. Elements identified as reimbursed costs are generally recorded as a reduction to the reported expenses. Elements identified as damages or interest are generally recorded in other income in the condensed consolidated statement of operations. During the year ended December 31, 2020, the Company collected a lump sum payment of $454,034 from Apple, Inc., because of a favorable court decision relating to a patent infringement case. The court decision identified the following as the basis of the award: $302,428 for past royalties, $41,271 in damages for willful infringement, $108,221 for interest, and $2,114 in reimbursement for court costs and attorney’s fees. Elements of the payment were recognized in the Company’s condensed consolidated statement of operations as follows:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td colspan="4" style="vertical-align: middle;" valign="bottom"> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Classification of Payment Received in the Company’s Condensed Consolidated Statement of Operations</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td colspan="4" style="vertical-align: middle; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Year Ended:</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: middle; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">December 31, 2020</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; width: 88%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Revenue (royalties)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">302,428</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; width: 88%;" valign="bottom"> <div style="text-align: left; text-indent: -9pt; margin-left: 9pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Operating expenses: selling, general and administrative (reimbursed litigation costs)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2,114</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; width: 88%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Other income: gain (willful infringement)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">41,271</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; width: 88%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -9pt; margin-left: 9pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Other income: interest income (pre- and post-judgment interest)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">108,221</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Total cash received</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">454,034</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> 454034000 302428000 41271000 -108221000 -2114000 <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td colspan="4" style="vertical-align: middle;" valign="bottom"> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Classification of Payment Received in the Company’s Condensed Consolidated Statement of Operations</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td colspan="4" style="vertical-align: middle; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Year Ended:</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: middle; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">December 31, 2020</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; width: 88%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Revenue (royalties)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">302,428</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; width: 88%;" valign="bottom"> <div style="text-align: left; text-indent: -9pt; margin-left: 9pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Operating expenses: selling, general and administrative (reimbursed litigation costs)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2,114</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; width: 88%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Other income: gain (willful infringement)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">41,271</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; width: 88%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -9pt; margin-left: 9pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Other income: interest income (pre- and post-judgment interest)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">108,221</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Total cash received</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">454,034</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> 302428000 -2114000 41271000 -108221000 454034000 <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Licensing Costs</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Included in operating expenses are licensing costs we incurred in conjunction with the proceeds received from Apple Inc., pursuant to a favorable court decision relating to a patent infringement case.</div> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Contingent Gains</div> <div><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">ASC Topic 450-30-25, Contingent Gains, prohibits recognition of contingent gains until realized. Accordingly, we do not record contingent gains ahead of such realization. Management generally considers any such gains as realized only upon the collection of cash.</div> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Cash and Cash Equivalents</div> <div><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">We consider all highly liquid investments purchased with original maturities of three months or less at the date of purchase to be cash equivalents. Our cash and cash equivalents are not subject to significant interest rate risk due to the short maturities of these investments.</div> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Investments</div> <div><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Investments are classified as available-for-sale and are recorded at fair market value. Unrealized gains and losses are reported as other comprehensive income. Realized gains and losses are recorded in income in the period they are realized using specific identification of each security’s cost basis. We invest our excess cash primarily in highly liquid debt instruments including corporate, government and federal agency securities, with contractual maturities less than two years. By policy, we limit the amount of credit exposure to any one issuer.</div> P2Y <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Concentration of Credit Risk and Other Risks and Uncertainties</div> <div><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Our cash and cash equivalents are primarily maintained at two major financial institutions in the United States. Deposits held with these financial institutions may exceed the amount of insurance provided on such deposits. A portion of those balances are insured by the Federal Deposit Insurance Corporation, or FDIC. In 2022, we had, at times, funds that were uninsured. We do not believe that we are subject to any unusual financial risk beyond the normal risk associated with commercial banking relationships. We have not experienced any losses on our deposits of cash and cash equivalents.</div> 2 <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Fair Value</div> <div><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The carrying amounts of our financial instruments, including cash equivalents, accounts payable, and accrued liabilities, approximate fair value because of their generally short maturities.</div> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Property and Equipment</div> <div><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Property and equipment are stated at historical cost, less accumulated depreciation, and amortization. Depreciation and amortization are computed using the accelerated and straight-line methods over the estimated useful lives of the assets, which range from <span style="-sec-ix-hidden:Fact_be8da1632eb444e58e0db2ef072b6f03">five</span> to seven years. Repair and maintenance costs are charged to expense as incurred.</div> P7Y <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Leases</div> <div><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company determines if an arrangement is a lease at inception in accordance with ASC Topic 842. Operating lease right-of-use (“ROU”) assets are included in Prepaid expenses, and other assets on the Condensed Consolidated Balance Sheets. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term.</div> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Intangible Assets</div> <div><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">We record intangible assets at cost, less accumulated amortization. Amortization of intangible assets is provided over their estimated useful lives, which can range from 3 to 15 years, on either a straight-line basis or as revenue is generated by the assets.</div> P3Y P15Y <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Impairment of Long-Lived Assets</div> <div><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">We identify and record impairment losses on long-lived assets used in operations when events and changes in circumstances indicate that the carrying amount of an asset might not be recoverable, but not less than annually. Recoverability is measured by comparison of the anticipated future net undiscounted cash flows to the related assets’ carrying value. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the asset.</div> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Research and Development</div> <div><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Research and development costs include expenses paid to outside development consultants and compensation related expenses for our engineering staff. Research and development costs are expensed as incurred.</div> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Income Taxes</div> <div><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">We account for income taxes using the asset and liability method. The asset and liability method requires the recognition of deferred tax assets and liabilities for expected future tax consequences of temporary differences that currently exist between the tax basis and financial reporting basis of our assets and liabilities. We calculate current and deferred tax provisions based on estimates and assumptions that could differ from actual results reflected on the income tax returns filed during the following years. Adjustments based on filed returns are recorded when identified in the subsequent years. The effect on deferred taxes for a change in tax rates is recognized in income in the period that the tax rate change is enacted. In assessing our deferred tax assets, we consider whether it is more likely than not that all or some portion of the deferred tax assets will not be realized.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">The 2017 U.S. Tax Cuts and Jobs Act changes IRC Section 174, regarding capitalization of book research and development (“R&amp;D”) expenses for income tax purposes.  Effective for tax years beginning in 2022 IRC Section 174 requires the capitalization of book R&amp;D expenses which are capitalized and amortized over 5 years for domestic R&amp;D expenses and over 15 years for foreign R&amp;D expenses.  To date there has been limited guidance from the IRS on how to quantify the amount of book R&amp;D expenses subject to capitalization, including the indirect expenses supporting the R&amp;D function.  Due to the limited guidance, some assumptions were made in our estimates.</div> <div><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">A valuation allowance is provided for deferred income tax assets when, in our judgment, based upon currently available information and other factors, it is more likely than not that all or a portion of such deferred income tax assets will not be realized. The determination of the need for a valuation allowance is based on an on-going evaluation of current information including, among other things, historical operating results, estimates of future earnings in different taxing jurisdictions and the expected timing of the reversals of temporary differences. We believe the determination to record a valuation allowance to reduce a deferred income tax asset is a significant accounting estimate because it is based, among other things, on an estimate of future taxable income in the United States and certain other jurisdictions, which is susceptible to change and may or may not occur, and because the impact of adjusting a valuation allowance may be material. In determining when to release the valuation allowance established against our net deferred income tax assets, we consider all available evidence, both positive and negative. We continually assess our ability to generate sufficient taxable income during future periods in which our deferred tax assets may be realized. If and when we believe it is more likely than not that we will recover our deferred tax assets, we will reverse the valuation allowance as an income tax benefit in our statements of operations.</div> <div><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">We account for our uncertain tax positions in accordance with U.S. GAAP, which utilizes a two-step approach to evaluate tax positions. Step one, recognition, requires evaluation of the tax position to determine if based solely on technical merits it is more likely than not to be sustained upon examination. Step two, measurement, is addressed only if a position is more likely than not to be sustained. In step two, the tax benefit is measured as the largest amount of benefit, determined on a cumulative probability basis, which is more likely than not to be realized upon ultimate settlement with tax authorities. If a position does not meet the more likely than not threshold for recognition in step one, no benefit is recorded until the first subsequent period in which the more likely than not standard is met, the issue is resolved with the taxing authority, or the statute of limitations expires. Positions previously recognized are derecognized when we subsequently determine the position no longer is more likely than not to be sustained. Evaluation of tax positions, their technical merits, and measurements using cumulative probability are highly subjective management estimates. Actual results could differ materially from these estimates.</div> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Stock-Based Compensation</div> <div><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">We account for stock-based compensation using the fair value recognition method in accordance with U.S. GAAP. We recognize these compensation costs on a straight-line basis over the requisite service period of the award, which is generally a vesting term of 4 years. We recognize forfeitures, if any, when they occur. In addition, we record stock-based compensation expense for awards granted to non-employees at fair value of the consideration received or the fair value of the equity instruments issued, as they vest, over the performance period (See Note 6 - Stock-Based Compensation).</div> P4Y <div><span style="font-style: italic; font-weight: bold;"><span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-variant: normal; text-transform: none;">Earnings per Share </span> </span> </div> <div><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Basic earnings per share are computed by dividing earnings available to common stockholders by the weighted average number of outstanding common shares during the period. Diluted earnings per share is computed by dividing net income by the weighted average number of shares outstanding during the period increased to include the number of additional shares of common stock that would have been outstanding if the potentially dilutive securities had been issued.</div> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">New Accounting Pronouncements</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">In </span>December 2019, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2019-12 Income Taxes (Topic 740). The amendments in this ASU simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify U. S. GAAP for other areas of Topic 740 by clarifying and amending existing guidance. The amendments in this ASU are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. We adopted this ASU on January 1, 2021 and there was no material impact on our financial position or cash flows as a result.</div> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Note 3 − Property and Equipment</div> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"> </div> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Our major classes of property and equipment were as follows:</div> <div style="text-align: left;"><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">December 31</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">2022</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Office furniture</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">79</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">79</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Computer equipment</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">92</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">92</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Total</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">171</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">171</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Less accumulated depreciation</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(160</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(153</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Total property and equipment, net</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">11</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">18</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div style="text-align: left;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Depreciation expense for 2022, 2021 and 2020 was $7, $4, and $5, respectively.</div> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Our major classes of property and equipment were as follows:</div> <div style="text-align: left;"><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">December 31</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">2022</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Office furniture</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">79</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">79</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Computer equipment</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">92</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">92</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Total</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">171</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">171</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Less accumulated depreciation</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(160</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(153</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Total property and equipment, net</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">11</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">18</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> 79000 79000 92000 92000 171000 171000 160000 153000 11000 18000 7000 4000 5000 <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Note 4 − Commitments, Contingencies and Related Party Transactions</div> <div style="text-align: left;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">We lease our offices under an operating lease with a third party expiring in <span style="-sec-ix-hidden:Fact_c1f9d20eb7044cbe874ac1f7acec3f69">October 2023</span>. We recognize rent expense on a straight-line basis over the term of the lease. Rent expense was $54 in 2022 and $56 for both 2021 and 2020. Future minimum rents due under the lease total $46 in 2023, when the lease expires.</div> <div><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">We entered into a service agreement for the use of an aircraft from K2 Investment Fund LLC (“LLC”) for business travel for our employees. We incurred approximately $1,123, $791, and $324 in rental fees and reimbursements to the LLC in 2022, 2021 and 2020, respectively. We pay for the Company’s business usage of the aircraft and have no right to purchase. Our Chief Executive Officer and Chief Administrative Officer are the managing partners of the LLC and control the equity interests of the LLC. We entered into a 12-month non-exclusive agreement with the LLC for use of the plane at a rate of $8 per flight hour, with no minimum usage requirement. The agreement contains other terms and conditions normal in such transactions and can be cancelled by either us or the LLC with 30 days’ notice. The agreement renews on an annual basis unless terminated by either party. Neither party has exercised their termination rights.</div> 54000 56000 56000 46000 1123000 791000 324000 P12M 8000 P30D <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Note 5 − Stock Plan</div> <div style="text-align: left;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">We have an equity incentive plan for employees and others called the VirnetX Holding Corporation 2013 Equity Incentive Plan (the “2013 Plan”), which has been approved by our stockholders. To the extent that any award should expire, become un-exercisable or is otherwise forfeited, the shares subject to such award will again become available for issuance under the 2013 Plan. The 2013 Plan provides for the granting of stock options and restricted stock units purchase rights (“RSUs”) to our employees and consultants. Stock options granted under the 2013 Plan may be incentive stock options or nonqualified stock options. Incentive stock options (“ISOs”) may only be granted to our employees (including officers and directors). Nonqualified stock options (“NSOs”) and stock purchase rights may be granted to our employees and consultants. The 2013 Plan expires in 2023.</div> <div><br/></div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In April 2021, the Board approved an amendment and restatement of the 2013 Plan to, among other things, increase the shares reserved under the Plan by 2,500,000 shares (the “Plan Amendment”). Our stockholders approved the Plan Amendment at the 2021 Annual Meeting of the Stockholders held on June 3, 2021. The 2013 Plan generally provides for the granting of shares of our common stock, including stock options and RSUs. Options may be granted under the 2013 Plan with an exercise price determined by our Board of Directors, or a duly appointed committee thereof, provided, however, that the exercise price of an option granted to any employee shall be not less than 100% of the fair market value at the date of grant in the case of ISOs or 85% of the fair market value at the date of grant in the case of an NSO. The exercise price of an ISO or NSO granted to one of our Named Executive Officers shall not be less than 100% fair market value of the shares at the date of grant and the exercise price of an ISO granted to a 10% shareholder shall not be less than 110% of the fair market value of the shares on the date of grant. Stock options granted under the 2013 Plan typically vest over four years and have a 10-year term. All RSUs are considered to be granted at the fair value of our stock on the date of grant because they have no exercise price. RSUs typically vest over four years. As of December 31, 2022, there were 1,563,345 shares available for grant under the 2013 Plan.</div> 2500000 1 0.85 1 1.10 P4Y P10Y P4Y 1563345 <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Note 6 − Stock-Based Compensation</div> <div><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The following tables summarize information and activity under the plan for the indicated periods.</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td colspan="12" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Options Outstanding</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Options Vested and Exercisable </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Range of<span style="font-size: 10pt; font-family: 'Times New Roman';"><br/> </span>Exercise Prices</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Number</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Outstanding</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Weighted</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Average</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Remaining</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Contractual</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Life (Years)</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Weighted</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Average</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exercise</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Price</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Number</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exercisable</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Weighted</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Average</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Remaining</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Contractual</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Life (Years)</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Weighted</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Average</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exercise</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Price</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;" valign="bottom">$ 1.22 - 1.58</td> <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">801,004</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">9.40</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$ <br/> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">1.48</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">122,001</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">9.38</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$ <br/> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">1.45</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 28%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$ <span style="text-indent: 0pt;">2.35</span> -  <span style="text-indent: 0pt;">6.95</span> </div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">5,504,396</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">5.66</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">4.50</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">4,602,729</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">5.17</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">4.42</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 28%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$ <span style="text-indent: 0pt;">14.52</span> - <span style="text-indent: 0pt;">35.05</span> </div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">510,625</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">0.93</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">20.32</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">510,625</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">0.93</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">20.32</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 28%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">6,816,025</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">5.75</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">5.33</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">5,235,355</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">4.86</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">5.90</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"/> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="14" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Options</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Number of</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Shares</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Weighted</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Average</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exercise</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Price</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Weighted</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Average</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Remaining</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Contractual</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Life (Years)</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Aggregate</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Intrinsic</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Value</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom">Outstanding at December 31, 2019</td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">5,630,021</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$<br/> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">8.49</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">—</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$<br/> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">—</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 52%;" valign="bottom">Options granted</td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">747,500</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">6.07</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">—</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">—</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom">Options exercised</td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">(262,031</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">3.99</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">—</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">—</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 52%; padding-bottom: 2px;" valign="bottom">Options cancelled</td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">(302,969</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">)</td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">5.30</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">—</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">—</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Outstanding at December 31, <span style="text-indent: 0pt;">2020</span></div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">5,812,521</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">8.55</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Options granted</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">999,500</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">4.43</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Options exercised</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"/> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Options cancelled</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(414,584</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">22.54</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Outstanding at December 31, <span style="text-indent: 0pt;">2021</span></div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">6,397,437</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">6.99</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Options granted</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">801,004</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">1.48</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Options exercised</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Options cancelled</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(382,416</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">25.06</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Outstanding at December 31, <span style="text-indent: 0pt;">2022</span></div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">6,816,025</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">5.33</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">5.75</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">3</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Options exercisable at December 31, <span style="text-indent: 0pt;">2022</span></div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">5,235,355</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">5.90</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">4.86</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"/> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">RSUs</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Number of</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">RSUs</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Weighted</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Average</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Grant Date</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Fair Value</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Aggregate</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Intrinsic</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Value</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom">Outstanding at December 31, 2019</td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">498,489</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">4.71</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">—</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 64%;" valign="bottom">RSUs granted</td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">218,329</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">6.89</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">—<br/> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom">RSUs vested</td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">(212,495</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">4.63</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">—<br/> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 64%; padding-bottom: 2px;" valign="bottom">RSUs cancelled</td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">—</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">—</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">—</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Outstanding at December 31, <span style="text-indent: 0pt;">2020</span></div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">504,323</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">5.69</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 64%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">RSUs granted</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">236,661</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">4.61</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">RSUs vested</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(215,165</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">5.23</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 64%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">RSUs cancelled</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(16,664</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">5.45</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Outstanding at December 31, <span style="text-indent: 0pt;">2021</span></div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">509,155</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">5.38</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 64%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">RSUs granted</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">258,363</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">1.46</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">RSUs vested</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(215,413</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">5.15</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 64%; padding-bottom: 4px;" valign="bottom">RSUs cancelled<br/> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">—</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">—</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">—</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Outstanding at December 31, <span style="text-indent: 0pt;">2022</span></div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">552,105</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">3.65</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Intrinsic value is calculated as the difference between the per-share market price of our common stock on the last trading day of 2022, which was $1.30 and the exercise price of the options. For options exercised, the intrinsic value is the difference between market price and the exercise price on the date of exercise. In 2022 and 2021, no options were exercised. In 2020, we received cash proceeds of $1,046 from stock options exercised. The total intrinsic value of options exercised was $151 in 2020.<br/> </div> <div><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Stock-based compensation expense is included in operating expense for each period as follows:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Stock-Based Compensation by Type of Award</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Year Ended</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">December 31, 2022</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Year Ended</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">December 31, 2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="text-align: left; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Year Ended</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">December 31, 2020</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Stock options</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2,303</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">3,067</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$<br/> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">2,872</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 64%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">RSUs</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">1,027</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">1,117</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">1,066</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Total stock-based compensation expense</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">3,330</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">4,184</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">$ <br/> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">3,938</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">As of December 31, 2022, there was $3,972 of unrecognized stock-based compensation expense related to unvested stock options and $1,449 of unrecognized stock-based compensation expense related to unvested RSUs. These costs are expected to be recognized over a weighted-average period of 2.66 and 2.43 years, respectively.</div> <div><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The fair value of each option grant was estimated on the date of grant using the Black-Scholes option pricing model using the following weighted average assumptions:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"/> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Year Ended</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">December 31, 2022</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Year Ended</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">December 31, 2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="text-align: left; vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Year Ended</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">December 31, 2020</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Expected stock price volatility</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">85.39</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">%</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">90.58</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">%</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">93.45</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">%</td> </tr> <tr> <td style="vertical-align: bottom; width: 64%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Risk-free interest rate</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">3.09</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">%</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">1.06</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">%</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">0.63</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">%</td> </tr> <tr> <td style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Expected life term</div> </td> <td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">6.2 years</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">6.2 years</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">6.2 years</td> <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 64%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Expected dividends</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">0</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">%</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">0</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">%</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">0</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">%</td> </tr> </table> <div><br/> </div> <div style="text-align: justify;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Based on the Black-Scholes option pricing model, the weighted average estimated fair value of employee stock options granted was $1.09, $3.32 and $4.62 per share during 2022, 2021 and 2020, respectively. </span> </div> <div style="text-align: justify; color: rgb(0, 0, 0); margin-top: 8pt; background-color: rgb(255, 255, 255); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The expected life was determined using the simplified method outlined in ASC 718, “<span style="font-style: italic;">Compensation - Stock Compensation</span>”. Expected volatility of the stock options was based upon historical data and other relevant factors.</div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The following tables summarize information and activity under the plan for the indicated periods.</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td colspan="12" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Options Outstanding</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Options Vested and Exercisable </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Range of<span style="font-size: 10pt; font-family: 'Times New Roman';"><br/> </span>Exercise Prices</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Number</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Outstanding</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Weighted</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Average</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Remaining</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Contractual</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Life (Years)</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Weighted</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Average</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exercise</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Price</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Number</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exercisable</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Weighted</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Average</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Remaining</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Contractual</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Life (Years)</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Weighted</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Average</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exercise</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Price</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;" valign="bottom">$ 1.22 - 1.58</td> <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">801,004</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">9.40</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$ <br/> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">1.48</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">122,001</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">9.38</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$ <br/> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">1.45</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 28%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$ <span style="text-indent: 0pt;">2.35</span> -  <span style="text-indent: 0pt;">6.95</span> </div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">5,504,396</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">5.66</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">4.50</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">4,602,729</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">5.17</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">4.42</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 28%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$ <span style="text-indent: 0pt;">14.52</span> - <span style="text-indent: 0pt;">35.05</span> </div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">510,625</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">0.93</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">20.32</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">510,625</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">0.93</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">20.32</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 28%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">6,816,025</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">5.75</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">5.33</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">5,235,355</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">4.86</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">5.90</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> </tr> </table> 1.22 1.58 801004 P9Y4M24D 1.48 122001 P9Y4M17D 1.45 2.35 6.95 5504396 P5Y7M28D 4.5 4602729 P5Y2M1D 4.42 14.52 35.05 510625 P0Y11M4D 20.32 510625 P0Y11M4D 20.32 6816025 P5Y9M 5.33 5235355 P4Y10M9D 5.9 <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"/> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="14" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Options</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Number of</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Shares</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Weighted</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Average</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exercise</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Price</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Weighted</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Average</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Remaining</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Contractual</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Life (Years)</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Aggregate</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Intrinsic</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Value</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom">Outstanding at December 31, 2019</td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">5,630,021</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$<br/> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">8.49</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">—</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$<br/> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">—</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 52%;" valign="bottom">Options granted</td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">747,500</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">6.07</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">—</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">—</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom">Options exercised</td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">(262,031</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">3.99</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">—</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">—</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 52%; padding-bottom: 2px;" valign="bottom">Options cancelled</td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">(302,969</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">)</td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">5.30</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">—</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">—</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Outstanding at December 31, <span style="text-indent: 0pt;">2020</span></div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">5,812,521</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">8.55</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Options granted</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">999,500</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">4.43</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Options exercised</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"/> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Options cancelled</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(414,584</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">22.54</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Outstanding at December 31, <span style="text-indent: 0pt;">2021</span></div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">6,397,437</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">6.99</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Options granted</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">801,004</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">1.48</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Options exercised</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Options cancelled</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(382,416</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">25.06</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Outstanding at December 31, <span style="text-indent: 0pt;">2022</span></div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">6,816,025</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">5.33</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">5.75</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">3</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Options exercisable at December 31, <span style="text-indent: 0pt;">2022</span></div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">5,235,355</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">5.90</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">4.86</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> </tr> </table> 5630021 8.49 747500 6.07 262031 3.99 302969 5.3 5812521 8.55 999500 4.43 0 0 414584 22.54 6397437 6.99 0 801004 1.48 0 0 382416 25.06 6816025 5.33 P5Y9M 3000 5235355 5.9 P4Y10M9D 2000 <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"/> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">RSUs</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Number of</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">RSUs</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Weighted</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Average</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Grant Date</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Fair Value</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Aggregate</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Intrinsic</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Value</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom">Outstanding at December 31, 2019</td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">498,489</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">4.71</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">—</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 64%;" valign="bottom">RSUs granted</td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">218,329</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">6.89</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">—<br/> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom">RSUs vested</td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">(212,495</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">4.63</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">—<br/> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 64%; padding-bottom: 2px;" valign="bottom">RSUs cancelled</td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">—</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">—</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">—</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Outstanding at December 31, <span style="text-indent: 0pt;">2020</span></div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">504,323</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">5.69</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 64%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">RSUs granted</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">236,661</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">4.61</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">RSUs vested</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(215,165</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">5.23</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 64%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">RSUs cancelled</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(16,664</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">5.45</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Outstanding at December 31, <span style="text-indent: 0pt;">2021</span></div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">509,155</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">5.38</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 64%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">RSUs granted</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">258,363</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">1.46</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">RSUs vested</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(215,413</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">5.15</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 64%; padding-bottom: 4px;" valign="bottom">RSUs cancelled<br/> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">—</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">—</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">—</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Outstanding at December 31, <span style="text-indent: 0pt;">2022</span></div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">552,105</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">3.65</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> 498489 4.71 0 218329 6.89 212495 4.63 0 0 504323 5.69 0 236661 4.61 215165 5.23 16664 5.45 509155 5.38 0 258363 1.46 215413 5.15 0 0 552105 3.65 0 1.3 -0 -0 1046000 151000 <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Stock-based compensation expense is included in operating expense for each period as follows:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Stock-Based Compensation by Type of Award</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Year Ended</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">December 31, 2022</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Year Ended</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">December 31, 2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="text-align: left; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Year Ended</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">December 31, 2020</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Stock options</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2,303</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">3,067</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$<br/> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">2,872</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 64%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">RSUs</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">1,027</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">1,117</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">1,066</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Total stock-based compensation expense</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">3,330</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">4,184</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">$ <br/> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">3,938</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> 2303000 3067000 2872000 1027000 1117000 1066000 3330000 4184000 3938000 3972000 1449000 P2Y7M28D P2Y5M4D <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The fair value of each option grant was estimated on the date of grant using the Black-Scholes option pricing model using the following weighted average assumptions:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"/> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Year Ended</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">December 31, 2022</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Year Ended</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">December 31, 2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="text-align: left; vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Year Ended</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">December 31, 2020</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Expected stock price volatility</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">85.39</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">%</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">90.58</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">%</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">93.45</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">%</td> </tr> <tr> <td style="vertical-align: bottom; width: 64%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Risk-free interest rate</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">3.09</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">%</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">1.06</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">%</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">0.63</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">%</td> </tr> <tr> <td style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Expected life term</div> </td> <td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">6.2 years</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">6.2 years</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">6.2 years</td> <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 64%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Expected dividends</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">0</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">%</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">0</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">%</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">0</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">%</td> </tr> </table> 0.8539 0.9058 0.9345 0.0309 0.0106 0.0063 P6Y2M12D P6Y2M12D P6Y2M12D 0 0 0 1.09 3.32 4.62 <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Note 7 − Earnings Per Share</div> <div><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Basic earnings per share are based on the weighted average number of shares outstanding for a period. Diluted earnings per share are based upon the weighted average number of shares and potentially dilutive common shares outstanding. Potential common shares outstanding principally include stock options and RSUs under our stock plan and warrants. During 2022 and 2021, we incurred losses; therefore, the effect of any common stock equivalent would be anti-dilutive during those years.</div> <div><br/> </div> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The table below sets forth the basic and diluted loss per share calculations:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td rowspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="10" rowspan="1" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"> <span style="font-weight: bold;">Year Ended December 31,</span></td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"/> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">2022</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom">2020<br/> </td> <td colspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Net (loss) income<br/> </div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(36,260</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(42,921</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">280,429</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 64%;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Basic weighted average number of shares outstanding</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">71,335<br/> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">71,159<br/> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">70,850</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 64%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Effect of dilutive securities</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">766</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Diluted weighted average number of shares outstanding</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">71,335</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">71,159</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">71,616</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 64%;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Basic (loss) earnings per share</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(0.51</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(0.60</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">3.96</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 64%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Diluted (loss) earnings per share</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(0.51</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(0.60</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">$</td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">3.92</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The table below sets forth the basic and diluted loss per share calculations:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td rowspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="10" rowspan="1" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"> <span style="font-weight: bold;">Year Ended December 31,</span></td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"/> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">2022</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom">2020<br/> </td> <td colspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Net (loss) income<br/> </div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(36,260</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(42,921</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">280,429</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 64%;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Basic weighted average number of shares outstanding</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">71,335<br/> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">71,159<br/> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">70,850</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 64%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Effect of dilutive securities</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">766</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Diluted weighted average number of shares outstanding</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">71,335</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">71,159</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">71,616</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 64%;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Basic (loss) earnings per share</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(0.51</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(0.60</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">3.96</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 64%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Diluted (loss) earnings per share</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(0.51</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(0.60</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">$</td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">3.92</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> </table> -36260000 -42921000 280429000 71335000 71159000 70850000 0 0 766000 71335000 71159000 71616000 -0.51 -0.6 3.96 -0.51 -0.6 3.92 <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Note 8 − Common Stock</div> <div style="text-align: left;"><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Each share of common stock has the right to one vote<span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">. The holders of common stock are entitled to receive dividends whenever funds are legally available and when declared by our Board of Directors, subject to the prior rights of holders of all classes of stock outstanding having priority rights as to dividends. Our restated articles of incorporation authorize us to issue up to </span>100,000,000<span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"> shares of $</span>0.0001<span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"> par value common stock.</span></div> <div style="text-align: left;"><br/> </div> <div style="text-align: justify;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">On July 30, 2018 we filed a universal shelf registration statement on SEC Form S-3. This replacement registration statement was declared effective by the SEC on August 16, 2018. We used the universal shelf proceeds for development and marketing of our software product and services, and general corporate purposes. The universal shelf registration expired August 16, 2021.</span> </div> <div><br/> </div> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Dividends</div> <div><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">On May 8, 2020, we declared a special cash dividend to shareholders of record as of the close of business on May 18, 2020 of $1 per share of common stock, payable on May 26, 2020. The timing and amounts of future dividends, if any, will depend on market conditions, corporate business and financial considerations and regulatory requirements.</div> <div><br/> </div> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Warrants</div> <div style="text-align: left;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In 2020, we issued warrants for the purchase of 25,000 shares of common stock at an exercise price of $5.75 per share, exercisable on the date of grant expiring in <span style="-sec-ix-hidden:Fact_e6276139707746e8ac0c845615626105">April 2025</span>. The weighted average fair value at the grant date was $4.16 per warrant. The fair value at the grant date was estimated utilizing the Black-Scholes valuation model with the following weighted average assumptions (i) dividend yield on our common stock of 0 percent (ii) expected stock price volatility of 97 percent (iii) a risk-free interest rate of 0.27 percent and (iv) and expected option term of 5 years.</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Warrants Issued</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exercise</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> Price</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Outstanding and</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exercisable</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">December 31, 2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Issued</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exercised</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Terminated /</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Cancelled</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Outstanding and </div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exercisable</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">December 31, 2022</div> </td> <td colspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1%;" valign="bottom"> </td> <td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); width: 16%; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Expiration Date</div> </td> <td colspan="1" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">25,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">5.75</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">25,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">25,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td style="vertical-align: bottom; width: 16%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"> <div style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">April 30, 2025</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"> </td> </tr> </table> <div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In April 2020, 25,000 warrants with an exercise price of $7.00 per share expired.</span><br/> </div> 1 100000000 0.0001 2020-05-08 2020-05-18 1 2020-05-26 25000 5.75 4.16 0 0.97 0.0027 P5Y <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Warrants Issued</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exercise</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> Price</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Outstanding and</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exercisable</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">December 31, 2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Issued</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exercised</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Terminated /</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Cancelled</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Outstanding and </div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exercisable</div> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">December 31, 2022</div> </td> <td colspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1%;" valign="bottom"> </td> <td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); width: 16%; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Expiration Date</div> </td> <td colspan="1" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">25,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">5.75</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">25,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">25,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td style="vertical-align: bottom; width: 16%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"> <div style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">April 30, 2025</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"> </td> </tr> </table> 25000 5.75 25000 0 0 0 25000 2025-04-30 25000 7 <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Note 9 − Employee Benefit Plan</div> <div style="text-align: left;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">We sponsor a defined contribution 401k plan covering substantially all our employees. Our matching contribution to the plan was approximately $179, $145, and $112 in 2022, 2021 and 2020, respectively.</div> 179000 145000 112000 <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Note 10 − Income Taxes</div> <div style="text-align: left;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The income tax provision (benefit) is comprised of the following:</div> <div style="text-align: left;"><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"/> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Year Ended<span style="font-size: 10pt; font-family: 'Times New Roman';"><br/> </span>December 31, 2022</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Year Ended<span style="font-size: 10pt; font-family: 'Times New Roman';"><br/> </span>December 31, 2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"><span style="font-weight: bold;">Year Ended<span style="font-size: 10pt; font-family: 'Times New Roman';"><br/> </span>December 31, 2020</span></td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Current:</div> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Federal</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">661</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$</td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">35,122</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 64%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">State</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">3</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">35</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">950</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">Foreign</td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">—</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">—</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">—</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 64%;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">3</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">696</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">36,072</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Deferred:</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 64%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Federal</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">15,920</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(7,025</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">(8,816</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">)</td> </tr> <tr> <td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">State</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">109</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">124</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">(233</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 64%; padding-bottom: 4px;" valign="bottom"><br/> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">16,029</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">(6,901</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">)</td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">(9,049</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">)</td> </tr> <tr> <td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Total income tax (benefit) provision</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">$</td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">16,032</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(6,205</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$</td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">27,023</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">A reconciliation of the United States federal statutory income tax rate to our effective income tax rate is as follows:</div> <div style="text-align: left;"><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"/> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Year Ended<span style="font-size: 10pt; font-family: 'Times New Roman';"><br/> </span>December 31, 2022</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Year Ended<span style="font-size: 10pt; font-family: 'Times New Roman';"><br/> </span>December 31, 2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"><span style="font-weight: bold;">Year Ended<span style="font-size: 10pt; font-family: 'Times New Roman';"><br/> </span>December 31, 2020</span></td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">United States federal statutory rate</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">21.00</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">%</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">21.00</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">%</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">21.00</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">%</td> </tr> <tr> <td style="vertical-align: bottom; width: 64%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">State taxes, net of federal benefit</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(0.55</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)%</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(0.31</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)%</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">0.17</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">%</td> </tr> <tr> <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Valuation allowance</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(91.21</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)%</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">(12.22</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)%</td> </tr> <tr> <td style="vertical-align: bottom; width: 64%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Stock based compensation</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(9.44</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)%</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(6.68</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)%</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">(0.01</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">)%</td> </tr> <tr> <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">R&amp;D Credit</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">1.22</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">%</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">0.19</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">%</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">(0.21</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)%</td> </tr> <tr> <td style="vertical-align: bottom; width: 64%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Other</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(0.29</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)%</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(1.57</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)%</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">0.06</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">%</td> </tr> <tr> <td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Effective income tax rate</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">(79.27</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)%</td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">12.63</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">%</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">8.79</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">%</td> </tr> </table> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"> <br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The Company’s effective tax rate for 2022 and 2020 was substantially lower than the statutory Federal income tax rate primarily due to the change in valuation allowance. The Company’s effective tax rate for 2021 was substantially lower than the statutory Federal income tax rate primarily due to the effect of stock based compensation, including expiring options.</div> <div> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Deferred tax assets (liabilities) consist of the following:</div> <div style="text-align: left;"><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"/> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">As of<span style="font-size: 10pt; font-family: 'Times New Roman';"><br/> </span>December 31, 2022</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">As of<span style="font-size: 10pt; font-family: 'Times New Roman';"><br/> </span>December 31, 2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Deferred tax assets:</div> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Reserves and accruals</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">147</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">58</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Research and development credits and other credits</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">430</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">92</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Net operating loss carry forward</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">11,988</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">9,519</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Stock based compensation</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">5,018</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">6,287</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Other</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">970</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Total deferred tax assets</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">18,553</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">15,956</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Valuation allowance</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(18,553)</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Deferred tax assets after valuation allowance</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">15,956</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Total deferred tax liability <span style="color: rgb(0, 0, 0);">– depreciation</span> and amortization<br/> </div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(6</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Net deferred tax assets</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">15,950</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div style="text-align: left;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;">Pursuant to changes in IRC Section 174 effective for 2022, we capitalized direct and indirect research and development costs in our tax return totaling $5,140; $514 of these expenses will be amortized in our 2022 tax return. At December 31, 2022, we had federal and state net operating loss carryforwards of approximately $57,085 and $108,745, respectively. Federal net operating loss carryforwards do not expire. None of the state net operating loss carryforward is apportioned to a deferred tax asset, because currently we do not have operations in states where losses accumulated. The state net operating loss carryforward begins expiring in <span style="-sec-ix-hidden:Fact_c1d0879db08e4c719f3ef581405b2426">2029</span>.</div> <div><br/></div> <div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="background-color: #FFFFFF; margin: 0px 0px 0px; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-transform: none;">We are required to recognize the financial statement effects of a tax position when it is more likely than not, based on the technical merits, that the position will be sustained upon examination. At December 31, 2022, we have no uncertain tax positions.</div> <div style="text-align: justify; color: rgb(0, 0, 0); margin-top: 8pt; background-color: rgb(255, 255, 255); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Our tax years for 2005 and forward are subject to examination by the U.S. tax authority and various state tax authorities. These years are open due to NOLs and tax credits generated in these years were utilized in 2020. The statute of limitation for these years shall expire three years after the date of filing 2020 income tax returns, which is October 2024.</div> <div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="text-align: justify; color: rgb(0, 0, 0); margin-top: 8pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Our policy is to recognize interest and penalties, if any, accrued on any unrecognized tax benefits, as a component of income tax expense. We had no interest or penalties accrued in 2022.</span><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The income tax provision (benefit) is comprised of the following:</div> <div style="text-align: left;"><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"/> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Year Ended<span style="font-size: 10pt; font-family: 'Times New Roman';"><br/> </span>December 31, 2022</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Year Ended<span style="font-size: 10pt; font-family: 'Times New Roman';"><br/> </span>December 31, 2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"><span style="font-weight: bold;">Year Ended<span style="font-size: 10pt; font-family: 'Times New Roman';"><br/> </span>December 31, 2020</span></td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Current:</div> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Federal</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">661</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$</td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">35,122</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 64%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">State</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">3</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">35</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">950</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">Foreign</td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">—</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">—</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">—</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 64%;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">3</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">696</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">36,072</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Deferred:</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 64%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Federal</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">15,920</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(7,025</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">(8,816</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">)</td> </tr> <tr> <td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">State</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">109</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">124</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">(233</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 64%; padding-bottom: 4px;" valign="bottom"><br/> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">16,029</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">(6,901</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">)</td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">(9,049</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">)</td> </tr> <tr> <td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Total income tax (benefit) provision</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">$</td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">16,032</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(6,205</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$</td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">27,023</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> 0 661000 35122000 3000 35000 950000 0 0 0 3000 696000 36072000 15920000 -7025000 -8816000 109000 124000 -233000 16029000 -6901000 -9049000 16032000 -6205000 27023000 <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">A reconciliation of the United States federal statutory income tax rate to our effective income tax rate is as follows:</div> <div style="text-align: left;"><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"/> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Year Ended<span style="font-size: 10pt; font-family: 'Times New Roman';"><br/> </span>December 31, 2022</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Year Ended<span style="font-size: 10pt; font-family: 'Times New Roman';"><br/> </span>December 31, 2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"><span style="font-weight: bold;">Year Ended<span style="font-size: 10pt; font-family: 'Times New Roman';"><br/> </span>December 31, 2020</span></td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">United States federal statutory rate</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">21.00</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">%</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">21.00</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">%</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">21.00</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">%</td> </tr> <tr> <td style="vertical-align: bottom; width: 64%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">State taxes, net of federal benefit</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(0.55</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)%</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(0.31</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)%</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">0.17</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">%</td> </tr> <tr> <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Valuation allowance</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(91.21</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)%</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">(12.22</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)%</td> </tr> <tr> <td style="vertical-align: bottom; width: 64%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Stock based compensation</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(9.44</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)%</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(6.68</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)%</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">(0.01</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">)%</td> </tr> <tr> <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">R&amp;D Credit</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">1.22</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">%</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">0.19</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">%</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">(0.21</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)%</td> </tr> <tr> <td style="vertical-align: bottom; width: 64%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Other</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(0.29</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)%</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(1.57</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)%</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">0.06</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">%</td> </tr> <tr> <td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Effective income tax rate</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">(79.27</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)%</td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">12.63</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">%</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">8.79</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">%</td> </tr> </table> 0.21 0.21 0.21 -0.0055 -0.0031 0.0017 -0.9121 0 -0.1222 -0.0944 -0.0668 -0.0001 -0.0122 -0.0019 0.0021 -0.0029 -0.0157 0.0006 -0.7927 0.1263 0.0879 <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Deferred tax assets (liabilities) consist of the following:</div> <div style="text-align: left;"><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"/> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">As of<span style="font-size: 10pt; font-family: 'Times New Roman';"><br/> </span>December 31, 2022</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">As of<span style="font-size: 10pt; font-family: 'Times New Roman';"><br/> </span>December 31, 2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Deferred tax assets:</div> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Reserves and accruals</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">147</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">58</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Research and development credits and other credits</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">430</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">92</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Net operating loss carry forward</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">11,988</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">9,519</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Stock based compensation</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">5,018</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">6,287</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Other</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">970</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Total deferred tax assets</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">18,553</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">15,956</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Valuation allowance</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(18,553)</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Deferred tax assets after valuation allowance</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">15,956</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Total deferred tax liability <span style="color: rgb(0, 0, 0);">– depreciation</span> and amortization<br/> </div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(6</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Net deferred tax assets</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">15,950</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> 147000 58000 430000 92000 11988000 9519000 5018000 6287000 970000 0 18553000 15956000 18553000 0 0 15956000 0 6000 0 15950000 5140000 514000 57085000 108745000 0 0 <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Note 11 − Fair Value Measurement</div> <div><br/> </div> <div style="text-align: justify; margin-top: 4.9pt; margin-right: 5.7pt;"><span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Fair value is the price that would result from an orderly transaction between market participants at the measurement date. A fair value hierarchy prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement). Level 2 measurements utilize either directly or indirectly observable inputs in markets other than quoted prices in active markets.</span></div> <div><span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="margin-top: 0.35pt; font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="text-align: justify; margin-right: 5.6pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Our financial instruments are stated at amounts that equal, or approximate, fair value. When we estimate fair value, we utilize market data or assumptions that we believe market participants would use in pricing the financial instrument, including assumptions about risk and inputs to the valuation technique. We use valuation techniques, primarily the income and market approach, which maximizes the use of observable inputs and minimize the use of unobservable inputs for recurring fair value measurements.</div> <div><span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="text-align: justify; color: rgb(0, 0, 0); margin-top: 8pt; margin-left: 36pt;"><span style="font-style: normal; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; text-transform: none;"><span style="font-style: italic;">Mutual funds:</span> Valued at the quoted net asset value (NAV) of shares held.</span></div> <div><span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="text-align: justify; color: rgb(0, 0, 0); margin-top: 8pt; margin-left: 36pt;"><span style="font-style: normal; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; text-transform: none;"><span style="font-style: italic;">U.S. agency and treasury securities:</span> Fair value measured at the closing price reported on the active market on which the individual securities are traded.</span></div> <div><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The following table shows the adjusted cost, gross unrealized gains, gross unrealized losses, and fair value of our financial assets as of December 31, 2022 and 2021 (in thousands):</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"/> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="22" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">December 31, 2022</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Adjusted<span style="font-size: 10pt; font-family: 'Times New Roman';"><br/> </span>Cost</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Unrealized<span style="font-size: 10pt; font-family: 'Times New Roman';"><br/> </span>Gains</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Unrealized<span style="font-size: 10pt; font-family: 'Times New Roman';"><br/> </span>Losses</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Fair<span style="font-size: 10pt; font-family: 'Times New Roman';"><br/> </span>Value</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Cash<span style="font-size: 10pt; font-family: 'Times New Roman';"><br/> </span>and Cash<span style="font-size: 10pt; font-family: 'Times New Roman';"><br/> </span>Equivalents</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Investments<span style="font-size: 10pt; font-family: 'Times New Roman';"><br/> </span>Available<span style="font-size: 10pt; font-family: 'Times New Roman';"><br/> </span>for Sale</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Cash</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">16,949</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">16,949</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">16,949</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 28%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Level 1:</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Mutual funds</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">66,493</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">66,493</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">66,493</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 28%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">U.S. agency and treasury securities</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">68,958</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">9</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(386</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">68,581</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">3,119</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">65,462</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 28%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">135,451</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">9</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(386</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">135,074</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">69,612</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">65,462</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 28%; padding-bottom: 4px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Total</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">152,400</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">9</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(386</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">152,023</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">86,561</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">65,462</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"/> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="22" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">December 31, 2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Adjusted<span style="font-size: 10pt; font-family: 'Times New Roman';"><br/> </span>Cost</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Unrealized<span style="font-size: 10pt; font-family: 'Times New Roman';"><br/> </span>Gains</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Unrealized<span style="font-size: 10pt; font-family: 'Times New Roman';"><br/> </span>Losses</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Fair<span style="font-size: 10pt; font-family: 'Times New Roman';"><br/> </span>Value</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Cash<span style="font-size: 10pt; font-family: 'Times New Roman';"><br/> </span>and Cash<span style="font-size: 10pt; font-family: 'Times New Roman';"><br/> </span>Equivalents</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Investments<span style="font-size: 10pt; font-family: 'Times New Roman';"><br/> </span>Available<span style="font-size: 10pt; font-family: 'Times New Roman';"><br/> </span>for Sale</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Cash</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">35,428</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">35,428</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">35,428</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 28%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Level 1:</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Mutual funds</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">106,590</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">106,590</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">106,590</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 28%; padding-bottom: 2px;" valign="bottom">U.S. agency and treasury securities<br/> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">27,304</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">—</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">(50</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">)</td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">27,254</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">—</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">27,254</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 28%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">133,894</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(50</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">133,844</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">106,590</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">27,254</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 28%; padding-bottom: 4px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Total</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">169,322</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(50</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">169,272</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">142,018</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">27,254</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div><span style="font-family: 'Times New Roman';"><br/> </span> </div> <div><span style="font-family: 'Times New Roman';"> </span></div> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The maturities of our investments generally range from within <span style="-sec-ix-hidden:Fact_f531af3c1d534154afccf3fdfd7b331a">one</span> to two years. Actual maturities could differ from contractual maturities due to call or prepayment provisions.</div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The following table shows the adjusted cost, gross unrealized gains, gross unrealized losses, and fair value of our financial assets as of December 31, 2022 and 2021 (in thousands):</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"/> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="22" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">December 31, 2022</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Adjusted<span style="font-size: 10pt; font-family: 'Times New Roman';"><br/> </span>Cost</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Unrealized<span style="font-size: 10pt; font-family: 'Times New Roman';"><br/> </span>Gains</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Unrealized<span style="font-size: 10pt; font-family: 'Times New Roman';"><br/> </span>Losses</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Fair<span style="font-size: 10pt; font-family: 'Times New Roman';"><br/> </span>Value</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Cash<span style="font-size: 10pt; font-family: 'Times New Roman';"><br/> </span>and Cash<span style="font-size: 10pt; font-family: 'Times New Roman';"><br/> </span>Equivalents</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Investments<span style="font-size: 10pt; font-family: 'Times New Roman';"><br/> </span>Available<span style="font-size: 10pt; font-family: 'Times New Roman';"><br/> </span>for Sale</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Cash</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">16,949</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">16,949</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">16,949</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 28%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Level 1:</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Mutual funds</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">66,493</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">66,493</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">66,493</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 28%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">U.S. agency and treasury securities</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">68,958</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">9</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(386</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">68,581</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">3,119</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">65,462</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 28%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">135,451</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">9</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(386</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">135,074</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">69,612</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">65,462</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 28%; padding-bottom: 4px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Total</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">152,400</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">9</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(386</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">152,023</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">86,561</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">65,462</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"/> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="22" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">December 31, 2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Adjusted<span style="font-size: 10pt; font-family: 'Times New Roman';"><br/> </span>Cost</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Unrealized<span style="font-size: 10pt; font-family: 'Times New Roman';"><br/> </span>Gains</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Unrealized<span style="font-size: 10pt; font-family: 'Times New Roman';"><br/> </span>Losses</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Fair<span style="font-size: 10pt; font-family: 'Times New Roman';"><br/> </span>Value</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Cash<span style="font-size: 10pt; font-family: 'Times New Roman';"><br/> </span>and Cash<span style="font-size: 10pt; font-family: 'Times New Roman';"><br/> </span>Equivalents</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Investments<span style="font-size: 10pt; font-family: 'Times New Roman';"><br/> </span>Available<span style="font-size: 10pt; font-family: 'Times New Roman';"><br/> </span>for Sale</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Cash</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">35,428</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">35,428</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">35,428</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 28%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Level 1:</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Mutual funds</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">106,590</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">106,590</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">106,590</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 28%; padding-bottom: 2px;" valign="bottom">U.S. agency and treasury securities<br/> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">27,304</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">—</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">(50</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">)</td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">27,254</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">—</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">27,254</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 28%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">133,894</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(50</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">133,844</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">106,590</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">27,254</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 28%; padding-bottom: 4px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Total</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">169,322</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(50</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">169,272</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">142,018</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">27,254</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> </tr> </table> 16949000 16949000 16949000 66493000 0 0 66493000 66493000 0 68958000 9000 386000 68581000 3119000 65462000 135451000 9000 386000 135074000 69612000 65462000 152400000 152023000 86561000 65462000 35428000 35428000 35428000 106590000 0 0 106590000 106590000 0 27304000 0 50000 27254000 0 27254000 133894000 0 50000 133844000 106590000 27254000 169322000 169272000 142018000 27254000 P2Y <div><span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </div> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">Note 12 − Litigation (all dollar amounts in this section are expressed in thousands except for rates per device)</div> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;"> <br/> </div> <div><span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">We have several intellectual property infringement lawsuits pending in the United States Court of Appeals for the Federal Circuit (“USCAFC”).</div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;"> <br/> </div> <div><span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">VirnetX Inc. v. Apple, Inc. (Case 6:12-CV-00855-LED) (“Apple II”)</div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;"> <br/> </div> <div><span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">This case began on November 6, 2012, when we filed a complaint against Apple in United States District Court (“USDC”) in which we alleged that Apple infringed on certain of our patents, (U.S. Patent Nos. 6,502,135, 7,418,504, 7,921,211 and 7,490,151). We sought damages and injunctive relief. The accused products include the iPhone 5, iPod Touch 5th Generation, iPad 4th Generation, iPad mini, and the latest Macintosh computers. Post-trial motions hearing was held on July 18, 2018. On August 31, 2018, the USDC entered a Final Judgment and issued its Memorandum Opinion and Order regarding post-trial motions, affirming the jury’s verdict of $502,600 and granting VirnetX motions for supplemental damages, a sunset royalty, and the royalty rate of $1.20 per infringing iPhone, iPad and Mac products, pre-judgment and post-judgment interest and costs. Apple filed a notice of appeal with the United States Court of Appeals for the Federal Circuit (“USCAFC”) in the Apple II case.</div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;"> <br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">On October 9, 2018, USCAFC docketed the appeal as Case No. 19-1050 - VirnetX Inc. v. Apple Inc. On January 24, 2019 Apple filed its opening brief. We filed our response brief on March 1, 2019. Apple filed its reply brief on April 5, 2019. The oral arguments were heard on October 4, 2019. On November 22, 2019, the USCAFC issued an opinion affirming the district court’s findings that Apple is precluded from making certain invalidity arguments and that Apple infringed the ‘135 and ‘151 patents; reversing the USDC’s finding that Apple infringed the ‘504 and ‘211 patents; and remanding the case for proceedings on damages. Apple sought panel and en banc rehearing, which the USCAFC denied on February 10, 2020.</span></div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> <br/> </span></div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">On February 22, 2020, the USDC issued a scheduling order for the parties to brief the court about the need for a new trial for recalculating the damages. We filed our motion for entry of judgment on February 28, 2020. The arguments on this matter were heard on April 14, 2020. In its order, unsealed on May 1, 2020, the USDC denied VirnetX’s motion for entry of a new judgment based on the prior jury verdict and ordered a new jury trial on damages. On August 10, 2020, the USDC granted Apple’s motion for continuance and reset the date to October 26, 2020. On October 30, 2020, a jury returned a $502,800 verdict in favor of VirnetX based on Apple’s infringement of two network security patents: VirnetX US Patents No. 6,502,135 and No. 7,490,151. The jury verdict called for damages of $0.84 per accused device since the 2013 launch of Apple’s iOS 7 operating system and represents 598,629,580 infringing units from US sales only. On January 15, 2021, the district court denied Apple’s motion for judgment as a matter of law, and on February 4, 2021, Apple filed a notice of appeal to the USCAFC.</span></div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> <br/> </span></div> <div style="text-align: justify; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">On February 22, 2021, USCAFC docketed the appeal as Case No. 19-1672. Apple’s opening brief was filed on June 2, 2021. VirnetX filed its responsive brief on July 26, 2021. Apple filed its reply brief on September 13, 2021. The briefing is complete, and oral arguments were held on September 8, 2022. On March 31, 2023, the Federal Circuit issued its decision vacating the district court’s judgement in this matter and remanding it back to the district court with instructions to dismiss the case as moot. We are evaluating all of our available options in this matter, including potentially seeking rehearing or certiorari review.<br/> </div> <div><br/></div> <div style="text-align: justify; font-weight: bold; margin-right: 6.35pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">VirnetX Inc. v. Mangrove Partners Master Fund, Ltd., Apple Inc. (USCAFC Case 20-2271) and VirnetX Inc. v. Mangrove Partners Master Fund, Ltd., Apple Inc., and Black Swamp, LLC (USCAFC Case 20-2272)</div> <div style="text-align: justify; font-weight: bold; margin-right: 6.35pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); margin-right: 5.65pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">On September 15, 2020, we filed with the USCAFC an appeal of the invalidity findings by the Patent Trial and Appeal Board (“PTAB”) in inter-partes review proceedings IPR2015-01046 and IPR2016-00062 involving our U.S. Patent No. 6,502,135, and an appeal of the invalidity findings by the PTAB in inter-partes review proceedings IPR2015-1047, IPR2016- 00063, and IPR2016-00167 involving our U.S. Patent No. 7,490,151. On September 25, 2020, the USCAFC issued an order consolidating the two appeals. On December 15, 2020, we filed a motion to vacate the PTAB decisions below and to remand these appeals to the PTAB. On March 16, 2021, the USCAFC denied the motion without prejudice to us raising the challenges made in the motion in our opening brief. Our opening brief was filed on June 7, 2021.</div> <div style="text-align: justify; color: rgb(0, 0, 0); margin-right: 5.65pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/> </div> <div style="text-align: justify; margin-right: 5.65pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-weight: normal;">On June 23, 2021, the USCAFC entered an order directing us (and parties in other appeals that raised Appointments Clause challenges) to file a brief explaining how they believe their cases should proceed in light of the Supreme Court’s decision in United States v. Arthrex, Inc., 141 S. Ct. 1970 (2021). On July 7, 2021, we filed a brief in response to the court’s order. Other parties, including the U.S. Patent and Trademark Office (“USPTO”) filed their responses on July 21, 2021. On August 19, 2021, USCAFC issued an order remanding these appeals for the limited purpose of allowing VirnetX the opportunity to request rehearing of the PTAB’s final written decisions by the Director of the USPTO. The USCAFC retained jurisdiction over the appeals in the meantime. On September 20, 2021, we filed our requests for Director rehearing with the USPTO. On October 29, 2021, our requests for Director rehearing were denied. We subsequently filed an amended opening brief to the USCAFC on December 10, 2021, the other parties filed response briefs on February 2, 2022, and we filed a reply brief on February 22, 2022. All the briefings have been completed. The oral arguments in this matter were held on September 8, 2022. </span>On March 30, 2023, the USCAFC issued its decision affirming PTAB’s decisions finding certain claims of the ‘135 patent and the ‘151 patent to be unpatentable. We are evaluating all of our available options in this matter, including potentially seeking rehearing or certiorari review.</div> <div> <br/> </div> <div><span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">VirnetX Inc. v. Hirshfeld (USCAFC Case 17-2593, -2594) </span></div> <div><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); margin-right: 5.65pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">On September 22, 2017, we filed with the USCAFC an appeal of the invalidity findings by the PTAB in inter-partes review proceeding IPR2016-00693 involving our U.S. Patent No. 7,418,504, and an appeal of the invalidity findings by the PTAB in inter-partes review proceeding IPR2016-00957 involving our U.S. Patent No. 7,921,211. On September 16, 2021, USCAFC issued an order remanding these appeals for the limited purpose of allowing VirnetX the opportunity to request rehearing of the PTAB’s final written decisions by the Director of the USPTO. The USCAFC retained jurisdiction over the appeals in the meantime. On October 18, 2021, we filed our requests for Director rehearing with the USPTO. On January 7, 2022, our requests for Director rehearing were denied. On January 21, 2022, we informed the USCAFC about the denial of Director rehearing and requested that the court dismiss the appeal involving IPR2016-00957 as moot and vacate the PTAB’s underlying decision. On April 4, 2022, the USCAFC vacated the PTAB’s decision in IPR2016-00957 and remanded Appeal No. 17-2594 with instructions to dismiss. In the April 4, 2022 order, the USCAFC further set a briefing schedule, in Appeal No. 17-2593. VirnetX filed its opening brief on September 12, 2022. The USPTO filed its response brief on December 20, 2022. VirnetX filed its reply brief on February 14, 2023, and we currently await scheduling of oral arguments.</div> <div style="font-weight: bold; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/> </div> <div style="font-weight: bold; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">VirnetX Inc. v. Cisco Systems, Inc. (USCAFC Case 19-1671)</div> <div style="font-weight: bold; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); margin-right: 5.65pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"> On March 18, 2019, we filed with the USCAFC an appeal of the invalidity findings by the PTAB in inter-partes re-examination proceeding 95/001,679 involving our U.S. Patent No. 6,502,135. On October 5, 2021, USCAFC issued an order remanding these appeals for the limited purpose of allowing VirnetX the opportunity to request rehearing of the PTAB’s final written decisions by the Director of the PTO. The USCAFC retained jurisdiction over the appeals in the meantime. Our request for Director rehearing with the PTO was filed on November 5, 2021. On January 10, 2022, our request for Director rehearing was denied. We informed the USCAFC about the denial of Director rehearing. VirnetX’s opening brief was filed on June 23, 2022. The USPTO’s response brief was filed on August 2, 2022, and Cisco’s response brief was filed on September 2, 2022. VirnetX filed its reply brief on October 7, 2022, and we currently await scheduling of oral arguments. </span></div> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br/> </div> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">VirnetX Inc. v. Apple Inc. (USCAFC Case 22-1523) (“Apple Reexam I”)</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">On March 10, 2022, we filed with the USCAFC an appeal of the invalidity findings by the PTAB in inter-partes re-examination proceeding 95/001,682 involving our U.S. Patent No. 6,502,135. Our opening brief was filed on August 22, 2022. Apple and USPTO each filed a response brief on December 28, 2022. VirnetX filed its reply brief on February 8, 2023, and we currently await scheduling of oral arguments.</div> <div><br/></div> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">VirnetX Inc. v. Apple Inc. (USCAFC Case 22-1997</span>)<span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;"> (“Apple Reexam II”)</span></div> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;"> <br/> </span></div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">On July 6, 2022, we filed with the USCAFC an appeal of the invalidity findings by the PTAB in inter-partes re-examination proceeding 95/001,697 involving our U.S. Patent No. 7,490,151. On October 17, 2022, we filed a motion to remand the appeal in light of the PTAB’s refusal to permit Director rehearing. On January 23, 2023, the USCAFC denied that motion without prejudice to the parties raising their arguments in the merits briefs. VirnetX’s opening brief is currently due April 24, 2023.</div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"> <br/> </div> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">VirnetX Inc. v. Cisco Systems, Inc. (USCAFC Case 22-2234)</div> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">On September 16, 2022, we filed with the USCAFC an appeal of the invalidity findings by the PTAB in inter-partes re-examination proceeding 95/001,851 involving our U.S. Patent No. 7,418,504. We filed our opening brief on February 28, 2023. </div> <div style="text-align: justify; margin-right: 1pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/> </div> <div><span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><span style="font-size: 10pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">McKool Smith P.C. v. VirnetX, Inc., AAA Case No. 01-20-0003-7975</span></div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><span style="font-size: 10pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> <br/> </span></div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">On March 23, 2020, the law firm of McKool Smith, P.C. (“McKool”) filed a Demand for Arbitration against VirnetX, Inc. with the American Arbitration Association (“AAA”). In its demand, McKool claimed that a retention agreement it entered into in 2010 with VirnetX entitled it to a contingency fee arising from the recent 2020 payment made in the Apple I case. McKool claimed it was owed approximately $36,300 (or 8% of the Apple I payment). We filed a general response with the AAA denying McKool’s claim and contested the matter vigorously. An evidentiary hearing was held on the matter during the week of February 22, 2021 and the parties submitted additional briefings. On April 19, 2021, the arbitrator awarded McKool $36,323 in damages, plus pre-judgment interest in the amount of 5% simple interest from March 23, 2020 to April 18, 2021, and post-judgment interest in the amount of 5%, compounded annually, until payment of the award. We accrued the resulting $38,284 as of March 31, 2021 and paid that amount to McKool on April 20, 2021. <span style="font-weight: bold;">This matter is now closed.</span></div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;"><span style="font-weight: bold;"> <br/> </span></div> <div><span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">Other Legal Matters</div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;"> <br/> </div> <div><span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">One or more potential intellectual property infringement claims may also be available to us against certain other companies who have the resources to defend against any such claims. Although we believe these potential claims are likely valid, commencing a lawsuit can be expensive and time-consuming, and there is no assurance that we could prevail on such potential claims if we made them. In addition, bringing a lawsuit may lead to potential counterclaims which may distract our management and our other resources, including capital resources, from efforts to successfully commercialize our products.</div> <div><span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">Currently, we are not a party to any other pending legal proceedings and are not aware of any proceeding threatened or contemplated against us.</div> 502600000 1.2 502800000 2 0.84 598629580 2 36300000 0.08 36323000 0.05 0.05 38284000 38284000 <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Note 13 − Leases</div> <div><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">We lease office space under an operating lease which expires on October 31, 2023. At December 31, 2022, the underlying ROU asset and lease liability totaled $45. At December 31, 2021, the underlying ROU asset and lease liability totaled $98. Lease expense totaled $54 in 2022 and $56 in 2021 and 2020.</div> <div><span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify;">We also lease a facility for corporate promotional and marketing purposes which was prepaid at inception and originally expired in 2024. In September 2020, the lease was extended for one year to 2025, due to COVID use-restrictions. No other terms of the original agreement were affected and there was no impact on cash flow. At December 31, 2022 and 2021, the ROU asset totaled $648 and $948, respectively; lease expense totaled $300, $300 and $356, during 2022, 2021 and 2020, respectively.</div> 45000 45000 98000 98000 54000 56000 56000 P1Y 648000 948000 300000 300000 356000 <div style="text-align: left; margin-bottom: 8pt; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Note 14 − Subsequent Event</div> <div style="margin: 0px 0px 0px; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">On March 30, 2023, we declared a special cash dividend of $1.00 per common share to be paid on or about April 17, 2023 to shareholders of record on April 10, 2023. If the final outcome of the Apple II litigation described elsewhere in this Form 10-K results in proceeds to us, we are committed to distribute to our shareholders a substantial portion of the net proceeds (after legal costs, licensing costs and taxes), after the case concludes.</div> 2023-03-30 1 2023-04-17 2023-04-10 EXCEL 66 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 67 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 68 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 69 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 136 293 1 false 43 0 false 10 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://virnetx.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 010000 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://virnetx.com/role/ConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 010100 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://virnetx.com/role/ConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 020000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://virnetx.com/role/ConsolidatedStatementsOfOperations CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 030000 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME Sheet http://virnetx.com/role/ConsolidatedStatementsOfComprehensiveLossIncome CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME Statements 5 false false R6.htm 040000 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Sheet http://virnetx.com/role/ConsolidatedStatementsOfStockholdersEquity CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statements 6 false false R7.htm 040100 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) Sheet http://virnetx.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) Statements 7 false false R8.htm 050000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://virnetx.com/role/ConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 8 false false R9.htm 060100 - Disclosure - Formation and Business of the Company Sheet http://virnetx.com/role/FormationAndBusinessOfCompany Formation and Business of the Company Notes 9 false false R10.htm 060200 - Disclosure - Summary of Significant Accounting Policies Sheet http://virnetx.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 10 false false R11.htm 060300 - Disclosure - Property and Equipment Sheet http://virnetx.com/role/PropertyAndEquipment Property and Equipment Notes 11 false false R12.htm 060400 - Disclosure - Commitments, Contingencies and Related Party Transactions Sheet http://virnetx.com/role/CommitmentsContingenciesAndRelatedPartyTransactions Commitments, Contingencies and Related Party Transactions Notes 12 false false R13.htm 060500 - Disclosure - Stock Plan Sheet http://virnetx.com/role/StockPlan Stock Plan Notes 13 false false R14.htm 060600 - Disclosure - Stock-Based Compensation Sheet http://virnetx.com/role/StockbasedCompensation Stock-Based Compensation Notes 14 false false R15.htm 060700 - Disclosure - Earnings Per Share Sheet http://virnetx.com/role/EarningsPerShare Earnings Per Share Notes 15 false false R16.htm 060800 - Disclosure - Common Stock Sheet http://virnetx.com/role/CommonStock Common Stock Notes 16 false false R17.htm 060900 - Disclosure - Employee Benefit Plan Sheet http://virnetx.com/role/EmployeeBenefitPlan Employee Benefit Plan Notes 17 false false R18.htm 061000 - Disclosure - Income Taxes Sheet http://virnetx.com/role/IncomeTaxes Income Taxes Notes 18 false false R19.htm 061100 - Disclosure - Fair Value Measurement Sheet http://virnetx.com/role/FairValueMeasurement Fair Value Measurement Notes 19 false false R20.htm 061200 - Disclosure - Litigation Sheet http://virnetx.com/role/Litigation Litigation Notes 20 false false R21.htm 061300 - Disclosure - Leases Sheet http://virnetx.com/role/Leases Leases Notes 21 false false R22.htm 061400 - Disclosure - Subsequent Event Sheet http://virnetx.com/role/SubsequentEvent Subsequent Event Notes 22 false false R23.htm 070200 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://virnetx.com/role/SummaryOfSignificantAccountingPolicies 23 false false R24.htm 080200 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://virnetx.com/role/SummaryOfSignificantAccountingPolicies 24 false false R25.htm 080300 - Disclosure - Property and Equipment (Tables) Sheet http://virnetx.com/role/PropertyAndEquipmentTables Property and Equipment (Tables) Tables http://virnetx.com/role/PropertyAndEquipment 25 false false R26.htm 080600 - Disclosure - Stock-Based Compensation (Tables) Sheet http://virnetx.com/role/StockbasedCompensationTables Stock-Based Compensation (Tables) Tables http://virnetx.com/role/StockbasedCompensation 26 false false R27.htm 080700 - Disclosure - Earnings Per Share (Tables) Sheet http://virnetx.com/role/EarningsPerShareTables Earnings Per Share (Tables) Tables http://virnetx.com/role/EarningsPerShare 27 false false R28.htm 080800 - Disclosure - Common Stock (Tables) Sheet http://virnetx.com/role/CommonStockTables Common Stock (Tables) Tables http://virnetx.com/role/CommonStock 28 false false R29.htm 081000 - Disclosure - Income Taxes (Tables) Sheet http://virnetx.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://virnetx.com/role/IncomeTaxes 29 false false R30.htm 081100 - Disclosure - Fair Value Measurement (Tables) Sheet http://virnetx.com/role/FairValueMeasurementTables Fair Value Measurement (Tables) Tables http://virnetx.com/role/FairValueMeasurement 30 false false R31.htm 090100 - Disclosure - Formation and Business of the Company (Details) Sheet http://virnetx.com/role/FormationAndBusinessOfCompanyDetails Formation and Business of the Company (Details) Details http://virnetx.com/role/FormationAndBusinessOfCompany 31 false false R32.htm 090200 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesTables 32 false false R33.htm 090300 - Disclosure - Property and Equipment (Details) Sheet http://virnetx.com/role/PropertyAndEquipmentDetails Property and Equipment (Details) Details http://virnetx.com/role/PropertyAndEquipmentTables 33 false false R34.htm 090400 - Disclosure - Commitments, Contingencies and Related Party Transactions (Details) Sheet http://virnetx.com/role/CommitmentsContingenciesAndRelatedPartyTransactionsDetails Commitments, Contingencies and Related Party Transactions (Details) Details http://virnetx.com/role/CommitmentsContingenciesAndRelatedPartyTransactions 34 false false R35.htm 090500 - Disclosure - Stock Plan (Details) Sheet http://virnetx.com/role/StockPlanDetails Stock Plan (Details) Details http://virnetx.com/role/StockPlan 35 false false R36.htm 090600 - Disclosure - Stock-Based Compensation, Information about Stock Options Outstanding (Details) Sheet http://virnetx.com/role/StockbasedCompensationInformationAboutStockOptionsOutstandingDetails Stock-Based Compensation, Information about Stock Options Outstanding (Details) Details 36 false false R37.htm 090602 - Disclosure - Stock-Based Compensation, Summary of Activity (Details) Sheet http://virnetx.com/role/StockbasedCompensationSummaryOfActivityDetails Stock-Based Compensation, Summary of Activity (Details) Details 37 false false R38.htm 090604 - Disclosure - Stock-Based Compensation, Stock-Based Compensation by Type of Award (Details) Sheet http://virnetx.com/role/StockbasedCompensationStockbasedCompensationByTypeOfAwardDetails Stock-Based Compensation, Stock-Based Compensation by Type of Award (Details) Details 38 false false R39.htm 090606 - Disclosure - Stock-Based Compensation, Fair Value Assumptions Used (Details) Sheet http://virnetx.com/role/StockbasedCompensationFairValueAssumptionsUsedDetails Stock-Based Compensation, Fair Value Assumptions Used (Details) Details 39 false false R40.htm 090700 - Disclosure - Earnings Per Share (Details) Sheet http://virnetx.com/role/EarningsPerShareDetails Earnings Per Share (Details) Details http://virnetx.com/role/EarningsPerShareTables 40 false false R41.htm 090800 - Disclosure - Common Stock, Summary (Details) Sheet http://virnetx.com/role/CommonStockSummaryDetails Common Stock, Summary (Details) Details 41 false false R42.htm 090802 - Disclosure - Common Stock, Warrants (Details) Sheet http://virnetx.com/role/CommonStockWarrantsDetails Common Stock, Warrants (Details) Details 42 false false R43.htm 090900 - Disclosure - Employee Benefit Plan (Details) Sheet http://virnetx.com/role/EmployeeBenefitPlanDetails Employee Benefit Plan (Details) Details http://virnetx.com/role/EmployeeBenefitPlan 43 false false R44.htm 091000 - Disclosure - Income Taxes, Components of Provision (Benefit) for Income Taxes (Details) Sheet http://virnetx.com/role/IncomeTaxesComponentsOfProvisionBenefitForIncomeTaxesDetails Income Taxes, Components of Provision (Benefit) for Income Taxes (Details) Details 44 false false R45.htm 091002 - Disclosure - Income Taxes, Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details) Sheet http://virnetx.com/role/IncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails Income Taxes, Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details) Details 45 false false R46.htm 091004 - Disclosure - Income Taxes, Components of Deferred Tax Assets (Liabilities) (Details) Sheet http://virnetx.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsLiabilitiesDetails Income Taxes, Components of Deferred Tax Assets (Liabilities) (Details) Details 46 false false R47.htm 091006 - Disclosure - Income Taxes, Pre-tax Income (Losses) and Operating Loss Carryforwards (Details) Sheet http://virnetx.com/role/IncomeTaxesPretaxIncomeLossesAndOperatingLossCarryforwardsDetails Income Taxes, Pre-tax Income (Losses) and Operating Loss Carryforwards (Details) Details 47 false false R48.htm 091008 - Disclosure - Income Taxes, Income Tax Uncertainties (Details) Sheet http://virnetx.com/role/IncomeTaxesIncomeTaxUncertaintiesDetails Income Taxes, Income Tax Uncertainties (Details) Details 48 false false R49.htm 091100 - Disclosure - Fair Value Measurement (Details) Sheet http://virnetx.com/role/FairValueMeasurementDetails Fair Value Measurement (Details) Details http://virnetx.com/role/FairValueMeasurementTables 49 false false R50.htm 091200 - Disclosure - Litigation (Details) Sheet http://virnetx.com/role/LitigationDetails Litigation (Details) Details http://virnetx.com/role/Litigation 50 false false R51.htm 091300 - Disclosure - Leases (Details) Sheet http://virnetx.com/role/LeasesDetails Leases (Details) Details http://virnetx.com/role/Leases 51 false false R52.htm 091400 - Disclosure - Subsequent Event (Details) Sheet http://virnetx.com/role/SubsequentEventDetails Subsequent Event (Details) Details http://virnetx.com/role/SubsequentEvent 52 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 6 fact(s) appearing in ix:hidden were eligible for transformation: dei:CurrentFiscalYearEndDate, us-gaap:LeaseExpirationDate1, us-gaap:OperatingLossCarryforwardsExpirationDate, us-gaap:PropertyPlantAndEquipmentUsefulLife, vhc:AvailableForSaleSecuritiesDebtMaturityPeriod, vhc:ClassOfWarrantOrRightExpirationDate - brhc10048883_10k.htm 11 brhc10048883_10k.htm brhc10048883_ex23-1.htm brhc10048883_ex31-1.htm brhc10048883_ex31-2.htm brhc10048883_ex32-1.htm brhc10048883_ex32-2.htm vhc-20221231.xsd vhc-20221231_cal.xml vhc-20221231_def.xml vhc-20221231_lab.xml vhc-20221231_pre.xml image00001.jpg http://fasb.org/srt/2022 http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 72 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "brhc10048883_10k.htm": { "axisCustom": 0, "axisStandard": 20, "baseTaxonomies": { "http://fasb.org/srt/2022": 1, "http://fasb.org/us-gaap/2022": 610, "http://xbrl.sec.gov/dei/2022": 37 }, "contextCount": 136, "dts": { "calculationLink": { "local": [ "vhc-20221231_cal.xml" ] }, "definitionLink": { "local": [ "vhc-20221231_def.xml" ] }, "inline": { "local": [ "brhc10048883_10k.htm" ] }, "labelLink": { "local": [ "vhc-20221231_lab.xml" ] }, "presentationLink": { "local": [ "vhc-20221231_pre.xml" ] }, "schema": { "local": [ "vhc-20221231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 479, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 5, "http://virnetx.com/20221231": 2, "http://xbrl.sec.gov/dei/2022": 6, "total": 13 }, "keyCustom": 30, "keyStandard": 263, "memberCustom": 14, "memberStandard": 29, "nsprefix": "vhc", "nsuri": "http://virnetx.com/20221231", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://virnetx.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060200 - Disclosure - Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "10", "role": "http://virnetx.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060300 - Disclosure - Property and Equipment", "menuCat": "Notes", "order": "11", "role": "http://virnetx.com/role/PropertyAndEquipment", "shortName": "Property and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060400 - Disclosure - Commitments, Contingencies and Related Party Transactions", "menuCat": "Notes", "order": "12", "role": "http://virnetx.com/role/CommitmentsContingenciesAndRelatedPartyTransactions", "shortName": "Commitments, Contingencies and Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "vhc:StockPlanTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060500 - Disclosure - Stock Plan", "menuCat": "Notes", "order": "13", "role": "http://virnetx.com/role/StockPlan", "shortName": "Stock Plan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "vhc:StockPlanTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060600 - Disclosure - Stock-Based Compensation", "menuCat": "Notes", "order": "14", "role": "http://virnetx.com/role/StockbasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060700 - Disclosure - Earnings Per Share", "menuCat": "Notes", "order": "15", "role": "http://virnetx.com/role/EarningsPerShare", "shortName": "Earnings Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "vhc:CommonStockDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060800 - Disclosure - Common Stock", "menuCat": "Notes", "order": "16", "role": "http://virnetx.com/role/CommonStock", "shortName": "Common Stock", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "vhc:CommonStockDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060900 - Disclosure - Employee Benefit Plan", "menuCat": "Notes", "order": "17", "role": "http://virnetx.com/role/EmployeeBenefitPlan", "shortName": "Employee Benefit Plan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "061000 - Disclosure - Income Taxes", "menuCat": "Notes", "order": "18", "role": "http://virnetx.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "061100 - Disclosure - Fair Value Measurement", "menuCat": "Notes", "order": "19", "role": "http://virnetx.com/role/FairValueMeasurement", "shortName": "Fair Value Measurement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20221231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "010000 - Statement - CONSOLIDATED BALANCE SHEETS", "menuCat": "Statements", "order": "2", "role": "http://virnetx.com/role/ConsolidatedBalanceSheets", "shortName": "CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20221231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "061200 - Disclosure - Litigation", "menuCat": "Notes", "order": "20", "role": "http://virnetx.com/role/Litigation", "shortName": "Litigation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "061300 - Disclosure - Leases", "menuCat": "Notes", "order": "21", "role": "http://virnetx.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "061400 - Disclosure - Subsequent Event", "menuCat": "Notes", "order": "22", "role": "http://virnetx.com/role/SubsequentEvent", "shortName": "Subsequent Event", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "070200 - Disclosure - Summary of Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "23", "role": "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfCondensedIncomeStatementTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "080200 - Disclosure - Summary of Significant Accounting Policies (Tables)", "menuCat": "Tables", "order": "24", "role": "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfCondensedIncomeStatementTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "080300 - Disclosure - Property and Equipment (Tables)", "menuCat": "Tables", "order": "25", "role": "http://virnetx.com/role/PropertyAndEquipmentTables", "shortName": "Property and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "080600 - Disclosure - Stock-Based Compensation (Tables)", "menuCat": "Tables", "order": "26", "role": "http://virnetx.com/role/StockbasedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "080700 - Disclosure - Earnings Per Share (Tables)", "menuCat": "Tables", "order": "27", "role": "http://virnetx.com/role/EarningsPerShareTables", "shortName": "Earnings Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "080800 - Disclosure - Common Stock (Tables)", "menuCat": "Tables", "order": "28", "role": "http://virnetx.com/role/CommonStockTables", "shortName": "Common Stock (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "081000 - Disclosure - Income Taxes (Tables)", "menuCat": "Tables", "order": "29", "role": "http://virnetx.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20221231", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "U003", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "010100 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://virnetx.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20221231", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "U003", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "081100 - Disclosure - Fair Value Measurement (Tables)", "menuCat": "Tables", "order": "30", "role": "http://virnetx.com/role/FairValueMeasurementTables", "shortName": "Fair Value Measurement (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20221231_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember", "decimals": "INF", "first": true, "lang": null, "name": "vhc:NumberOfPatentsAndPendingApplicationsOwned", "reportCount": 1, "unique": true, "unitRef": "U004", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090100 - Disclosure - Formation and Business of the Company (Details)", "menuCat": "Details", "order": "31", "role": "http://virnetx.com/role/FormationAndBusinessOfCompanyDetails", "shortName": "Formation and Business of the Company (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20221231_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember", "decimals": "INF", "first": true, "lang": null, "name": "vhc:NumberOfPatentsAndPendingApplicationsOwned", "reportCount": 1, "unique": true, "unitRef": "U004", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "U001", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090200 - Disclosure - Summary of Significant Accounting Policies (Details)", "menuCat": "Details", "order": "32", "role": "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesDetails", "shortName": "Summary of Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": "INF", "lang": null, "name": "vhc:ConcentrationRiskNumberOfFinancialInstitutions", "reportCount": 1, "unique": true, "unitRef": "U005", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20221231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090300 - Disclosure - Property and Equipment (Details)", "menuCat": "Details", "order": "33", "role": "http://virnetx.com/role/PropertyAndEquipmentDetails", "shortName": "Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20221231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20221231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090400 - Disclosure - Commitments, Contingencies and Related Party Transactions (Details)", "menuCat": "Details", "order": "34", "role": "http://virnetx.com/role/CommitmentsContingenciesAndRelatedPartyTransactionsDetails", "shortName": "Commitments, Contingencies and Related Party Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20221231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090500 - Disclosure - Stock Plan (Details)", "menuCat": "Details", "order": "35", "role": "http://virnetx.com/role/StockPlanDetails", "shortName": "Stock Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20210401to20210430_PlanNameAxis_Plan2013Member", "decimals": "0", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20221231_AwardTypeAxis_EmployeeStockOptionMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090600 - Disclosure - Stock-Based Compensation, Information about Stock Options Outstanding (Details)", "menuCat": "Details", "order": "36", "role": "http://virnetx.com/role/StockbasedCompensationInformationAboutStockOptionsOutstandingDetails", "shortName": "Stock-Based Compensation, Information about Stock Options Outstanding (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20221231_AwardTypeAxis_EmployeeStockOptionMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20221231", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:SharePrice", "reportCount": 1, "unique": true, "unitRef": "U003", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090602 - Disclosure - Stock-Based Compensation, Summary of Activity (Details)", "menuCat": "Details", "order": "37", "role": "http://virnetx.com/role/StockbasedCompensationSummaryOfActivityDetails", "shortName": "Stock-Based Compensation, Summary of Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20221231", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:SharePrice", "reportCount": 1, "unique": true, "unitRef": "U003", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "U001", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090604 - Disclosure - Stock-Based Compensation, Stock-Based Compensation by Type of Award (Details)", "menuCat": "Details", "order": "38", "role": "http://virnetx.com/role/StockbasedCompensationStockbasedCompensationByTypeOfAwardDetails", "shortName": "Stock-Based Compensation, Stock-Based Compensation by Type of Award (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231_IncomeStatementLocationAxis_OperatingExpenseMember", "decimals": "-3", "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "reportCount": 1, "unitRef": "U006", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090606 - Disclosure - Stock-Based Compensation, Fair Value Assumptions Used (Details)", "menuCat": "Details", "order": "39", "role": "http://virnetx.com/role/StockbasedCompensationFairValueAssumptionsUsedDetails", "shortName": "Stock-Based Compensation, Fair Value Assumptions Used (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": "2", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "U003", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "U001", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "020000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS", "menuCat": "Statements", "order": "4", "role": "http://virnetx.com/role/ConsolidatedStatementsOfOperations", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": "-3", "lang": null, "name": "vhc:LicensingCosts", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U001", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090700 - Disclosure - Earnings Per Share (Details)", "menuCat": "Details", "order": "40", "role": "http://virnetx.com/role/EarningsPerShareDetails", "shortName": "Earnings Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": "-3", "lang": null, "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20221231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "U002", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090800 - Disclosure - Common Stock, Summary (Details)", "menuCat": "Details", "order": "41", "role": "http://virnetx.com/role/CommonStockSummaryDetails", "shortName": "Common Stock, Summary (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231_StatementEquityComponentsAxis_CommonStockMember", "decimals": "INF", "lang": null, "name": "vhc:NumberOfVotesEntitledToEachShareOfCommonStock", "reportCount": 1, "unique": true, "unitRef": "U007", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unitRef": "U006", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090802 - Disclosure - Common Stock, Warrants (Details)", "menuCat": "Details", "order": "42", "role": "http://virnetx.com/role/CommonStockWarrantsDetails", "shortName": "Common Stock, Warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20200430_AwardTypeAxis_WarrantMember", "decimals": "2", "lang": null, "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "reportCount": 1, "unique": true, "unitRef": "U003", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090900 - Disclosure - Employee Benefit Plan (Details)", "menuCat": "Details", "order": "43", "role": "http://virnetx.com/role/EmployeeBenefitPlanDetails", "shortName": "Employee Benefit Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "091000 - Disclosure - Income Taxes, Components of Provision (Benefit) for Income Taxes (Details)", "menuCat": "Details", "order": "44", "role": "http://virnetx.com/role/IncomeTaxesComponentsOfProvisionBenefitForIncomeTaxesDetails", "shortName": "Income Taxes, Components of Provision (Benefit) for Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "U006", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "091002 - Disclosure - Income Taxes, Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)", "menuCat": "Details", "order": "45", "role": "http://virnetx.com/role/IncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails", "shortName": "Income Taxes, Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "U006", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20221231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "091004 - Disclosure - Income Taxes, Components of Deferred Tax Assets (Liabilities) (Details)", "menuCat": "Details", "order": "46", "role": "http://virnetx.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsLiabilitiesDetails", "shortName": "Income Taxes, Components of Deferred Tax Assets (Liabilities) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20221231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20221231", "decimals": "-3", "first": true, "lang": null, "name": "vhc:CapitalizedDirectAndIndirectResearchAndDevelopmentCosts", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "091006 - Disclosure - Income Taxes, Pre-tax Income (Losses) and Operating Loss Carryforwards (Details)", "menuCat": "Details", "order": "47", "role": "http://virnetx.com/role/IncomeTaxesPretaxIncomeLossesAndOperatingLossCarryforwardsDetails", "shortName": "Income Taxes, Pre-tax Income (Losses) and Operating Loss Carryforwards (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20221231", "decimals": "-3", "first": true, "lang": null, "name": "vhc:CapitalizedDirectAndIndirectResearchAndDevelopmentCosts", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20221231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "091008 - Disclosure - Income Taxes, Income Tax Uncertainties (Details)", "menuCat": "Details", "order": "48", "role": "http://virnetx.com/role/IncomeTaxesIncomeTaxUncertaintiesDetails", "shortName": "Income Taxes, Income Tax Uncertainties (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20221231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20221231", "decimals": "-3", "first": true, "lang": null, "name": "vhc:CashAndAvailableForSaleSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "091100 - Disclosure - Fair Value Measurement (Details)", "menuCat": "Details", "order": "49", "role": "http://virnetx.com/role/FairValueMeasurementDetails", "shortName": "Fair Value Measurement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20221231", "decimals": "-3", "first": true, "lang": null, "name": "vhc:CashAndAvailableForSaleSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U001", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "030000 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME", "menuCat": "Statements", "order": "5", "role": "http://virnetx.com/role/ConsolidatedStatementsOfComprehensiveLossIncome", "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": "-3", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20210419to20210419_LitigationCaseAxis_McKoolSmithPCVVirnetXIncAAACaseNo012000037975Member", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LossContingencyDamagesAwardedValue", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "091200 - Disclosure - Litigation (Details)", "menuCat": "Details", "order": "50", "role": "http://virnetx.com/role/LitigationDetails", "shortName": "Litigation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20210419to20210419_LitigationCaseAxis_McKoolSmithPCVVirnetXIncAAACaseNo012000037975Member", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LossContingencyDamagesAwardedValue", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231_PropertyPlantAndEquipmentByTypeAxis_BuildingMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unitRef": "U001", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "091300 - Disclosure - Leases (Details)", "menuCat": "Details", "order": "51", "role": "http://virnetx.com/role/LeasesDetails", "shortName": "Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:OperatingLeaseLiability", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20221231_PropertyPlantAndEquipmentByTypeAxis_OfficeMember", "decimals": "-3", "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DividendsPayableDateDeclaredDayMonthAndYear", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "091400 - Disclosure - Subsequent Event (Details)", "menuCat": "Details", "order": "52", "role": "http://virnetx.com/role/SubsequentEventDetails", "shortName": "Subsequent Event (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20230330to20230330_SubsequentEventTypeAxis_SubsequentEventMember", "decimals": null, "lang": "en-US", "name": "us-gaap:DividendsPayableDateDeclaredDayMonthAndYear", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20191231_StatementEquityComponentsAxis_CommonStockAndAdditionalPaidInCapitalMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "040000 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "menuCat": "Statements", "order": "6", "role": "http://virnetx.com/role/ConsolidatedStatementsOfStockholdersEquity", "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20191231_StatementEquityComponentsAxis_CommonStockAndAdditionalPaidInCapitalMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockDividendsPerShareCashPaid", "reportCount": 1, "unique": true, "unitRef": "U003", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "040100 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)", "menuCat": "Statements", "order": "7", "role": "http://virnetx.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical", "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockDividendsPerShareCashPaid", "reportCount": 1, "unique": true, "unitRef": "U003", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U001", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "050000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "menuCat": "Statements", "order": "8", "role": "http://virnetx.com/role/ConsolidatedStatementsOfCashFlows", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": "-3", "lang": null, "name": "vhc:AmortizationOfWarrantIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060100 - Disclosure - Formation and Business of the Company", "menuCat": "Notes", "order": "9", "role": "http://virnetx.com/role/FormationAndBusinessOfCompany", "shortName": "Formation and Business of the Company", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "brhc10048883_10k.htm", "contextRef": "c20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 43, "tag": { "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "U.S. [Member]" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://virnetx.com/role/FormationAndBusinessOfCompanyDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://virnetx.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r539", "r540", "r541" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://virnetx.com/role/DocumentAndEntityInformation" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r539", "r540", "r541" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://virnetx.com/role/DocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r539", "r540", "r541" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://virnetx.com/role/DocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://virnetx.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://virnetx.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r539", "r540", "r541" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://virnetx.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://virnetx.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://virnetx.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://virnetx.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r542" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://virnetx.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://virnetx.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://virnetx.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://virnetx.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://virnetx.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://virnetx.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://virnetx.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r537" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://virnetx.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://virnetx.com/role/DocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://virnetx.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r537" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://virnetx.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://virnetx.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r537" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://virnetx.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://virnetx.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r543" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://virnetx.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://virnetx.com/role/DocumentAndEntityInformation" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r537" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://virnetx.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r537" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://virnetx.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r537" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://virnetx.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r537" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://virnetx.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://virnetx.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r544" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://virnetx.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r539", "r540", "r541" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://virnetx.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://virnetx.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r536" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://virnetx.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r538" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://virnetx.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://virnetx.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r191", "r192", "r277", "r282", "r504", "r507", "r509" ], "lang": { "en-us": { "role": { "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.", "label": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://virnetx.com/role/CommitmentsContingenciesAndRelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "srt_ExecutiveOfficerMember": { "auth_ref": [ "r560" ], "lang": { "en-us": { "role": { "documentation": "Person with designation of executive officer.", "label": "Executive Officer [Member]", "terseLabel": "Named Executive Officers [Member]" } } }, "localname": "ExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://virnetx.com/role/StockPlanDetails" ], "xbrltype": "domainItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of judicial proceeding, alternative dispute resolution or claim.", "label": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://virnetx.com/role/LitigationDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Judicial proceeding, alternative dispute resolution or claim. For example, but not limited to, name of case, category of litigation, or other differentiating information.", "label": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://virnetx.com/role/LitigationDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r264", "r265", "r266", "r267", "r317", "r460", "r474", "r484", "r485", "r520", "r531", "r535", "r573", "r619", "r620", "r621", "r622", "r623", "r624" ], "lang": { "en-us": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://virnetx.com/role/CommonStockSummaryDetails", "http://virnetx.com/role/FairValueMeasurementDetails", "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r264", "r265", "r266", "r267", "r317", "r460", "r474", "r484", "r485", "r520", "r531", "r535", "r573", "r619", "r620", "r621", "r622", "r623", "r624" ], "lang": { "en-us": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://virnetx.com/role/FairValueMeasurementDetails", "http://virnetx.com/role/StockPlanDetails", "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r264", "r265", "r266", "r267", "r300", "r317", "r348", "r349", "r350", "r436", "r460", "r474", "r484", "r485", "r520", "r531", "r535", "r566", "r573", "r620", "r621", "r622", "r623", "r624" ], "lang": { "en-us": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://virnetx.com/role/CommonStockSummaryDetails", "http://virnetx.com/role/FairValueMeasurementDetails", "http://virnetx.com/role/StockPlanDetails", "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r264", "r265", "r266", "r267", "r300", "r317", "r348", "r349", "r350", "r436", "r460", "r474", "r484", "r485", "r520", "r531", "r535", "r566", "r573", "r620", "r621", "r622", "r623", "r624" ], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://virnetx.com/role/CommonStockSummaryDetails", "http://virnetx.com/role/FairValueMeasurementDetails", "http://virnetx.com/role/StockPlanDetails", "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r191", "r192", "r277", "r282", "r508", "r509" ], "lang": { "en-us": { "role": { "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.", "label": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://virnetx.com/role/CommitmentsContingenciesAndRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfCondensedIncomeStatementTableTextBlock": { "auth_ref": [ "r555", "r635" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of condensed income statement, including, but not limited to, income statements of consolidated entities and consolidation eliminations.", "label": "Classification of Payment Received in Condensed Consolidated Statement of Operations" } } }, "localname": "ScheduleOfCondensedIncomeStatementTableTextBlock", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r560", "r616" ], "lang": { "en-us": { "role": { "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.", "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://virnetx.com/role/StockPlanDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Title of individual, or nature of relationship to individual or group of individuals.", "label": "Relationship to Entity [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://virnetx.com/role/StockPlanDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r10" ], "calculation": { "http://virnetx.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Accrued Liabilities, Current", "verboseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r240", "r241" ], "calculation": { "http://virnetx.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivables" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r68", "r164" ], "calculation": { "http://virnetx.com/role/PropertyAndEquipmentDetails": { "order": 0.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r19", "r20", "r21", "r169", "r470", "r479", "r480" ], "calculation": { "http://virnetx.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r18", "r21", "r126", "r426", "r475", "r476", "r549", "r550", "r551", "r556", "r557", "r558" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Loss [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r5", "r534" ], "calculation": { "http://virnetx.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r109", "r110", "r320" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "verboseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r74", "r78", "r85" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Warrants issued for services" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net (loss) income to net cash from operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AirTransportationEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment used for the primary purpose of air transportation.", "label": "Air Transportation Equipment [Member]", "terseLabel": "Aircraft [Member]" } } }, "localname": "AirTransportationEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/CommitmentsContingenciesAndRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AircraftRentalAndLandingFees": { "auth_ref": [ "r25" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenses incurred related to the lease of aircraft from outside third parties that are used in the entity's business operations and direct costs incurred at airports primarily consisting of fees paid to the airport authority for takeoff and landing, gate and facility fees, and other related fees.", "label": "Rental fees incurred for use of aircraft" } } }, "localname": "AircraftRentalAndLandingFees", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/CommitmentsContingenciesAndRelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r352" ], "calculation": { "http://virnetx.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Stock-based compensation", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedStatementsOfCashFlows", "http://virnetx.com/role/StockbasedCompensationStockbasedCompensationByTypeOfAwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r138", "r150", "r165", "r188", "r228", "r231", "r235", "r246", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r394", "r396", "r409", "r534", "r571", "r572", "r617" ], "calculation": { "http://virnetx.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r160", "r170", "r188", "r246", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r394", "r396", "r409", "r534", "r571", "r572", "r617" ], "calculation": { "http://virnetx.com/role/ConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Adjusted Cost, Gross Unrealized Gains, Gross Unrealized Losses and Fair Value of Financial Assets [Abstract]" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/FairValueMeasurementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r50" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Unrealized Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/FairValueMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r51" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Unrealized Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/FairValueMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "auth_ref": [ "r49", "r253" ], "calculation": { "http://virnetx.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Debt Securities, Available-for-Sale, Current", "verboseLabel": "Investments available for sale" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableforsaleSecuritiesMember": { "auth_ref": [ "r244" ], "lang": { "en-us": { "role": { "documentation": "Investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available-for-Sale Securities [Member]", "terseLabel": "Total Investment Securities [Member]" } } }, "localname": "AvailableforsaleSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/FairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AwardDateAxis": { "auth_ref": [ "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600" ], "lang": { "en-us": { "role": { "documentation": "Information by date or year award under share-based payment arrangement is granted.", "label": "Award Date [Axis]" } } }, "localname": "AwardDateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/CommonStockWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AwardDateDomain": { "auth_ref": [ "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600" ], "lang": { "en-us": { "role": { "documentation": "Date or year award under share-based payment arrangement is granted.", "label": "Award Date [Domain]" } } }, "localname": "AwardDateDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/CommonStockWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r323", "r324", "r325", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r347", "r348", "r349", "r350", "r351" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/CommonStockWarrantsDetails", "http://virnetx.com/role/StockPlanDetails", "http://virnetx.com/role/StockbasedCompensationInformationAboutStockOptionsOutstandingDetails", "http://virnetx.com/role/StockbasedCompensationStockbasedCompensationByTypeOfAwardDetails", "http://virnetx.com/role/StockbasedCompensationSummaryOfActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BuildingMember": { "auth_ref": [ "r67" ], "lang": { "en-us": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.", "label": "Building [Member]", "terseLabel": "Office [Member]" } } }, "localname": "BuildingMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/CommitmentsContingenciesAndRelatedPartyTransactionsDetails", "http://virnetx.com/role/LeasesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r36", "r162", "r505" ], "calculation": { "http://virnetx.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "verboseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/FairValueMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r37" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r31", "r36", "r40" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents, end of period", "periodStartLabel": "Cash and cash equivalents, beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r31", "r135" ], "calculation": { "http://virnetx.com/role/ConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Net (decrease) increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashMember": { "auth_ref": [ "r162" ], "lang": { "en-us": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.", "label": "Cash [Member]" } } }, "localname": "CashMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/FairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock Disclosures [Abstract]", "terseLabel": "Common Stock [Abstract]" } } }, "localname": "ClassOfStockDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/CommonStockSummaryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r287" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Exercise price (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/CommonStockWarrantsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Warrant or Right [Line Items]" } } }, "localname": "ClassOfWarrantOrRightLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/CommonStockWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r287" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "verboseLabel": "Warrants issued (in shares)" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/CommonStockWarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightTable": { "auth_ref": [ "r86", "r87" ], "lang": { "en-us": { "role": { "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Class of Warrant or Right [Table]" } } }, "localname": "ClassOfWarrantOrRightTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/CommonStockWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r15", "r141", "r154" ], "calculation": { "http://virnetx.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and contingencies (Note 4)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments, Contingencies and Related Party Transactions [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsDisclosureTextBlock": { "auth_ref": [ "r72" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.", "label": "Commitments, Contingencies and Related Party Transactions" } } }, "localname": "CommitmentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/CommitmentsContingenciesAndRelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockDividendsPerShareCashPaid": { "auth_ref": [ "r85" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.", "label": "Dividends per share (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareCashPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r556", "r557", "r610" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/CommonStockSummaryDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value (in dollars per share)", "verboseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/CommonStockSummaryDetails", "http://virnetx.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized (in shares)", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/CommonStockSummaryDetails", "http://virnetx.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r4", "r78" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r4", "r534" ], "calculation": { "http://virnetx.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, par value $0.0001 per share Authorized: 100,000,000 shares at December 31, 2022 and December 31, 2021, Issued and outstanding: 71,424,650 and 71,232,856 shares, at December 31, 2022 and December 31, 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Employee Benefit Plan [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred tax assets [Abstract]" } } }, "localname": "ComponentsOfDeferredTaxAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components of Deferred Tax Assets and Liabilities [Abstract]" } } }, "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r22", "r175", "r177", "r182", "r464", "r471" ], "calculation": { "http://virnetx.com/role/ConsolidatedStatementsOfComprehensiveLossIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive (loss) income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedStatementsOfComprehensiveLossIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r147", "r222" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration of Credit Risk and Other Risks and Uncertainties" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r124", "r510" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Basis of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r554", "r606", "r608" ], "calculation": { "http://virnetx.com/role/IncomeTaxesComponentsOfProvisionBenefitForIncomeTaxesDetails": { "order": 0.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/IncomeTaxesComponentsOfProvisionBenefitForIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "auth_ref": [ "r554", "r606" ], "calculation": { "http://virnetx.com/role/IncomeTaxesComponentsOfProvisionBenefitForIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Foreign Tax Expense (Benefit)", "terseLabel": "Foreign" } } }, "localname": "CurrentForeignTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/IncomeTaxesComponentsOfProvisionBenefitForIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r119", "r379", "r387", "r554" ], "calculation": { "http://virnetx.com/role/IncomeTaxesComponentsOfProvisionBenefitForIncomeTaxesDetails": { "order": 0.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "Current Income Tax Expense (Benefit)", "totalLabel": "Current income tax provision (benefit)" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/IncomeTaxesComponentsOfProvisionBenefitForIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current [Abstract]" } } }, "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/IncomeTaxesComponentsOfProvisionBenefitForIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r554", "r606", "r608" ], "calculation": { "http://virnetx.com/role/IncomeTaxesComponentsOfProvisionBenefitForIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "State" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/IncomeTaxesComponentsOfProvisionBenefitForIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesMember": { "auth_ref": [ "r58" ], "lang": { "en-us": { "role": { "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions.", "label": "Debt Securities [Member]", "terseLabel": "Highly Liquid Debt Investments [Member]" } } }, "localname": "DebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r554", "r607", "r608" ], "calculation": { "http://virnetx.com/role/IncomeTaxesComponentsOfProvisionBenefitForIncomeTaxesDetails": { "order": 0.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Deferred Federal Income Tax Expense (Benefit)", "terseLabel": "Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/IncomeTaxesComponentsOfProvisionBenefitForIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r365", "r366" ], "calculation": { "http://virnetx.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred tax assets" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r34", "r119", "r380", "r386", "r387", "r554" ], "calculation": { "http://virnetx.com/role/IncomeTaxesComponentsOfProvisionBenefitForIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "totalLabel": "Deferred income tax provision (benefit)" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/IncomeTaxesComponentsOfProvisionBenefitForIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred [Abstract]" } } }, "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/IncomeTaxesComponentsOfProvisionBenefitForIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r1", "r2", "r139", "r148", "r374" ], "calculation": { "http://virnetx.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Tax Liabilities, Gross", "negatedLabel": "Total deferred tax liability - depreciation and amortization" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r554", "r607", "r608" ], "calculation": { "http://virnetx.com/role/IncomeTaxesComponentsOfProvisionBenefitForIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Deferred State and Local Income Tax Expense (Benefit)", "terseLabel": "State" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/IncomeTaxesComponentsOfProvisionBenefitForIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r375" ], "calculation": { "http://virnetx.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r604" ], "calculation": { "http://virnetx.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets, Net", "totalLabel": "Net deferred tax assets" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r604" ], "calculation": { "http://virnetx.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsLiabilitiesDetails": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Deferred tax assets after valuation allowance" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r117", "r605" ], "calculation": { "http://virnetx.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Net operating loss carry forward" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Operating Loss Carryforwards, Components [Abstract]", "terseLabel": "Income Taxes [Abstract]" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/IncomeTaxesPretaxIncomeLossesAndOperatingLossCarryforwardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r117", "r605" ], "calculation": { "http://virnetx.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Deferred Tax Assets, Other", "terseLabel": "Other" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": { "auth_ref": [ "r115", "r117", "r605" ], "calculation": { "http://virnetx.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.", "label": "Research and development credits and other credits" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": { "auth_ref": [ "r117", "r605" ], "calculation": { "http://virnetx.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.", "label": "Stock based compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": { "auth_ref": [ "r117", "r605" ], "calculation": { "http://virnetx.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsLiabilitiesDetails": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.", "label": "Reserves and accruals" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r376" ], "calculation": { "http://virnetx.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsLiabilitiesDetails": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.", "label": "Matching contribution to defined contribution plan" } } }, "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/EmployeeBenefitPlanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r34", "r66" ], "calculation": { "http://virnetx.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedStatementsOfCashFlows", "http://virnetx.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r298", "r521", "r522", "r523", "r524", "r525", "r526", "r527" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r322", "r353", "r354", "r356", "r361", "r532" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "verboseLabel": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockbasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DividendPayableDateToBePaidDayMonthAndYear": { "auth_ref": [ "r39" ], "lang": { "en-us": { "role": { "documentation": "Date the declared dividend will be paid, in YYYY-MM-DD format.", "label": "Dividends Payable, Date to be Paid", "terseLabel": "Dividend payable date" } } }, "localname": "DividendPayableDateToBePaidDayMonthAndYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/CommonStockSummaryDetails", "http://virnetx.com/role/SubsequentEventDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DividendsCash": { "auth_ref": [ "r85", "r146" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid cash dividends declared for classes of stock, for example, but not limited to, common and preferred.", "label": "Dividends, Cash", "negatedLabel": "Dividends" } } }, "localname": "DividendsCash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPayableAmountPerShare": { "auth_ref": [ "r39" ], "lang": { "en-us": { "role": { "documentation": "The per share amount of a dividend declared, but not paid, as of the financial reporting date.", "label": "Dividends Payable, Amount Per Share", "terseLabel": "Cash dividend (in dollars per share)" } } }, "localname": "DividendsPayableAmountPerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/CommonStockSummaryDetails", "http://virnetx.com/role/SubsequentEventDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_DividendsPayableDateDeclaredDayMonthAndYear": { "auth_ref": [ "r39" ], "lang": { "en-us": { "role": { "documentation": "Date the dividend to be paid was declared, in YYYY-MM-DD format.", "label": "Dividends Payable, Date Declared", "terseLabel": "Dividend declared date" } } }, "localname": "DividendsPayableDateDeclaredDayMonthAndYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/CommonStockSummaryDetails", "http://virnetx.com/role/SubsequentEventDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DividendsPayableDateOfRecordDayMonthAndYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date the holder must own the stock to be entitled to the dividend, in YYYY-MM-DD format.", "label": "Dividends Payable, Date of Record", "terseLabel": "Dividend record date" } } }, "localname": "DividendsPayableDateOfRecordDayMonthAndYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/CommonStockSummaryDetails", "http://virnetx.com/role/SubsequentEventDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Federal [Member]" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/IncomeTaxesPretaxIncomeLossesAndOperatingLossCarryforwardsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r183", "r198", "r199", "r200", "r201", "r202", "r206", "r208", "r210", "r211", "r212", "r216", "r400", "r401", "r465", "r472", "r512" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (loss) earnings per share (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedStatementsOfOperations", "http://virnetx.com/role/EarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r183", "r198", "r199", "r200", "r201", "r202", "r208", "r210", "r211", "r212", "r216", "r400", "r401", "r465", "r472", "r512" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (loss) earnings per share (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedStatementsOfOperations", "http://virnetx.com/role/EarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r42", "r43" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareReconciliationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Calculation of basic and diluted loss per share [Abstract]" } } }, "localname": "EarningsPerShareReconciliationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/EarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r213", "r214", "r215", "r217" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "verboseLabel": "Earnings Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/EarningsPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r368" ], "calculation": { "http://virnetx.com/role/IncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "totalLabel": "Effective income tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/IncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Effective Tax Rate Reconciliation [Abstract]" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/IncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r189", "r368", "r388" ], "calculation": { "http://virnetx.com/role/IncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": { "order": 1.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "United States federal statutory rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/IncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r603", "r609" ], "calculation": { "http://virnetx.com/role/IncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": { "order": 3.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Valuation allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/IncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "auth_ref": [ "r603", "r609" ], "calculation": { "http://virnetx.com/role/IncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": { "order": 9.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Other" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/IncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": { "auth_ref": [ "r602", "r603" ], "calculation": { "http://virnetx.com/role/IncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": { "order": 8.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.", "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent", "terseLabel": "Stock based compensation" } } }, "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/IncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r603", "r609" ], "calculation": { "http://virnetx.com/role/IncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": { "order": 2.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "State taxes, net of federal benefit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/IncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": { "auth_ref": [ "r603", "r609" ], "calculation": { "http://virnetx.com/role/IncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": { "order": 7.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent", "negatedLabel": "R&D Credit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/IncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r12" ], "calculation": { "http://virnetx.com/role/ConsolidatedBalanceSheets": { "order": 10.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued payroll and related expenses" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Additional Disclosure [Abstract]", "terseLabel": "Stock Plan [Abstract]" } } }, "localname": "EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockPlanDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockbasedCompensationStockbasedCompensationByTypeOfAwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Compensation cost not yet recognized [Abstract]" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockbasedCompensationStockbasedCompensationByTypeOfAwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r355" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted-average period for recognition of unrecognized stock-based compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockbasedCompensationStockbasedCompensationByTypeOfAwardDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r601" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized stock-based compensation expense expected to be recognized related to unvested RSUs" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockbasedCompensationStockbasedCompensationByTypeOfAwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r601" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Unrecognized stock-based compensation expense expected to be recognized related to unvested stock options" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockbasedCompensationStockbasedCompensationByTypeOfAwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Stock Options [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockPlanDetails", "http://virnetx.com/role/StockbasedCompensationInformationAboutStockOptionsOutstandingDetails", "http://virnetx.com/role/StockbasedCompensationStockbasedCompensationByTypeOfAwardDetails", "http://virnetx.com/role/StockbasedCompensationSummaryOfActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r78", "r158", "r179", "r180", "r181", "r193", "r194", "r195", "r197", "r203", "r205", "r218", "r247", "r288", "r357", "r358", "r359", "r382", "r383", "r399", "r413", "r414", "r415", "r416", "r417", "r418", "r426", "r475", "r476", "r477" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/CommonStockSummaryDetails", "http://virnetx.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/FairValueMeasurementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r402", "r403", "r407" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/FairValueMeasurementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r129", "r130" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Adjusted Cost, Gross Unrealized Gains, Gross Unrealized Losses and Fair Value of Financial Assets" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/FairValueMeasurementTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r131" ], "lang": { "en-us": { "role": { "documentation": "Class of asset.", "label": "Asset Class [Domain]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/FairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r129", "r132" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/FairValueMeasurementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r278", "r302", "r303", "r304", "r305", "r306", "r307", "r403", "r433", "r434", "r435", "r518", "r519", "r528", "r529", "r530" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/FairValueMeasurementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r402", "r403", "r404", "r405", "r408" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/FairValueMeasurementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurement [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r406" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "verboseLabel": "Fair Value Measurement" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/FairValueMeasurement" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r278", "r302", "r307", "r403", "r433", "r528", "r529", "r530" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/FairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Fair Value, Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/FairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r278", "r302", "r303", "r304", "r305", "r306", "r307", "r433", "r434", "r435", "r518", "r519", "r528", "r529", "r530" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/FairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r406", "r408" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Recurring [Member]" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/FairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r133", "r134" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r242", "r243", "r248", "r249", "r250", "r251", "r252", "r254", "r255", "r256", "r279", "r285", "r398", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r516", "r561", "r562", "r563", "r628", "r629", "r630", "r631", "r632", "r633", "r634" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Estimated useful lives" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r257", "r258", "r259", "r260", "r462", "r463" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/FormationAndBusinessOfCompanyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/FormationAndBusinessOfCompanyDetails", "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r60", "r62" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/FormationAndBusinessOfCompanyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net [Abstract]", "terseLabel": "Intangible Assets [Abstract]" } } }, "localname": "FiniteLivedIntangibleAssetsNetAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GainContingenciesByNatureAxis": { "auth_ref": [ "r570" ], "lang": { "en-us": { "role": { "documentation": "Information by nature of gain contingency.", "label": "Gain Contingencies, Nature [Axis]" } } }, "localname": "GainContingenciesByNatureAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/LitigationDetails", "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GainContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Gain Contingencies [Line Items]" } } }, "localname": "GainContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/LitigationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GainContingenciesTable": { "auth_ref": [ "r570" ], "lang": { "en-us": { "role": { "documentation": "Sets forth the existing conditions, situations, or sets of circumstances involving uncertainties as of the balance sheet date (or before issuance of the financial statements) that might result in a gain, typically reflecting care to avoid misleading implications as to the likelihood of realization, and previously disclosed contingent gains that were recognized as income in the period.", "label": "Gain Contingencies [Table]" } } }, "localname": "GainContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/LitigationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GainContingencyNatureDomain": { "auth_ref": [ "r570" ], "lang": { "en-us": { "role": { "documentation": "Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or before issuance of the financial statements) that might result in a gain, typically reflecting care to avoid misleading implications as to the likelihood of realization.", "label": "Gain Contingency, Nature [Domain]" } } }, "localname": "GainContingencyNatureDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/LitigationDetails", "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainContingencyPatentsFoundInfringedUponNumber": { "auth_ref": [ "r570" ], "lang": { "en-us": { "role": { "documentation": "Number of entity's patents that another entity was found to have infringed.", "label": "Number of patents allegedly infringed upon by Apple, Inc." } } }, "localname": "GainContingencyPatentsFoundInfringedUponNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/LitigationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_GainContingencyQuantitiesPatentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Gain Contingency, Quantities, Patents [Abstract]", "terseLabel": "Litigation [Abstract]" } } }, "localname": "GainContingencyQuantitiesPatentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/LitigationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GainLossRelatedToLitigationSettlement": { "auth_ref": [ "r567" ], "calculation": { "http://virnetx.com/role/ConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 }, "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesDetails": { "order": 2.0, "parentTag": "us-gaap_LossContingencyDamagesPaidValue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.", "label": "Gain (willful infringement)", "verboseLabel": "Gain on settlement" } } }, "localname": "GainLossRelatedToLitigationSettlement", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedStatementsOfOperations", "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeographicDistributionAxis": { "auth_ref": [ "r466", "r467", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r515" ], "lang": { "en-us": { "role": { "documentation": "Information by geographic distribution of business activity identified as either domestic or foreign. Excludes names of countries, states and provinces, and cities.", "label": "Geographic Distribution [Axis]" } } }, "localname": "GeographicDistributionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/FormationAndBusinessOfCompanyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GeographicDistributionDomain": { "auth_ref": [ "r466", "r467", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503" ], "lang": { "en-us": { "role": { "documentation": "Allocation of business activity identified as domestic or foreign. Excludes names of countries, states and provinces, and cities.", "label": "Geographic Distribution [Domain]" } } }, "localname": "GeographicDistributionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/FormationAndBusinessOfCompanyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "auth_ref": [ "r59", "r61" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.", "label": "Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r65", "r70" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment of Long-Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r23", "r136", "r142", "r156", "r228", "r230", "r234", "r236", "r467", "r514" ], "calculation": { "http://virnetx.com/role/ConsolidatedStatementsOfOperations": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "(Loss) income before taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r261", "r262" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockbasedCompensationStockbasedCompensationByTypeOfAwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r262" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockbasedCompensationStockbasedCompensationByTypeOfAwardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r113" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/IncomeTaxesPretaxIncomeLossesAndOperatingLossCarryforwardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/IncomeTaxesPretaxIncomeLossesAndOperatingLossCarryforwardsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r189", "r369", "r372", "r378", "r384", "r389", "r391", "r392", "r393" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "verboseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r190", "r204", "r205", "r227", "r367", "r385", "r390", "r473" ], "calculation": { "http://virnetx.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 }, "http://virnetx.com/role/IncomeTaxesComponentsOfProvisionBenefitForIncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Income tax (provision) benefit", "totalLabel": "Total income tax (benefit) provision" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedStatementsOfOperations", "http://virnetx.com/role/IncomeTaxesComponentsOfProvisionBenefitForIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r178", "r363", "r364", "r372", "r373", "r377", "r381" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r38" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Cash paid for income taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r33" ], "calculation": { "http://virnetx.com/role/ConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Accounts payable and accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r33" ], "calculation": { "http://virnetx.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": { "auth_ref": [ "r33" ], "calculation": { "http://virnetx.com/role/ConsolidatedStatementsOfCashFlows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.", "label": "Increase (Decrease) in Deferred Income Taxes", "negatedLabel": "Deferred income taxes" } } }, "localname": "IncreaseDecreaseInDeferredIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "auth_ref": [ "r33" ], "calculation": { "http://virnetx.com/role/ConsolidatedStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Increase (Decrease) in Employee Related Liabilities", "terseLabel": "Accrued payroll and related expenses" } } }, "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "auth_ref": [ "r33" ], "calculation": { "http://virnetx.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Liabilities", "terseLabel": "Other liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r33" ], "calculation": { "http://virnetx.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidTaxes": { "auth_ref": [ "r33" ], "calculation": { "http://virnetx.com/role/ConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of consideration paid in advance for income and other taxes that provide economic benefits in future periods.", "label": "Increase (Decrease) in Prepaid Taxes", "negatedLabel": "Prepaid income taxes" } } }, "localname": "IncreaseDecreaseInPrepaidTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "verboseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IntellectualPropertyMember": { "auth_ref": [ "r121" ], "lang": { "en-us": { "role": { "documentation": "Intangible asset arising from original creative thought. Include, but is not limited to, trademarks, patents, and copyrights.", "label": "Intellectual Property [Member]" } } }, "localname": "IntellectualPropertyMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/FormationAndBusinessOfCompanyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestAndOtherIncome": { "auth_ref": [], "calculation": { "http://virnetx.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).", "label": "Interest and Other Income", "terseLabel": "Interest and other income, net" } } }, "localname": "InterestAndOtherIncome", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestAndOtherIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Income [Abstract]" } } }, "localname": "InterestAndOtherIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r245", "r626" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment in financial asset.", "label": "Investment, Policy [Policy Text Block]", "terseLabel": "Investments" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments [Abstract]" } } }, "localname": "InvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestorMember": { "auth_ref": [ "r614", "r615" ], "lang": { "en-us": { "role": { "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value.", "label": "Investor [Member]", "terseLabel": "10% Shareholder [Member]" } } }, "localname": "InvestorMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockPlanDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseExpirationDate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.", "label": "Lease Expiration Date", "verboseLabel": "Operating lease, expiration date" } } }, "localname": "LeaseExpirationDate1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/CommitmentsContingenciesAndRelatedPartyTransactionsDetails" ], "xbrltype": "dateItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LeasesOperatingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases, Operating [Abstract]", "terseLabel": "Commitments, Contingencies and Related Party Transactions [Abstract]" } } }, "localname": "LeasesOperatingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/CommitmentsContingenciesAndRelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LegalMattersAndContingenciesTextBlock": { "auth_ref": [ "r73" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.", "label": "Legal Matters and Contingencies [Text Block]", "verboseLabel": "Litigation" } } }, "localname": "LegalMattersAndContingenciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/Litigation" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/LeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r423" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/LeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r422" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseDescriptionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Description [Abstract]", "verboseLabel": "Leases [Abstract]" } } }, "localname": "LesseeOperatingLeaseDescriptionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/LeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r424" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Future minimum rents due in 2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/CommitmentsContingenciesAndRelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r613" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "verboseLabel": "Term of lease" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/CommitmentsContingenciesAndRelatedPartyTransactionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r425" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r11", "r188", "r246", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r395", "r396", "r397", "r409", "r513", "r571", "r617", "r618" ], "calculation": { "http://virnetx.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r9", "r140", "r152", "r534", "r553", "r564", "r611" ], "calculation": { "http://virnetx.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r13", "r161", "r188", "r246", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r395", "r396", "r397", "r409", "r534", "r571", "r617", "r618" ], "calculation": { "http://virnetx.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LitigationSettlementExpense": { "auth_ref": [], "calculation": { "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesDetails": { "order": 1.0, "parentTag": "us-gaap_LossContingencyDamagesPaidValue", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.", "label": "Litigation Settlement, Expense", "negatedLabel": "Selling, general and administrative (reimbursed litigation costs)" } } }, "localname": "LitigationSettlementExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationSettlementInterest": { "auth_ref": [], "calculation": { "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesDetails": { "order": 3.0, "parentTag": "us-gaap_LossContingencyDamagesPaidValue", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest expense (income) directly attributable to an award in settlement of litigation.", "label": "Litigation Settlement Interest", "negatedLabel": "Interest income (pre- and post-judgment interest)" } } }, "localname": "LitigationSettlementInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "auth_ref": [ "r263", "r546" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of loss contingency liability.", "label": "Contingency accrued amount" } } }, "localname": "LossContingencyAccrualAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/LitigationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyAccrualPayments": { "auth_ref": [ "r567" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow reducing loss contingency liability.", "label": "Contingency accrued amount paid" } } }, "localname": "LossContingencyAccrualPayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/LitigationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyDamagesAwardedValue": { "auth_ref": [ "r567", "r568", "r569" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of damages awarded to the plaintiff in the legal matter.", "label": "Loss Contingency, Damages Awarded, Value", "terseLabel": "Amount of damages awarded in patent infringement case" } } }, "localname": "LossContingencyDamagesAwardedValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/LitigationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyDamagesPaidValue": { "auth_ref": [ "r567", "r568", "r569" ], "calculation": { "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of damages paid to the plaintiff in the legal matter.", "label": "Loss Contingency, Damages Paid, Value", "totalLabel": "Total cash received" } } }, "localname": "LossContingencyDamagesPaidValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyDamagesSoughtValue": { "auth_ref": [ "r567", "r568", "r569" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.", "label": "Contingency fee sought by plaintiff" } } }, "localname": "LossContingencyDamagesSoughtValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/LitigationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MutualFundMember": { "auth_ref": [ "r574" ], "lang": { "en-us": { "role": { "documentation": "Regulated investment instrument that pools funds from multiple investors to invest principally in a portfolio of securities and money market instruments to match the investment objective.", "label": "Mutual Fund [Member]", "verboseLabel": "Mutual Funds [Member]" } } }, "localname": "MutualFundMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/FairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r186" ], "calculation": { "http://virnetx.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r186" ], "calculation": { "http://virnetx.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash (used in) provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r31", "r32", "r35" ], "calculation": { "http://virnetx.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash (used in) provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r24", "r35", "r143", "r155", "r159", "r173", "r176", "r181", "r188", "r196", "r198", "r199", "r200", "r201", "r204", "r205", "r209", "r228", "r230", "r234", "r236", "r246", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r401", "r409", "r514", "r571" ], "calculation": { "http://virnetx.com/role/ConsolidatedStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://virnetx.com/role/ConsolidatedStatementsOfComprehensiveLossIncome": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://virnetx.com/role/ConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net (loss) income", "totalLabel": "Net (loss) income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedStatementsOfCashFlows", "http://virnetx.com/role/ConsolidatedStatementsOfComprehensiveLossIncome", "http://virnetx.com/role/ConsolidatedStatementsOfOperations", "http://virnetx.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://virnetx.com/role/EarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonUsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "Non-US [Member]", "terseLabel": "Foreign [Member]" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/FormationAndBusinessOfCompanyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OfficeEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.", "label": "Office Furniture [Member]" } } }, "localname": "OfficeEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingExpenseMember": { "auth_ref": [ "r128" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing expenses associated with normal operations.", "label": "Operating Expense [Member]" } } }, "localname": "OperatingExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockbasedCompensationStockbasedCompensationByTypeOfAwardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://virnetx.com/role/ConsolidatedStatementsOfOperations": { "order": 0.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expense" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expense:", "terseLabel": "Operating expense [Abstract]" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedStatementsOfOperations", "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r228", "r230", "r234", "r236", "r514" ], "calculation": { "http://virnetx.com/role/ConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "(Loss) income from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r612" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Lease expense", "terseLabel": "Rent expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/CommitmentsContingenciesAndRelatedPartyTransactionsDetails", "http://virnetx.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r421" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Lease liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r420" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating lease ROU assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasedAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Leased Assets [Line Items]" } } }, "localname": "OperatingLeasedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/CommitmentsContingenciesAndRelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r115" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Net operating loss carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/IncomeTaxesPretaxIncomeLossesAndOperatingLossCarryforwardsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsExpirationDate": { "auth_ref": [ "r115" ], "lang": { "en-us": { "role": { "documentation": "Expiration date of each operating loss carryforward included in operating loss carryforward, in YYYY-MM-DD format.", "label": "Operating loss carryforwards, expiration date" } } }, "localname": "OperatingLossCarryforwardsExpirationDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/IncomeTaxesPretaxIncomeLossesAndOperatingLossCarryforwardsDetails" ], "xbrltype": "dateItemType" }, "us-gaap_OperatingLossCarryforwardsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Loss Carryforwards [Line Items]" } } }, "localname": "OperatingLossCarryforwardsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/IncomeTaxesPretaxIncomeLossesAndOperatingLossCarryforwardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsTable": { "auth_ref": [ "r116" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "Operating Loss Carryforwards [Table]" } } }, "localname": "OperatingLossCarryforwardsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/IncomeTaxesPretaxIncomeLossesAndOperatingLossCarryforwardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Formation and Business of the Company [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r0", "r127" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "verboseLabel": "Formation and Business of the Company" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/FormationAndBusinessOfCompany" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": { "auth_ref": [ "r17", "r19", "r410", "r411", "r412" ], "calculation": { "http://virnetx.com/role/ConsolidatedStatementsOfComprehensiveLossIncome": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Change in foreign currency translation, net", "verboseLabel": "Change in foreign currency translation, net" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedStatementsOfComprehensiveLossIncome", "http://virnetx.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r122", "r123", "r125", "r174", "r177" ], "calculation": { "http://virnetx.com/role/ConsolidatedStatementsOfComprehensiveLossIncome": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "totalLabel": "Total other comprehensive (loss) gain, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedStatementsOfComprehensiveLossIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other comprehensive (loss) income, net of tax:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedStatementsOfComprehensiveLossIncome" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r171", "r172" ], "calculation": { "http://virnetx.com/role/ConsolidatedStatementsOfComprehensiveLossIncome": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "Change in unrealized (loss) gain on investments, net", "terseLabel": "Change in unrealized investment (loss) gain, net" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedStatementsOfComprehensiveLossIncome", "http://virnetx.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r12", "r534" ], "calculation": { "http://virnetx.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other liabilities, current" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r14" ], "calculation": { "http://virnetx.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PatentsMember": { "auth_ref": [ "r120" ], "lang": { "en-us": { "role": { "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.", "label": "Patents [Member]" } } }, "localname": "PatentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/FormationAndBusinessOfCompanyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsOfDividendsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Dividend [Abstract]", "terseLabel": "Subsequent Event [Abstract]" } } }, "localname": "PaymentsOfDividendsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/CommonStockSummaryDetails", "http://virnetx.com/role/SubsequentEventDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PaymentsOfDividendsCommonStock": { "auth_ref": [ "r30" ], "calculation": { "http://virnetx.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.", "label": "Payments of Ordinary Dividends, Common Stock", "negatedLabel": "Dividends paid on common stock" } } }, "localname": "PaymentsOfDividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r185" ], "calculation": { "http://virnetx.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "negatedLabel": "Taxes paid on cashless exercise of restricted stock units" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r27", "r48", "r184" ], "calculation": { "http://virnetx.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Payments to Acquire Debt Securities, Available-for-Sale", "negatedLabel": "Purchase of investments" } } }, "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r28" ], "calculation": { "http://virnetx.com/role/ConsolidatedStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchase of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r300", "r301", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r318", "r530" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "Retirement Benefits [Text Block]", "verboseLabel": "Employee Benefit Plan" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/EmployeeBenefitPlan" ], "xbrltype": "textBlockItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockPlanDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockPlanDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PositiveOutcomeOfLitigationMember": { "auth_ref": [ "r570" ], "lang": { "en-us": { "role": { "documentation": "A potential favorable result upon resolution of a litigation matter, whether through trial, arbitration, mediation, or settlement of a legal threat made to another party, which results in collection of a damages award in cash or in other tangible or intangible assets.", "label": "Positive Outcome of Litigation [Member]" } } }, "localname": "PositiveOutcomeOfLitigationMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/LitigationDetails", "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r3", "r280" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r3", "r280" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r3", "r534" ], "calculation": { "http://virnetx.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, par value $0.0001 per share Authorized: 10,000,000 shares at December 31, 2022 and December 31, 2021, Issued and outstanding: 0 shares at December 31, 2022 and December 31, 2021" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r548" ], "calculation": { "http://virnetx.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent": { "auth_ref": [ "r137", "r149", "r547" ], "calculation": { "http://virnetx.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Noncurrent", "terseLabel": "Prepaid expenses and other assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidTaxes": { "auth_ref": [ "r506", "r517", "r565" ], "calculation": { "http://virnetx.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid income tax" } } }, "localname": "PrepaidTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r29" ], "calculation": { "http://virnetx.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from sale of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://virnetx.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds from sale or maturity of investments" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r29", "r107" ], "calculation": { "http://virnetx.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from exercise of options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedStatementsOfCashFlows", "http://virnetx.com/role/StockbasedCompensationSummaryOfActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r69" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/CommitmentsContingenciesAndRelatedPartyTransactionsDetails", "http://virnetx.com/role/LeasesDetails", "http://virnetx.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r71", "r481", "r482", "r483" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/PropertyAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r67", "r163" ], "calculation": { "http://virnetx.com/role/PropertyAndEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/PropertyAndEquipmentDetails", "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r69", "r153", "r469", "r534" ], "calculation": { "http://virnetx.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://virnetx.com/role/PropertyAndEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedBalanceSheets", "http://virnetx.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Net, by Type [Abstract]", "terseLabel": "Property and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentNetByTypeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r69", "r481", "r482" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r69" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/PropertyAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r67" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/CommitmentsContingenciesAndRelatedPartyTransactionsDetails", "http://virnetx.com/role/LeasesDetails", "http://virnetx.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Useful lives" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r111", "r157", "r625" ], "calculation": { "http://virnetx.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "verboseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock": { "auth_ref": [ "r63", "r64", "r157" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.", "label": "Research and Development" } } }, "localname": "ResearchDevelopmentAndComputerSoftwarePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Purchase Rights (\"RSU\") [Member]", "verboseLabel": "RSUs [Member]" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockPlanDetails", "http://virnetx.com/role/StockbasedCompensationStockbasedCompensationByTypeOfAwardDetails", "http://virnetx.com/role/StockbasedCompensationSummaryOfActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r6", "r85", "r151", "r478", "r480", "r534" ], "calculation": { "http://virnetx.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r158", "r193", "r194", "r195", "r197", "r203", "r205", "r247", "r357", "r358", "r359", "r382", "r383", "r399", "r475", "r477" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated Deficit (Retained Earnings) [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r225", "r226", "r229", "r232", "r233", "r237", "r238", "r239", "r297", "r298", "r461" ], "calculation": { "http://virnetx.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 }, "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesDetails": { "order": 0.0, "parentTag": "us-gaap_LossContingencyDamagesPaidValue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenue (royalties)", "verboseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedStatementsOfOperations", "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r299", "r511" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRecognitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue Recognition [Abstract]", "terseLabel": "Revenue Recognition [Abstract]" } } }, "localname": "RevenueRecognitionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RisksAndUncertaintiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Concentration of Credit Risk and Other Risks and Uncertainties [Abstract]" } } }, "localname": "RisksAndUncertaintiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/CommonStockSummaryDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of Available-for-sale Securities [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": { "auth_ref": [ "r52", "r53", "r54", "r55", "r56", "r57", "r144", "r145" ], "lang": { "en-us": { "role": { "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.", "label": "Schedule of Available-for-sale Securities [Table]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "auth_ref": [ "r105" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.", "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]", "terseLabel": "Stock-Based Compensation by Type of Award" } } }, "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockbasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r118" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Income Tax Provision (Benefit)" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r114" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Deferred Tax Assets and Liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r559" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Basic and Diluted Loss Per Share Calculations" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/EarningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r112" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Effective Income Tax Rate Reconciliation" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r105", "r108" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockbasedCompensationStockbasedCompensationByTypeOfAwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r60", "r62", "r462" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/FormationAndBusinessOfCompanyDetails", "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfOperatingLeasedAssetsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Schedule of Operating Leased Assets [Table]" } } }, "localname": "ScheduleOfOperatingLeasedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/CommitmentsContingenciesAndRelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r69" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Schedule of Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/PropertyAndEquipmentDetails", "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r319", "r321", "r323", "r324", "r325", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r347", "r348", "r349", "r350", "r351" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockPlanDetails", "http://virnetx.com/role/StockbasedCompensationSummaryOfActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r88" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "RSU Activity" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockbasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": { "auth_ref": [ "r106" ], "lang": { "en-us": { "role": { "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockbasedCompensationInformationAboutStockOptionsOutstandingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": { "auth_ref": [ "r106" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]", "terseLabel": "Information about Stock Options Outstanding" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockbasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r88", "r97", "r99" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockbasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r103" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Fair Value Assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockbasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r75", "r76", "r77", "r79", "r80", "r81", "r82", "r83", "r84", "r85", "r166", "r167", "r168", "r219", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r520", "r545", "r552" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/CommonStockSummaryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r86", "r87" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Information about Warrants Outstanding" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/CommonStockTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r26" ], "calculation": { "http://virnetx.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Disclosure [Abstract]", "terseLabel": "Information about Stock Options Outstanding [Abstract]" } } }, "localname": "ShareBasedArrangementsToObtainGoodsAndServicesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockbasedCompensationInformationAboutStockOptionsOutstandingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Noncash Expense [Abstract]", "terseLabel": "Stock-Based Compensation [Abstract]", "verboseLabel": "Share-based Compensation [Abstract]" } } }, "localname": "ShareBasedCompensationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockbasedCompensationStockbasedCompensationByTypeOfAwardDetails", "http://virnetx.com/role/StockbasedCompensationSummaryOfActivityDetails", "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r532" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Vesting period", "verboseLabel": "Option vesting term" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockPlanDetails", "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "RSUs cancelled (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockbasedCompensationSummaryOfActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "RSUs cancelled (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockbasedCompensationSummaryOfActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r338" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "RSUs granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockbasedCompensationSummaryOfActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r338" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "RSUs granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockbasedCompensationSummaryOfActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r335", "r336" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Outstanding, end of period (in shares)", "periodStartLabel": "Outstanding, beginning of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockbasedCompensationSummaryOfActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "RSUs, number of RSUs [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockbasedCompensationSummaryOfActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r335", "r336" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Outstanding, end of period (in dollars per share)", "periodStartLabel": "Outstanding, beginning of period (in dollars per share)", "terseLabel": "Weighted average fair value of warrants at grant date (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/CommonStockWarrantsDetails", "http://virnetx.com/role/StockbasedCompensationSummaryOfActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "RSUs, weighted average grant date fair value [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockbasedCompensationSummaryOfActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "RSUs vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockbasedCompensationSummaryOfActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "RSUs vested (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockbasedCompensationSummaryOfActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair value assumptions used in estimating fair value of each option grant [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockbasedCompensationFairValueAssumptionsUsedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r349" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Dividend yield", "terseLabel": "Expected dividends" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/CommonStockWarrantsDetails", "http://virnetx.com/role/StockbasedCompensationFairValueAssumptionsUsedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r348" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected stock price volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/CommonStockWarrantsDetails", "http://virnetx.com/role/StockbasedCompensationFairValueAssumptionsUsedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/CommonStockWarrantsDetails", "http://virnetx.com/role/StockbasedCompensationFairValueAssumptionsUsedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockPlanDetails", "http://virnetx.com/role/StockbasedCompensationSummaryOfActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "auth_ref": [ "r94" ], "lang": { "en-us": { "role": { "documentation": "Number of non-option equity instruments exercised by participants.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised", "terseLabel": "Exercised (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/CommonStockWarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations": { "auth_ref": [ "r95" ], "lang": { "en-us": { "role": { "documentation": "Number of shares under non-option equity instrument agreements that were either cancelled or expired.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations", "negatedLabel": "Terminated/ cancelled (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/CommonStockWarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "auth_ref": [ "r93" ], "lang": { "en-us": { "role": { "documentation": "Net number of non-option equity instruments granted to participants.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted", "terseLabel": "Issued (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/CommonStockWarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "auth_ref": [ "r89", "r91" ], "lang": { "en-us": { "role": { "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "periodEndLabel": "Outstanding and Exercisable (in shares)", "periodStartLabel": "Outstanding and Exercisable (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/CommonStockWarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "Increase of shares authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockPlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r106" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Shares available for grant (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockPlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Options, additional disclosures [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockbasedCompensationSummaryOfActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r329" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "periodEndLabel": "Options exercisable, end of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockbasedCompensationSummaryOfActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r329" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "periodEndLabel": "Options exercisable, end of period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockbasedCompensationSummaryOfActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r342" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Total intrinsic value of options exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockbasedCompensationSummaryOfActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r581" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "negatedLabel": "Options cancelled (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockbasedCompensationSummaryOfActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r581" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Options cancelled (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockbasedCompensationSummaryOfActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r331" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Options granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockbasedCompensationSummaryOfActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r341" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Options granted, weighted average grant date fair value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockbasedCompensationFairValueAssumptionsUsedDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r106" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Options outstanding, aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockbasedCompensationSummaryOfActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r327", "r328" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding, end of period (in shares)", "periodStartLabel": "Outstanding, beginning of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockbasedCompensationSummaryOfActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Options, number of shares [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockbasedCompensationSummaryOfActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r327", "r328" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding, end of period (in dollars per share)", "periodStartLabel": "Outstanding, beginning of period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockbasedCompensationSummaryOfActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Options, weighted average exercise price [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockbasedCompensationSummaryOfActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r323", "r324", "r325", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r347", "r348", "r349", "r350", "r351" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Equity Award [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/CommonStockWarrantsDetails", "http://virnetx.com/role/StockPlanDetails", "http://virnetx.com/role/StockbasedCompensationInformationAboutStockOptionsOutstandingDetails", "http://virnetx.com/role/StockbasedCompensationStockbasedCompensationByTypeOfAwardDetails", "http://virnetx.com/role/StockbasedCompensationSummaryOfActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r332" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Options exercised (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockbasedCompensationSummaryOfActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r331" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Options granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockbasedCompensationSummaryOfActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r326", "r345", "r346", "r347", "r348", "r351", "r360", "r361" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-Based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "auth_ref": [ "r102" ], "lang": { "en-us": { "role": { "documentation": "Information by range of option prices pertaining to options granted.", "label": "Exercise Price Range [Axis]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockbasedCompensationInformationAboutStockOptionsOutstandingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "auth_ref": [ "r104" ], "lang": { "en-us": { "role": { "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockbasedCompensationInformationAboutStockOptionsOutstandingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockbasedCompensationInformationAboutStockOptionsOutstandingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": { "auth_ref": [ "r104" ], "lang": { "en-us": { "role": { "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Exercise price range, lower range limit (in dollars per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockbasedCompensationInformationAboutStockOptionsOutstandingDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": { "auth_ref": [ "r96" ], "lang": { "en-us": { "role": { "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable", "terseLabel": "Options vested and exercisable, number exercisable (in shares)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockbasedCompensationInformationAboutStockOptionsOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": { "auth_ref": [ "r90" ], "lang": { "en-us": { "role": { "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.", "label": "Options outstanding, number outstanding (in shares)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockbasedCompensationInformationAboutStockOptionsOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": { "auth_ref": [ "r104" ], "lang": { "en-us": { "role": { "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Exercise price range, upper range limit (in dollars per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockbasedCompensationInformationAboutStockOptionsOutstandingDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "verboseLabel": "Per share market price of common stock on last trading day of year (in dollars per share)" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockbasedCompensationSummaryOfActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "RSUs, aggregate intrinsic value [Abstract]" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockbasedCompensationSummaryOfActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding", "terseLabel": "Outstanding, end of period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockbasedCompensationSummaryOfActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r533" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "terseLabel": "Term of award" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockPlanDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r347" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Expected life term", "terseLabel": "Expected option term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/CommonStockWarrantsDetails", "http://virnetx.com/role/StockbasedCompensationFairValueAssumptionsUsedDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r106" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Options exercisable, aggregate intrinsic value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockbasedCompensationSummaryOfActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r106" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Options exercisable, weighted average remaining contractual life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockbasedCompensationSummaryOfActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r100" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Options outstanding, weighted average remaining contractual life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockbasedCompensationSummaryOfActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": { "auth_ref": [ "r92" ], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price", "terseLabel": "Options vested and exercisable, weighted average exercise price (in dollars per share)" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockbasedCompensationInformationAboutStockOptionsOutstandingDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r101" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Options vested and exercisable, weighted average remaining contractual life" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockbasedCompensationInformationAboutStockOptionsOutstandingDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": { "auth_ref": [ "r90" ], "lang": { "en-us": { "role": { "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Options outstanding, weighted average exercise price (in dollars per share)" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockbasedCompensationInformationAboutStockOptionsOutstandingDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r100" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Options outstanding, weighted average remaining contractual life" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockbasedCompensationInformationAboutStockOptionsOutstandingDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r41", "r187" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "verboseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State [Member]" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/IncomeTaxesPretaxIncomeLossesAndOperatingLossCarryforwardsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r16", "r78", "r158", "r179", "r180", "r181", "r193", "r194", "r195", "r197", "r203", "r205", "r218", "r247", "r288", "r357", "r358", "r359", "r382", "r383", "r399", "r413", "r414", "r415", "r416", "r417", "r418", "r426", "r475", "r476", "r477" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/CommonStockSummaryDetails", "http://virnetx.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF CASH FLOWS [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONSOLIDATED BALANCE SHEETS [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r193", "r194", "r195", "r218", "r461" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r3", "r4", "r78", "r85", "r332" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedLabel": "Options exercised (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/StockbasedCompensationSummaryOfActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r3", "r4", "r78", "r85" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Common stock issued for cash, net" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r3", "r4", "r85", "r98" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Common stock issued for options/RSUs, net" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r4", "r7", "r8", "r47", "r534", "r553", "r564", "r611" ], "calculation": { "http://virnetx.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedBalanceSheets", "http://virnetx.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedBalanceSheets", "http://virnetx.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/SubsequentEventDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r419", "r428" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/SubsequentEventDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r419", "r428" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/SubsequentEventDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r419", "r428" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/SubsequentEventDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r419", "r428" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/SubsequentEventDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Event [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r427", "r429" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Event" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/SubsequentEvent" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/CommonStockSummaryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Subsidiary, Sale of Stock [Line Items]" } } }, "localname": "SubsidiarySaleOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/CommonStockSummaryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r242", "r243", "r279", "r285", "r398", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r561", "r562", "r563", "r628", "r629", "r630", "r631", "r632", "r633", "r634" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasuryAndGovernmentMember": { "auth_ref": [ "r468", "r528", "r627" ], "lang": { "en-us": { "role": { "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).", "label": "US Treasury and Government [Member]", "terseLabel": "U.S. Agency and Treasury Securities [Member]" } } }, "localname": "USTreasuryAndGovernmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/FairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r362", "r371" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Uncertain tax positions" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/IncomeTaxesIncomeTaxUncertaintiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "auth_ref": [ "r370" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "terseLabel": "Accrued interest and penalties" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/IncomeTaxesIncomeTaxUncertaintiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r44", "r45", "r46", "r220", "r221", "r223", "r224" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrants [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/CommonStockWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r559" ], "calculation": { "http://virnetx.com/role/EarningsPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Effect of dilutive securities (in shares)" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r207", "r212" ], "calculation": { "http://virnetx.com/role/EarningsPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted average shares outstanding diluted (in shares)", "totalLabel": "Diluted weighted average number of shares outstanding (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedStatementsOfOperations", "http://virnetx.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r206", "r212" ], "calculation": { "http://virnetx.com/role/EarningsPerShareDetails": { "order": 0.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted average shares outstanding basic (in shares)", "terseLabel": "Basic weighted average number of shares outstanding (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://virnetx.com/role/ConsolidatedStatementsOfOperations", "http://virnetx.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "vhc_ATMAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An at-the-market (\"ATM\") equity offering sales agreement.", "label": "ATM Agreement [Member]" } } }, "localname": "ATMAgreementMember", "nsuri": "http://virnetx.com/20221231", "presentation": [ "http://virnetx.com/role/CommonStockSummaryDetails" ], "xbrltype": "domainItemType" }, "vhc_AccruedLicensingCosts": { "auth_ref": [], "calculation": { "http://virnetx.com/role/ConsolidatedBalanceSheets": { "order": 9.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of costs incurred and are directly related to generating license revenue. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark.", "label": "Accrued Licensing Costs", "terseLabel": "Accrued licensing costs" } } }, "localname": "AccruedLicensingCosts", "nsuri": "http://virnetx.com/20221231", "presentation": [ "http://virnetx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "vhc_AmortizationOfCapitalizedDirectAndIndirectResearchAndDevelopmentCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amortization of capitalized direct and indirect research and development costs during the period.", "label": "Amortization of Capitalized Direct and Indirect Research and Development Costs", "terseLabel": "Amortization of capitalized direct and indirect research and development costs" } } }, "localname": "AmortizationOfCapitalizedDirectAndIndirectResearchAndDevelopmentCosts", "nsuri": "http://virnetx.com/20221231", "presentation": [ "http://virnetx.com/role/IncomeTaxesPretaxIncomeLossesAndOperatingLossCarryforwardsDetails" ], "xbrltype": "monetaryItemType" }, "vhc_AmortizationOfWarrantIssuanceCosts": { "auth_ref": [], "calculation": { "http://virnetx.com/role/ConsolidatedStatementsOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortization of warrant issuance costs during the period.", "label": "Amortization of Warrant Issuance Costs", "terseLabel": "Amortization of warrants issuance costs" } } }, "localname": "AmortizationOfWarrantIssuanceCosts", "nsuri": "http://virnetx.com/20221231", "presentation": [ "http://virnetx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "vhc_AvailableForSaleSecuritiesDebtMaturityPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of maturity of a debt security categorized as neither trading nor held-to-maturity, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Available-for-sale Securities, Debt Maturity Period", "terseLabel": "Maturities of investments" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturityPeriod", "nsuri": "http://virnetx.com/20221231", "presentation": [ "http://virnetx.com/role/FairValueMeasurementDetails" ], "xbrltype": "durationItemType" }, "vhc_AvailableForSaleSecuritiesExcludingCashAndCashEquivalents": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading, excluding cash and cash equivalents.", "label": "Available-for-sale Securities, Excluding Cash and Cash Equivalents", "terseLabel": "Investments Available for Sale" } } }, "localname": "AvailableForSaleSecuritiesExcludingCashAndCashEquivalents", "nsuri": "http://virnetx.com/20221231", "presentation": [ "http://virnetx.com/role/FairValueMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "vhc_CapitalizedDirectAndIndirectResearchAndDevelopmentCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of capitalized direct and indirect research and development costs.", "label": "Capitalized Direct and Indirect Research and Development Costs", "terseLabel": "Capitalized direct and indirect research and development costs" } } }, "localname": "CapitalizedDirectAndIndirectResearchAndDevelopmentCosts", "nsuri": "http://virnetx.com/20221231", "presentation": [ "http://virnetx.com/role/IncomeTaxesPretaxIncomeLossesAndOperatingLossCarryforwardsDetails" ], "xbrltype": "monetaryItemType" }, "vhc_CashAndAvailableForSaleSecuritiesAmortizedCostBasis": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the cost of cash and debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.", "label": "Cash and Available-for-sale Securities, Amortized Cost Basis", "terseLabel": "Adjusted Cost" } } }, "localname": "CashAndAvailableForSaleSecuritiesAmortizedCostBasis", "nsuri": "http://virnetx.com/20221231", "presentation": [ "http://virnetx.com/role/FairValueMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "vhc_CashAndAvailableForSaleSecuritiesFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of cash and investment in debt and equity securities categorized neither as held-to-maturity nor trading.", "label": "Cash and Available-for-sale Securities, Fair Value Disclosure", "terseLabel": "Fair Value" } } }, "localname": "CashAndAvailableForSaleSecuritiesFairValueDisclosure", "nsuri": "http://virnetx.com/20221231", "presentation": [ "http://virnetx.com/role/FairValueMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "vhc_ClassOfWarrantOrRightExpirationDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date the warrants or rights are to expire, in CCYY-MM-DD format.", "label": "Class of Warrant or Right, Expiration Date", "terseLabel": "Expiration date" } } }, "localname": "ClassOfWarrantOrRightExpirationDate", "nsuri": "http://virnetx.com/20221231", "presentation": [ "http://virnetx.com/role/CommonStockWarrantsDetails" ], "xbrltype": "dateItemType" }, "vhc_CommonStockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Abstract]" } } }, "localname": "CommonStockAbstract", "nsuri": "http://virnetx.com/20221231", "xbrltype": "stringItemType" }, "vhc_CommonStockAndAdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock that is subordinate to all other stock of the issuer and excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders related to additional paid-in capital.", "label": "Common Stock and Additional Paid-in Capital [Member]", "terseLabel": "Common Stock and Additional Paid-in Capital [Member]" } } }, "localname": "CommonStockAndAdditionalPaidInCapitalMember", "nsuri": "http://virnetx.com/20221231", "presentation": [ "http://virnetx.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "vhc_CommonStockDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for common stock.", "label": "Common Stock Disclosure [Text Block]", "verboseLabel": "Common Stock" } } }, "localname": "CommonStockDisclosureTextBlock", "nsuri": "http://virnetx.com/20221231", "presentation": [ "http://virnetx.com/role/CommonStock" ], "xbrltype": "textBlockItemType" }, "vhc_ConcentrationRiskNumberOfFinancialInstitutions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of financial institutions holding the company's cash and cash equivalents.", "label": "Concentration Risk, Number of Financial Institutions", "terseLabel": "Number of financial institutions holding company's cash" } } }, "localname": "ConcentrationRiskNumberOfFinancialInstitutions", "nsuri": "http://virnetx.com/20221231", "presentation": [ "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "integerItemType" }, "vhc_ContractualMaturitiesOfInvestmentSecurities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of investment securities, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Contractual Maturities of Investment Securities", "terseLabel": "Contractual maturities of investment securities" } } }, "localname": "ContractualMaturitiesOfInvestmentSecurities", "nsuri": "http://virnetx.com/20221231", "presentation": [ "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "durationItemType" }, "vhc_ExercisePriceRange1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Options within the stated exercise price range.", "label": "Exercise Price Range 1 [Member]", "terseLabel": "$1.22 - 1.58 [Member]" } } }, "localname": "ExercisePriceRange1Member", "nsuri": "http://virnetx.com/20221231", "presentation": [ "http://virnetx.com/role/StockbasedCompensationInformationAboutStockOptionsOutstandingDetails" ], "xbrltype": "domainItemType" }, "vhc_ExercisePriceRange2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Options within the stated exercise price range.", "label": "Exercise Price Range 2 [Member]", "terseLabel": "$2.35 - 6.95 [Member]" } } }, "localname": "ExercisePriceRange2Member", "nsuri": "http://virnetx.com/20221231", "presentation": [ "http://virnetx.com/role/StockbasedCompensationInformationAboutStockOptionsOutstandingDetails" ], "xbrltype": "domainItemType" }, "vhc_ExercisePriceRange3Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents options within the stated exercise price range.", "label": "Exercise Price Range 3 [Member]", "terseLabel": "$14.52 - 35.05 [Member]" } } }, "localname": "ExercisePriceRange3Member", "nsuri": "http://virnetx.com/20221231", "presentation": [ "http://virnetx.com/role/StockbasedCompensationInformationAboutStockOptionsOutstandingDetails" ], "xbrltype": "domainItemType" }, "vhc_FormationAndBusinessOfTheCompanyDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Formation and Business of the Company Disclosure [Abstract]", "terseLabel": "Formation and Business of the Company Disclosure [Abstract]" } } }, "localname": "FormationAndBusinessOfTheCompanyDisclosureAbstract", "nsuri": "http://virnetx.com/20221231", "presentation": [ "http://virnetx.com/role/FormationAndBusinessOfCompanyDetails" ], "xbrltype": "stringItemType" }, "vhc_GainContingenciesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for an existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) that might result in a gain, typically reflecting care to avoid misleading implications as to the likelihood of realization, and describes and quantifies a gain recognized in the period resulting from resolution of a previously disclosed gain contingency.", "label": "Gain Contingencies [Policy Text Block]", "terseLabel": "Contingent Gains" } } }, "localname": "GainContingenciesPolicyTextBlock", "nsuri": "http://virnetx.com/20221231", "presentation": [ "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "vhc_IncentiveStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A type of employee stock option that can be granted only to employees and confer a U.S. tax benefit. ISOs are also sometimes referred to as incentive share options or Qualified Stock Options by IRS.", "label": "Incentive Stock Options [Member]" } } }, "localname": "IncentiveStockOptionsMember", "nsuri": "http://virnetx.com/20221231", "presentation": [ "http://virnetx.com/role/StockPlanDetails" ], "xbrltype": "domainItemType" }, "vhc_IncreaseDecreaseInAccruedLicensingCosts": { "auth_ref": [], "calculation": { "http://virnetx.com/role/ConsolidatedStatementsOfCashFlows": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in accrued licensing costs during the reporting period.", "label": "Increase (Decrease) in Accrued Licensing Costs", "terseLabel": "Accrued licensing costs" } } }, "localname": "IncreaseDecreaseInAccruedLicensingCosts", "nsuri": "http://virnetx.com/20221231", "presentation": [ "http://virnetx.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "vhc_InformationAboutWarrantsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Information About Warrants [Abstract]", "terseLabel": "Warrants [Abstract]" } } }, "localname": "InformationAboutWarrantsAbstract", "nsuri": "http://virnetx.com/20221231", "presentation": [ "http://virnetx.com/role/CommonStockWarrantsDetails" ], "xbrltype": "stringItemType" }, "vhc_K2InvestmentFundLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The counterparty from which the Company leased the use of an aircraft for business travel for employees of the Company", "label": "K2 Investment Fund LLC [Member]" } } }, "localname": "K2InvestmentFundLLCMember", "nsuri": "http://virnetx.com/20221231", "presentation": [ "http://virnetx.com/role/CommitmentsContingenciesAndRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "vhc_LeaseExtensionPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The extension period of lease agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lease Extension Period", "terseLabel": "Lease extension period" } } }, "localname": "LeaseExtensionPeriod", "nsuri": "http://virnetx.com/20221231", "presentation": [ "http://virnetx.com/role/LeasesDetails" ], "xbrltype": "durationItemType" }, "vhc_LicensingCosts": { "auth_ref": [], "calculation": { "http://virnetx.com/role/ConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate licensing costs related to revenues.", "label": "Licensing Costs", "verboseLabel": "Licensing costs" } } }, "localname": "LicensingCosts", "nsuri": "http://virnetx.com/20221231", "presentation": [ "http://virnetx.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "vhc_LicensingCostsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the licensing costs.", "label": "Licensing Costs [Policy Text Block]", "terseLabel": "Licensing Costs" } } }, "localname": "LicensingCostsPolicyTextBlock", "nsuri": "http://virnetx.com/20221231", "presentation": [ "http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "vhc_LitigationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation [Abstract]" } } }, "localname": "LitigationAbstract", "nsuri": "http://virnetx.com/20221231", "xbrltype": "stringItemType" }, "vhc_LitigationSettlementNumberOfInfringingUnits": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of infringing units in judgment or settlement of litigation.", "label": "Litigation Settlement, Number of Infringing Units", "terseLabel": "Number of infringing units" } } }, "localname": "LitigationSettlementNumberOfInfringingUnits", "nsuri": "http://virnetx.com/20221231", "presentation": [ "http://virnetx.com/role/LitigationDetails" ], "xbrltype": "integerItemType" }, "vhc_LossContingencyDamagesPerAccusedDevice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Damages awarded to the plaintiff per accused device.", "label": "Loss Contingency Damages Per Accused Device", "terseLabel": "Damages awarded per accused device" } } }, "localname": "LossContingencyDamagesPerAccusedDevice", "nsuri": "http://virnetx.com/20221231", "presentation": [ "http://virnetx.com/role/LitigationDetails" ], "xbrltype": "perUnitItemType" }, "vhc_LossContingencyDamagesSoughtContingencyFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The contingency fee as a percentage of the award the plaintiff seeks in the legal matter.", "label": "Loss Contingency, Damages Sought, Contingency Fee, Percentage", "terseLabel": "Contingency fee as percentage of payment" } } }, "localname": "LossContingencyDamagesSoughtContingencyFeePercentage", "nsuri": "http://virnetx.com/20221231", "presentation": [ "http://virnetx.com/role/LitigationDetails" ], "xbrltype": "percentItemType" }, "vhc_LossContingencyNumberOfAppealsConsolidated": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of appeals consolidated in a court order.", "label": "Loss Contingency, Number of Appeals Consolidated", "terseLabel": "Number of appeals consolidated" } } }, "localname": "LossContingencyNumberOfAppealsConsolidated", "nsuri": "http://virnetx.com/20221231", "presentation": [ "http://virnetx.com/role/LitigationDetails" ], "xbrltype": "integerItemType" }, "vhc_LossContingencyPostJudgmentInterestParentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The post-judgment interest percentage.", "label": "Loss Contingency, Post Judgment Interest Parentage", "terseLabel": "Post-judgment interest percentage" } } }, "localname": "LossContingencyPostJudgmentInterestParentage", "nsuri": "http://virnetx.com/20221231", "presentation": [ "http://virnetx.com/role/LitigationDetails" ], "xbrltype": "percentItemType" }, "vhc_LossContingencyPreJudgmentInterestParentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The pre-judgment interest percentage.", "label": "Loss Contingency, Pre-Judgment Interest Parentage", "terseLabel": "Pre-judgment interest percentage" } } }, "localname": "LossContingencyPreJudgmentInterestParentage", "nsuri": "http://virnetx.com/20221231", "presentation": [ "http://virnetx.com/role/LitigationDetails" ], "xbrltype": "percentItemType" }, "vhc_McKoolSmithPCVVirnetXIncAAACaseNo012000037975Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information about litigation regarding McKool Smith P.C. v. VirnetX, Inc., AAA (Case No. 01-20-0003-7975).", "label": "McKool Smith P.C. v. VirnetX, Inc., AAA (Case No. 01-20-0003-7975) [Member]", "terseLabel": "McKool Smith P.C. v. VirnetX, Inc., AAA (Case No. 01-20-0003-7975) [Member]" } } }, "localname": "McKoolSmithPCVVirnetXIncAAACaseNo012000037975Member", "nsuri": "http://virnetx.com/20221231", "presentation": [ "http://virnetx.com/role/LitigationDetails" ], "xbrltype": "domainItemType" }, "vhc_NonqualifiedStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A type of employee stock option where the holders pay ordinary income tax on the difference between the grant price and the price at which they exercise the option.", "label": "Nonqualified Stock Options [Member]" } } }, "localname": "NonqualifiedStockOptionsMember", "nsuri": "http://virnetx.com/20221231", "presentation": [ "http://virnetx.com/role/StockPlanDetails" ], "xbrltype": "domainItemType" }, "vhc_NumberOfPatentsAndPendingApplicationsOwned": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents number of patents and pending applications owned by the entity.", "label": "Number of patents and pending applications owned", "terseLabel": "Number of patents and pending applications" } } }, "localname": "NumberOfPatentsAndPendingApplicationsOwned", "nsuri": "http://virnetx.com/20221231", "presentation": [ "http://virnetx.com/role/FormationAndBusinessOfCompanyDetails" ], "xbrltype": "integerItemType" }, "vhc_NumberOfVotesEntitledToEachShareOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Refers to number of votes entitled to each share of common stock.", "label": "Number of votes entitled to each share of common stock" } } }, "localname": "NumberOfVotesEntitledToEachShareOfCommonStock", "nsuri": "http://virnetx.com/20221231", "presentation": [ "http://virnetx.com/role/CommonStockSummaryDetails" ], "xbrltype": "integerItemType" }, "vhc_OfficeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating lease for office space.", "label": "Office [Member]", "terseLabel": "Office [Member]" } } }, "localname": "OfficeMember", "nsuri": "http://virnetx.com/20221231", "presentation": [ "http://virnetx.com/role/LeasesDetails" ], "xbrltype": "domainItemType" }, "vhc_Plan2013Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Refers to plan 2013 of equity based compensation arrangement plan.", "label": "Plan 2013 [Member]", "terseLabel": "2013 Plan [Member]" } } }, "localname": "Plan2013Member", "nsuri": "http://virnetx.com/20221231", "presentation": [ "http://virnetx.com/role/StockPlanDetails" ], "xbrltype": "domainItemType" }, "vhc_PromotionalAndMarketingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating lease for a facility used for corporate promotional and marketing purposes.", "label": "Promotional and Marketing [Member]", "verboseLabel": "Corporate Promotional and Marketing Facility [Member]" } } }, "localname": "PromotionalAndMarketingMember", "nsuri": "http://virnetx.com/20221231", "presentation": [ "http://virnetx.com/role/LeasesDetails" ], "xbrltype": "domainItemType" }, "vhc_RateOfAircraftLease": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Refers to the rate of aircraft lease in dollars per flight hour.", "label": "Rate of Aircraft Lease", "terseLabel": "Rate of aircraft lease (in dollars per flight hour)" } } }, "localname": "RateOfAircraftLease", "nsuri": "http://virnetx.com/20221231", "presentation": [ "http://virnetx.com/role/CommitmentsContingenciesAndRelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "vhc_RoyaltyRatePerDeviceUsedInInfringementDamages": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty rate per device used in calculating infringement damages by the court.", "label": "Royalty Rate per Device Used in Infringement Damages", "terseLabel": "Royalty rate per device used in calculating infringement damages" } } }, "localname": "RoyaltyRatePerDeviceUsedInInfringementDamages", "nsuri": "http://virnetx.com/20221231", "presentation": [ "http://virnetx.com/role/LitigationDetails" ], "xbrltype": "decimalItemType" }, "vhc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisePriceAsPercentageOfFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise price of stock options granted as percentage of fair market value of shares at the date of grant.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercise Price as Percentage of Fair Value", "terseLabel": "Exercise price of option granted as percentage of fair market value of shares at date of grant" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisePriceAsPercentageOfFairValue", "nsuri": "http://virnetx.com/20221231", "presentation": [ "http://virnetx.com/role/StockPlanDetails" ], "xbrltype": "percentItemType" }, "vhc_StockPlanAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Plan [Abstract]" } } }, "localname": "StockPlanAbstract", "nsuri": "http://virnetx.com/20221231", "xbrltype": "stringItemType" }, "vhc_StockPlanTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of the description of the plan, the basis for determining contributions, including the employee groups covered, and the nature and effect of significant matters affecting comparability of information for all periods presented. For leveraged ESOPs and pension reversion ESOPs, the disclosure may include the basis for releasing shares and how dividends on allocated and unallocated shares are used.", "label": "Stock Plan [Text Block]", "verboseLabel": "Stock Plan" } } }, "localname": "StockPlanTextBlock", "nsuri": "http://virnetx.com/20221231", "presentation": [ "http://virnetx.com/role/StockPlan" ], "xbrltype": "textBlockItemType" }, "vhc_TermOfNoticeForCancellationOfLease": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Refers to the term of notice for cancellation of lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Term of Notice for Cancellation of Lease", "terseLabel": "Term of notice for cancellation of lease" } } }, "localname": "TermOfNoticeForCancellationOfLease", "nsuri": "http://virnetx.com/20221231", "presentation": [ "http://virnetx.com/role/CommitmentsContingenciesAndRelatedPartyTransactionsDetails" ], "xbrltype": "durationItemType" }, "vhc_UniversalShelfRegistrationStatementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Refers to single prospectus for multiple, undefined future offerings.", "label": "Universal Shelf Registration Statement [Member]" } } }, "localname": "UniversalShelfRegistrationStatementMember", "nsuri": "http://virnetx.com/20221231", "presentation": [ "http://virnetx.com/role/CommonStockSummaryDetails" ], "xbrltype": "domainItemType" }, "vhc_VirnetXIncVAppleIncCase612CV00855LEDAppleIIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information about litigation regarding VirnetX Inc. v. Apple, Inc. (Case 6:12-CV-00855-LED) (\"Apple II\").", "label": "VirnetX Inc. v. Apple, Inc. (Case 6:12-CV-00855-LED) (\"Apple II\") [Member]" } } }, "localname": "VirnetXIncVAppleIncCase612CV00855LEDAppleIIMember", "nsuri": "http://virnetx.com/20221231", "presentation": [ "http://virnetx.com/role/LitigationDetails" ], "xbrltype": "domainItemType" }, "vhc_VirnetXIncVCiscoSystemsIncEtAlCase610CV00417LEDAppleIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information about litigation regarding VirnetX Inc. v. Cisco Systems, Inc. et al. (Case 6:10-CV-00417-LED) (\"Apple I\").", "label": "VirnetX Inc. v. Cisco Systems, Inc. et al. (Case 6:10-CV-00417-LED) (\"Apple I\") [Member]" } } }, "localname": "VirnetXIncVCiscoSystemsIncEtAlCase610CV00417LEDAppleIMember", "nsuri": "http://virnetx.com/20221231", "presentation": [ "http://virnetx.com/role/LitigationDetails" ], "xbrltype": "domainItemType" }, "vhc_VirnetXIncVTheMangrovePartnersCase202271AndCase202272ConsolidatedAppealMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information about litigation regarding VirnetX Inc. v. The Mangrove Partners (Case 20-2271 and Case 20-2272) (\"Consolidated Appeal\").", "label": "VirnetX Inc. v. The Mangrove Partners (Case 20-2271 and Case 20-2272) (\"Consolidated Appeal\") [Member]", "terseLabel": "VirnetX Inc. v. The Mangrove Partners (Case 20-2271 and Case 20-2272) (\"Consolidated Appeal\") [Member]" } } }, "localname": "VirnetXIncVTheMangrovePartnersCase202271AndCase202272ConsolidatedAppealMember", "nsuri": "http://virnetx.com/20221231", "presentation": [ "http://virnetx.com/role/LitigationDetails" ], "xbrltype": "domainItemType" }, "vhc_WarrantIssuanceDate2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance date of warrant that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant Issuance Date 2 [Member]", "terseLabel": "Warrants Issued in 2020 [Member]" } } }, "localname": "WarrantIssuanceDate2Member", "nsuri": "http://virnetx.com/20221231", "presentation": [ "http://virnetx.com/role/CommonStockWarrantsDetails" ], "xbrltype": "domainItemType" } }, "unitCount": 10 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "44", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5558-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62586-112803", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a-c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "8B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL6284393-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(e))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "https://asc.fasb.org/topic&trid=2235017", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28129-110885", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30304-110892", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/subtopic&trid=77888251", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(4)", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r491": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(5)", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r492": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)(i)", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r493": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)(ii)", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r494": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r495": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r496": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r497": { "Name": "Regulation S-K (SK)", "Number": "229", "Publisher": "SEC", "Section": "1402", "Subsection": "Instruction 5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r498": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1406", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r499": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1406", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1406", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r501": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1406", "Subparagraph": "(4)", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r502": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1406", "Subparagraph": "(5)", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r503": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1406", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r504": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(m)", "Publisher": "SEC", "Section": "4", "Subparagraph": "(1)(iii)", "Subsection": "08", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(4)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124267575&loc=SL82921835-210448", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r536": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r537": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r538": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r539": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r541": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r542": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r543": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r544": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27340-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=6397426&loc=d3e17499-108355", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r58": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "740", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126970579&loc=d3e23163-113944", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(b))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r628": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r629": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "40", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=118172244&loc=d3e17916-109280", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r630": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r631": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r632": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r633": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r634": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r635": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "12", "Subsection": "04", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=16397303&loc=d3e19347-109286", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org/topic&trid=2155823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 73 0001140361-23-015369-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-23-015369-xbrl.zip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¾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end